SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 10 - K


(Mark One)

/X/ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 [FEE REQUIRED]

For the fiscal year ended December 31, 1996

/ / TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 [NO FEE REQUIRED]

For the transition period from to
Commission file number 1-3619

PFIZER INC.

(Exact name of registrant as specified in its charter)

                   Delaware                                  13-5315170
        (State or other jurisdiction of                   (I.R.S. Employer
        incorporation or organization)                 Identification Number)
             235 East 42nd Street
              New York, New York                               10017
   (Address of principal executive offices)                  (Zip Code)

                                 (212) 573-2323
               (Registrant's telephone number including area code)
           Securities registered pursuant to Section 12(b) of the Act:

=========================================================================
      Title of each class                          Name of each exchange
                                                    on which registered
- -------------------------------------------------------------------------
Common Stock, $.05 par value                      New York Stock Exchange
Preferred Stock Purchase Rights                   New York Stock Exchange
=========================================================================

Securities registered pursuant to Section 12(g) of the Act:

None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes X No

Indicate by check mark if disclosure of delinquent filers pursuant to

Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in the definitive proxy or information statement incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. /X/

The aggregate market value of the voting stock held by non-affiliates of the registrant computed by reference to the closing price at which the stock was sold as of February 28, 1997 was approximately $59.1 billion.

The number of shares outstanding of each of the registrant's classes of common stock as of February 28, 1997 was 646,441,139 shares of common stock, all of one class.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the 1996 Annual Report to Shareholders       Parts I, II and IV
Portions of the Proxy Statement for the 1997
 Annual Meeting of Shareholders                          Parts I, III, and IV
- -------------------------------------------------------------------------------


PART I

ITEM 1. BUSINESS

General

Pfizer Inc. (the "Company") is a research-based global health care company. The Company discovers, develops, manufactures and sells innovative technology-intensive products in three business segments: Health Care, which includes a broad range of prescription pharmaceuticals, orthopedic implants, medical devices and surgical equipment; Animal Health, which includes animal health products and feed supplements; and Consumer Health Care, which includes a variety of nonprescription drugs and personal care products.

Business Segments

The Company's operations include three business segments: Health Care, Animal Health and Consumer Health Care. The Company's businesses offer complementary synergies in research, manufacturing and regulatory oversight, which helps leverage the Company's investments and expertise in each area. A description of the three business segments is set forth on page 58 of the Company's 1996 Annual Report to Shareholders. Comparative segment sales, income and related financial information for 1996, 1995 and 1994 are set forth in the table entitled "Segment Information" on page 39 of that same Annual Report. A graph captioned "Net Sales by Business Segment" and a table captioned "Percentage Change in Net Sales" on pages 30 and 31, respectively, of the Annual Report present segment sales information over the same three years. All such sections from the Annual Report are incorporated herein by reference.

Health Care

The Health Care segment is comprised of two business groups: the Pfizer Pharmaceuticals Group and the Hospital Products Group.

Pfizer Pharmaceuticals Group

Effective January 1997, the Company combined its previously separate U.S. and international pharmaceutical organizations into a single integrated organization called "Pfizer Pharmaceuticals Group." Management is in the process of bringing together the operations of the two formerly separate groups.

The Company's worldwide pharmaceutical products are comprised primarily of drugs in the following major therapeutic classes: cardiovascular diseases, infectious diseases and central nervous system disorders. The Company also has significant products for treatment of diabetes, allergies and arthritis/inflammation. In 1996, pharmaceuticals contributed 72% of the Company's consolidated revenues, as compared to 71% in 1995 and 73% in 1994. Pharmaceutical revenues in 1996 were principally from products launched since the late 1980s, including Norvasc (amlodipine besylate), Cardura (doxazosin mesylate), Diflucan (fluconazole), Zithromax (azithromycin) and Zoloft (sertraline).

Cardiovascular disease products are the Company's largest therapeutic product line, accounting for roughly 30% of the Company's consolidated net sales for each of the past three years. Sales of both Norvasc, a once-a-day calcium channel blocker for hypertension and angina, as well as Cardura, an alpha blocker for hypertension and benign prostatic hyperplasia, grew substantially in 1996. Sales of Procardia XL, a once-a-day calcium channel blocker for hypertension and angina, decreased during 1996, reflecting the product's maturity and the Company's increasing emphasis on Norvasc, but still exceeded one billion dollars.

Worldwide infectious disease product sales increased mainly on the strength of Diflucan and Zithromax. Diflucan, an anti-fungal agent, is indicated for use in a variety of fungal infections including vaginal candidiasis and certain infections that afflict AIDS and immunosuppressed cancer patients. Zithromax is an oral antibiotic which drew significant growth in 1996 from its approval for use in new indications.

2

Zoloft, for treatment of depression and obsessive compulsive disorder, experienced substantial growth again in 1996. During 1996, the Company introduced Zyrtec in the U.S. for the treatment of seasonal and perennial allergic rhinitis and chronic urticaria. Zyrtec, the most widely-prescribed antihistamine in Europe, has been marketed worldwide by the Belgian company, UCB S.A. Zyrtec is licensed to the Company for sales in the U.S. and Canada, and the Company and a subsidiary of UCB S.A. copromote Zyrtec in the U.S.

Hospital Products Group

The Hospital Products Group consists of two divisions - Howmedica and the Medical Devices Division. Howmedica manufactures and markets orthopedic implants and related reconstructive products. The Medical Devices Division consists of three core businesses - Schneider/NAMIC, Valleylab and American Medical Systems. The Group's four major business lines are musculoskeletal products, interventional cardiology and radiology products, surgical instrumentation and urology products. In each of 1996 and 1995, the sales of the Hospital Products Group accounted for thirteen percent of the Company's consolidated net sales, compared with fourteen percent in 1994.

Howmedica's musculoskeletal products, including reconstructive hip and knee implants, bone cement, trauma products and internal and external fixation devices, were complemented by the 1996 acquisition of the Leibinger companies. Leibinger produces implantable devices used in oral and craniomaxillofacial surgery and specialty surgical instruments. Schneider/NAMIC is a worldwide manufacturer and supplier of angioplasty catheters, stents for vascular and non-vascular applications and single-patient-use medical products, primarily for use in the diagnosis and treatment of atherosclerotic cardiovascular disease. Valleylab manufactures electrosurgical and ultrasonic surgical equipment used in open and minimally invasive surgical procedures. American Medical Systems manufactures impotence and incontinence implants.

The Hospital Products Group was also strengthened by the 1996 acquisitions of Corvita Corporation and Vesta Medical, Inc. Corvita develops, manufactures and markets synthetic vascular grafts and is developing stent-graft devices for diseased or damaged arteries. Vesta Medical, Inc. has developed technology for treatment of dysfunctional uterine bleeding.

Animal Health

The Animal Health Group discovers, develops, manufactures and sells animal health products for the prevention and treatment of diseases in livestock, poultry, companion animals and other animals. The Company is a significant manufacturer of antibiotics, antiparasitics and anticoccidial products for food animals, as well as vaccines and various companion animal products. In 1995, the Company acquired the SmithKline Beecham Animal Health business, a major producer of animal vaccines and companion animal products. This operation essentially doubled the revenues of the Animal Health Group and complemented the Company's existing animal health business in terms of product, species and geographic sales coverage. In 1996, Animal Health Group sales accounted for eleven percent of the Company's consolidated net sales, compared with twelve percent in 1995 and eight percent in 1994.

In 1996, the Company received U.S. Food and Drug Administration ("FDA") approval of Dectomax (doramectin), a treatment for internal and external parasites, primarily in cattle. Dectomax was already available in many countries outside the U.S. and is a major Animal Health Group product. It provides a long duration of activity against a broader spectrum of parasites than other currently available injectable products. Also in 1996, the Company received U.S. regulatory approval for Rimadyl, a non-steroidal anti-inflammatory for treatment of osteo-arthritis in dogs, Domitor and Antisedan, a sedative and reversing agent for use in dogs, and Aviax, an ionophore anticoccidial for poultry.

The principal products of the Animal Health Group are Dectomax; Stafac (virginiamycin), a feed additive anti-infective for poultry, cattle and swine; Terramycin LA-200 (oxytetracycline), an injectable version of the Terramycin broad spectrum antibiotic used for a variety of animal diseases; the Banminth (pyrantel tartrate), Nemex (pyrantel pamoate), Valbazen (albendazole) and Paratect (morantel tartrate) anthelmintics for internal parasites; Coxistac (salinomycin) and Aviax (semduramicin) anticoccidials primarily for poultry; Mecadox (carbadox), an antibacterial for pigs; and Advocin (danofloxacin), for treating respiratory and enteric diseases in livestock and poultry. The Company also manufactures and sells an extensive line of cattle, swine and companion animal vaccines including BoviShield, Leukocell, RespiSure and Vanguard.

3

Consumer Health Care

The Company's Consumer Health Care products include proprietary non-prescription health items, baby care products and toiletries, and a number of products sold only in selected international markets. Among the Group's better-known over-the-counter ("OTC") brands in the U.S. are Visine eyedrops, Ben-Gay topical analgesics, Desitin ointments, Unisom sleep aids, Plax pre-brushing dental rinse, Rid anti-lice products, Bain de Soleil skin care products and Barbasol shave creams and gels. Several line extensions building on these brands have been introduced in recent years. In 1996, the Company acquired the Cortizone and Hemorid brands to expand this product portfolio. Cortizone is a hydrocortisone skin care product and Hemorid is the only brand of hemorrhoidal preparation expressly designed for women. In both 1996 and 1995, sales of the Consumer Health Group accounted for four percent of the Company's consolidated net sales, compared with five percent in 1994.

The Consumer Health Care business provides a platform for expanded commercialization of certain prescription medications through the evolution to OTC medications. For example, an OTC formulation of Feldene for treatment of chronic shoulder and back pain was launched under the brand name "Juscoat" in Japan in February 1996. Similarly, Diflucan One was marketed in the U.K. as a treatment for vaginal candidiasis and Zyrtec is sold in Canada under the Reactine brand name. Also in 1996, the Company acquired the rights to an antihistimine eye drop formulation that previously had been available only by prescription. Using that technology, the Company launched a new product, OcuHist, as an extension of its OTC ophthalmic product line. Subject to applicable regulatory approval and market conditions, the Company expects to pursue similar launches for other products over time.

Research and Product Development

Innovation fueled by the Company's research and development operations is key to the continued commercial success of all its businesses. The Company's strategic focus on discovering, developing and bringing to market innovative products that address major unmet health care needs has been supported by substantial research and development investments. The Company spent approximately $1.7 billion in 1996, $1.4 billion in 1995, and $1.1 billion in 1994 on Company-sponsored research and development. For 1997, the Company has increased its annual worldwide research and development budget to approximately $2.0 billion.

The Company conducts research internally, through contracts with third party researchers, through collaborations with organizations such as universities and biotechnology companies, and in cooperation with other pharmaceutical and medical products firms. The Company also seeks out innovative technologies developed by third parties to acquire or incorporate into Company product lines through licensing or other arrangements.

Drug and medical product development is time consuming, expensive and unpredictable. On average, only one out of several thousand chemical compounds discovered by researchers proves to be both medically effective and safe enough to receive regulatory approval. The process from discovery to regulatory approval can take more than ten years. Efficiency in the development process so as to be the first to market with an innovative new pharmaceutical compound or medical product is important. As a result, the management of the Company's research and development organization strives for efficient handling of product candidates as a potential competitive advantage.

The Company currently has a number of pharmaceutical compounds and new therapies in all stages of development that is unprecedented in its history. In 1996, the Company's discovery scientists delivered seventeen new drug candidates to the early development stage. While each of those candidates is far from regulatory approval and faces a number of hurdles, these and other drug candidates are the foundation for potential new products in coming years. A table and discussion of existing major pharmaceutical products, supplemental filings for those products, and drug candidates in late and early stage development is set out under the heading "Major Pfizer Products and Selected Candidates in Development" on pages 8 and 9 of the Company's 1996 Annual Report to Shareholders. That table and discussion are incorporated herein by reference.

The Company's research operations also strive to add extra value to existing products. The 1996 FDA approval of Zoloft for the treatment of obsessive compulsive disorder is one example. Also in 1996, the FDA approved a new once-a-week form of Zithromax for prevention of Mycobacterium avium infections in AIDS patients and a pediatric dosage form of Zyrtec. Altogether, the Company has filed more than twenty Supplemental New Drug Applications with the FDA in the past five years to expand markets for its existing products.

4

The Company's competitors also devote substantial resources to research and development. This competition can result in product obsolescence for the Company as patient therapies improve. Consequently, the continual development of new and innovative products is important to the Company's businesses.

Marketing

In the Company's global prescription pharmaceuticals and hospital products businesses, products are promoted to health care providers as well as to Managed Care Organizations ("MCOs"). The Company also devotes significant resources to marketing directly to consumers in the United States, primarily through direct-to-consumer print and TV advertising. The Company's U.S. operations have several pharmaceutical and hospital products sales organizations that represent different groups of products. In 1996, an additional U.S. pharmaceutical sales organization was created to help market the portfolio of existing products and represent new products. This raised the number of U.S. pharmaceutical sales representatives to more than 3,300. Similar sales organizations are used in overseas operations. Through these marketing organizations, the Company endeavors to gain access to MCO formularies by demonstrating unique qualities of its pharmaceutical and hospital products. The Company also works with MCOs to assist them with disease management and other tools.

Marketing of prescription pharmaceuticals depends to a degree on complex decisions about the scope of clinical trials made years before product approval. All drugs must complete basic clinical trials required by regulatory authorities to show they are safe and effective for treating a particular medical problem. A manufacturer may choose, however, to undertake additional studies in order to demonstrate additional advantages of a compound, such as a better safety profile or improved cost effectiveness, but such studies can be costly and take years to complete. Decisions about whether and when to undertake such additional studies can have a major impact on later marketing claims and strategies.

Separate sales organizations are used by the Company's Animal Health and Consumer Health Care businesses to promote their particular products. The Animal Health business' advertising and promotion are generally targeted to health professionals, directly and through medical journals. The Consumer Health Care business uses substantial consumer advertising to promote its brand-name products. In addition, the Company sponsors general advertising to educate the public about the Company's innovative medical research.

The Company's pharmaceutical products are sold principally to wholesale resellers, but the Company also sells directly to retailers, including hospitals, clinics, government agencies and pharmacies. Hospital products are generally sold directly to medical institutions, but distributors and dealers provide a supplementary channel. Animal health and nutrition products are sold through veterinarians, drug wholesalers, distributors, retail outlets and directly to users, including feed manufacturers and animal producers. Consumer health care products are promoted by heavy consumer advertising and sold through a variety of retailers.

Apart from the Consumer Health Care Group's sales to WalMart, which represents more than fifteen percent of its U.S. business, none of the Company's business segments is dependent on a single customer, or a few customers, such that a loss of any one or more would have a material adverse effect on the particular business segment. No customer accounted for ten percent or more of the Company's consolidated revenues in 1996. See, however, the discussion below in the sections entitled "Competition" and "Government Regulation and Price Constraints."

International Operations

Outside the United States, the Company has significant operations, both direct and through distributors that, in general, parallel its United States businesses. In 1996, the Company had net sales in excess of $100 million in each of thirteen foreign countries and in excess of ten million dollars in each of 32 additional countries, with no single country other than the U.S. contributing more than ten percent of total net sales. Japan is the Company's second largest national market, with 1996 sales again exceeding one billion dollars, although declining slightly from 1995 results due to lower valuations of the Japanese yen versus the U.S. dollar. Growth in some European markets exceeded twenty percent, while in selected emerging market nations, the growth rate was even higher. If the world economy continues to grow and bring prosperity to more people in emerging markets, the Company expects it could see the greatest rate of growth of its health care businesses

5

in those markets. The table "Geographic Data" on page 40 of the 1996 Annual Report to Shareholders gives a breakdown of sales and other data by major geographic areas, and is incorporated herein by reference.

The Company's international businesses are subject, in varying degrees, to a number of risks inherent in carrying on business in certain countries, including possible nationalization, expropriation and other restrictive government actions such as capital regulations. In addition, the values of currencies change and can either favorably or unfavorably affect the Company's financial position and results of operations. It is impossible to predict future changes in foreign exchange values or the effect they will have on the Company. Further information with respect to the financial instruments used in the Company's risk management programs is incorporated by reference from the Notes entitled "Financial Instruments and Risk Management" and "Fair Value of Financial Instruments" beginning on page 46 of the 1996 Annual Report to Shareholders.

Patents and Intellectual Property Rights

Patent protection is of material importance in the Company's marketing in the United States and in most major foreign markets. Various patents owned by or licensed to the Company cover pharmaceutical and hospital products, pharmaceutical formulations, processes for manufacturing products, and intermediates useful in such manufacturing. Patent protection for individual products extends for varying periods in accordance with the date of patent filing or grant and the legal term of patents in the various countries where patent protection is secured. The protection afforded, which may also vary from country to country, depends upon the type of patent and the scope of its coverage.

While the expiration of a product patent normally results in the loss of marketing exclusivity for the covered product and a resulting dramatic reduction in sales, in some cases commercial benefits may continue to be derived from: (i) trade secret advantages pertaining to the manufacture of the product;
(ii) subsequent patents on processes and intermediates related to the economical manufacture of the active ingredients; (iii) patents relating to special formulations of the product or delivery mechanisms; and (iv) adaptation of the active ingredient to over-the-counter products. The effect of product patent expiration also depends upon other factors such as the nature of the market and the position of the product in it, the growth of the market, the complexities and economics of manufacture of the product, and the requirements of generic drug laws administered by the Food and Drug Administration and similar laws in other countries.

The Company owns or is licensed under a number of U.S. and foreign patents relating to its products and manufacturing processes which, in the aggregate, are of material importance in its businesses. Based on current product sales, and in view of the vigorous competition with products sold by others, the Company does not consider any single patent or related group of patents to be significant in relation to its business as a whole, except for the Procardia XL, Zithromax, Diflucan, Zoloft and Norvasc patents. Procardia XL (nifedipine GITS) employs a novel drug delivery system developed and patented by Alza Corporation. The Company holds an exclusive license to use this delivery system with nifedipine until 2003. Other forms of sustained-release nifedipine using different delivery systems from the patented technology used in Procardia XL have been approved or are reported to be in various stages of development by other companies. The one drug that has been approved has not been AB-rated by the FDA as therapeutically equivalent to Procardia XL. It is not possible to predict the timing and impact on sales of Procardia XL of competition from such products. Zithromax (azithromycin) is a novel, broad spectrum macrolide antibiotic patented by and sourced in crude bulk form from Pliva, a Croatian company that is one of the largest pharmaceutical companies in eastern Europe. Zithromax is exclusively licensed to the Company for sales and marketing in all major countries of the world. Pliva's U.S. patent on Zithromax expires in 2005. The Company's basic patents relating to Diflucan, Zoloft and Norvasc expire in the U.S. between 2004 and 2007. The patent on Cardura, the Company's alpha blocker for hypertension and benign prostatic hyperplasia, expires in 2000.

The Company's products are sold around the world under brand-name trademarks that are considered in the aggregate to be of material importance. Trademark protection continues in some countries as long as used; in other countries, as long as registered. Registrations generally are for fixed, but renewable, terms.

Competition in research, involving the development of new products and processes and the improvement of existing products and processes, is intense, and can result from time to time in unforecast patented product and process obsolescence as patient treatment therapies improve. The ongoing development of innovative new products, and the protection of the intellectual property behind those products, are important to the Company's success in all areas of its business.

6

Under international agreements over recent years, protection of intellectual property rights has been improving somewhat in emerging market nations. As noted above, the Company is experiencing the greatest rates of growth in its business in some of those nations. Its continued business in those countries is dependent to a large degree on continuing improvement of intellectual property rights. Pursuant to the North American Free Trade Agreement, Mexico improved its patent law to provide patent protection to pharmaceutical products. The General Agreement on Tariffs and Trade ("GATT") also requires countries to amend their intellectual property laws to provide patent protection for pharmaceutical products by the end of no more than a ten-year transition period. A number of countries are in this process of amending their patent laws. The Company is hopeful this will result eventually in strong enforcement of intellectual property rights in more international markets.

Neither the amounts paid by the Company for license rights, nor amounts received by the Company in connection with licenses granted by it to third parties, are considered material to the operations of the Company as a whole.

Competition

The competition is intense in all of the Company's business segments and includes many competitors. No single entity competes with the Company in all of its businesses, but each of the Company's businesses faces substantial competition in its respective markets. The principal methods of competition vary from one product category and business group to another, but technological innovation in efficacy, safety, patients' ease of use and cost effectiveness are the foundations of competitive advantage. The industry is noteworthy for its technological focus on unmet medical needs and improving therapies. This has led to the Company's multi-billion dollar research and development investments over the past decade.

In recent years, the comparison of the total cost of treatment therapies incorporating pharmaceuticals versus treatments for the same condition using other therapies has become an important basis of competition. Even breakthrough technologies are often marketed by comparing their total treatment cost with the costs of alternative therapies.

The Company's pharmaceutical sales organization has proven to be a valuable competitive asset. The ability of the Company's product representatives to reach the medical community and communicate information about the Company's products is important in responding to competitive efforts and launching new products.

The Company's Hospital Products Group faces intense competition in its markets. Many companies of various sizes and with various resources compete against practically all of the Company's products. Consolidations of complementary firms in this business have increased the market position of some competitors in recent years, but the Company has also broadened its product lines.

The principal methods of competition with respect to animal health products vary somewhat, but include product innovation, service, price, quality and effective transfer of technological advances to veterinary professionals and consumers through advertising and promotion. A substantial number of other companies manufacture and sell one or more competitive products. There are hundreds of producers of animal health products throughout the world.

Many other companies, large and small, manufacture and sell one or more products that are similar to the Company's consumer health products. The Company is a competitor in the OTC market, and its principal methods of competition include product quality, product innovation, customer satisfaction, broad distribution capabilities, significant advertising and promotion efforts and price. In general, achieving consumer acceptance of the Company's consumer products involves heavy expenditures for advertising, promotion and marketing.

In this environment of growing competitive pressures on profit margins, the Company has continued measures to control its expenses. Although research and development budgets have grown significantly, in other areas such as manufacturing, distribution and sales administration, the Company has restructured and consolidated facilities. These measures have been designed to adopt new manufacturing and logistics efficiencies and reduce or contain operating expenses. See the Note, "Restructuring Program" in the Notes to Consolidated Financial Statements on page 49 and the discussion in the second paragraph under the heading "Operating Activities" on page 35 of the 1996 Annual Report to Shareholders, which are incorporated herein by reference. In furtherance of such efforts, in 1996 the Company announced the consolidation of its previously separate U.S. and international pharmaceutical sales and operating divisions into a single unified "Pfizer Pharmaceuticals Group" and combined certain businesses in its Hospital Products Group.

7

Managed Care Organizations

The growth of Managed Care Organizations ("MCOs") in the past decade has been a major factor in the changing health care marketplace. Well over half the U.S. population now participates in some version of managed care. Marketing of prescription drugs to MCOs and Pharmacy Benefit Managers ("PBMs") that serve many of those organizations have become more and more important to the Company's business.

MCOs include medical insurance companies, health-maintenance organizations, alliances of physicians, and medical plan administrators. The market power of MCOs has been increasing in recent years due to the growing numbers of patients enrolled in these organizations. At the same time, these organizations have been consolidating into fewer, even larger entities. This further enhances their bargaining strength and importance as sales channels for the Company.

A major objective of MCOs is to contain and, where possible, reduce health care expenditures. Among other measures, they typically use volume and long-term contracts to negotiate discounts from pharmaceutical and medical device providers. They control cost by using their purchasing power to bargain for lower supplier prices, and by emphasizing primary and preventive care, out-patient treatment, and procedures performed at doctors' offices and clinics. Hospitalization and surgery, typically the most expensive forms of treatment, are carefully managed.

As a means of reducing their cost for medications and hospital products, MCOs and PBMs develop formularies, which are lists of products compiled by boards of physicians and pharmacists. Formularies can be based on the prices and therapeutic benefits of the available products. Due to their lower basic price, generic medicines may be favored. The breadth of the products covered by their formularies can vary considerably from one MCO to another, and many formularies include alternative and competitive products for treatment of particular medical problems. MCOs employ a variety of means to encourage the use of products listed on their formularies.

Exclusion of a product from a formulary can lead to sharply reduced usage of the product in the MCO patient population. Consequently, pharmaceutical and hospital products companies compete aggressively to have their products included on these formularies. Where possible, companies compete for inclusion based upon unique features of their products, such as greater efficacy, better patient ease of use or fewer side effects. A lower overall cost of therapy is also a method of competition. Products that demonstrate fewer therapeutic advantages must compete for inclusion based primarily on price.

In contrast to the effect MCOs have had on prices, they have also led to greater usage of some drugs. Certain drugs can avert the need for more costly treatments such as hospitalization, professional therapy, or even surgery, and become favored first-line treatments for MCOs. In addition, the trend of Medicare patients to opt for alternatives to those traditional programs and convert to forms of managed care may increase overall pharmaceutical usage among that population.

The effect of these developments has not only created pressure on prices, but also has raised volumes for products that are successful in being included on formularies. To date, the Company has been generally, although not universally, successful in having its products included on MCO formularies.

As another means of addressing the interests of MCOs, some pharmaceutical manufacturers, including the Company, have been developing disease management programs, which aid MCOs in managing their patient populations. These programs can help MCOs effectively address various aspects of certain disease categories, including prevention, diagnosis and treatment concomitant with pharmaceutical use. The programs can provide a comprehensive treatment program, including pharmaceutical products and communication tools for patients, that not only improves the quality of care but lowers costly complications of chronic diseases. Disease management programs can be attractive to MCOs by enhancing patient communications and compliance, which is important to effective treatment.

Generic Products

One of the biggest competitive challenges faced by the Company in the United States is posed by generic pharmaceutical manufacturers. Upon the expiration of patents on important products (such as Feldene in the U.S. in 1992) the Company can lose the major portion of U.S. sales of such products within a year. Generic competitors operate without the large research and development expenses that the Company bears. For example, the approximately $2 billion the Company expects to spend in 1997 on research to develop new and better medical treatments will constitute a significant

8

portion of its total expenses. Generic manufacturers do not incur most of these expenses, and generally can afford to charge much less for those products whose U.S. patent protection has expired.

As noted above, MCOs that focus merely on the immediate cost of drugs may favor generics to brand-name drugs. Governments also encourage the use of generics as alternatives to brand-name drugs for their Medicaid and Medicare programs. Laws in the U.S. generally allow, and in some cases require, pharmacists to substitute a generic drug that has been rated under appropriate government procedures to be therapeutically equivalent for a branded drug unless the prescribing physician expressly forbids the substitution in accordance with applicable procedures.

Further supporting generic competition, the FDA approval process often exempts generic drugs from costly and time-consuming clinical trials. Generics typically do not have to demonstrate their safety or efficacy, and need only demonstrate bio-equivalence to the pioneer drug to obtain approval. Some pharmaceutical firms that had concentrated solely on the manufacture of patented drugs have entered the generic market in recent years. Some offer generic versions of their own brand-name products. The Company has not followed that strategy, choosing instead to focus on developing and marketing innovative new products and treatments.

Raw Materials

Raw materials essential to the Company's businesses are purchased worldwide in the ordinary course of business from numerous suppliers. In general, these materials are widely available from multiple sources and no serious shortages or delays have been encountered, nor are any anticipated in 1997. There is a trend towards the development and use of more complicated pharmaceutical compounds, however, which may tend to increase manufacturing costs and plant and process development in the future.

Government Regulation and Price Constraints

Pharmaceutical and hospital products companies are subject to heavy regulation by a number of country, state and local agencies. Of particular importance is the Food and Drug Administration ("FDA") in the United States, which has jurisdiction bearing on all the Company's businesses. The FDA administers requirements covering the testing, approval, safety, effectiveness, manufacturing, labeling and marketing of pharmaceuticals and medical products. In some cases, FDA requirements and/or reviews have increased the amount of time and money necessary to develop new products and bring them to market in the United States. Such requirements can be costly and extend the time it takes to launch innovative new products.

The FDA also regulates consumer health and, along with the U.S. Department of Agriculture and the Environmental Protection Agency, animal health products. Certain regulatory actions pertaining to Company products are discussed in Item 3 herein.

In 1995, the new European Medicines Evaluation Agency ("EMEA") instituted a new "centralized" drug-approval process for the member states of the European Union ("EU"). This centralized procedure supplements the traditional decentralized approach and allows for a single central approval that is valid in all EU member countries. While it is expected that it will take several years for the EMEA to be fully operational, a harmonized, centralized regulatory agency in Europe could benefit the Company's businesses.

In recent years, various legislative proposals have been offered in Congress and in some state legislatures that would effect major changes in the health care system. Some states have passed such legislation, and further federal and state proposals are expected. These could include pharmaceutical price constraints and restrictions on access to certain products. Similar issues have also arisen in recent years in various foreign countries. The Company cannot predict the outcome of such initiatives, but will work to maintain patient access to its products and to oppose unwarranted pricing constraints.

Also in the U.S., additional proposals have called for substantial changes in the Medicare and Medicaid programs. If such changes are enacted, they may require significant reductions from currently projected expenditures. Driven by budget concerns, Medicaid managed care systems have been under consideration in several states. If the Medicare and Medicaid programs implement changes that severely restrict the access of a significant population of program participants to innovative new medicines, this could have a significant adverse effect on the Company. On the other hand, relatively little pharmaceutical use is currently covered by Medicare. As noted above, if changes to these programs shift patients to MCOs that cover pharmaceuticals, patient usage of pharmaceuticals potentially could increase.

9

Under existing legislation in the U.S. applicable to pharmaceutical companies, the Company is obliged to extend rebates to state Medicaid agencies based on each state's reimbursement of pharmaceutical products under the Medicaid program. The Company is also obliged to provide discounts on purchases of pharmaceutical products by the Department of Veterans Affairs and by certain entities funded by the Public Health Service. See the discussion regarding rebates on page 31 of the Company's 1996 Annual Report for details on the cost to the Company of such discounts and rebates, which is incorporated herein by reference.

The Company encounters similar regulatory and legislative issues in most of the foreign countries where it does business. Moreover, in many international markets, prices of pharmaceuticals are controlled by the government. As in the U.S., the primary thrust of governmental inquiry and action is toward determining drug safety and effectiveness, but also with mechanisms for controlling the prices of prescription drugs and the profits of prescription drug companies. The EU has adopted directives concerning the classification, labeling, advertising and wholesale distribution of medical products for human use. The Company's policies and procedures are already consistent with the substance of these directives. Consequently, it is believed that they will not have any material effect on the Company's business.

The Company is also subject to the jurisdiction of various other regulatory agencies, such as the Federal Trade Commission in the U.S., and is, therefore, subject to potential administrative proceedings and actions by those agencies. Such actions may include product recalls and seizures and other civil and criminal sanctions. Under certain circumstances, the Company has deemed it advisable to initiate product recalls voluntarily.

Although it is difficult to predict the future effect of these broad and expanding legislative and regulatory requirements, the Company believes that its development of new and improved products should enable it to compete effectively within this environment. See, also, the discussion below under the heading "Environmental Law Compliance."

Environmental Law Compliance

Most of the Company's manufacturing and certain research operations are affected by federal, state and local laws relating to the discharge of materials into the environment or otherwise relating to the protection of the environment. The Company has made and intends to continue to make the necessary expenditures for compliance with these laws. The Company is also remediating environmental contamination resulting from past industrial activity at certain sites (see Item 3, "Legal Proceedings"). As a consequence, the Company incurred capital and operational expenditures in 1996 for environmental protection and remediation of certain past industrial activity as follows: environment-related capital expenditures, $42 million; other environmental-related expenses, $56 million. While it is not feasible to predict with certainty the future costs related to such remediation activities or capital expenditures and operating costs for such environmental compliance, the Company does not believe that they will have a material effect on the capital expenditures, earnings or competitive position of the Company.

Corporate/Financial Subsidiaries

The Company conducts international banking operations through a subsidiary, Pfizer International Bank Europe ("PIBE"), based in Dublin, Ireland. PIBE, incorporated under the laws of Ireland, operates under a banking license from the Central Bank of Ireland. It makes loans and accepts deposits in a number of currencies in international markets. PIBE is an active Euromarket lender through its portfolio of loans and money market instruments to high quality corporations and sovereigns. Loans are made on a short and medium term basis, typically with floating market-based interest rates. The Company also owns an insurance operation, The Kodiak Company Limited, which reinsures certain assets, inland transport and marine cargo of the Company's international operations. Combined financial data and segment information for these subsidiaries are set out in the Note "Financial Subsidiaries" on page 46 of the Company's 1996 Annual Report to Shareholders, and are incorporated herein by reference.

Tax Matters

The discussions of tax-related matters (including certain U.S. and overseas assessments relating to prior years) set out under the heading "Tax Legislation" in the Financial Review section on page 37 of the Company's 1996 Annual Report to

10

Shareholders and under the Note therein entitled "Taxes on Income" in the Notes to the Consolidated Financial Statements on pages 49 and 50 of the Annual Report are incorporated herein by reference. The proposed IRS adjustments relating to the tax accounting treatment of certain swaps and related transactions undertaken by the Company in 1987 and 1988 have been settled with no material effect on the financial position or the results of operations of the Company.

Employees

In the Company's innovation-intensive business, the performance of its employees is the foundation to its success. As of December 31, 1996, the Company employed approximately 46,500 persons in its operations throughout the world. Geographically, this total breaks down as follows: United States, 19,400; Europe, 13,300; Asia, 7,300; Canada/Latin America, 5,000; and Africa/Middle East, 1,500. The Company has a good relationship with its employees.

CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS
(Cautionary Statements Under the Private Securities Litigation Reform Act of 1995)

The disclosure and analysis set forth herein and in the Company's 1996 Annual Report to Shareholders contain certain forward-looking statements, particularly statements relating to future actions, performance or results of current and anticipated products, sales efforts, expenditures, and financial results. From time to time, the Company also provides forward-looking statements in other publicly-released materials, both written and oral. Forward-looking statements provide current expectations or forecasts of future events such as new products, product approvals, revenues and financial performance. These statements are identified as any statement that does not relate strictly to historical or current facts. They use words such as "plans", "expects", "will" and other words and phrases of similar meaning. In all cases, a broad variety of risks and uncertainties, both known and unknown, as well as inaccurate assumptions can affect the realization of the expectations or forecasts in those statements. Consequently, no forward-looking statement can be guaranteed. Actual future results may vary materially.

The Company undertakes no obligation to update any forward-looking statements, but investors are advised to consult any further disclosures by the Company on this subject in its subsequent filings pursuant to the Securities Exchange Act of 1934. Furthermore, as permitted by the Private Securities Litigation Reform Act of 1995, the Company provides these cautionary statements identifying factors that could cause the Company's actual results to differ materially from expected and historical results. It is not possible to foresee or identify all such factors. Consequently, this list should not be considered an exhaustive statement of all potential risks, uncertainties and inaccurate assumptions.

In the U.S., many of the Company's pharmaceutical products are subject to increasing price pressures as managed care groups, institutions and government agencies seek price discounts. Federal and state government efforts to reduce Medicare and Medicaid expenses are expected to increase the use of managed care and to offer incentives to beneficiaries to join these plans. This may result in managed care influencing prescription decisions for a larger segment of the population. International operations are also subject to increasing degrees of government regulations. It is expected that pressures on pricing and operating results will continue in 1997 as a result of market competition and environment.

The Company's products Feldene and Glucotrol have been subject to generic competition since 1992 and 1994, respectively. The combined U.S. net sales of these products were $59, $95 and $203 million in 1996, 1995 and 1994, respectively.

In mid-1993, the FDA approved a New Drug Application for a competitor's sustained-release form of nifedipine for the treatment of hypertension. This product uses a different delivery system from the patented technology used in Procardia XL, the Company's product, which is approved for the treatment of hypertension and angina and has a delivery system that is patent-protected until 2003. Other forms of sustained-release nifedipine have been reported to be in various stages of development by other companies. It is not possible to predict the timing and impact of possible future competition on sales of Procardia XL. Net sales of Procardia XL were $1,005 million in 1996, $1,133 million in 1995, and $1,177 million in 1994.

During 1995, the authors of several nonclinical studies questioned the safety of calcium channel blockers, including the Company's immediate-release nifedipine capsules. Although the clinical evidence supported the safety of these medications, the FDA convened an advisory panel to review their safety. In January 1996, the advisory panel recommended that labeling for immediate-release nifedipine capsules (approved only to treat a form of angina) be clarified. However, the advisory panel specifically noted that there were no data which questioned the safety of the newer sustained-release and intrinsically

11

long-acting calcium channel blockers, such as the Company's Procardia XL and Norvasc, which are approved for both hypertension and angina and are prescribed for the vast majority of American patients on calcium channel blockers. The safety and effectiveness of these new long-acting calcium channel blockers in lowering blood pressure and controlling angina are supported by a large body of data from numerous studies and the daily clinical experiences of physicians around the world. It is not possible to predict the impact, if any, of these nonclinical studies or the FDA panel's findings and recommendations on its future sales, but the Company does not believe that any impact will have a material adverse effect on its financial position or results of operations.

Sales and earnings growth could be impacted by changes in foreign exchange rates. The Company manages its foreign exchange risk through a variety of techniques. For further details, see the footnote "Financial Instruments and Risk Management" beginning on page 46 of the 1996 Annual Report to Shareholders.

Pursuant to the Small Jobs Protection Act of 1996, Section 936 of the Internal Revenue Code (the possessions corporation income tax credit) was repealed for tax years beginning after December 31, 1995. That Act provided that existing credit claimants, such as the Company, are eligible to continue using the credit against the tax arising from manufacturing income earned in a U.S. possession for an additional ten-year period. The amount of manufacturing income eligible for the credit during this additional period is subject to a cap based on prior years' income earned by the Company in Puerto Rico. This ten-year extension period does not apply to investment income earned in a possession, the credit on which expired as of July 1, 1996. This legislation does not affect the amendments made to Section 936 by the Omnibus Budget Reconciliation Act of 1993 which provided for a five-year phase-down of the possession tax credit from 100% to 40%. In addition, the 1996 Act extended the R&D tax credit for eleven months effective July 1, 1996.

In October 1996, the Accounting Standards Executive Committee of the American Institute of Certified Public Accountants issued Statement of Position ("SOP") 96-1, Environmental Remediation Liabilities, which will be effective in 1997. SOP 96-1 provides guidance on accounting for the recognition, measurement, display and disclosure of environmental liabilities. The Company's adoption of SOP 96-1 is not expected to have a material impact on its financial position, results of operations, or cash flows.

In July 1996, the Emerging Issues Task Force of the Financial Accounting Standards Board reached a consensus on Issue 96-14, Accounting for the Costs Associated with Modifying Computer Software for the Year 2000, which provides that costs associated with modifying computer software for the year 2000 be expensed as incurred. The Company is assessing the extent of the necessary modifications to its computer software.

Issuance of new or revised accounting standards and rules in addition to those specified above could affect reported financial results.

Risks and uncertainties particularly apply with respect to product-related forward-looking statements. In view of the many considerations that bear upon regulatory approval and marketing of pharmaceutical and hospital products around the world, it is always possible that current expectations in these areas may not be realized. The outcome of the lengthy and complex process of new product development is inherently uncertain. A candidate can fail at any stage of the process and one or more late-stage product candidates could fail to receive regulatory approval. Regulatory delays, the inability to identify viable new chemical compounds or successfully complete clinical trials, claims and concerns about safety and efficacy, new discoveries and products by competitors, and claims about adverse side effects are a few of the factors that could adversely affect the realization of product-related forward-looking statements.

Difficulties or delays in pharmaceutical product manufacturing or marketing including, but not limited to, the inability to build up production capacity commensurate with demand, or the failure to gain market acceptance of approved products could affect future results. Similar difficulties or delays can also affect the development of the Company's other businesses, namely hospital products, animal health and consumer health care.

The Company currently has several products whose annual sales approach or exceed one billion dollars. Three products alone (Norvasc, Procardia XL and Zoloft) accounted for approximately half of the Company's 1996 pharmaceutical sales. If any of the Company's major products were to become subject to a controversy that affects doctor or patient confidence, or subject to increased pressure from competitive products, or if a new, more effective treatment regimen should be introduced, the impact on the Company's revenues could be significant.

12

As discussed above under the heading "Marketing", decisions about research studies made early in the development process of a drug candidate can have a substantial impact on marketing strategy once it receives approval. The Company endeavors to plan clinical trials prudently, but there is no guarantee that a proper balance of speed and testing will be made in each case.

Factors mentioned in the discussions above about product obsolescence, generic competition, marketing issues, government regulations and the competitive environment generally will be important to future results.

Changing business conditions, including inflation and fluctuations in interest rates and foreign currency exchange rates, in the many countries where the Company does business directly or through subsidiaries will affect future results. For example, in 1997, in accordance with generally accepted accounting principles, the Company will change the functional currency of its Mexican operations to the U.S. dollar since the cumulative rate of Mexico's inflation exceeded 100% for the three-year period ending December 31, 1996. This change is not expected to have a material effect on the Company's financial position or results of operations.

Competitive factors including managed care organizations, institutions, government agencies and retailers seeking price discounts, technological advances attained by competitors, patents granted to competitors, and generic competition as the Company's products mature, could affect prices, revenues and expenses.

Government laws and regulations affecting domestic and international operations, including trade, monetary and fiscal policies, taxes, price controls, unstable governments and legal systems and intergovernmental disputes, possible nationalization, as well as actions affecting approvals of products and licensing could affect revenue opportunities, expenses and capital movements.

Growth in costs and expenses, changes in product mix and the impact of divestitures, restructuring and other unusual items that could result from evolving business strategies, evaluation of asset realization, and organizational restructuring could affect future results. For example, the Company may be unable to continue or maintain the margin improvements achieved in recent years.

Changing governmental or social conditions could affect utilization of some Company products.

Claims have been brought against the Company and its subsidiaries for various legal, environmental and tax matters. In addition, the Company's operations are subject to international, federal, state and local environmental laws and regulations. See the discussion of "Legal Proceedings" in Item 3 and the tax assessment discussion in Item 1 under the caption "Tax Matters", and updates of such matters in subsequent reports to the SEC.

Business combinations among the Company's competitors could affect the Company's competitive position in the pharmaceutical, hospital products, animal health and consumer health care businesses. Similarly, combinations among the Company's major customers could increase their purchasing power in dealing with the Company.

Investments in new product introductions and research could exceed corresponding sales growth, thereby producing higher costs without a proportional increase in revenues.

ITEM 2. PROPERTIES

The Company's world headquarters are located in New York City, comprised of a 33-story office building plus adjacent and nearby buildings. Altogether, they include over one million square feet of office space, the majority of which is owned.

The Company's major research and development facilities are located in manufacturing/R&D complexes containing multiple buildings in Groton, Connecticut and Sandwich, England. The Groton and Sandwich facilities, respectively, contain over three million square feet and several hundred thousand square feet of floor space. Other important research facilities are located in Japan and France. A number of smaller research and development operations around the world focus principally on their local markets. Research and development facilities have been expanding in recent years.

13

Principal manufacturing facilities within the United States and its territories are located in Groton, Connecticut; Brooklyn, New York; Vigo County, Indiana; Barceloneta, Puerto Rico; Lee's Summit, Missouri; Lincoln, Nebraska and Parsippany and Rutherford, New Jersey. Outside the U.S., major manufacturing facilities are located in a number of locations in Europe, Latin America, Asia, Australia and Canada. Smaller plants in the U.S. and various countries serve local or specialized markets. The Company's manufacturing facilities have capacities that the Company considers appropriate to its needs.

The Company also owns and leases space for distribution, customer-service, sales and marketing and administrative operations around the world. Most facilities housing research and manufacturing are owned. In general, the Company's properties are well maintained, adequate and suitable to their purposes. For example, a modern distribution facility in Memphis, Tennessee consolidated that function and serves the U.S. through advanced systems. The Note "Property, Plant and Equipment" on page 48 of the Company's Annual Report to Shareholders, which discloses amounts invested in land, buildings and equipment, and the discussion in the third paragraph under the heading "Investing Activities" on page 35 of that Report, which describes capital expenditures of the Company, are incorporated herein by reference. See, also, the discussion under the Note entitled "Lease Commitments" on page 52 of the Company's 1996 Annual Report to Shareholders, which is also incorporated herein by reference.

ITEM 3. LEGAL PROCEEDINGS

The Company is involved in a number of claims and litigations, including product liability claims and litigations considered normal in the nature of its businesses. These include suits involving various pharmaceutical and hospital products that allege either reaction to or injury from use of the product.

As previously disclosed, numerous claims have been brought against the Company and Shiley Incorporated, a wholly owned subsidiary, alleging either personal injury from fracture of 60 degree or 70 degree Shiley Convexo Concave ("C/C") heart valves, or anxiety that properly functioning implanted valves might fracture in the future, or personal injury from a prophylactic replacement of a functioning valve.

In an attempt to resolve all claims alleging anxiety that properly functioning valves might fracture in the future, the Company entered into a settlement agreement in January 1992 in Bowling v. Shiley, et al., a case brought in the United States District Court for the Southern District of Ohio, that establishes a worldwide settlement class of people with C/C heart valves and their spouses, except those who elect to exclude themselves. The settlement provides for a Consultation Fund of $90 to $140 million (depending on the number of claims filed) from which valve recipients who make claims will receive payments that are intended to cover their cost of consultation with cardiologists or other health care providers with respect to their valves. The number of claims filed fixes the fund amount at $90 million. The settlement agreement establishes a second fund of at least $75 million to support C/C valve-related research, including the development of techniques to identify valve recipients who may have significant risk of fracture, and to cover the unreimbursed medical expenses that valve recipients may incur for certain procedures related to the valves. The Company's obligation as to coverage of these unreimbursed medical expenses is not subject to any dollar limitation. Following a hearing on the fairness of the settlement, it was approved by the court on August 19, 1992. An appeal of the court's approval of the settlement was dismissed on December 21, 1993 by the United States Court of Appeals for the Sixth Circuit. A motion for rehearing en banc was denied on March 4, 1994, and the U.S. Supreme Court denied a writ of certiorari on October 3, 1994. On August 8, 1994, the Sixth Circuit dismissed an appeal from the denial of a motion by the same appellants to vacate the judgment approving the settlement, and the U.S. Supreme Court denied a writ of certiorari on January 9, 1995. Another appeal to the Sixth Circuit by the same appellants regarding the denial of their earlier motion to intervene affirmed the denial and all judgments entered by the District Court, and denied all pending motions, on December 16, 1996. A motion for a rehearing en banc before the Sixth Circuit filed by the same appellants was denied. It is expected that most of the costs arising from the Bowling class settlement will be covered by insurance and the proceeds of the sale of certain product lines of the Shiley businesses in 1992. Of approximately 900 implantees (and spouses of some of them) who opted out of the Bowling settlement class, eight have cases pending; approximately 792 have been resolved; and approximately 100 have never filed a case or claim.

Several claims relating to elective reoperations of valve recipients are currently pending. Some of these claims relate to elective reoperations covered by the Bowling class settlement described above, and, therefore, the claimants are entitled to certain benefits in accordance with the settlement. Such claimants, if they irrevocably waive all of the benefits of the settlement, may pursue separate litigation to recover damages in spite of the class settlement. The Company is defending these claims.

14

Generally, the plaintiffs in all of the pending heart valve litigations discussed above seek money damages. Based on the experience of the Company in defending these claims to date, including available insurance and reserves, the Company is of the opinion that these actions should not have a material adverse effect on the financial position or the results of operations of the Company.

On September 30, 1993, Dairyland Insurance Co., a carrier providing excess liability coverage ("excess carrier") in the early 1980s, commenced an action in the California Superior Court in Orange County, seeking a declaratory judgment that it was not obligated to provide insurance coverage for Shiley heart valve liability claims. On October 8, 1993, the Company filed cross-complaints against Dairyland and filed third-party complaints against 73 other excess carriers who sold excess liability policies covering periods from 1979 to 1985, seeking damages and declaratory judgments that they are obligated to pay for defense and indemnity to the extent not paid by other carriers. A significant portion of such claims has been resolved and the remainder is involved in pretrial discovery. On April 26, 1996, the trial court entered an order stating that implanting an allegedly defective heart valve is not an appropriate trigger of insurance coverage in at least one and perhaps all working valve lawsuits. This decision, even if it is applied to all claims alleging anxiety that properly functioning valves might fracture in the future, does not deal with fracture claims, which are also part of the Company's claims, and as to which a further motion by the carriers is pending.

The Company's operations are subject to federal, state, local and foreign environmental laws and regulations. Under the Comprehensive Environmental Response Compensation and Liability Act of 1980, as amended ("CERCLA" or "Superfund"), the Company has been designated as a potentially responsible party by the United States Environmental Protection Agency with respect to certain waste sites with which the Company may have had direct or indirect involvement. Similar designations have been made by some state environmental agencies under applicable state superfund laws. Such designations are made regardless of the extent of the Company's involvement. There are also claims that the Company may be a responsible party or participant with respect to several waste site matters in foreign jurisdictions. Such claims have been made by the filing of a complaint, the issuance of an administrative directive or order, or the issuance of a notice or demand letter. These claims are in various stages of administrative or judicial proceedings. They include demands for recovery of past governmental costs and for future investigative or remedial actions. In many cases, the dollar amount of the claim is not specified. In most cases, claims have been asserted against a number of other entities for the same recovery or other relief as was asserted against the Company. The Company is currently participating in remedial action at a number of sites under federal, state, local and foreign laws.

To the extent possible with the limited amount of information available at this time, the Company has evaluated its responsibility for costs and related liability with respect to the above sites and is of the opinion that the Company's liability with respect to these sites should not have a material adverse effect on the financial position or the results of operations of the Company. In arriving at this conclusion, the Company has considered, among other things, the payments that have been made with respect to the sites in the past; the factors, such as volume and relative toxicity, ordinarily applied to allocate defense and remedial costs at such sites; the probable costs to be paid by the other potentially responsible parties; total projected remedial costs for a site, if known; existing technology; and the currently enacted laws and regulations. The Company anticipates that a portion of these costs and related liability will be covered by available insurance.

Through the early 1970s, Pfizer Inc. (Minerals Division) and Quigley Company, Inc. ("Quigley"), a wholly owned subsidiary, sold a minimal amount of one construction product and several refractory products containing some asbestos. These sales were discontinued thereafter. Although these sales represented a minor market share, the Company has been named as one of a number of defendants in numerous lawsuits. These actions, and actions related to the Company's sale of talc products in the past, claim personal injury resulting from exposure to asbestos-containing products, and nearly all seek general and punitive damages. In these actions, the Company or Quigley is typically one of a number of defendants, and both are members of the Center for Claims Resolution (the "CCR"), a joint defense organization of twenty defendants that is defending these claims. The Company and Quigley are responsible for varying percentages of defense and liability payments for all members of the CCR. Prior to September 1990, the cases involving talc products were defended by the CCR, but the Company is now overseeing its own defense of these actions. A number of cases alleging property damage from asbestos-containing products installed in buildings have also been brought against the Company.

On January 15, 1993, a class action complaint and settlement agreement were filed in the United States District Court for the Eastern District of Pennsylvania involving all personal injury claims by persons who have been exposed to asbestos-containing products but who have not yet filed a personal injury action against the members of the CCR (Future Claims Settlement). The Future Claims Settlement agreement establishes a claims-processing mechanism that will provide historic settlement values upon proof of impaired medical condition as well as claims-processing rates over ten years. In addition,

15

the shares allocated to the CCR members eliminate joint and several liability. The court has determined that the Future Claims Settlement is fair and reasonable. Subsequently, the court entered an injunction enforcing its determination. Plaintiffs filed an appeal from that injunction in the United States Court of Appeals for the Third Circuit and on May 10, 1996, a panel of the Third Circuit reversed the order of the District Court and directed that the preliminary injunction be vacated. Although the Third Circuit subsequently denied the motion of the CCR members including the Company and Quigley, for rehearing of that determination, it agreed to stay its mandate while review is sought in the United States Supreme Court. On November 1, 1996, the United States Supreme Court granted a writ of certiorari to hear the appeal, which was argued February 18, 1997. In the event that the Future Claims Settlement is not upheld, it is not expected to have a material impact on the Company's exposure or on the availability of insurance for the vast majority of such cases. It is expected, too, that the CCR will attempt to resolve such cases outside of the Future Claims Settlement in the same manner as heretofore.

At approximately the time it filed the Future Claims Settlement class action, the CCR settled approximately 16,360 personal injury cases on behalf of its members, including the Company and Quigley. The CCR has continued to settle remaining and opt-out cases and claims on a similar basis to past settlements. The total pending number of active personal injury claims, exclusive of those covered by the Future Claims Settlement preliminary injunction and those which are inactive or have been settled in principle as of December 28, 1996, is 11,415 asbestos cases against Quigley; 3,882 asbestos cases against the Company; and 68 talc cases against the Company.

Costs incurred by the Company in defending the asbestos personal injury claims and the property damage claims, as well as settlements and damage awards in connection therewith, are largely insured against under policies issued by several primary insurance carriers and a number of excess carriers.

The Company believes that its costs incurred in defending and ultimately disposing of the asbestos personal injury claims, whether or not the Future Claims Settlement is eventually upheld, as well as the property damage claims, will be largely covered by insurance policies issued by carriers that have agreed to provide coverage, subject to deductibles, exclusions, retentions and policy limits. In connection with the Future Claims Settlement, the defendants commenced a third-party action against their respective excess insurance carriers that have not agreed to provide coverage seeking a declaratory judgment that (a) the Future Claims Settlement is fair and reasonable as to the carriers; (b) the carriers had adequate notice of the Future Claims Settlement; and (c) the carriers are obligated to provide coverage for asbestos personal injury claims. Even if the Future Claims Settlement is not eventually upheld, it is expected that the insurance coverage action against the insurance carriers that have not agreed to provide coverage for asbestos personal injury claims will be pursued. Based on the Company's experience in defending the claims to date and the amount of insurance coverage available, the Company is of the opinion that the actions should not ultimately have a material adverse effect on the financial position or the results of operations of the Company.

The United States Environmental Protection Agency - Region I and the Department of Justice have informed the Company that the federal government is contemplating an enforcement action arising primarily out of a December 1993 multimedia environmental inspection, as well as certain state inspections, of the Company's Groton, Connecticut facility. The Company is engaged in discussions with the governmental agencies and does not believe that an enforcement action, if brought, will have a material adverse effect on the financial position or the results of operations of the Company.

The Company has been named, together with numerous other manufacturers of brand name prescription drugs and certain companies that distribute brand name prescription drugs, in suits in federal and state courts brought by various groups of retail pharmacy companies. The federal cases consist principally of a class action by retail pharmacies (including approximately 30 named plaintiffs)(the "Federal Class Action"), as well as additional actions by approximately 3,500 individual retail pharmacies and a group of chain and supermarket pharmacies (the "individual actions"). These cases, which have been transferred to the United States District Court for the Northern District of Illinois and coordinated for pretrial purposes, allege that the defendant drug manufacturers violated the Sherman Act by unlawfully agreeing with each other (and, as alleged in some cases, with wholesalers) not to extend to retail pharmacy companies the same discounts allegedly extended to mail order pharmacies, managed care companies and certain other customers, and by unlawfully discriminating against retail pharmacy companies by not extending them such discounts. On November 15, 1994, the federal court certified a class (the Federal Class Action) consisting of all persons or entities who, since October 15, 1989, bought brand name prescription drugs from any manufacturer or wholesaler defendant, but specifically excluding government entities, mail order pharmacies, HMOs, hospitals, clinics and nursing homes. Fifteen manufacturer defendants, including the Company, agreed to settle the Federal Class Action subject to court approval. The Company's share pursuant to an Agreement as of January 31, 1996, was $31.25 million, payable in four annual installments without interest. The Company continues to believe that there was no conspiracy and specifically denied liability in the Settlement Agreement,

16

but had agreed to settle to avoid the monetary and other costs of litigation. The settlement was filed with the Court on February 9, 1996 and went through preliminary and final fairness hearings. By orders of April 4, 1996, the Court:
(1) rejected the settlement; (2) denied the motions of the manufacturers (including the Company) for summary judgment; (3) granted the motions of the wholesalers for summary judgment; and (4) denied the motion to exclude purchases by other than direct purchasers. The decision on the wholesalers has been made final, and been appealed. The decision on the indirect purchasers has been certified, and accepted, for appeal. The Court has put off setting a trial date while these matters are pending.

In May 1996, thirteen manufacturer defendants, including the Company, entered into an Amendment to the Settlement Agreement which was filed with the Court on May 6, 1996. The Company's financial obligations under the Settlement Agreement will not be increased. The Settlement Agreement, as amended, received final approval June 21, 1996. An appeal of that approval is pending.

In addition, consumer class actions have been filed in state courts and the District of Columbia, alleging injury to consumers as well as retail pharmacies from the failure to give discounts to retail pharmacy companies. Both a consumer class and a retailer class have been certified in separate California actions. Consumer class actions filed in Colorado, New York and Washington have been dismissed; Washington and New York are now on appeal. The Company was dismissed from a consumer class action in Wisconsin. Consumer class actions are also pending in Alabama, Arizona, Florida, Kansas, Maine, Michigan, Minnesota and the District of Columbia. On February 3, 1997, the District Court for the District of Columbia certified a limited consumer class. Retailer class actions are also pending in Alabama and Minnesota.

The Company believes that these brand name prescription drug antitrust cases, which generally seek damages and certain injunctive relief, are without merit, and has moved to have them dismissed.

The Federal Trade Commission is conducting an investigation focusing on the pricing practices at issue in the above pharmacy antitrust litigation. In July 1996, the Commission issued a subpoena for documents to the Company, among others, to which the Company has responded.

Schneider (USA) Inc. and Schneider (Europe) AG have been named, together with Advanced Cardiovascular Systems, Inc., in a federal antitrust action brought on January 2, 1996, by Boston Scientific Corporation and SciMed Life Systems, Inc. (a subsidiary of Boston Scientific) in the U.S. District Court, District of Massachusetts. The suit alleges that the defendants unlawfully obtained and enforced certain patents covering rapid exchange angioplasty catheters and conspired against the plaintiffs by, among other allegations, their settlement of patent infringement litigation in December of 1991. The suit seeks unspecified treble damages and injunctive relief. The Company believes that the case is without merit, and has moved to have it dismissed.

FDA administrative proceedings relating to Plax are pending, principally an industry-wide call for data on all anti-plaque products by the FDA. The call for data notice specified that products that have been marketed for a material time and to a material extent may remain on the market pending FDA review of the data, provided the manufacturer has a good faith belief that the product is generally recognized as safe and effective and is not misbranded. The Company believes that Plax satisfied these requirements and prepared a response to the FDA's request, which was filed on June 17, 1991. This filing, as well as the filings of other manufacturers, is still under review and is currently being considered by an FDA Advisory Committee.

On January 15, 1997, an action was filed in Circuit Court, Chambers County, Alabama, and certified by an ex parte order as a class action, purportedly on behalf of a class of consumers, variously defined by the laws or types of laws governing their rights and encompassing residents of up to 47 states. The complaint alleges that the Company's claims for Plax were untrue, entitling them to a refund of their purchase price for purchases since 1988. The action was removed to the U.S. District Court for the Northern District of Alabama, which vacated the class certification order. A motion to remand to state court is pending. The Company believes the complaint is without merit.

In April 1996, the Company received a Warning Letter from the FDA relating to the timeliness and completeness of required post marketing reports for pharmaceutical products. The letter did not raise any safety issue about Pfizer drugs. The Company has been implementing remedial actions designed to remedy the issues raised in the letter.

In August 1996, the Company received a Warning Letter from the FDA relating to certain promotional materials used in the marketing of Zoloft. The Company has been in communication with the FDA on this matter and the discussions are proceeding. Two purported consumer class actions involving Zoloft were filed, in Circuit Court, Dallas County, Texas, on

17

December 3, and in Superior Court, San Diego County, California, on December 26, 1996. Each complaint alleges that Pfizer's promotional materials improperly implied that the FDA had approved Zoloft as safe and effective for certain indications, and that patients for whom Zoloft was prescribed as a result of the promotion were entitled to a refund of their purchase price. Both suits have been removed to federal court; the plaintiffs in the Texas suit have moved to remand the case to state court. The Company believes the suits are without merit.

A consolidated class action on behalf of persons who allegedly purchased Pfizer common stock during the March 24, 1989 through February 26, 1990 period is pending in the U.S. District Court for the Southern District of New York. This lawsuit, which commenced on July 13, 1990, alleges that the Company and certain officers and former directors and officers violated federal securities law by failing to disclose potential liability arising out of personal injury suits involving Shiley heart valves and seeks damages in an unspecified amount. Even though it is believed that this suit is without merit, in order to avoid the monetary and other costs of litigation, the Company has entered into an agreement to settle this action for $9.75 million, subject to a court determination of the fairness of the settlement. Following a fairness hearing held December 13, 1996, the court affirmed the settlement and dismissed the action. A derivative action commenced on April 2, 1990 against certain directors and officers and former directors and officers alleging breaches of fiduciary duty and other common law violations in connection with the manufacture and distribution of Shiley heart valves is pending in the Superior Court, Orange County, California. The complaint seeks, among other forms of relief, damages in an unspecified amount. Even though it is believed that the suit is without merit, in order to avoid the monetary and other costs of litigation, the Company has entered into an agreement to settle this action by way of a $15 million payment by the Company's insurance carrier to the Company with an attorneys' fee to be paid by the Company out of the proceeds of the settlement to the shareholders' attorneys who brought the case. The settlement is subject to court approval and a fairness hearing is scheduled for April 11, 1997.

A purported class action entitled Bradshaw v. Pfizer Inc. and Howmedica Inc. is pending in the U.S. District Court, Northern District of Ohio. The action sought monetary and injunctive relief, including medical monitoring, on behalf of patients implanted with the Howmedica P.C.A. one-piece acetabular hip component, which was manufactured by Howmedica from 1983 to 1990. The complaint alleges that the prostheses were defectively designed and manufactured and posed undisclosed risks to implantees. The federal magistrate judge has recommended that the district court deny the plaintiffs' motion to certify the case as a class action. The Company believes that the suit is without merit. On February 4, 1997, the Company was served with fifteen separate actions in the United States District Court for the District of New Jersey, brought by some of the same individuals previously identified as members of the purported class in the Bradshaw action, represented by the same lawyers, and making the same allegations. The Company believes that most if not all of these cases are without merit.

The Company and/or Howmedica, along with other device manufacturers and numerous orthopedic surgeons, have been named as defendants in approximately 700 cases (among over 1,600 pending) in numerous state and federal courts seeking damages relating to alleged improper design, manufacture, and/or promotion of bone screws for unapproved use in spinal pedicles. Neither Howmedica nor the Company manufactured or sold pedicle screws in the U.S., but the claims allege a conspiracy among all of the defendants to over-promote the devices. The federal cases have been consolidated by the Multidistrict Panel in the U.S. District Court in Philadelphia, which ruled on April 8, 1996 that all claims against the manufacturers except express warranty and improper promotion are preempted. The recent decisions of the United States Supreme Court in Lohr v. Medtronic may impact the availability of the pre-emption defense in this case (and in other medical device cases). The Company believes the cases are without merit and during the fourth quarter over 150 of the cases against Howmedica and/or the Company have been dismissed, leaving a year-end total of 617.

From 1994 to 1995, seven purported class actions were filed against American Medical Systems ("AMS") in federal courts in South Carolina (subsequently transferred to Minnesota), California, Minnesota (2), Indiana, Ohio and Louisiana. The California, Ohio and Indiana suits and one Minnesota suit also name Pfizer Inc. as a defendant, based on its ownership of AMS. The suits seek monetary and injunctive relief on the basis of allegations that implantable penile prostheses are prone to unreasonably high rates of mechanical failure and/or various autoimmune diseases as a result of silicone materials. On September 30, 1994, the federal Judicial Panel on Multidistrict Litigation denied the various plaintiffs' motions to consolidate or coordinate the cases for pretrial proceedings. On February 28, 1995, the Court in the Ohio suit conditionally granted plaintiffs' motion for class certification; on March 3, 1995, the court in the California suit denied plaintiffs' motion for class certification; and on October 25, 1995, the court in the Indiana suit denied plaintiffs' motion for class certification; on February 15, 1996, the United States Court of Appeals for the Sixth Circuit reversed the Ohio Court's conditional certification; on May 15, 1996, the purported Minnesota class actions were dismissed without prejudice (following which plaintiffs' counsel have filed several actions in Minnesota State Court on behalf of over 200 individuals); and a motion to

18

strike the class allegations in the Louisiana case was granted by the Court on July 23, 1996. The Company believes the suits are without merit.

During late 1996, over 300 individual suits alleging injuries from penile implants were filed in Circuit Court in Minneapolis by individuals who were allegedly members of one or more of the discontinued purported class actions described above and/or who are represented by the same lawyers. The Company believes that most if not all of these cases are without merit.

In June 1993, the Ministry of Justice of the State of Sao Paulo, Brazil commenced a civil public action against the Company's Brazilian subsidiary, Laboratorios Pfizer Ltda. ("Pfizer Brazil") asserting that during a period in 1991, Pfizer Brazil withheld sale of the pharmaceutical product Diabinese in violation of antitrust and consumer protection laws. The action seeks the award of moral, economic and personal damages to individuals and the payment to a public reserve fund. On February 8, 1996, the trial court issued a decision holding Pfizer Brazil liable. The award of damages to individuals and the payment into the public reserve fund will be determined in a subsequent phase of the proceedings. The trial court's opinion sets out a formula for calculating the payment into the public reserve fund which could result in a sum of approximately $88 million. The total amount of damages payable to eligible individuals under the decision would depend on the number of persons eventually making claims. Pfizer Brazil is appealing this decision. The Company believes that this action is without merit and should not have a material adverse effect on the financial position or the results of operations of the Company.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

Not applicable.

19

EXECUTIVE OFFICERS OF THE COMPANY

The following executive officers of the Company as of March 10, 1997 hold the offices indicated until their successors have been chosen and qualified after the next annual meeting of shareholders.

Name                                         Age                                Position
- ----                                         ---                                --------
Brian W. Barrett                             57             Vice President; President - Animal Health Group
M. Kenneth Bowler                            54             Vice President, Federal Government Relations
C. L. Clemente                               59             Senior Vice President, Corporate Affairs; Secretary and Corporate
                                                                 Counsel; Member of the Corporate Management Committee
Donald F. Farley                             54             Vice President; President, Consumer Health Care Group
George A. Forcier                            58             Vice President, Quality Control
P. Nigel Gray                                58             Vice President; President - Hospital Products Group
Gary N. Jortner                              51             Vice President; Vice President, Product Development-Pfizer
                                                                 Pharmaceuticals Group
Karen L. Katen                               48             Vice President; Executive Vice President - Pfizer Pharmaceuticals
                                                                 Group and President - U.S. Pharmaceuticals; Member of the
                                                                 Corporate Management Committee
J. Patrick Kelly                             39             Vice President;  Senior Vice President, Disease Management - U.S.
                                                                 Pharmaceuticals
Alan G. Levin                                34             Vice President;  Treasurer
Henry A. McKinnell                           54             Executive Vice President; President - Pfizer Pharmaceuticals Group;
                                                                 Member of the Corporate Management Committee
Brower A. Merriam                            62             Vice President - Animal Health Policy
Victor P. Micati                             57             Vice President; Executive Vice President - Pfizer Pharmaceuticals
                                                                 Group and Area President, Europe; Member of the Corporate
                                                                 Management Committee
Paul S. Miller                               57             Senior Vice President; General Counsel; Member of the Corporate
                                                                 Management Committee
George M. Milne, Jr.                         53             Vice President; President, Central Research; Member of the Corporate
                                                                 Management Committee
John F. Niblack                              58             Executive Vice President; Member of the Corporate Management
                                                                 Committee
William J. Robison                           61             Senior Vice President - Employee Resources; Member of the Corporate
                                                                 Management Committee
Herbert V. Ryan                              59             Vice President;  Controller
Craig Saxton                                 54             Vice President; Executive Vice President, Central Research
David L. Shedlarz                            48             Senior Vice President and Chief Financial Officer; Member of the
                                                                 Corporate Management Committee
Mohand Sidi Said                             58             Vice President; Senior Vice President - Pfizer Pharmaceuticals Group
                                                                 and Area President, Asia/Africa/Middle East
William C. Steere, Jr.                       60             Chairman of the Board and Chief Executive Officer; Chair of the
                                                                 Corporate Management Committee
Frederick W. Telling                         45             Vice President, Corporate Strategic Planning and Policy

Information concerning Messrs. Steere and Miller and Drs. McKinnell and Niblack is contained in, and incorporated herein by reference from, the discussion under the captions "Directors Whose Terms Expire in 1998" and "Named Executive Officers Who Are Not Directors" in the Company's Proxy Statement for its 1997 Annual Meeting of Shareholders.

20

Brian W. Barrett
Mr. Barrett joined Pfizer Canada in 1966, where he served in various financial positions, including Chief Financial Officer of the Canadian subsidiary. In 1971, he was appointed Assistant Controller of Pfizer International in New York; in 1973, Director of International Planning and in 1976, Director of Planning. In 1980, Mr. Barrett was appointed Vice President - Corporate Strategic Planning; in 1983, he became Vice President - Finance for Pfizer International; in 1985, President - Africa/Middle East; and in 1991, President - Asia/Canada. In 1992, Mr. Barrett was elected Vice President of the Company and in 1993 became President, Northern Asia, Australasia and Canada - International Pharmaceuticals Group. Mr. Barrett was named Executive Vice President, International Pharmaceuticals Group, in 1995 and President - Animal Health Group in April 1996.

M. Kenneth Bowler
Mr. Bowler joined the Company in 1989, and has been Vice President - Federal Government Relations since 1990. He formerly served as Staff Director for the House Ways and Means Committee.

C. L. Clemente
Mr. Clemente joined the Company in 1964 and has served in a number of domestic and international positions, including Vice President; General Counsel and Secretary, Pfizer International, Inc. and Vice President of Coty, formerly Pfizer's fragrance and cosmetic division. In 1983, he was named Associate General Counsel of Pfizer Inc. In 1986, he was elected Vice President; General Counsel and Secretary of the Company. He became a member of the Corporate Management Committee of the Company in 1991. In 1992, he was elected Senior Vice President - Corporate Affairs; Secretary and Corporate Counsel.

Donald F. Farley
Mr. Farley joined the Company in 1965 as Production Engineer for the Chemical Division. After serving in a number of positions of increasing responsibility within the Chemical Division, he was named its Vice President, Operations in 1982. In 1986, he became Senior Vice President of the Division, and in 1988, Executive Vice President - Specialty Chemicals. In 1992, Mr. Farley was named President of the Specialty Chemicals Group, later named the Food Science Group. In 1993 he was elected a Vice President of the Company. In 1996, Mr. Farley was named President of the Company's Consumer Health Care Group.

George A. Forcier
Dr. Forcier joined the Company in 1966 as Analytical Research Chemist for the Company's Medical Research Laboratories. In 1970, he was named Project Leader, in 1979 Manager, and in 1981, Assistant Director, of the Analytical Research Department. In 1986 he was named Director of the Analytical Research and Development Department and in 1991, he became Group Director. In 1994, Dr. Forcier became Vice President - Quality Control of the Company.

P. Nigel Gray
Mr. Gray joined the Company in 1975 as Export Sales Manager for Howmedica U.K., Ltd. in England, and progressed through a number of positions of increasing responsibility before being named Vice President, Marketing for Howmedica Europe in 1983. In 1987, Mr. Gray became Senior Vice President and General Manager of Howmedica International in Staines, England, then President of Howmedica International in 1992. In 1993, he came to New York as Executive Vice President of the Company's Hospital Products Division and President of the Medical Devices Division, and in 1994, he was elected a Vice President of the Company. In 1995, Mr. Gray assumed his current position as President of the Company's Hospital Products Group.

Gary N. Jortner
Mr. Jortner joined the Company in 1973 as a Systems Analyst for Pfizer Pharmaceuticals. In 1974, he transferred to product management and progressed through a series of promotions that resulted in his being named Group Product Manager for Pfizer Labs in 1978. In 1981, he became Vice President of Marketing for Pfizer Labs. In 1986, he was promoted to Vice President of Operations for Pfizer Labs. In 1991, he was named Vice President and General Manager, Pfizer Labs Division. In 1992, Mr. Jortner was elected Vice President of the Company. In 1994, he was named Vice President; Group Vice President, Disease Management - U.S. Pharmaceuticals Group. Effective January 1, 1997, he was named Vice President, Product Development - Pfizer Pharmaceuticals Group.

Karen L. Katen
Ms. Katen joined the Company in 1974 as a Marketing Associate for Pfizer Pharmaceuticals. Beginning in 1975, she progressed through a number of positions of increasing responsibility in the Roerig product management group which resulted in her being named Group Product Manager in 1978. In 1980, she transferred to Pfizer Labs as a Group Product Manager and later became Director, Product Management. In 1983, she returned to Roerig as Vice President-Marketing. In 1986, she was named Vice President and General Manager-Roerig Division. In 1992, she was elected Vice President of the Company. In 1993, Ms. Katen became Executive Vice President of the U.S. Pharmaceuticals Group and, in 1995, Ms. Katen assumed her present position as

21

President of the U.S. Pharmaceuticals Group. Effective January 1, 1997, she was named Executive Vice President - Pfizer Pharmaceuticals Group.

J. Patrick Kelly
Mr. Kelly joined Pfizer in 1981 as a Marketing Research Associate in the Pharmaceuticals Division. He became Product Analyst in 1982 and in 1983 was made Marketing Associate in the Roerig Division. He progressed through a series of positions of increasing responsibility and became Group Product Manager in Roerig in 1989. In 1992, he was named Vice President - Marketing, Roerig in the U.S. Pharmaceuticals Group and in 1994 became its Group Vice President - Disease Management. In 1996, he was elected a Vice President of the Company.

Alan G. Levin
Mr. Levin joined the Company in 1987 as Senior Operations Auditor for the Controllers Division. In 1988 he joined the Treasurer's Division as Controller of the Pfizer International Bank in San Juan, Puerto Rico. He returned to New York in 1991 as Director-Finance, Asia, and in 1993 was named Senior Director-Finance, Asia. In 1995, Mr. Levin was elected Treasurer of the Company. In 1997, he was elected Vice President, Treasurer.

Brower A. Merriam
Mr. Merriam joined the Company in 1969 as Country Manager for Peru, and in 1971, he was appointed Country Manager for Argentina. In 1973, he was appointed President of Pfizer Latin America. He was appointed Director of Pfizer International in 1984, and in 1988 assumed the position of President for Latin America, Southeast Asia, Indo-Pacific and Canada. In 1990, he was appointed Executive Vice President of Pfizer International. In 1991, he became Executive Vice President of the Animal Health Group and in 1992 was appointed its President. Mr. Merriam was elected a Vice President of the Company in 1992. In 1996, Mr. Merriam was named Vice President - Animal Health Policy.

Victor P. Micati
Mr. Micati joined the Company in 1965 as a Management Candidate for Pfizer Labs. Beginning in 1966, he progressed through a number of positions of increasing responsibility in the Pfizer Labs division, which resulted in his being named Vice President - Marketing in 1971. In 1972, he became Vice President of Pharmaceutical Development for International Pharmaceuticals. In 1980, he was named Executive Vice President of Pfizer Europe. Mr. Micati returned to the International Pharmaceutical Division in 1984 as Senior Vice President, and in 1990 was named President, Europe. In 1992, he was elected Vice President of the Company. Mr. Micati was named Executive Vice President, International Pharmaceuticals Group, in 1996, and in 1997 was named Executive Vice President of the newly-created Pfizer Pharmaceuticals Group.

George M. Milne, Jr.
Dr. Milne joined the Company in 1970 as a Research Scientist. In 1973, he was named Senior Research Scientist and progressed through a number of positions of increasing responsibility which resulted in his being named Vice President, Research and Development Operations in 1985. In 1988, Dr. Milne became Senior Vice President, Research and Development, and in 1993, he was elected Vice President of the Company and President, Central Research.

William J. Robison
Mr. Robison joined the Company in 1961 as a Sales Representative for Pfizer Labs. After serving in a number of positions of increasing responsibility in the Labs division, he was appointed Vice President of Sales in 1980, and Senior Vice President Pfizer Labs in 1986. In 1990, he was appointed Vice President and General Manager of Pratt Pharmaceuticals. In 1992, he was named President of the Consumer Health Care Group, and was elected Vice President of the Company. In 1996, Mr. Robison was elected Senior Vice President - Employee Resources.

Herbert V. Ryan
Mr. Ryan joined Pfizer in 1962 as Supervisor, Capital Assets. In 1964 he was named Supervisor, Corporate Ledger, and in 1966 became Director, Corporate Accounting. In 1981 he was appointed Assistant Controller, Corporate Accounting, and in 1993, Mr. Ryan was elected Corporate Controller. In 1997, Mr. Ryan was elected Vice President; Controller.

Craig Saxton
Dr. Saxton joined the Company in 1976 as Clinical Projects Director for the Central Research Division of Pfizer Limited in Sandwich, England. In 1981, he was named Senior Associate Medical Director for the International Division of Pfizer Inc., and in 1982 became the Division's Vice President, Medical Director. Dr. Saxton became Senior Vice President, Clinical Research and Development for the Central Research Division in 1988. In 1993, he was named Executive Vice President - Central Research and was elected a Vice President of the Company.

22

David L. Shedlarz
Mr. Shedlarz joined the Company in 1976 as Senior Financial Analyst for the Pharmaceuticals Division. After serving in a number of positions of increasing responsibility, he was named Production Controller in 1979 and Assistant Group Controller in 1981. In 1984, he became Group Controller and in 1989 was named Vice President of Finance for the Pharmaceuticals Group. In 1992, Mr. Shedlarz was elected Vice President - Finance of the Company. In 1995, Mr. Shedlarz became Chief Financial Officer of the Company. In 1996, Mr. Shedlarz was made Senior Vice President and Chief Financial Officer effective January 1, 1997 with responsibility for the worldwide Hospital Products Group.

Mohand Sidi Said
Mr. Sidi Said first joined Pfizer in Algeria in 1965 as a professional sales representative. During his career with the Company, he has held a variety of management assignments in Morocco, Kenya, Egypt, France, Belgium, and the United States. He was elected an executive officer of the Company in 1996, when he became a Vice President of the Company and was also named Senior Vice President
- - Pfizer Pharmaceuticals Group and Area President - Asia/Africa/Middle East/Japan.

Frederick W. Telling
Dr. Telling joined the Company in 1977 as Associate Personnel Manager for the Pharmaceuticals Division, and progressed through a number of positions of increasing responsibility before being named Director of Planning for the Pharmaceuticals Division in 1981. In 1987, he was named Vice President of Planning and Policy, and in 1994, Senior Vice President of Planning and Policy for USPG. In 1994, Dr. Telling was elected Vice President, Corporate Strategic Planning and Policy.

23

PART II

ITEM 5. MARKET FOR THE REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

The principal market for the Company's Common Stock is the New York Stock Exchange. It is also listed on the London, Paris, Brussels, and Swiss Stock Exchanges. The Company's Common Stock is also traded on various United States regional stock exchanges. Additional information required by this item is incorporated by reference from the table "Quarterly Consolidated Statement of Income" found on page 59 of the 1996 Annual Report to Shareholders.

ITEM 6. SELECTED FINANCIAL DATA

Historical financial information is incorporated by reference from the "Financial Summary" on page 60 of the 1996 Annual Report to Shareholders.

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Information required by this item is incorporated by reference from the "Financial Review" on pages 30 through 37 of the 1996 Annual Report to Shareholders.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

Information required by this item is incorporated by reference from the "Independent Auditors' Report" found on page 38 and from the consolidated financial statements and supplementary data found on pages 39 through 58 of the 1996 Annual Report to Shareholders.

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

Not applicable.

PART III

ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT

Information with regard to the Directors of the Company is incorporated herein by reference from the discussion under Item 1 of the Company's Proxy Statement for its 1997 Annual Meeting of Shareholders. The balance of the response to this item is contained in the discussion entitled "Executive Officers of the Company" in Part I hereof.

ITEM 11. EXECUTIVE COMPENSATION

Information with regard to executive compensation is incorporated herein by reference from the discussion under the heading "Compensation of Executive Officers" in the Company's Proxy Statement for its 1997 Annual Meeting of Shareholders.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

Information with regard to security ownership of certain beneficial owners and management is incorporated by reference from the discussion under the heading "Security Ownership of Management" and the following tables in the Company's Proxy Statement for its 1997 Annual Meeting of Shareholders.

24

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

Information with regard to certain relationships and related transactions is incorporated herein by reference from the discussion under the heading "Related Transactions" in the Company's Proxy Statement for its 1997 Annual Meeting of Shareholders.

PART IV

ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K

14 (a)(1) Financial Statements

The following consolidated financial statements, related notes and independent auditors' report, from the 1996 Annual Report to Shareholders, are incorporated herein by reference into Item 8 of Part II of this report:

                                                      Page in the 1996
                                                      Annual Report to
                                                        Shareholders
                                                        ------------
Independent Auditors' Report.........................        38
Segment Information..................................        39
Geographic Data......................................        40
Consolidated Statement of Income.....................        41
Consolidated Statement of Shareholders' Equity.......        42
Consolidated Balance Sheet...........................        43
Consolidated Statement of Cash Flows.................        44
Notes to Consolidated Financial Statements...........       45-58
Quarterly Consolidated Statement of Income...........        59

14(a)(2) Financial Statement Schedules

Schedules are omitted because they are not required or the information is given elsewhere in the financial statements. The financial statements of unconsolidated subsidiaries are omitted because, considered in the aggregate, they would not constitute a significant subsidiary.

14(a)(3) Exhibits

    3(i)   - Restated Certificate of Incorporation of the Company as of
             April 28, 1995 is incorporated herein by reference from the
             Company's quarterly report on form 10-Q for the period ended
             April 2, 1995. The Certificate of Correction thereto filed with
             the Secretary of State of Delaware on May 12, 1995 is filed
             herewith.
   3(ii) -   By-laws of the Company as amended June 23, 1994 are incorporated
             herein by reference from Exhibit 3(ii) of the Company's Form 8-K
             Current Report dated June 23, 1994.
    4(i)   - The Rights Agreement dated as of September 24, 1987 between
             the Company and The Chase Manhattan Bank, N.A. and the First
             Amendment thereto dated as of May 25, 1989 are filed herewith.
   10(i) -   Stock and Incentive Plan is filed herewith.
  10(ii) -   Pfizer Retirement Annuity Plan is filed herewith.
 10(iii) -   The form of severance agreement with the Company's Named
             Executive Officers disclosed in the Proxy Statement for its 1997
             Annual Meeting of Shareholders is incorporated herein by
             reference from Exhibit 10.1 to the Company's Report on Form 10-K
             for its 1994 fiscal year.
  10(iv) -   Nonfunded Deferred Compensation and Supplemental Savings Plan is
             filed herewith.
   10(v) -   Executive Annual Incentive Plan (proposed) is incorporated
             herein by reference from the exhibit to the Company's Proxy
             Statement for its 1997 Annual Meeting of Shareholders.
  10(vi) -   Performance-Contingent Share Award Program is incorporated
             herein by reference from Exhibit 10.3 to the Company's Report on
             form 10-Q for the period ended September 29, 1996.
 10(vii) -   Nonfunded Supplemental Retirement Plan is filed herewith.
10(viii) -   The form of Indemnification Agreement with Directors is filed
             herewith.
  10(ix) -   The form of Indemnification Agreement with Named Executive
             Officers is filed herewith.

25

   10(x) -   Non-Employee Directors' Retirement Plan [frozen as of
             October 1996] is filed herewith.
  10(xi) -   Annual Retainer Unit Award Plan (for non-employee Directors) is
             incorporated herein by reference from Exhibit 10.1 to the
             Company's Report on form 10-Q for the period ended September 29,
             1996.
 10(xii) -   Pfizer Inc. Nonfunded Deferred Compensation and Unit Award
             Plan for Non-Employee Directors is incorporated herein by
             reference from Exhibit 10.2 to the Company's Report on Form 10-Q
             for the period ended September 29, 1996.
10(xiii) -   Restricted Stock Plan for Non-Employee Directors is filed
             herewith.
      11 -   Computation of Earnings Per Common Share and Fully Diluted
             Earnings Per Common Share.
      12 -   Computation of Ratio of Earnings to Fixed Charges.
   13(a) -   The 1996 Annual Report to Shareholders, which, except for
             those portions expressly incorporated herein by reference, is
             furnished solely for the information of the Commission and is
             not to be deemed "filed".
   13(b) -   Annual Report of the Pfizer Savings and Investment Plan on Form
             11-K for the fiscal year ended December 31, 1996.
   13(c) -   Annual Report of the Pfizer Savings and Investment Plan for
             Employees Resident in Puerto Rico on Form 11-K for the fiscal
             year ended December 31, 1996.
      21 -   Subsidiaries of the Registrant.
      23 -   Consent of KPMG Peat Marwick LLP, independent certified public
             accountants.
      27 -   Financial Data Schedule


      (b)  Reports on Form 8-K

The Company filed no report on Form 8-K during the last quarter of 1996.

Exhibits to the Form 10-K are available upon request at a charge of ten cents per page. Requests should be directed to C. L. Clemente, Secretary, Pfizer Inc., 235 East 42nd Street, New York, NY 10017.

26

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Pfizer Inc.

                                By /s/ C.L. Clemente,
                                   -------------------------------------------
Dated: March 27, 1997                    C.L. Clemente, Senior Vice President,
                                         Secretary and Corporate Counsel

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

             Signatures                                                Title                                      Date
             ----------                                                -----                                      ----


  /s/ William C. Steere, Jr.)              Chairman of the Board, Director (Principal Executive Officer)     March 27, 1997
- -----------------------------------
      (William C. Steere, Jr.)

     /s/ (David L. Shedlarz)               Senior Vice President and Chief Financial Officer (Principal
 -----------------------------------       Financial Officer)                                                March 27, 1997
         (David L. Shedlarz)

      /s/ (Herbert V. Ryan)
- ------------------------------------       Vice President - Controller (Principal Accounting Officer)        March 27, 1997
          (Herbert V. Ryan)

     /s/ (Michael S. Brown)
- ------------------------------------       Director                                                          March 27, 1997
         (Michael S. Brown)

     /s/ (M. Anthony Burns)
- ------------------------------------       Director                                                          March 27, 1997
         (M. Anthony Burns)

      /s/ (W. Don Cornwell)
- ------------------------------------       Director                                                          March 27, 1997
          (W. Don Cornwell)

     /s/ (George B. Harvey)
- ------------------------------------       Director                                                          March 27, 1997
         (George B. Harvey)

    /s/ (Constance J. Horner)
- ------------------------------------       Director                                                          March 27, 1997
        (Constance J. Horner)

   /s/ (Stanley O. Ikenberry)
- ------------------------------------       Director                                                          March 27, 1997
       (Stanley O. Ikenberry)

      /s/ (Harry P. Kamen)
- ------------------------------------       Director                                                          March 27, 1997
          (Harry P. Kamen)

    /s/ (Thomas G. Labrecque)
- ------------------------------------       Director                                                          March 27, 1997
        (Thomas G. Labrecque)

     /s/ (Felix G. Rohatyn)
- ------------------------------------       Director                                                          March 27, 1997
         (Felix G. Rohatyn)

      /s/ (Ruth J. Simmons)
- ------------------------------------       Director                                                          March 27, 1997
          (Ruth J. Simmons)

     /s/ (Jean-Paul Valles)
- ------------------------------------       Director                                                          March 27, 1997
         (Jean-Paul Valles)


CERTIFICATE OF CORRECTION

OF

RESTATED CERTIFICATE OF INCORPORATION

OF

PFIZER INC.

PFIZER INC., a corporation organized and existing under the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY:

1. The name of the corporation is Pfizer Inc.

2. That a Restated Certificate of Incorporation of the Corporation (the "Restated Certificate") was filed with the Secretary of State of Delaware on April 28, 1995 and that said Certificate requires correction as permitted by
Section 103(f) of the General Corporation Law of the State of Delaware.

3. The inaccuracy or defect in said Restated Certificate to be corrected is that the par value per share of the Corporation's common stock stated in Article FOURTH, Paragraph D, Section 2 (A) (i) of the Restated Certificate inadvertently was not amended to reflect the Corporation's present par value per share and, therefore, is corrected to read as follows:

"(i) in the event the Board of Directors of the Company shall, at any time after the issuance of any share of Series A Preferred Stock, declare a cash dividend payable on the Common Stock, $.05 par value per share, of the Company (the "Common Stock"), a preferential cash dividend in an amount per share (rounded to the nearest cent) equal to 100 times the per share amount of such cash dividend declared on a share of the Common Stock and..."

IN WITNESS WHEREOF, said PFIZER INC. has caused this Certificate of Correction to be signed by Eileen R. Walton, its Assistant Secretary, this 11th day of May, 1995.

PFIZER INC.

By:  /s/ Eileen R. Walton
     --------------------------
        Eileen R. Walton
        Assistant Secretary


RIGHTS AGREEMENT

This Agreement, dated as of September 24, 1987, between PFIZER INC., a Delaware corporation (the "Company"), and THE CHASE MANHATTAN BANK, N.A., a national banking association (the "Rights Agent").

W I T N E S S E T H :

WHEREAS, on September 24, 1987, the Board of Directors of the Company authorized the issuance of, and declared a dividend payable in, one right (a "Right") for each share of Common Stock, $0.10 par value per share, of the Company outstanding as of the close of business on October 5, 1987 (the "Record Date"), each such Right representing the right to purchase one one-hundredth of a share of Series A Junior Participating Preferred Stock ("Preferred Stock") of the Company having the rights and preferences set forth in the form of Certificate of Designations attached hereto as Exhibit A, upon the terms and subject to the conditions hereinafter set forth: and

WHEREAS, the Board of Directors of the Company presently intends to authorize the issuance of one Right with respect to each share of Common Stock which may be issued between the Record Date and the Expiration Date (as such terms are hereinafter defined);

1

NOW, THEREFORE, in consideration of the premises and the mutual agreements herein set forth, the parties hereby agree as follows:

Section 1. Certain Definitions. For purposes of this Agreement, the following terms shall have the meanings indicated:

(a) "Acquiring Person" shall mean any Person (as such term is hereinafter defined) who or which, together with all Affiliates (as such term is hereinafter defined) and Associates (as such term is hereinafter defined) of such Person, shall be the Beneficial Owner as such term is hereinafter defined) of 20% or more of the shares of Common Stock of the Company then outstanding; provided, however, that an Acquiring Person shall not include an Exempt Person (as such term is hereinafter defined).

(b) "Affiliate" shall have the meaning ascribed to such term in Rule 12b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended ("Exchange Act"), as in effect on the date hereof.

2

(c) "Associate" of a Person (as such term is hereinafter defined) shall mean (i) with respect to a corporation, any officer or director thereof or of any Sub-sidiary (as such term is hereinafter defined) thereof, or any Beneficial Owner (as such term is hereinafter defined) of 10% or more of any class of equity security thereof, (ii) with respect to an association, any officer or director thereof or of a Subsidiary thereof, (iii) with respect to a partnership, any general partner thereof or any limited partner thereof who is directly or indirectly, the Beneficial Owner of a 10% ownership interest therein,
(iv) with respect to a business trust, any officer or trustee thereof or of any Subsidiary thereof, (v) with respect to any other trust or an estate, any trustee, executor or similar fiduciary or any Person who has a 20% or greater interest as a beneficiary in the income from or principal of such trust or estate or who otherwise has a substantial beneficial interest in such trust or estate, (vi) with respect to a natural person, any relative or spouse of such person, or any relative of such spouse, who has the same home as such person, and (vii) any Affiliate of such Person.

(d) A person shall be deemed the "Beneficial Owner" of, or to "Beneficially Own", any securities:

(i) which such Person or any of such Person's Affiliates or Associates beneficially owns, directly or indirectly, for purpose of Section 13(d) of the Exchange Act and Regulation 13D-G thereunder (or any comparable or successor law or regulation), in each case as in effect on the date hereof; and

3

(ii) which such Person or any of such Person's Affiliates or Associates has (A) the right to acquire (whether such right is exercisable immediately or only after the passage of time or the fulfillment of a condition or both) pursuant to any agreement, arrangement or understanding, or upon the exercise of conversion rights, exchange rights, other rights (other than these Rights), warrants or options, or otherwise; provided, however, that a Person shall not be deemed the "Beneficial Owner" of, or to "Beneficially Own", securities tendered pursuant to a tender or exchange offer made by such Person or any of such Person's Affiliates or Associates until such tendered securities are accepted for purchase or exchange or (B) the right to vote, alone or in concert with others, pursuant to any agreement, arrangement or understanding (whether or not in writing); provided, however, that a Person shall not be deemed the "Beneficial Owner" of, or to "Beneficially Own", any securities if the agreement, arrangement or understanding to vote such security (1) arises solely from a revocable proxy or consent given in response to a proxy or consent solicitation made pursuant to, and in accordance with, the applicable rules and regulations under the Exchange Act and (2) is not at the time reportable by such Person on a Schedule 13D report under the Exchange Act (or any comparable or successor report), other than by reference to a proxy or consent solicitation being conducted by such Person; or

4

(iii) which are beneficially owned, directly or indirectly, by any other Person with which such Person or any of such Person's Affiliates or Associates has any agreement, arrangement or understanding (whether or not in writing) for the purpose of acquiring, holding, voting (except as described in clause B of subparagraph (ii) of this paragraph (d)) or disposing of any securities of the Company.

(e) "Business Day" shall mean any day other than a Saturday, Sunday, or a day on which banking institutions in the State of New York are authorized or obligated by law or executive order to close.

(f) "Close of Business" on any given date shall mean 5:00 P.M., New York time, on such date; provided, however, that if such date is not a Business Day it shall mean 5:00 P.M., New York time, on the next succeeding Business Day.

5

(g) "Common Stock" shall mean the Common Stock (presently $0.10 par value) of the Company. "Common Stock" when used with reference to the Principal Party (as such term is hereinafter defined) shall mean the capital stock or other equity security with the greatest voting power of the Principal Party and, when used with reference to any Person other than the Company or the Principal Party, shall mean the capital stock or other equity security with the greatest voting power of such Person or, if such Person is a Subsidiary of or is controlled by another Person, the Person which ultimately controls such first mentioned Person.

(h) "Distribution Date" shall have the meaning set forth in
Section 3(b) hereof.

(i) "Exchange Act" shall have the meaning set forth in Section l(b) hereof.

(j) "Exempt Person" shall mean the Company, any Subsidiary of the Company, any employee benefit plan or employee stock plan of the Company or of any Subsidiary of the Company, or any trust or other entity organized, appointed, established or holding Common Stock for or pursuant to the terms of any such plan.

(k) "Exercise Price" shall have the meaning set forth in Sections 4 and 7(b) hereof.

(1) "Expiration Date" shall have the meaning set forth in
Section 7(a) hereof.

(m) "Fair Market Value" of any property shall mean the fair market value of such property as determined in accordance with Section ll(b) hereof.

(n) "Final Expiration Date" shall have the meaning set forth in Section 7(a) hereof.

6

(o) "Person" shall mean any individual, firm, corporation or other entity.

(p) "Principal Party" shall have the meaning set forth in
Section 13(b) hereof.

(q) "Redemption Price" shall have the meaning set forth in
Section 23(a) hereof.

(r) "Right Certificate" shall have the meaning set forth in
Section 3(b) hereof.

(s) "Stock Acquisition Date" shall mean the first date by which both (i) an Acquiring Person has become such and (ii) a public announcement of such fact has been made by either the Company or such Acquiring Person.

(t) "Subsidiary" of a Person shall mean any corporation or other entity of which securities or other ownership interests having voting power sufficient to elect a majority of the board of directors or other persons performing similar functions are beneficially owned, directly or indirectly, by such Person or by any corporation or other entity that is otherwise controlled by such Person.

(u) "Summary of Rights" shall have the meaning set forth in
Section 3(a) hereof.

(v) "Trading Day" shall have the meaning set forth in Section ll(b) hereof.

(w) "Transfer Tax" shall mean any tax or charge, including any documentary stamp tax, imposed or collected by any governmental or regulatory authority in respect of any transfer of any security, instrument or right, including Rights, shares of Common Stock and shares of Preferred Stock.

7

Any determination required to be made by the Board of Directors of the Company for purposes of applying the definitions contained in this Section 1 shall be made by the Board of Directors in its good faith judgment, which determination shall be binding on the Rights Agent and the holders of the Rights.

Section 2. Appointment of Rights Agent. The Company hereby appoints the Rights Agent to act as agent for the Company and the holders of the Rights in accordance with the terms and conditions hereof, and the Rights Agent hereby accepts such appointment. The Company may from time to time appoint such Co-Rights Agents as it may deem necessary or desirable.

Section 3. Issuance of Right Certificates.

(a) On the Record Date (or as soon as practicable thereafter), the Company or the Rights Agent shall send a copy of a Summary of Rights, in substantially the form attached hereto as Exhibit C (the "Summary of Rights"), by first class mail, postage prepaid, to each record holder of the Common Stock as of the close of business on the Record Date, at the address of such holder shown on the records of the Company.

8

(b) Until the close of business on the tenth day after the earlier to occur of (i) the Stock Acquisition Date or (ii) the date of the commencement by any Person (other than an Exempt Person) of, or the first public announcement of the intent of any Person (other than an Exempt Person) to commence. a tender or exchange offer upon the successful consummation of which such Person, together with its Affiliates and Associates, would be the Beneficial Owner of 30% or more of the then outstanding shares of Common Stock of the Company (irrespective of whether any shares are actually purchased pursuant to any such offer) (the earlier of such dates being herein referred to as the "Distribution Date"), (x) the Rights shall be evidenced (subject to the provisions of Section 3(a)) by the certificates for Common Stock registered in the name of the holders of the Common Stock (which certificates for Common Stock shall also constitute certificates for Rights) and not by separate Right certificates and the record holders of such certificates for Common Stock shall be the record holders of the Rights represented thereby and (y) each Right shall be transferable only simultaneously and together with the transfer of a share of Common Stock (subject to adjustment as hereinafter provided). Until the Distribution Date (or, if earlier, the Expiration Date or Final Expiration Date), the surrender for transfer of any certificate for Common Stock shall constitute the surrender for transfer of the Right of Rights associated with the Common Stock evidenced thereby, whether or not a copy of the Summary of Rights is transferred simultaneously with such share certificate.

(c) Certificates for Common Stock issued after the Record Date but prior to the earliest of the Distribution Date, the Expiration Date, or the Final Expiration Date shall' have impressed, printed, written or stamped thereon or otherwise affixed thereto the following legend:

9

This certificate also evidences and entitles the holder hereof to the same number of Rights as the number of shares of Common Stock represented by this certificate, such Rights being on the terms provided under the Rights Agreement between Pfizer Inc. and The Chase Manhattan Bank, N.A. (the "Rights Agent"), dated as of September 24, 1987 (the "Rights Agreement"), the terms of which are incorporated herein by reference and a copy) of which is on file at the principal executive offices of Pfizer Inc. Under certain circumstances, as set forth in the Rights Agreement, such Rights shall be evidenced by separate certificates and shall no longer be evidenced by this certificate. Pfizer, Inc. shall mail to the registered holder of this certificate a copy of the Rights Agreement without charge within five days after receipt of a written request therefor. Under certain circumstances as provided in the Rights Agreement, Rights issued to or owned by Acquiring Persons or their Affiliates or Associates (as defined in the Rights Agreement) and any subsequent holder of such Rights shall be null and void.

(d) As promptly as practicable after the Distribution Date, the Rights Agent shall send, by first class mail, postage prepaid, to each record holder of the Common Stock as of the close of business on the Distribution Date, as shown by the records of the Company, at the address of such holder shown on such records, a certificate in the form provided by Section 4 hereof (a "Right Certificate"), evidencing one Right for each share of Common Stock so held. As of and after the Distribution Date, the Rights shall be evidenced solely by Right Certificates and may be transferred by the transfer of the Right Certificate as permitted hereby, separately and apart from any transfer of one or more shares of Common Stock.

10

Section 4. Form of Right Certificates.

(a) The Right Certificates (and the forms of election to purchase shares, certificate and assignment to be printed on the reverse thereof), when, as and if issued, shall be substantially in the form set forth in Exhibit B hereto and may have such marks of identification or designation and such legends, summaries or endorsements printed thereon as may be required to comply with any law or with any rule or regulation made pursuant thereto or with any rule or regulation of any stock exchange on which the Common Stock or the Rights may from time to time be listed or as the Company may deem appropriate to conform to usage or otherwise and as are not inconsistent with the provisions of this Rights Agreement. Subject to the provisions of Section 22 hereof, Right Certificates evidencing Rights whenever issued, (i) shall be dated as of the date of issuance of the Rights they represent and (ii) subject to adjustment from time to time as provided herein, on their face shall entitle the holders thereof to purchase such number of shares (including fractional shares which are integral multiples of one-hundredth of a share) of Preferred Stock as shall be set forth therein at the price payable upon exercise of a Right provided by
Section 7(b) hereof as the same may from time to time be adjusted as provided herein, (the "Exercise Price").

(b) Notwithstanding any other provision of this Rights Agreement, any Right Certificate that represents Rights beneficially owned by an Acquiring Person or any Affiliate or Associate thereof shall have impressed on, printed on, written on or otherwise affixed to it (if the Company or the Rights Agent has knowledge that such Person is an Acquiring Person or an Associate or Affiliate or a nominee of any of the foregoing) the following legend:

11

The Beneficial Owner of the Rights represented by this Right Certificate is an Acquiring Person or an Affiliate or an Associate of an Acquiring Person. Accordingly, this Right Certificate and the Rights represented hereby may be or become void in the circumstances specified in Section 7(e) of the Rights Agreement.

Section 5. Countersignature and Registration.

(a) Each Right Certificate shall be executed on behalf of the Company by its Chairman of the Board of Directors, President or any Vice President, either manually or by facsimile signature, and have affixed thereto the Company's seal or a facsimile thereof which shall be attested by the Secretary or an Assistant Secretary of the Company, either manually or by facsimile signature. Each Right Certificate shall be countersigned by the Rights Agent either manually or by facsimile signature and shall not be valid for any purpose unless so countersigned. In case any officer of the Company who shall have signed any Right Certificate shall cease to be such officer of the Company before countersignature by the Rights Agent and issuance and delivery of the certificate by the Company, such Right Certificate, nevertheless, may be countersigned by the Rights Agent and issued and delivered with the same force and effect as though the person who signed such Right Certificates had not ceased to be such officer of the Company. Any Right Certificate may be signed on behalf of the Company by any person who, on the date of the execution of such Right Certificate, shall be a proper officer of the Company to sign such Right Certificate, although at the date of the execution of this Rights Agreement any such person was not such an officer.

12

(b) Following the Distribution Date, the Rights Agent will keep or cause to be kept, at its Shareholder Services Office or offices designated in such state as the appropriate place for surrender of certificates upon exercise or transfer books for registration and transfer of the Right Certificates issued hereunder. Such books shall show the names and addresses of the respective holders of the Right Certificates, the number of Rights evidenced on its face by each of the Right Certificates and the date of each of the Right Certificates.

Section 6. Transfer, Split Up, Combination and Exchange of Right Certificates; Mutilated, Destroyed, Lost or Stolen Right Certificates.

13

(a) Subject to the provisions of Section 14(b) hereof, at any time after the close of business on the Distribution Date, and at or prior to the close of business on the earlier of the Expiration Date or the Final Expiration Date, any Right Certificate, may be (i) transferred or (ii) split up, combined or exchanged for one or more other Right Certificates, entitling the registered holder to purchase a like number of shares of Preferred Stock as the Right Certificate surrendered then entitled such holder to purchase. Any registered holder desiring to transfer any Right Certificate shall surrender the Right Certificate at the shareholder services office of the Rights Agent with the form of certificate and assignment on the reverse side thereof endorsed (or with a written instrument of transfer in form satisfactory to the Company and the Rights Agent enclosed with such Right Certificate), executed by the registered holder thereof or his attorney authorized in writing, and with such signature guaranteed by a commercial bank or brokerage firm registered with the New York Stock Exchange. Any registered holder desiring to split up, combine or exchange any Right Certificate shall make such request in writing delivered to the Rights Agent, and shall surrender the Right Certificate to be split up, combined or exchanged at the office of the Rights Agent designated for such purpose. Thereupon, the Rights Agent shall countersign and deliver to the person entitled thereto a Right Certificate or Right Certificates, as the case may be, as so requested. The Company may require payment of a sum sufficient to cover any Transfer Tax that may be imposed in connection with any transfer, split up, combination or exchange of any Right Certificates.

(b) Upon receipt by the Company and the Rights Agent of evidence reasonably satisfactory to them of the loss, theft, destruction or mutilation of a Right Certificate, and, in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to them and, if requested by the Company, reimbursement to the Company and the Rights Agent of all reasonable expenses incidental thereto, or upon surrender to the Rights Agent and cancellation of a mutilated Right Certificate, the Company shall issue and deliver a new Right Certificate of like tenor to the Rights Agent for delivery to the registered owner in lieu of the Right Certificate so lost, stolen, destroyed or mutilated.

14

Section 7. Exercise of Rights: Exercise Price; Expiration Date of Rights.

(a) The Rights shall not be exercisable until, and shall become exercisable on, the Distribution Date. The Rights may be exercised, in whole or in part, at any time commencing with the Distribution Date upon surrender of the Right Certificate, with the form of election to purchase and certificate on the reverse side thereof duly executed (with signatures duly guaranteed), to the Rights Agent at the office of the Rights Agent designated for such purpose, together with payment of the Exercise Price with respect to each Right exercised, subject to adjustment as hereinafter provided, at or prior to the close of business on the earlier of (i) October 5, 1997 (the "Final Expiration Date") or (ii) the date on which the Rights are redeemed as provided in Section 23 hereof (such earlier date being herein referred to as the "Expiration Date").

(b) The Exercise Price of $300 shall initially be for each one one-hundredth (1/100) of a share of Preferred Stock issued pursuant to the exercise of a Right. The Exercise Price and the number of shares of Preferred Stock or other securities to be acquired upon exercise of a Right shall be subject to adjustment from time to time as provided in Sections 11 and 13 hereof. The Exercise Price shall be payable in lawful money of the United States of America, in accordance with paragraph (c) below.

15

c) Upon receipt of a Right Certificate with the form of election to purchase and certificate duly executed, accompanied by payment by check or money order payable to the order of the Company or the Rights Agent of the Exercise Price or so much thereof as is necessary for the purchase of shares or other securities to be purchased upon exercise of the Rights and an amount equal to any applicable Transfer Tax, the Rights Agent shall thereupon promptly
(i) requisition from the Company, as transfer agent of the Preferred Stock, (or such other transfer agent, if applicable) one or more certificates representing the number of shares of Preferred Stock to be so purchased, which requests the Company hereby authorizes and directs itself, as transfer agent, (or such other transfer agent, if applicable) to comply with, (ii) as provided in Section
14(b), at the election of the Company, cause depository receipts to be issued in lieu of fractional shares of Preferred Stock, (iii) when appropriate, requisition from the Company the amount of cash to be paid in lieu of issuing fractional shares in accordance with Section 14(b) hereof and (iv) cause such Preferred Stock certificates and/or depository receipts or cash payments to be delivered to or upon the order of the registered holder of such Right Certificate, registered in such name or names as may be designated by such holder, and, when appropriate, after receipt, promptly deliver such cash to or upon the order of the registered holder of such Right Certificate; provided, however, that in the case of a purchase of securities, other than Preferred Stock, pursuant to Section 13 hereof, the Rights Agent shall promptly take the appropriate action corresponding in such case to that referred to in the foregoing clauses (i) through (iv)of this section 7(c). Notwithstanding the foregoing provisions of this Section 7(c), the Company may suspend the issuance of shares of Preferred Stock upon exercise of a Right for a reasonable period, not in excess of 90 days, during which the Company seeks to register under the Securities Act of 1933, as amended, and any applicable securities law of any other jurisdiction the shares of Preferred Stock to be issued pursuant to the Rights; provided, however, that nothing contained in this Section 7(c) shall relieve the Company of its obligations under Section 9(c) hereof.

16

(d) In case the registered holder of any Right Certificate shall exercise less than all the Rights evidenced thereby, a new Right Certificate evidencing Rights equivalent to the Rights remaining unexercised shall be issued by the Rights Agent to the registered holder of such Right Certificate or his assign, subject to the provisions of Section 14(b) hereof.

(e) Notwithstanding any provision of this Rights Agreement to the contrary, upon the occurrence of any of the events described in subparagraph (A) or (B) of Section 11(a)(ii) hereof, any Rights that are at the time of the occurrence of such event Beneficially Owned by an Acquiring Person or by any Associate or Affiliate of such Acquiring Person (which Acquiring Person or Affiliate or Associate engages in, or realizes any benefit of, one or more of the transactions described in subparagraph (A) of Section 11(a)(ii) hereof or realizes any of the benefits referred to in subparagraph (B) of Section 11(a)(ii) hereof, as the case may be) shall become null and void and no holder of such Rights shall have any right with respect to such Rights under any provision of this Rights Agreement from and after the occurrence of such event nor may any Person subsequently become a holder of such Rights.

17

(f) The Company shall not effect any amendment to the Certificate of Designations for the Preferred Stock which would materially affect the rights, privileges or powers of the Preferred Stock, without the prior approval of the holders of two-thirds or more of the then outstanding shares of Preferred Stock and the prior written consent of the holders of two-thirds or more of the then outstanding Rights.

(g) Notwithstanding anything in this Agreement to the contrary, neither the Rights Agent nor the Company shall be obligated to undertake any action with respect to a registered holder upon the occurrence of any purported exercise as set forth in this Section 7 unless such registered holder shall have (i) completed and signed the certificate following the form of election to purchase set forth on the reverse side of the Right Certificate surrendered for such exercise and (ii) provided such additional evidence of the identity of the Beneficial Owner (or former Beneficial Owner) or Affiliates or Associates thereof as the Company shall reasonably request.

18

Section 8. Cancellation and Destruction of Right Certificates. All Right Certificates surrendered for the purpose of exercise, transfer, split up, combination or exchange shall, if surrendered to the Company or to any of its agents, be delivered to the Rights Agent for cancellation or in canceled form, or, if surrendered to the Rights Agent, shall be canceled by it, and no Right Certificates shall be issued in lieu thereof except as expressly permitted by any of the provisions of this Rights Agreement. The Company shall deliver to the Rights Agent for cancellation and retirement, and the Rights Agent shall cancel and retire, any Right Certificate purchased or acquired by the Company otherwise than upon the exercise thereof. The Rights Agent shall deliver all canceled Right Certificates to the Company, or shall, at the written request of the Company, destroy such canceled Right Certificates, and in such case shall deliver a certificate of destruction thereof to the Company.

Section 9. Reservation and Availability of Shares of Preferred Stock.

(a) The Company covenants and agrees that it will cause to be reserved and kept available out of its authorized and unissued shares of preferred stock or out of authorized and issued shares of Preferred Stock held in its treasury, such number of shares of Preferred Stock as will from time to time be sufficient to permit the exercise in full of all outstanding Rights. The Company shall take such action as may be required for it to comply with the foregoing sentence of this Section 9(a).

19

(b) The Company shall use its best efforts to cause, from and after such time as the Rights become exercisable, all shares of Preferred Stock issued or reserved for issuance in accordance with this Rights Agreement to be listed, upon official notice of issuance, upon the principal national securities exchange, if any, upon which the Common Stock is listed or, if the principal market for the Common Stock is not on any national securities exchange, to be eligible for quotation in the National Association of Securities Dealers' Automated Quotation System or any successor thereto or other comparable quotation system.

(c) The Company covenants and agrees that it will take all such action as may be necessary to insure that all shares of Preferred Stock delivered upon exercise of Rights shall, at the time of delivery of the certificates for such shares (subject to payment of the Exercise Price in respect thereof), be duly and validly authorized and issued and fully paid and nonassessable shares.

(d) The Company further covenants and agrees that it will pay when due and payable any and all federal and state Transfer Taxes which may be payable in respect of the issuance or delivery of the Right Certificates or of any shares of Preferred Stock issued or delivered upon the exercise of Rights. The Company shall not, however, be required to pay any Transfer Tax which may be payable in respect of any transfer or delivery of a Right Certificate to a Person other than, or the issuance or delivery of certificates for Preferred Stock upon exercise of Rights in a name other than that of, the registered holder of the Right Certificate, and the Company shall not be required to issue or deliver a Right Certificate or certificate for Preferred Stock to a person other than such registered holder until any such Transfer Tax shall have been paid (any such Transfer Tax being payable by the holder of such Right Certificate at the time of surrender) or until it has been established to the Company's satisfaction that no such Transfer Tax is due.

20

Section 10. Preferred Stock Record Date. Each Person in whose name any certificate for shares of Preferred Stock is issued upon the exercise of Rights shall for all purposes be deemed to have become the holder of record of the Preferred Stock represented thereby on, and such certificate shall be dated as of, the date upon which the Right Certificate evidencing such Rights was duly surrendered and payment of the Exercise Price (and any applicable Transfer Taxes) was made; provided, however, that, if the date of such surrender and payment is a date upon which the Preferred Stock transfer books of the Company are closed, such person shall be deemed to have become the record holder of such shares on, and such certificate shall be dated as of, the next succeeding Business Day on which the Preferred Stock transfer books of the Company are open. Prior to the exercise of the Rights evidenced thereby, the holder of a Right Certificate, as such shall not be entitled to any rights of a stockholder of the Company with respect to shares for which the Rights shall be exercisable, including, without limitation, the right to vote, to receive dividends or other distributions or to exercise any preemptive rights, and shall not be entitled to receive any notice of any proceedings of the Company, except as provided herein.

21

Section 11. Adjustment of Exercise Price or Number of Shares. The Exercise Price, the number of shares which may be purchased upon exercise of a Right and the number of Rights outstanding are subject to adjustment from time to time as provided in this Section 11.

(a) (i) In the event the Company shall at any time after the date of this Rights Agreement (A) declare or pay any dividend on Common Stock payable in shares of Common Stock, (B) subdivide or split the outstanding shares of Common Stock into a greater number of shares or (C) combine or consolidate the outstanding shares of Common Stock into a smaller number of shares or effect a reverse split of the outstanding shares of Common Stock, then and in each such event the number of shares of preferred Stock issuable upon the exercise of a Right after the record date for such event (if one shall have established or, if not, after the date of such event) shall be the number of shares of Preferred Stock issuable immediately prior to such event multiplied by a fraction the numerator of which is the number of Rights outstanding immediately prior to such event and the denominator of which is the number of Rights outstanding immediately after such event and the Exercise Price after such event shall be the Exercise Price in effect immediately prior to such event multiplied by such fraction. If an event occurs which would require an adjustment under both this Section 11(a)(i) and Section 11(a)(ii) hereof, the adjustment provided for in this Section 11(a)(i) shall be in addition to, and shall be made prior to, any adjustment required pursuant to Section 11(a)(ii).

22

(ii) In the event that

(A) any Acquiring Person or any Associate or Affiliate of any Acquiring Person, at any time after the date of this Agreement, shall, directly or indirectly, (1) consolidate with or merge with and into the Company or any of its Subsidiaries or otherwise combine with the Company or any of its Subsidiaries and the Company or such Subsidiary shall be the continuing or surviving corporation of such consolidation, merger or combination and the Common Stock of the Company shall remain outstanding and no shares thereof shall be changed into or exchanged for stock or other securities of the Company or of any other Person or cash or any other property, or (2) in one or more transactions, other than in connection with the exercise of a Right or Rights and other than in connection with the exchange or conversion of securities exchangeable for or convertible into securities of the Company or of any Subsidiary of the Company, transfer any assets or property to the Company or any of its Subsidiaries in exchange (in whole or in part) for any shares of any class of capital stock of the Company or any of its Subsidiaries or any securities exchangeable for or convertible into shares of any class of capital stock of the Company or any Subsidiary of the Company, or otherwise obtain from the Company or any of its Subsidiaries, with or without consideration, any additional shares of any class of capital stock of the Company or any of its Subsidiaries or any securities exchangeable for or convertible into shares of any class of capital stock of the Company or any Subsidiary of the Company (other than as part of a pro rata distribution by the Company or such Subsidiary to all holders of such shares), or (3) sell, purchase, lease, exchange, mortgage, pledge, transfer or otherwise dispose of, to, from or with, as the case may be, the Company or any of its Subsidiaries, assets (including securities) on terms and conditions less favorable to the Company or such Subsidiary than the Company or such Subsidiary would be able to obtain in arm's length negotiation with an unaffiliated third party, or (4) receive any compensation from the Company or any of the Company's Subsidiaries for services, other than compensation for employment as a regular employee or fees for serving as a director at rates in accordance with the Company's (or its Subsidiary's) past practices, or (5) receive the benefit (except proportionately as a stockholder) of any loans, advances, guarantees, pledges or other financial assistance or any tax credits or other tax advantage provided by the Company or any of its Subsidiaries; or

23

(B) during such time as there is an Acquiring Person, there shall be any reclassification of securities (including any reverse stock split), or any recapitalization of the Company, or any merger or consolidation of the Company with any of its Subsidiaries or any other transaction or series of transactions involving the Company or any of its Subsidiaries (whether or not with or into or otherwise involving an Acquiring Person or any Affiliate or Associate of such Acquiring Person) which has the effect, directly or indirectly, of increasing by more than 1% the proportionate share of the outstanding shares of any class of equity securities of the Company or any of its Subsidiaries or securities exercisable for or convertible into equity securities of the Company or any of its Subsidiaries which is directly or indirectly beneficially owned by any Acquiring Person or any Affiliate and/or Associate of any Acquiring Person, then, on the first occurrence of any such event referred to in Sections 11(a)(ii)(A) or (B) hereof, proper provision shall be made so that each holder of a Right, except as provided in Section 7(e) hereof, shall thereafter have a right to receive for each Right, upon exercise thereof in accordance with the terms of this Rights Agreement and payment of the Exercise Price, the greater of (1) the number of shares of Preferred Stock for which such Right was exercisable immediately prior to such event or (2) such number of shares of Preferred Stock as, based on the Fair Market Value of the Preferred Stock (determined pursuant to Section 11(b) hereof) on the date of the occurrence of such event, have a value equal to twice the Exercise Price; provided, however, that if the transaction that would otherwise give rise to the foregoing adjustment is also subject to the provisions of
Section 13 hereof, then only the provisions of Section 13 hereof shall apply and no adjustment shall be made pursuant to this Section 11(a)(ii).

24

(iii) In the event that the Company does not have available sufficient authorized but unissued Preferred Stock to permit the adjustments required pursuant to the foregoing subparagraph (i) or the exercise in full of the Rights in accordance with the foregoing subparagraph (ii), the Company shall take all such action as may be necessary to authorize and reserve for issuance such number of additional shares of Preferred Stock as may from time to time be required to be issued upon the exercise in full of all Rights from time to time outstanding and, if necessary, shall use its best efforts to obtain stockholder approval thereof.

(b) For the purpose of this Rights Agreement, the "Fair Market Value" of any share of Preferred Stock, Common Stock or any other stock or any Right or other security or any other property on any date shall be determined as provided in this Section 11(b). In the case of a publicly-traded stock or other security, the Fair Market Value on any date shall be deemed to be the average of the daily closing prices per share of such stock or per unit of such other security for the 30 consecutive Trading Days (as such term is hereinafter defined) immediately prior to such date; provided, however, that in the event that the Fair Market Value per share of any share of common stock is determined during a period which includes any date that is within 30 Trading Days after (i) the ex-dividend date for a dividend or distribution on such stock payable in shares of Common Stock or securities convertible into shares of Common Stock, or (ii) the effective date of any subdivision, split, combination, consolidation, reverse stock split or reclassification of such stock, then, and in each such case, the Fair Market Value shall be appropriately adjusted by the Board of Directors of the Company to take into account ex-dividend or post-effective date trading. The closing price for any day shall be the last sale price, regular way, or, in case no such sale takes place on such day, the average of the closing bid and asked prices, regular way (in either case, as reported in the applicable transaction reporting system with respect to securities listed or admitted to trading on the New York Stock Exchange), or, if the securities are not listed or admitted to trading on the New York Stock Exchange, as reported in the applicable transaction reporting system with respect to securities listed on the principal national securities exchange on which such security is listed or admitted to trading; or, if not listed or admitted to trading on any national securities exchange, the last quoted price (or, if not so quoted, the average of the high bid and low asked prices) in the over-the-counter market, as reported by the National Association of Securities Dealers, Inc. Automated Quotation System ("NASDAQ") or such other system then in use; or, if no bids for such security are quoted by any such organization, the average of the closing bid and asked prices as furnished by a professional market maker making a market in such security selected by the Board of Directors of the Company. The term "Trading Day" shall mean a day on which the principal national securities exchange on which such security is listed or admitted to trading is open for the transaction of business or, if such security is not listed or admitted to trading on any national securities exchange, a Business Day. If a security is not publicly held or not so listed or traded, "Fair Market Value" shall mean the fair value per share of stock or per other unit of such other security, as determined by an independent investment banking firm experienced in the valuation of securities selected in good faith by the Board of Directors of the Company, or, if no such investment banking firm is, in the good faith judgment of the Board of Directors, available to make such determination, in good faith by the Board of Directors of the Company; provided, however, that for purposes of making the adjustment provided for by Section 11(a)(ii) hereof, the Fair Market Value of a share of Preferred Stock shall not be less than 100% of the product of the Fair Market Value of a share of Common Stock multiplied by the higher of the then Dividend Multiple or Vote Multiple applicable to the Preferred Stock (as defined in the Certificate of Designations relating to the Preferred Stock) and shall not exceed 105% of the product of the then Fair Market Value of a share of Common Stock multiplied by the higher of the then Dividend Multiple or Vote Multiple applicable to the Preferred Stock. In the case of property other than securities, the "Fair Market Value" thereof shall be determined in good faith by the Board of Directors of the Company based upon such appraisals or valuation reports of such independent experts as the Board of Directors of the Company shall in good faith determine to be appropriate in accordance with good business practices and the interests of the holders of Rights. Any such determination of Fair Market Value shall be described in a statement filed with the Rights Agent and shall be binding upon the Rights Agent.

25

(c) All calculations under this Section 11 shall be made to the nearest cent or to the nearest one-thousandth of a share, as the case may be.

(d) Irrespective of any adjustment or change in the Exercise Price or the number of shares of Preferred Stock issuable upon the exercise of the Rights, the Right Certificates theretofore and thereafter issued may continue to express the Exercise Price and the number of shares to be issued upon exercise of the Rights as in the initial Right Certificates issued hereunder but, nevertheless, shall represent the Rights as so adjusted.

(e) Anything in this Section 11 to the contrary notwithstanding, in the event of any reclassification of stock of the Company or any recapitalization, reorganization or partial liquidation of the Company or similar transaction, the Company shall be entitled to make such further adjustments in the number of shares of Preferred Stock which may be acquired upon exercise of the Rights, and such adjustments in the purchase price per share therefor, in addition to those adjustments expressly required by the other paragraphs of this
Section 11, as the Board of Directors of the Company shall determine to be necessary or appropriate in order for the holders of the Rights in such event to be treated equitably and n accordance with the purpose and intent of this Rights Agreement or in order that any such event shall not, but for such adjustment, in the opinion of counsel to the Company, result in the stockholders of the Company being subject to any United States federal income tax liability by reason thereof.

26

(f) In the event the Company shall at any time after the Record Date make any distribution on the shares of Common Stock of the Company, whether by way of a dividend or a reclassification of stock, a recapitalization, reorganization or partial liquidation of the Company or otherwise, in cash or any debt security, debt instrument, real or personal property or any other property (other than any shares of Common Stock or other capital stock of the Company and other than any right or warrant to acquire any such shares, including any debt security convertible into or exchangeable for any such share, at less than the Fair Market Value of such shares) and the amount of such cash dividend or the Fair Market Value of such debt security, debt instrument or property exceeds 150% of the aggregate amount of the cash dividends declared or paid on the Common Stock of the Company in the 15-month period immediately preceding such distribution, then and in each such event, unless such distribution is part of or is made in connection with a transaction to which Section 11(a)(ii) or Section 13 hereof applies, the Exercise Price shall be reduced by an amount equal to the cash or the Fair Market Value of such distribution, as the case may be, per share of Common Stock of the Company. For purposes hereof, the Fair Market Value of any property distributed to the holder of shares of Common Stock of the Company shall be the fair market value of such property as determined by an independent investment banking firm experienced in the valuation of securities or the other property so distributed, as the case may be, selected in good faith by the Board of Directors of the Company, or, if no such investment banking firm is in the good faith judgment of the Board of Directors available to make such determination, in good faith by the Board of Directors of the Company, whose determination shall be final and binding on the Company, the Rights Agent and the holders of Rights.

27

Section 12. Certification of Adjusted Exercise Price or Number of Shares. Whenever an adjustment is made as provided in Sections 11, 13, or
23(c), the Company shall (a) promptly prepare a certificate setting forth such adjustment, and a brief statement of the facts giving rise to such adjustment,
(b) promptly file with the Rights Agent and with the Company as transfer agent for the Preferred Stock (or such other transfer agent, if applicable) a copy of such certificate and (c) mail a brief statement of the effect of such adjustment to each holder of a Right Certificate in accordance with Section 25. Notwithstanding the foregoing sentence, the failure of the Company to make such certification or give such notice shall not affect the validity of or the force or effect of the requirement for such adjustment, and any adjustment to be made pursuant to Sections 11, 13 or 23(c) of this Rights Agreement shall be effective as of the date of the event giving rise to such adjustment. The Rights Agent shall be fully protected in relying on any such certificate and on any adjustment therein contained and shall not be deemed to have knowledge of any adjustment unless and until it shall have received such certificate.

Section 13. Consolidation, Merger or Sale or Transfer of Assets or Earning Power.

(a) In the event that, at any time on or after the Distribution Date, (x) the Company shall, directly or indirectly, consolidate with, or merge with and into; any other Person or Persons and the Company shall not be the surviving or continuing corporation of such consolidation or merger, or (y) any Person or Persons shall, directly or indirectly, consolidate with, or merge with and into, the Company, and the Company shall be the continuing or surviving corporation of such consolidation or merger and, in connection with such consolidation or merger, all or part of the outstanding shares of Common Stock shall be changed into or exchanged for stock or other securities of any other Person or of the Company or cash or any other property, or (z) the Company or one or more of its Subsidiaries shall, directly or indirectly, sell or otherwise transfer to any other Person or any Affiliate or Associate of such Person, in one or more transactions, or the Company or one or more of its Subsidiaries shall sell or otherwise transfer to any Persons in one or a series of related transactions, assets or earning power aggregating more than 50% of the assets or earning power of the Company and its Subsidiaries (taken as a whole), then, on the first occurrence of any such event, proper provision shall be made so that (i) each holder of record of a Right shall thereafter have the right to receive, upon the exercise thereof and payment of the Exercise Price in accordance with the terms of this Rights Agreement, such number of shares of validly issued, fully paid and non-assessable Common Stock of the Principal Party (as defined herein) as shall, based on the Fair Market Value of the Common Stock of the Principal Party on the date of consummation of such consolidation, merger, sale or transfer equal twice the Exercise Price; (ii) such Principal Party shall thereafter be liable for, and shall assume, by virtue of such consolidation, merger, sale or transfer, all the obligations and duties of the Company pursuant to this Rights Agreement; (iii) the term "Company" for all purposes of this Rights Agreement shall thereafter be deemed to refer to such Principal Party; and (iv) such Principal Party shall take such steps (including, but not limited to, the reservation of a sufficient number of shares of its Common Stock in accordance with the provisions of Section 9 hereof applicable to the reservation of Preferred Stock) in connection with such consummation as may be necessary to assure that the provisions hereof shall thereafter be applicable, as nearly as reasonably may be, in relation to its shares of Common Stock thereafter deliverable upon the exercise of the Rights; provided, however, that, upon the subsequent occurrence of any merger, consolidation, sale of all or substantially all of the assets, recapitalization, reclassification of shares, reorganization or other extraordinary transaction in respect of such Principal Party, each holder of a Right shall thereupon be entitled to receive, upon exercise of a Right and payment of the Exercise Price, such cash, shares, rights, warrants and other property which such holder would have been entitled to receive had it, at the time of such transaction, owned the shares of Common Stock of the Principal Party purchasable upon the exercise of a Right, and such Principal Party shall take such steps (including, but not limited to, reservation of shares of stack) as may be necessary to permit the subsequent exercise of the Rights in accordance with the terms hereof for such cash, shares, rights, warrants and other property.

28

(b) "Principal Party" shall mean

(i) in the case of any transaction described in (x) or (y) of the first sentence of Section 13(a) hereof: (A) the Person that is the issuer of the securities into which shares of Common Stock of the Company are converted in such merger or consolidation, or, if there is more than one such issuer, the issuer the Common Stock of which has the greatest market value or (B) if no securities are so issued, (x) the Person that is the other party to the merger or consolidation and that survives such merger or consolidation, or, if there is more than one such Person, the Person the Common Stock of which has the greatest market value or (y) if the Person that is the other party to the merger or consolidation does not survive the merger or consolidation, the Person that does survive the merger or consolidation (including the Company if it survives); and

(ii) in the case of any transaction described in (z) of the first sentence in Section 13(a), the Person that is the party receiving the greatest portion of the assets or earning power transferred pursuant to such transaction or transactions, or, if each Person that is a party to such transaction or transactions receives the same portion of the assets or earning power so transferred or if the Person receiving the greatest portion of the assets or earning power cannot be determined, whichever of such Persons as is the issuer of Common Stock having the greatest market value of shares outstanding; provided, however, that in any such case, if the Common Stock of such Person is not at such time and has not been continuously over the preceding 12-month period registered under Section 12 of the Exchange Act and such Person is a direct or indirect Subsidiary of another Person the Common Stock of which is and has been so registered, the term "Principal Party" shall refer to such other Person, or if such Person is a Subsidiary, directly or indirectly, of more than one person, the Common Stocks of all of which are and have been so registered, the term "Principal Party" shall refer to whichever of such Persons is the issuer of the Common Stock having the greatest market value of shares outstanding.

29

(c) The Company shall not consummate any consolidation, merger or sale or transfer of assets or earning power referred to in Section 13(a) unless prior thereto the Company and the Principal Party involved therein shall have executed and delivered to the Rights Agent an agreement confirming that the Principal Party shall, upon consummation of such consolidation, merger or sale or transfer of assets or earning power, assume this Rights Agreement in accordance with Sections 13(a) and (b) hereof and that all rights of first refusal or preemptive rights in respect of the issuance of shares of Common Stock of the Principal Party upon exercise of outstanding Rights have been waived and that such transaction shall not result in a default by the Principal Party under this Rights Agreement, and further providing that, as soon as practicable after the date of any consolidation, merger or sale or transfer of assets or earning power referred to in Section 13(a) hereof, the Principal Party will

(i) prepare and file a registration statement under the Securities Act of 1933, as amended (the "Securities Act"), with respect to the Rights and the securities purchasable upon exercise of the Rights on an appropriate form, use its best efforts to cause such registration statement to become effective as soon as practicable after such filing and use its best efforts to cause such registration statement to remain effective (with a prospectus at all times meeting the requirements of the Securities Act) until the date of expiration of the Rights, and similarly comply with applicable state securities laws;

(ii) use its best efforts to list (or continue the listing of) the Rights and the securities purchasable upon exercise of the Rights on a national securities exchange or to meet the eligibility requirements for quotation on NASDAQ; and

30

(iii) deliver to holders of the Rights historical financial statements for the Principal Party which comply in all respects with the requirements for registration on Form 10 (or any successor form) under the Exchange Act.

In the event that any of the transactions described in Section 13(a) hereof shall occur at any time after the occurrence of a transaction described in
Section 11(a)(ii) hereof, the Rights which have not theretofore been exercised shall, subject to the provisions of Section 7(e) hereof, thereafter be exercisable in the manner described in Section 13(a) (without taking into account any prior adjustment required by Section 11(a)(ii)).

Section 14. Fractional Rights and Fractional Shares.

(a) The Company shall not be required to issue fractions of Rights or to distribute Right Certificates which evidence fractional Rights (i.e., Rights to acquire less than one one-hundredth of a share of Preferred Stock), unless such fractional Rights result from a transaction referred to in
Section 11(a)(i) hereof. If the Company shall determine not to issue such fractional Rights, then, in lieu of such fractional Rights, there shall be paid to the holders of record of the Right Certificates with regard to which such fractional Rights would otherwise be issuable, an amount in cash equal to the same fraction of the Fair Market Value of a whole Right.

31

(b) The Company shall not be required to issue fractions of shares of Preferred Stock (other than fractions which are integral multiples of one-hundredth of a share) upon exercise of the Rights or to distribute certificates which evidence fractional shares (other than fractions which are integral multiples of one-hundredth of a share). In lieu of issuing fractions of shares of Preferred Stock, the Company may, at its election, issue depository receipts evidencing fractions of shares pursuant to an appropriate agreement between the Company and a depository selected by it, provided that such agreement shall provide that the holders of such depository receipts shall have all of the rights, privileges and preferences to which they would be entitled as owners of the Preferred Stock. With respect to fractional shares that are not integral multiples of one-hundredth of a share, if the Company does not issue such fractional shares or depository receipts in lieu thereof, there shall be paid to the holders of record of Right Certificates at the time such Right Certificates are exercised as herein provided an amount in cash equal to the same fraction of the Fair Market Value of a share of Preferred Stock.

(c) The holder of a Right by the acceptance of a Right expressly waives his right to receive any fractional Right or any fractional shares (other than fractions which are integral multiples of one-hundredth of a share) upon exercise of a Right.

Section 15. Rights of Action. All rights of action in respect of this Rights Agreement, except the rights of action given to the Rights Agent in Section 18 hereof, are vested in the respective registered holders of the Right Certificates (and, prior to the Distribution Date, the hold-ers of record of the Common Stock); and any holder of record of any Right Certificate (or, prior to the Distribution Date, of the Common Stock), without the consent of the Rights Agent or of the holder of any other Right Certificate (or, prior to the Distribution Date, of the Common Stock), may, in his own behalf and for his own benefit, enforce, and may institute and maintain any suit, action or proceeding against the Company to enforce, or otherwise act in respect of, his right to exercise the Rights evidenced by such Right Certificate in the manner provided in such Right Certificate and in this Rights Agreement. Without limiting the foregoing or any remedies available to the holders of Rights, it is specifically acknowledged that the holders of Rights would not have an adequate remedy at law for any breach of this Rights Agreement and will be entitled to specific performance of the obligations under, and injunctive relief against actual or threatened violations of, the obligations of any Person subject to this Rights Agreement.

32

Section 16. Agreement of Right Holders. Each holder of a Right by accepting the same consents and agrees with the Company and the Rights Agent and with every other holder of a Right that:

(a) prior to the Distribution Date, the Rights shall be evidenced (subject to the provisions of Section 3(b) hereof) by the certificates for Common Stock registered in the name of the holders of the Common Stock (which certificates for Common Stock shall also constitute certificates for Rights) and not by separate Right Certificates, and each Right shall be transferable only simultaneously and together with the transfer of shares of Common Stock;

(b) after the Distribution Date, the Right Certificates are transferable only on the registry books of the Rights Agent if surrendered at the office of the Rights Agent designated for such purpose, duly endorsed or accompanied by a proper instrument of transfer; and

(c) the Company and the Rights Agent may deem and treat the Person in whose name the Right Certificate (or, prior to the Distribution Date, the associated Common Stock certificate) is registered as the absolute owner thereof and of the Rights evidenced thereby (notwithstanding any notations of ownership or writing on the Right Certificates or the associated Common Stock certificate made by anyone to other than the Company or the Rights Agent) for all purposes whatsoever, and neither the Company nor the Rights Agent shall be affected by any notice to the contrary.

Section 17. Right Certificate Holder Not Deemed a Stockholder. No holder, as such, of any Right Certificate shall be entitled to vote, receive dividends or be deemed for any purpose the holder of Preferred Stock or any other securities which may at any time be issuable on the exercise of the Rights represented thereby, nor shall anything contained herein or in any Right Certificate be construed to confer upon the holder of any Right Certificate, as such, any of the rights of a stockholder of the Company or any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof (except as provided in Section 7(f) hereof), or to give or withhold consent to any corporate action (except as provided in Section 7(f) hereof), or to receive notice of meetings or other actions affecting stockholders (except as provided in Section 24 hereof), or to receive dividends or subscription rights, or otherwise, until the Right or Rights evidenced by such Right Certificate shall have been exercised in accordance with the provisions hereof.

33

Section 18. Concerning the Rights Agent.

(a) The Company agrees to pay to the Rights Agent reasonable compensation for all services rendered by it hereunder and, from time to time, on demand of the Rights Agent, its reasonable expenses and counsel fees and other disbursements incurred in the administration and execution of this Rights Agreement and the exercise and performance of its duties hereunder. The Company also agrees to indemnify the Rights Agent for, and to hold it harmless against, any loss, liability, or expense, incurred without gross negligence, bad faith or willful misconduct on the part of the Rights Agent, for anything done or omitted to be done by the Rights Agent in connection with the acceptance and administration of this Rights Agreement, including the cost and expenses of defending against any claim of liability relating to the Rights or this Rights Agreement.

(b) The Rights Agent shall be protected against, and shall incur no liability for or in respect of, any action taken, suffered or omitted by it in connection with its administration of this Rights Agreement in reliance upon any Right Certificate or certificate for Preferred Stock or for other securities of the Company, instrument of assignment or transfer, power of attorney, endorsement, affidavit, letter, notice, direction, consent, certificate, statement or other document or paper believed by it to be genuine and to be signed, executed and, where necessary, verified or acknowledged, by the proper person or persons.

Section 19. Merger or Consolidation of, or Change in Name of, the Rights Agent.

(a) Any corporation into which the Rights Agent or any successor Rights Agent may be merged or with which it may be consolidated, or any corporation resulting from any merger or consolidation to which the Rights Agent or any successor Rights Agent shall be a party, or any corporation succeeding to the corporate trust or stock transfer business of the Rights Agent or any successor Rights Agent, shall be the successor to the Rights Agent under this Rights Agreement without the execution or filing of any paper or any further act on the part of any of the parties hereto, provided that such corporation would be eligible for appointment as a successor Rights Agent under the provisions of Section 21 hereof. In case at the time such successor Rights Agent shall succeed to the agency created by this Rights Agreement any of the Rights Certificates shall have been countersigned but not delivered, any such successor Rights Agent may adopt the countersignature of the predecessor Rights Agent and deliver such Right Certificates so countersigned; and in case at that time any of the Right Certificates shall not have been countersigned, any successor Rights Agent may countersign such Right Certificates either in the name of the predecessor Rights Agent or in the name of the successor Rights Agent; and in all such cases such Right Certificates shall have the full force provided in the Right Certificates and in this Rights Agreement.

34

(b) In case at any time the name of the Rights Agent shall be changed and at such time any of the Right Certificates shall have been countersigned but not delivered, the Rights Agent may adopt the countersignature under its prior name and deliver Right Certificates so countersigned; in case at that time any of the Right Certificates shall not have been countersigned, the Rights Agent may countersign such Right Certificates either in its prior name or in its changed name; in all such cases such Right Certificates shall have the full force provided in the Right Certificates and in this Rights Agreement.

Section 20. Duties of Rights Agent. The Rights Agent undertakes the duties and obligations imposed by this Rights Agreement upon the following terms and conditions, by all of which the Company and the holders of Right Certificates, by their acceptance thereof, shall be bound:

(a) The Rights Agent may consult with legal counsel (who may be legal counsel for the Company), and the opinion of such counsel shall be full and complete authorization and protection to the Rights Agent as to any action taken or omitted by it in good faith and in accordance with such opinion.

(b) Whenever in the performance of its duties under this Rights Agreement the Rights Agent shall deem it necessary or desirable that any fact or matter be proved or established by the Company prior to taking or suffering any action hereunder, such fact or matter (unless other evidence in respect thereof be herein specifically prescribed) may be deemed to be conclusively proved and established by a certificate signed by the President or any Vice President and by the Treasurer or any Assistant Treasurer or the Secretary or any Assistant Secretary of the Company and delivered to the Rights Agent. Any such certificate shall be full authorization to the Rights Agent for any action taken or suffered in good faith by it under the provisions of this Rights Agreement in reliance upon such certificate.

(c) The Rights Agent shall be liable hereunder only for its own gross negligence, bad faith or willful misconduct.

(d) The Rights Agent shall not be liable for or by reason of any of the statements of fact or recitals contained in this Rights Agreement or in the Right Certificates (except its countersignature thereof) or be required to verify the same, but all such statements and recitals are and shall be deemed to have been made by the Company only.

35

(e) The Rights Agent shall not be under any responsibility in respect of the validity of this Rights Agreement or the execution and delivery hereof (except the due execution hereof by the Rights Agent) or in respect of the validity or execution of any Right Certificate (except its countersignature thereof); nor shall it be responsible for any breach by the Company of any covenant or condition contained in this Rights Agreement or in any covenant or condition contained in this Rights Agreement or in any Right Certificate; nor shall it be responsible for any adjustment required under the provisions of Sections 11 or 13 hereof or responsible for the manner, method or amount of any such adjustment or the ascertaining of the existence of facts that would require any such adjustment (except with respect to the exercise of Rights evidenced by Right Certificates after receipt of a certificate describing any such adjustment); nor shall it by any act hereunder be deemed to make any representation or warranty as to the authorization or reservation of any shares of Preferred Stock to be issued pursuant to this Rights Agreement or any Right Certificate or as to whether any shares of Preferred Stock will, when issued, be validly authorized and issued, fully paid and nonassessable.

(f) The Company agrees that it will perform, execute, acknowledge and deliver or cause to be performed, executed, acknowledged and delivered all such further and other acts, instruments and assurances as may reasonably be required by the Rights Agent for the carrying out or performing by the Rights Agent of the provisions of the Rights Agreement.

g) The Rights Agent is hereby authorized and directed to accept instructions with respect to the performance of its duties hereunder from the Chairman of the Board of Directors, the President or any Vice President or the Secretary or any Assistant Secretary or the Treasurer or any Assistant Treasurer of the Company, and to apply to such officers for advice or instructions in connection with its duties, and it shall not be liable for any action taken or suffered to be taken by it in good faith in accordance with instructions of any such officer. Any application by the Rights Agent for written instructions from the Company may; at the option of the Rights Agent, set forth in writing any action proposed to be taken or omitted by the Rights Agent with respect to its duties or obligations under this Rights Agreement and the date on and/or after which such action shall be taken or omitted and the Rights Agent shall not be liable for any action taken or omitted in accordance with a proposal included in any such application on or after the date specified therein (which date shall not be less than three business days after the date any such officer actually receives such application, unless any such officer shall have consented in writing to an earlier date) unless, prior to taking or omitting any such action, the Rights Agent has received written instructions in response to such application specifying the action to be taken or omitted.

(h) The Rights Agent and any shareholder, director, officer or employee of the Rights Agent may buy, sell or deal in any of the Rights or other securities of the Company or become pecuniarily interested in any transaction in which the Company may be interested, or contract with or lend money to the Company or otherwise act as fully and freely as though it were not the Rights Agent under this Rights Agreement. Nothing herein shall preclude the Rights Agent from acting in any other capacity for the Company or for any other legal entity.

36

(i) The Rights Agent may execute and exercise any of the rights or powers hereby vested in it or perform any duty hereunder either itself or by or through its attorneys or agents, and the Rights Agent shall not be answerable or accountable for any act, default, neglect or misconduct of any such attorneys or agents or for any loss to the Company resulting from any such act, default, neglect or misconduct, provided reasonable care was exercised in the selection and continued employment thereof.

Section 21. Change of Rights Agent. The Rights Agent or any successor Rights Agent may resign and be discharged from its duties under this Rights Agreement upon 30 days' notice in writing mailed to the Company and to each transfer agent of the Common Stock and the Preferred Stock by registered or certified mail. The Company may remove the Rights Agent or any successor Rights Agent (with or without cause) upon 30 days' notice in writing, mailed to the Rights Agent or successor Rights Agent, as the case may be, and to the Company, as transfer agent of the Common Stock, (or such other transfer agent or agents, if applicable) and the Preferred Stock by registered or certified mail. If the Rights Agent shall resign or be removed or shall otherwise become incapable of acting, the Company shall appoint a successor to the Rights Agent. Notwithstanding the foregoing provisions of this Section 21, in no event shall the resignation or removal of a Rights Agent be effective until a successor Rights Agent shall have been appointed and have accepted such appointment. If the Company shall fail to make such appointment within a period of 30 days after such removal or after it has been notified in writing of such resignation or incapacity by the resigning or incapacitated Rights Agent or by the holder of a Right Certificate (who shall, with such notice, submit his Right Certificate for inspection by the Company), then the incumbent Rights Agent or the holder of record of any Right Certificate may apply to any court of competent jurisdiction for the appointment of a new Rights Agent. Any successor Rights Agent, whether appointed by the Company or by such a court, shall be a corporation organized and doing business under the laws of the United States or of any state thereof, in good standing, having its office in the State of New York, which is authorized under such laws to exercise corporate trust or stock transfer powers and is subject to supervision or examination in the conduct of its corporate trust or stock transfer business by federal or state authorities and which has at the time of its appointment as Rights Agent a combined capital and surplus of at least $50,000,000. After appointment, the successor Rights Agent shall be vested with the same powers, rights, duties and responsibilities as if it had been originally named as Rights Agent without further act or deed, but the predecessor Rights Agent shall deliver and transfer to the successor Rights Agent any property at the time held by it hereunder, and execute and deliver any further assurance, conveyance, act or deed necessary for the purpose. Not later than the effective date of any such appointment, the Company shall file notice thereof in writing with the predecessor Rights Agent and each transfer agent of the Common Stock and Preference Stock, and mail a notice thereof in writing by mail to the registered holders of the Right Certificates. Failure to give any notice provided for in this Section 21, however, or any defect therein, shall not affect the legality or validity of the resignation or removal of the Rights Agent or the appointment of the successor Rights Agent, as the case may be. Notwithstanding the foregoing provisions, in the event of resignation, removal or incapacity of the Rights Agent, the Company shall have the authority to act as the Rights Agent until a successor Rights Agent shall have assumed the duties of the Rights Agent hereunder.

37

Section 22. Issuance of New Right Certificates.
Notwithstanding any of the provisions of this Rights Agreement or of the Rights to the contrary, the Company may, at its option, issue new Right Certificates evidencing Rights in such form as may be approved by its Board of Directors to reflect an adjustment or change in the Exercise Price per share and the number or kind or class of shares of stock or other securities or property purchasable under the Right Certificates made in accordance with the provisions of this Rights Agreement.

Section 23. Redemption.

(a) The Board of Directors of the Company may, at its option, redeem all but not less than all the then outstanding Rights, at any time prior to the close of business on the earlier of (i) the tenth day following the Stock Acquisition Date or (ii) the Final Expiration Date, at a redemption price of $.05 per Right, subject to adjustments as provided in subsection (c) below (the "Redemption Price").

(b) Immediately upon the action of the Board of Directors of the Company ordering the redemption of the Rights, and without any further action and without any notice, the right to exercise the Rights will terminate and the only right thereafter of the holders of Rights shall be to receive the Redemption Price. Within 10 days after the action of Board of Directors ordering the redemption of the Rights, the Company shall give notice of such redemption to the holders of the then outstanding Rights by mailing such notice to all such holders at their last addresses as they appear upon the registry books of the Rights Agent or, prior to the Distribution Date, on the registry books of the transfer agent for the Common Stock. Any notice which is mailed in the manner herein provided shall be deemed given, whether or not the holder receives the notice. Each notice of redemption will state the method by which the payment of the Redemption Price will be made.

(c) In the event the Company shall at any time after the date of this Rights Agreement (A) pay any dividend on Common Stock in shares of Common Stock, (B) subdivide or split the outstanding shares of Common Stock into a greater number of shares or (C) combine or consolidate the outstanding shares of Common Stock into a smaller number of shares or effect a reverse split of the outstanding shares of Common Stock, then and in each such event the Redemption Price shall be adjusted so that Redemption Price after such event shall equal the Redemption Price immediately prior to such event multiplied by a fraction the numerator of which is the number of shares of Common Stock outstanding immediately after such event and the denominator of which is the number of shares of Common Stock outstanding immediately prior to such event; provided, however, that in each case such adjustment to the Redemption Price shall be made only if the amount of the Redemption Price shall be reduced or increased by $.01 per Right.

38

Section 24. Notice of Proposed Actions.

(a) In case the Company, after the Distribution Date, shall propose (i) to effect any of the transactions referred to in Section 11(a)(i) or to pay any dividend to the holders of record of its Common Stock payable in stock of any class or to make any other distribution to the holders of record of its Common Stock (other than a regular periodic cash dividend at a rate not in excess of 125% of the rate of the last cash dividend theretofore paid), or (ii) to offer to the holders of record of its Common Stock options, warrants, or other rights to subscribe for or to purchase shares of Common Stock (including any security convertible into or exchangeable for Common Stock) or shares of stock of any class or any other securities, options, warrants, convertible or exchangeable securities or other rights, or (iii) to effect any reclassification of its Preferred Stock or Common Stock or any recapitalization or reorganization of the Company, or (iv) to effect any consolidation or merger with or into, or to effect any sale or other transfer (or to permit one or more of its Subsidiaries to effect any sale or other transfer), in one or more transactions, of more than 50% of the assets or earning power of the Company and its Subsidiaries (taken as a whole) to, any other Person or Persons, or (v) to effect the liquidation, dissolution or winding up of the Company, then, in each such case, the Company shall give to each holder of record of a Right Certificate, in accordance with Section 25, notice of such proposed action, which shall specify the record date for the purposes of such transaction referred to in Section 11(a)(i) or such dividend or distribution, or the date on which such reclassification, recapitalization, reorganization, consolidation, merger, sale or transfer of assets, liquidation, dissolution, or winding up is to take place and the record date for determining participation therein by the holders of record of Common Stock or Preferred Stock, if any such date is to be fixed, and such notice shall be so given in the case of any action covered by clause (i) or (ii) above at least 10 days prior to the record date for determining holders of record of the Preferred Stock for purposes of such action, and in the case of any such other action, at least 10 days prior to the date of the taking of such proposed action or the date or participation therein by the holders of record of Common Stock or Preferred Stock, whichever shall be the earlier. The failure to give notice required by this Section 24 or any defect therein shall not affect the legality or validity of the action taken by the Company or the vote upon any such action.

(b) In case any of the transactions referred to in either
Section 11(a)(ii) or Section 13 of this Rights Agreement are proposed, then, in any such case, the Company shall give to each holder of Rights, in accordance with Section 25 hereof, notice of the proposal of such transaction at least 10 days prior to consummating such transaction, which notice shall specify the proposed event and the consequences of the event to holders of Rights under
Section 11(a)(ii) or Section 13 hereof, as the case may be, and, upon consummating such transaction, shall similarly give notice thereof to each holder of Rights.

39

Section 25. Notices. Notices or demands authorized by this Rights Agreement to be given or made by the Rights Agent or by the holder of record of any Right Certificate or Right to or on the Company shall be sufficiently given or made if sent by mail, postage prepaid, addressed (until another address is filed in writing with the Rights Agent) as follows:

Chase Manhattan Bank One New York Plaza 14th Floor
New York, New York 10081 Attn.: Vice President, Shareholder Services Division

Subject to the provisions of Section 21, any notice or demand authorized by this Rights Agreement to be given or made by the Company or by the holder of record of any Right Certificate or Right to or on the Rights Agent shall be sufficiently given or made if sent by mail, postage prepaid, addressed (until another address is filed in writing with the Company) as follows:

Pfizer Inc.
225 East 42nd Street New York, New York 10019 Attn.: Secretary

Notices or demands authorized by this Rights Agreement to be given or made by the Company or the Rights Agent to the holder of record of any Right Certificate or right shall be sufficiently given or made if sent by mail, postage prepaid, addressed to such holder at the address of such holder as shown on the registry books of the Company.

Section 26. Supplements and Amendments. The Company and the Rights Agent, if the Company so directs, may from time to time supplement or amend this Rights Agreement without the approval of any holders of Right Certificates (i) in order to cure any ambiguity, (ii) to correct or supplement any provision contained herein which may be defective or inconsistent with any other provisions herein, (iii) prior to the Distribution Date, to otherwise amend or supplement in any respect any provision herein which the Company may deem necessary or desirable, or (iv) subsequent to the Distribution Date, to amend or supplement in any respect any provision herein which the Company may deem necessary or desirable and which shall not adversely affect the interest of the holders of Rights.

Section 27. Successors. All of the covenants and provisions of this Agreement by or for the benefit of the Company or the Rights Agent shall bind and inure to the bene-fit of their respective successors and assigns hereunder.

40

Section 28. Benefits of this Agreement. Nothing in this Rights Agreement shall be construed to give to any person or corporation other than the Company, the Rights Agent and the registered holders of the Right Certificates (and, prior to the Distribution Date, the Common Stock) any legal or equitable right, remedy or claim under this Rights Agreement; but this Rights Agreement shall be for the sole and exclusive benefit of the Company, the Rights Agent and the holders of record of the Right Certificates (and, prior to the Distribution Date, the Common Stock).

Section 29. Delaware Contract. This Rights Agreement and each Right Certificate issued hereunder shall be deemed to be a contract made under the laws of the State of Delaware and for all purposes shall be governed by and construed and enforced in accordance with the laws of such state applicable to contracts to be made and performed entirely within such state.

Section 30. Counterparts. This Rights Agreement may be executed in any number of counterparts and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.

Section 31. Descriptive Headings. Descriptive headings of the several Sections of this Rights Agreement are inserted for convenience only and shall not control or affect the meaning or construction of any of the provisions hereof.

Section 32. Severability. If any term, provision, covenant or restriction of this Rights Agreement is held by a court of competent jurisdiction or other authority to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Rights Agreement shall remain in full force and effect and shall in no way be affected, impaired or invalidated.

41

IN WITNESS WHEREOF, the parties hereto have caused this Rights Agreement to be duly executed, all as of the day and year first above written.

PFIZER INC.

By:   /s/ Edmund T. Pratt, Jr.

   -------------------------------
      Edmund T. Pratt, Jr.
       Chairman and Chief Executive

Officer

Attest:   /s/ Terence J. Gallagher

         ----------------------------
           Assistant General Counsel

(seal)

THE CHASE MANHATTAN BANK, N.A.

                                          By:   /s/ John E. Strain

                                              -----------------------------
                                                John E. Strain
                                                Vice President

Attest:    /s/ Robert C. Devlin

        -----------------------------
           Vice President

(seal)

42

FIRST AMENDMENT

TO

RIGHTS AGREEMENT

First Amendment, dated as of May 25, 1989, to the Rights Agreement, dated as of September 24, 1987 (the "Rights Agreement"), between Pfizer Inc., a Delaware corporation (the "Company"), and The Chase Manhattan Bank, N.A., a national banking association (the "Rights Agent").

W T T N E S S T H :

WHEREAS, the Company and the Rights Agent executed and delivered the Rights Agreement specifying the terms of the Rights (as defined therein); and

WHEREAS, the Board of Directors of the Company deems it desirable to amend the Rights Agreement pursuant to the provisions of Section 26 of the Rights Agreement to make certain modifications to the Rights Agreement and the terms of the Preferred Stock to be issued by the Company upon the exercise of Rights, all upon the terms and conditions hereinafter set forth.

NOW, THEREFORE, in consideration of the premises and the mutual agreements herein set forth, the parties hereby agree as follows:

1

1. All references herein to the Rights Agreement shall mean the copy thereof appearing as an exhibit to the Company's Registration Statement on Form 8-A with respect to the Rights filed with the Securities and Exchange Commission on October 5, 1987 pursuant to the "EDGAR" system.

2. a. The definition of the term "Acquiring Person" set forth in Section l(a) of the Rights Agreement hereby is amended to read in its

entirety as follows:

"'Acquiring Person' shall mean any Person (as such term is hereinafter defined) who or which, together with all Affiliates (as such term is hereinafter defined) and Associates (as such term is hereinafter defined) of such Person, shall be the Beneficial Owner (as such term is hereinafter defined) of 15% or more of the shares of Voting Stock (as such term is hereinafter defined) of the Company then outstanding; provided, however, that an Acquiring Person shall not include an Exempt Person (as such term is hereinafter defined), or any Person, together with all Affiliates and Associates of such Person, who or which would be an Acquiring Person by reason of (i) being the Beneficial Owner of shares of Voting Stock of the Company, the Beneficial Ownership of which was acquired by such Person (or his or its predecessor) pursuant to a transaction or series of related transactions approved by the Continuing Directors (as such term is hereinafter defined) of the Company and effected before such Person (or his or its predecessor) otherwise became an Acquiring Person, (ii) a reduction in the number of issued and outstanding shares of Voting Stock of the Company pursuant to a transaction or a series of related transactions approved by the Continuing Directors of the Company, or (iii) any action or transaction deemed by a resolution of the Continuing Directors of the Company not to cause such Person to become an Acquiring Person which resolution is passed prior to such Person (or his or its predecessor) otherwise becoming an Acquiring Person; provided, further, however, that in the event such Person does not become an Acquiring Person by reason of clause (i), (ii) or (iii) of this
Section l(a), such Person shall become an Acquiring Person in the event such Person thereafter acquires Beneficial Ownership of an additional 1% of the Voting Stock of the Company unless such Person would not become an Acquiring Person by reason of any provision of this Agreement, including clause (i), (ii) or (iii) of this Section l(a)."

b. The definition of the term "Beneficial Owner" set forth in
Section l(d) of the Rights Agreement hereby is amended by adding the following at the end of clause (iii) thereof:

"; provided, however, that for purposes of determining beneficial ownership of securities under this Rights Agreement, officers and directors of the Company shall not constitute a group (notwithstanding that they may be Associates of one another or may be deemed to constitute a group for purposes of the Exchange Act) and shall not be deemed to own shares owned by another officer or director of the Company."

c. The definition of the term "Right Certificate" set forth in
Section l(r) of the Rights Agreement hereby is amended by deleting the reference therein to "Section 3(b)" and inserting in its place "Section 3(d)."

d. Section 1 of the Rights Agreement hereby is amended by the insertion of the following new defined terms in the appropriate alphabetical order:

"'Continuing Director' shall mean any member of the Board of Directors, while such person is a member of the Board of Directors, who is not an Acquiring Person, or an Affiliate or Associate of an Acquiring Person, or representative or nominee of an Acquiring Person or of any such Affiliate or Associate, and who either (i) was a member of the Board of Directors prior to the Stock Acquisition Date, or (ii) subsequently became a member of the Board of Directors, and whose nomination for election or election to the Board of Directors was recommended or approved by a majority of the Continuing Directors then on the Board of Directors."

2

"'Voting Stock' shall mean (i) the Common Stock of the Company and (ii) any other shares of capital stock of the Company entitled to vote generally in the election of directors or entitled to vote together with the Common Stock in respect of any merger, consolidation, sale of all or substantially all of the Company's assets, liquidation, dissolution or windinq up."

3. Section 3(b) of the Rights Agreement hereby is amended to read in its entirety as follows:

"(b) Until the close of business on the earlier to occur of
(i) the tenth day after the Stock Acquisition Date or (ii) the tenth day (or such later date as may be determined by action of the Board of Directors prior to such time as any Person becomes an Acquiring Person) after the date of the commencement by any Person (other than an Exempt Person) of, or the first public announcement of the intent of any Person (other than an Exempt Person) to commence, a tender or exchange offer upon the successful consummation of which such Person, together with its Affiliates and Associates, would be the Beneficial Owner of 30% or more of the then outstanding shares of Voting Stock of the Company (irrespective of whether any shares are actually purchased pursuant to any such offer) (the earlier of such dates being herein referred to as the 'Distribution Date'), (x) the Rights shall be evidenced (subject to the provisions of Section 3(a)) by the certificates for Common Stock registered in the name of the holders of the Common Stock (which certificates for Common Stock shall also constitute certificates for Rights) and not by separate Right certificates and the record holders of such certificates for Common Stock shall be the record holders of the Rights represented thereby and (y) each Right shall be transferable only simultaneously and together with the transfer of a share of Common Stock (subject to adjustment as hereinafter provided). Until the Distribution Date (or, if earlier, the Expiration Date or Final Expiration date), the surrender for transfer of any certificate for Common Stock shall constitute the surrender for transfer of the Right or Rights associated with the Common Stock evidenced thereby, whether or not a copy of the Summary of Rights is transferred simultaneously with such share certificate."

4. Section 3(c) of the Rights Agreement hereby is amended by modifying the fifth line of the legend appearing therein to read in its entirety as follows:

"Agent, dated as of September 24, 1987, as amended by the First Amendment To Rights Agreement, dated as of May 25, 1989 (as amended, the "Rights Agreement"), the terms"

5. Section 4(a) of the Rights Agreement hereby is amended by deleting therefrom the parenthetical language appearing in lines 14 and 15 thereof.

3

6. Section 7(a) of the Rights Agreement hereby is amended by deleting the period at the end of the first sentence thereof and inserting in its place the following:

"(unless otherwise provided herein, including, without limitation, the restrictions on exercisability set forth in Section 23(a) hereof)."

7. Section 7(e) of the Rights Agreement hereby is amended to read in its entirety as follows:

"(e) Notwithstanding any provision of this Rights Agreement to the contrary, upon the occurrence of the event described in Section ll(a)(ii) hereof, any Rights that are at the time of the occurrence of such event Beneficially Owned by an Acquiring Person or by any Associate or Affiliate of such Acquiring Person shall become null and void and no holder of such Rights shall have any right with respect to such Rights under any provision of this Rights Agreement from and after the occurrence of such event nor may any Person subsequently become a holder of such Rights."

8. Section 7 of the Rights Agreement hereby is amended by deleting subsection (f) thereof in its entirety, without redesignating the remaining subsection of such Section 7.

9. Section ll(a)(ii) of the Rights Agreement hereby is amended to read in its entiretY as follows:

"(ii) In the event that any Person, alone or together with its Affiliates and Associates, shall become an Acquiring Person, except pursuant to a transaction approved in advance by a majority of the Continuing Directors provided the Continuing Directors constitute a majority of the Board of Directors (the "Trigger Event"), then, within ten days after occurrence of the Trigger Event, proper provision shall be made so that each holder of a Right, except as provided in Section 7(e) hereof, shall thereafter have a right to receive for each Right, upon exercise thereof in accordance with the terms of this Rights Agreement and payment of the Exercise Price, the greater of (1) the number of shares of Preferred Stock for which such Right was exercisable immediately prior to such event or (2) such number of shares of Preferred Stock, based on the Fair Market Value of the Preferred Stock (determined pursuant to
Section ll(b) hereof) on the date of the occurrence of such event, having a value equal to twice the Exercise Price; provided, however, that if the transaction that would otherwise give rise to the foregoing adjustment is also subject to the provisions of Section 13 hereof, then only the provisions of
Section 13 hereof shall apply and no adjustment shall be made pursuant to this
Section ll(a)(ii)."

10. Section ll(a)(iii) of the Rights Agreement hereby is amended by adding the following three new sentences at the end thereof:

4

"In lieu of issuing shares of Preferred Stock in accordance with the foregoing subparagraphs (i) and (ii), the Company may, if a majority of the Continuing Directors determines that such action is necessary or appropriate and not contrary to the interests of holders of Rights, elect to issue or pay, upon the exercise of the Rights, cash, property, shares of Preferred or Common Stock, or any combination thereof, having an aggregate Fair Market Value equal to the Fair Market Value of the shares of Preferred Stock which otherwise would have been issuable pursuant to Section ll(a)(ii), which Fair Market Value shall be determined by an investment banking firm selected by a majority of the Continuing Directors. For purposes of the preceding sentence, the Fair Market Value of the Preferred Stock shall be as determined pursuant to Section ll(b). Subject to Section 23 hereof, any such election by a majority of the Continuing Directors of the Company must be made and publicly announced within thirty (30) days after the date on which the event described in Section ll(a)(ii) occurs."

11. Section 11 of the Rights Agreement hereby is further amended by adding the following new subsection (g) thereto:

"(g) Before taking any action that would cause an adjustment reducing the purchase price per whole share of Preferred Stock upon exercise of the Rights below the then par value, if any, of the shares of Preferred Stock, the Company shall use its best efforts to take any corporate action which may, in the opinion of its counsel, be necessary in order that the Company may validly and legally issue fully paid and non-assessable shares of such Preferred Stock at such adjusted purchase price per share."

12. Section 13(a) hereby is amended by adding the following words at the beginning thereof and changing the capital "I" in the word "In" (formerly the first word there-of) to a lower case "i":

"Except pursuant to a transaction approved in advance by a majority of the Continuing Directors,"

13. Section 14 of the Rights Agreement hereby is amended by modifying subsections (b) and (c) thereof to read in their entirety as follows:

"(b) The Company shall not be required to issue fractions of shares of Preferred Stock upon exercise of the Rights or to distribute certificates which evidence fractional shares. In lieu of issuing fractions of shares of Preferred Stock, the Company may, at its election, deposit the number of whole shares of Preferred Stock which such fractional shares would aggregate (rounded to the lowest near whole number) with a depositary selected by it pursuant to an appropriate agreement between the Company and such depositary and cause such depositary to issue depositary receipts representing interests in the shares of Preferred Stock so deposited. If the Company does not cause depositary receipts to be issued in lieu of fractional shares of Preferred Stock, or if depositary receipts issued to one or more holders do not fully represent an interest in the fraction of share that such a holder would have otherwise been entitled to, there shall be paid to the holders of record of Right Certificates at the time such Right Certificates are exercised as herein provided an amount in cash equal to the product of (i)(A) the fraction of a share of Preferred Stock which each such holder would otherwise have been entitled to upon the exercise of his Rights (if no depository receipts are issued) or (B), if depository receipts are issued, the fraction, if any, resulting from the difference between the fraction in clause A and the fraction of a share represented by the depository receipts issued to such holder and (ii) the Fair Market Value of a share of Preferred Stock."

5

"(c) The holder of a Right by the acceptance of a Right expressly waives his right to receive any fractional Right or any fractional shares upon exercise of a Riqht."

14. Section 17 hereby is amended by deleting the parenthetical language appearing in lines nine and ten and ten and eleven thereof.

15. Section 23(a) of the Rights Agreement hereby is amended by inserting the following parenthetical language immediately after the word "Date" in clause (i) thereof:

"(or such later date as a majority of the Continuing Directors in office may determine)"

16. Section 23(a) of the Rights Agreement hereby is further amended by adding the following new sentence at the end thereof:

"Notwithstanding anything contained in this Agreement to the contrary, the Rights shall not be exercisable pursuant to Section ll(a)(ii) prior to the expiration of the Company's right of redemption hereunder."

17. Section 26 of the Rights Agreement hereby is amended by deleting the period at the end thereof and inserting in its place the following:

"(other than an Acquiring Person or any Affiliate or Associate of an Acquiring Person), provided, however, that this Agreement may be amended or supplemented following the Distribution Date only with the approval of a majority of the Continuing Directors and only if the Continuing Directors constitute a majority of the number of directors then in office."

18. Exhibits A and B to the Rights Agreement hereby are amended to read in their entirety as set forth on Exhibits A-l and B-l attached hereto, respectively. All references in the Rights Agreement to the "Series A Junior Participating Preferred Stock" or the "Preferred Stock" shall be deemed to refer to the Series A Junior Preferred Stock, the terms and provisions of which are set forth in Exhibit A-1 hereto.

19. This First Amendment may be executed in any number of counterparts and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.

20. Except as specifically provided in this First Amendment to the Rights Agreement, the Rights Agreement shall remain in full force and effect and shall in no way be amended, modified or affected.

6

IN WITNESS WHEREOF, the parties hereto have caused this First Amendment to the Rights Agreement to be duly executed, all as of the day and year first above written.

PFIZER INC.

By:


Edmund T. Pratt, Jr.

Chairman of the Board

Attest:


(seal)

THE CHASE MANHATTAN BANK, N.A.

By:


Attest:


(seal)

7

EXHIBIT 10(i)

PFIZER INC.

STOCK AND INCENTIVE PLAN

(As amended through 1/97)

1. Purpose

The purpose of the Stock and Incentive Plan (known as the "Stock Option and Incentive Plan of 1965 as amended" prior to the 1980 amendment thereof and hereinafter called the "Plan") is to furnish a material incentive to employees of the Company and its subsidiaries by making available to them the benefits of a larger Common Stock ownership in the Company through stock options and otherwise. It is believed that these increased incentives will not only induce the continued service of employees but will also stimulate their efforts towards the continued success of the Company and its subsidiaries, as well as assist in the recruitment of new employees.

2. Administration

Except to the extent otherwise provided in Section 4, the Plan shall be administered by the Employee Compensation and Management Development Committee, which is authorized, subject to the provisions of the Plan, to promulgate such rules and regulations as it deems necessary for the proper administration of the Plan and to make such determinations and to take all action in connection therewith or in relation to the Plan as it deems necessary or advisable.

3. Total Number of Shares

Subject to the provisions of Section 6(h), the maximum amount of stock which may be issued under the Plan is 169,000,000* shares of the Common Stock of

the Company (comprised of 12,000,000* shares authorized in 1965, 12,000,000*
shares authorized in 1969, 12,000,000** shares authorized in 1972, 12,000,000**
shares authorized in 1975, 12,000,000** shares authorized in 1980, 20,000,000***
shares authorized in 1983, 22,000,000*** shares authorized in 1986,

22,000,000*** shares authorized in 1989, 22,000,000**** shares authorized in 1992, and 23,000,000 shares authorized in 1996). No participant shall be granted
(i) options which would result in such participant receiving more than 240,000* shares of the total number of shares authorized in 1965, more than 240,000* shares of the total number of shares authorized in 1969, or more than 240,000** shares of the total number of shares authorized in 1972, or (ii) options or awards which would result in such participant receiving more than 240,000** shares of the total number of shares authorized in 1975, more than 400,000** shares of the total number of shares authorized in 1980, more than 400,000*** shares of the total number of shares authorized in 1983, more than 600,000*** shares of the total number of shares authorized in 1986, more than 600,000*** shares of the total number of shares authorized in 1989, more than 600,000**** shares of the total number of shares authorized in 1992, more than 600,000 shares of the total number of shares authorized in 1996, or (iii) any option, stock award or performance unit award which would result in ownership by such participant of more than five percent of the stock of the Company within the meaning of Section 422(b)(7) of the Internal Revenue Code, or (iv) [i] any incentive


See footnotes on next page.

stock option, as defined in Section 422A(b) of the Internal Revenue Code, granted on or before December 31, 1986, which would result in such participant receiving a grant of incentive stock options in any calendar year for stock exceeding $100,000, in aggregate fair market value, determined as of the time the option is granted, plus any unused limit carryover, as defined in Section 422A(c)(4) of the Internal Revenue Code, to the year in which such option is granted or [ii] any incentive stock option granted after December 31, 1986, which would result in such participant receiving a grant of incentive stock options for stock that would have an aggregate fair market value in excess of $100,000, determined as of the time that the option is granted, that would be exercisable for the first time by such participant during any calendar year. No option with respect to any shares authorized in 1975 shall be granted to the extent that shares authorized in 1972 are available therefor, or with respect to any shares authorized in 1980 to the extent that shares authorized in 1972 or shares authorized in 1975 are available therefor, or with respect to any shares authorized in 1983 to the extent that shares authorized in 1972, 1975 or 1980 are available therefor, or with respect to any shares authorized in 1986 to the extent that shares authorized in 1972, 1975, 1980 or 1983 are available therefor, or with respect to any shares authorized in 1989 to the extent that shares authorized in 1972, 1975, 1980, 1983, or 1986 are available therefor, or with respect to any shares authorized in 1992 to the extent that shares authorized in 1972, 1975, 1980, 1983, 1986 or 1989 are available therefor or with respect to any shares authorized in 1996 to the extent that shares authorized in 1972, 1975, 1980, 1983, 1986, 1989, or 1992 are available therefor. With respect to all options and stock awards granted on or after January 1, 1972, the records of the Company shall specify the number of shares authorized in 1965, the number of shares authorized in 1969, the number of shares authorized in 1972, the number of shares authorized in 1975, the number of shares authorized in 1980, the number of shares authorized in 1983, the number of shares authorized in 1986, the number of shares authorized in 1989, the number of shares authorized in 1992 and the number of shares authorized in 1996 covered by such options or awards. None of the shares authorized in 1965, 1969 or 1972 shall be available for stock awards.


* Adjusted for the three-for-one stock split in 1970, the two-for-one stock split in 1983 and the two-for-one stock split in 1991, and the two-for-one stock split in 1995.

** Adjusted for the two-for-one stock split in 1983, and the two-for-one stock split in 1991, and the two-for-one stock split in 1995.

*** Adjusted for the two-for-one stock split in 1991, and the two-for-one stock split in 1995.

**** Adjusted for the two-for-one stock split in 1995.

2

4. Participation in Plan

All employees of the Company or its subsidiaries shall be eligible to participate in this Plan. From time to time, the Employee Compensation and Management Development Committee shall determine the employees who shall be granted options under the Plan, the number of shares of Common Stock to be optioned to each such employee, and whether such options shall be "Qualified Stock Options" as defined in Section 422 of the Internal Revenue Code, "incentive stock options" as defined in Section 422A of the Internal Revenue Code, or non-qualified stock options, or Tandem Options as defined herein; and shall determine the individual employees who shall be granted stock appreciation rights under the Plan pursuant to Section 7; and who shall be awarded shares under the Plan pursuant to Section 8, as well as the number of shares of Common Stock to be so awarded, and the restrictions, if any, to be placed thereon and who shall be granted performance unit awards under the Plan pursuant to Section 9 and tandem awards under the Plan pursuant to Section 10; provided, however, that in the case of employees who are also directors of the Company or officers of the Company in categories designated by the Executive Compensation and Management Development Committee, the Executive Compensation and Management Development Committee shall make these determinations; and provided further, that the Executive Compensation and Management Development Committee, or such other Committee as the Board of Directors may appoint, shall make all determinations with respect to all stock appreciation rights that are exercisable in cash or partly in stock and partly in cash and with respect to all options related thereto.

5. Term of Plan

No option with respect to shares authorized in or prior to 1969 under this Plan shall be granted pursuant to this Plan after December 31, 1978, no option with respect to shares authorized in 1972 shall be granted pursuant to this Plan after December 31, 1992, no option, stock appreciation right or stock award, with respect to shares authorized in 1975 shall be granted pursuant to this Plan after December 31, 1992, no option, stock appreciation right, stock award, performance unit award or tandem award with respect to shares authorized in 1980 shall be granted pursuant to this Plan after December 31, 1992, no option, stock appreciation right, stock award, performance unit award or tandem award with respect to shares authorized in 1983 shall be granted pursuant to this Plan after December 31, 1992, no option, stock appreciation right, stock award, performance unit award or tandem award with respect to shares authorized in 1986 shall be granted pursuant to this Plan after December 31, 1995, no option, stock appreciation right, stock award, performance unit award or tandem award with respect to shares authorized in 1989 shall be granted pursuant to this Plan after December 31, 1998, no option, stock appreciation right, stock award, performance unit award or tandem award with respect to shares authorized in 1992 shall be granted pursuant to this Plan after December 31, 2001, no option, stock appreciation right, stock award, performance unit award or tandem award with respect to shares authorized in 1996 shall be granted pursuant to this Plan after December 31, 2005, but options, stock appreciation rights, performance unit awards, tandem awards and restrictions on awards may extend beyond such dates.

3

6. Terms and Conditions of Options

All options under the Plan shall be subject to the following terms and conditions:

(a) Option Price. The option price per share shall be not less than the fair market value of the Common Stock on the date the option is granted, as determined by the Committee in accordance with applicable provisions of the Internal Revenue Code and Treasury Department rulings and regulations thereunder.

(b) Number of Shares. The option shall state the number of shares of Common Stock covered thereby.

(c) Payment. At the time of the exercise of the option the option price shall be payable in cash and/or, if the option so provides, in shares of Common Stock valued at the market price at the time the option is exercised. The Committee may in its discretion require or permit payroll deductions or other suitable means to enable optionees to accumulate sufficient funds to exercise their options and pay the option price.

(d) Term of Option. A qualified option shall provide that it shall not be exercisable after the expiration of five years from the date such option is granted. An incentive stock option shall provide that it shall not be exercisable after the expiration of ten years from the date such option is granted. A non-qualified option may be exercisable for a period greater than ten years if so provided in the terms of the option.

(e) Exercise of Option. No option may be exercised during the first year of its term or such longer period as may be specified in the option; provided, however, in the event of a "Change of Control" of the Company, as that term is defined in Section 11(e), the Board may in its discretion make any options that are not yet exercisable immediately exercisable, and further provided the Committee may in its discretion make any options that are not yet exercisable immediately exercisable in cases where (i) an optionee's employment is to be terminated due to a divestiture or downsizing of a business, (ii) in the case of a retiring optionee who holds options with extended vesting provisions, or (iii) otherwise, where the Committee determines that such action is appropriate to prevent inequities with respect to an optionee. Thereafter, an optionee, subject to the terms of the option, may exercise the option in whole at any time or in part from time to time by giving written notice thereof addressed to the Treasurer of the Company, specifying the number of shares to be purchased and accompanied by payment of the option price therefor. In the event of death, the person designated in the optionee's Will, or in the absence of such designation, the legal representative of an optionee, or if a legal representative of the optionee has not been appointed, the optionee's surviving spouse, may in like manner exercise the option provided the same was exercisable by the optionee at the time of his death, but such privilege shall expire, subject to Section 6(d) and 6(g) (iii) hereof, (i) with respect to options granted on or before January 23, 1975, six months after the death of the optionee, unless the option shall be amended to substitute a one year period for such six month period or (ii) with respect to options granted after January 23, 1975,

4

one year after the death of the optionee; provided, however, in any event that if the option is not exercised by the last day in which it is exercisable, the option shall be exercised and the proceeds paid to the deceased optionee's estate.

(f) Outstanding Options. Any qualified option (referred to in this paragraph as "new Qualified Option") shall provide that it may not be exercised while there is outstanding any qualified stock option or restricted stock option which was granted to the optionee to purchase stock in the Company or a parent or subsidiary corporation of the Company (as defined, respectively, by sections 425(e) and (f) of the Internal Revenue Code of 1954) or in a predecessor corporation of any of such corporations, before the granting of said new Qualified Option. This limitation on exercise shall not apply during such time as such outstanding qualified or restricted options are to purchase Common Stock and the option price thereunder (determined as of the date of grant of the new option) is not more than the option price of the new Qualified Option.

(g) Termination of Option. The option, to the extent not exercised, shall terminate upon its expiration as set forth in Section 6(d) hereof, its surrender as set forth in Section 11(c) hereof, or upon breach by the optionee of any provision of the option, or when the optionee ceases to be an employee for any reason including retirement, whichever event shall first occur; however, if the option so provides, the Committee in its discretion may permit the optionee to exercise the option for reasons of hardship up to twelve months after termination, assuming that the option was otherwise exercisable; further except that, subject to Section 6(d) hereof (i) the optionee, if his employment is terminated as a result of a disability, and provided the option was exercisable at the time of termination of employment, may elect to exercise the option, subject to Section 6(e) hereof, within twelve months after the date of termination, (ii) in the event of his death while an employee, the option shall terminate as provided in Section 6(e) hereof, and (iii) notwithstanding subsections (i) and (ii) above, if the option so provides, in the event that the optionee has retired or is eligible for retirement under Sections 4a., b. or d. of the Company's Retirement Annuity Plan, or as the same may be amended from time to time, or under any pension or retirement plan maintained by the Company or any of its subsidiaries, the optionee, or in the event of death, the person designated in the optionee's Will, or in the absence of such designation, the legal representative of such optionee, or if a legal representative of the optionee has not been appointed, the optionee's surviving spouse, may elect to exercise the option at any time until such option expires by its terms; provided, however, in any event that if the option is not exercised by the last day in which it is exercisable, the option shall be exercised and the proceeds paid to the deceased optionee's estate; any subsequent reemployment of the optionee by the Company shall not affect such optionee's right to exercise the option as provided in this subsection (iii).

(h) Recapitalization. In the event of any change in the number or kind of outstanding shares of Common Stock of the Company by reason of a recapitalization, merger, consolidation, reorganization, separation, liquidation, stock split, stock dividend, combination of shares or any other change in the corporate structure or shares of stock of the Company, an appropriate adjustment will be made automatically, in accordance with applicable provisions of the Internal Revenue Code and Treasury Department rulings and regulations thereunder, in the number and kind of shares for which options may thereafter be granted both in the aggregate and as to each

5

optionee, as well as in the number and kind of shares subject to options theretofore granted and the option price payable upon exercise of such options.

(i) Transferability. The option shall provide that it will not be transferable by the optionee other than by Will or the laws of descent and distribution and shall be exercisable, during the optionee's lifetime, only by him; provided, however, that the Committee in its discretion may grant (or sanction by way of an amendment to an existing grant) non-qualified stock options which may be transferred by the optionee, solely as gifts during the optionee's lifetime, to any member of the optionee's immediate family or to a trust established for the exclusive benefit of one or more members of the optionee's immediate family, in which case the terms of such option shall so state. A transfer of an option pursuant to this subjection may be effected only by the Company at the written request of an optionee and shall become effective only when recorded in the Company's record of outstanding options. In the event an option is transferred as contemplated in this subsection, such option may not be subsequently transferred by the transferee other than by Will or the laws of descent and distribution, such option shall continue to be governed by and subject to the terms and conditions of this Plan and the relevant grant, and the transferee shall be entitled to the same rights as the optionee as if no transfer had taken place. As used in this subsection, "immediate family" shall mean any spouse, child, stepchild or grandchild, and shall include relationships arising from legal adoption.

(j) Applicable Law. The option shall contain a provision that it may not be exercised at a time when the exercise thereof or the issuance of shares thereunder would constitute a violation of any federal or state law or listing requirements of the New York Stock Exchange for such shares.

(k) Incorporation by Reference. The option shall contain a provision that all the applicable terms and conditions of this Plan are incorporated by reference therein.

(l) Tandem Award. Any option constituting a part of a tandem award authorized by Section 10 hereof shall be subject to the terms and conditions of such award.

(m) Other Provisions. The option shall contain such provisions as the Committee shall deem advisable consistent with the terms of the Plan as herein set forth. In addition, the qualified stock options and the incentive stock options shall contain such other provisions as may be necessary to meet the requirements of the Internal Revenue Code and the Treasury Department rulings and regulations issued thereunder with respect to qualified stock options and incentive stock options.

7. Stock Appreciation Rights

The Committee may, in its discretion, grant stock appreciation rights to the holder of any qualified or non-qualified stock option granted by the Company. Such appreciation rights shall be subject to such terms and conditions consistent with the Plan as the Committee shall impose from time to time, including the following:

6

(a) An appreciation right may be made part of any such option at the time of its grant or at any time thereafter prior to its expiration;

(b) Upon exercise of an appreciation right the holder shall be entitled to receive:

(i) a number of shares of the Common Stock of the Company determined by dividing:

(1) the number of shares which the optionee selects, not to exceed the total number of shares that the optionee is eligible to purchase as of the exercise date under the related option, multiplied by the amount, if any, by which the fair market value of a share of the Common Stock of the Company on the exercise date exceeds the option price provided in the related option, by

(2) the fair market value of a share of the Common Stock of the Company on the exercise date; provided, however, that the total number of shares which may be received pursuant to the exercise of an appreciation right shall not exceed the total number of shares subject to the related option; or

(ii) if so provided in the award, (a) payment of cash equal to the aggregate fair market value on the date of such exercise of the number of shares of Common Stock determined under clause (i); or (b) in part cash and in part shares; all as determined by the Committee in its sole discretion;

(c) No fractional share or cash in lieu thereof will be issued upon the exercise of any such right; and

(d) Exercise of an appreciation right, in whole or in part, shall exhaust and terminate the related option with respect to the number of shares used in the calculation under subsection (b)(i)(1) of this Section 7 in determining the number of shares issued upon such exercise of the appreciation right (or which would have been issued but for any cash payment). Upon such exercise of an appreciation right, the number of shares subject to reallocation under Section 13 shall be equal to the difference between the number of shares used in the calculation under subsection (b)(i)(1) of this Section 7 and the number of shares issued to the optionee pursuant to such exercise (or which would have been issued but for any cash payment).

8. Stock Awards

Stock awards will consist of shares of Common Stock of the Company issued to participating employees as additional compensation for their services to the Company. Stock awards shall be subject to the provisions of Section 3, this Section 8, Section 11(a), (c) and (d) and, during the period in which the restrictions or the Company's right of reacquisition hereinafter referred to are in effect, Section 11(b). Other than for stock awards determined in accordance with the Company's Performance-Contingent Award Program and paid out under this Plan, as to which

7

there shall be no waiting period, each stock award to a participant shall provide that the shares subject to such award may not be transferred or otherwise disposed of by the participant prior to the expiration of a period or periods specified therein, which shall not occur earlier than one year following the date of the award (except that the award may permit the earlier lapse of such restriction in the event of the participant's death or disability or retirement pursuant to any pension or retirement plan maintained by the Company or any of its subsidiaries), and that the Company shall have the right to reacquire such shares upon termination of the participant's employment with the Company while such restriction is in effect, such reacquisition to be upon the terms and conditions provided in the award. Stock awards shall also be subject to such other terms and conditions, not inconsistent therewith, as the Committee determines to be appropriate.

9. Performance Unit Awards

Performance unit awards will consist of performance units credited to participating employees. Each award shall specify the initial value of each performance unit, such value to be determined by reference to the book or market value of the Common Stock of the Company or to the Company's earnings or such other criteria related to the Company's performance as the Committee may deem appropriate. The award shall be payable in cash and/or Common Stock of the Company as the Committee shall determine in its sole discretion.

Subject to the provisions of this Section 9 and of Section 11, the Committee shall have exclusive authority to determine additional terms and conditions of each performance unit award. Such terms and conditions may include, without limitation, provisions under which:

(1) On the payment date prescribed in the award a participant shall become entitled to receive the full value of each such unit on such date, or such other amount as such award may specify;

(2) Each unit may accrue earnings determined by reference to earnings per share or dividends paid per share on the Common Stock of the Company, or to the prime or another specified lending rate, or to other criteria specified in the award and payable at such time or times as may be specified therein;

(3) The right of a participant to receive payments in respect of a performance unit may be made subject in whole or in part to the Company's attainment of earnings or other objectives specified in the award; and

(4) The determination of all relevant valuation and other data pertaining to the award shall be in the sole judgment of the Committee. Without limitation of the foregoing, in the event that an amount payable in respect of an award is based in whole or in part on the Company's earnings or the book value of its Common Stock, the Committee may make such adjustments to the publicly reported amounts of the Company's consolidated earnings or of such book value as it deems appropriate for changes in accounting practices or principles, for material acquisitions or dispositions of stock or property, for recapitalizations or reorganizations or for any other events

8

with respect to which the Committee determines such an adjustment to be appropriate in order to avoid distortion in the operation of the Plan.

Each award shall be evidenced by a written instrument which shall set forth the number of performance units covered thereby, the initial dollar value of each such unit, the terms and conditions, if any, under which such value may change prior to the vesting of the unit, the terms and conditions under which each such unit will vest and such other matters as the Committee in its sole discretion may deem appropriate. The Committee may from time to time establish such rules as it deems appropriate regarding the manner and timing of payments of amounts due in respect of vested units.

No performance unit award shall provide for the vesting in a participating employee of any performance unit covered thereby prior to the expiration of a period of one year after the date of the award, except that the award may provide for such vesting in the event of death or disability or retirement of the employee pursuant to a pension or retirement plan maintained by the Company or one of its subsidiaries prior to the expiration of such period. Each award shall provide that prior to the vesting of the units covered thereby they shall be subject to forfeiture (A) upon the termination of the recipient's employment with the Company, (B) as contemplated by Section 10 hereof, if such award is part of a tandem award, and (C) as may otherwise be specified in the award.

No participant shall be entitled to receive in respect of a performance unit payments of amounts exceeding twice the original value established for such unit.

The maximum dollar value of performance units which may be initially awarded to participants may not exceed 1,500,000 "Reference Units" in the aggregate for all participants, and 50,000 Reference Units for any one participant. For purposes of this paragraph:

(1) A Reference Unit shall be the equivalent of the greater of (a) the fair market value of one share of the Common Stock of the Company on the date as of which a particular award of performance units is made, or (b) the book value of a share of such Common Stock as at the end of the last completed fiscal year of the Company prior to such award date plus the cash dividends paid per share on such stock during such fiscal year; and

(2) Crediting of an award of performance units shall exhaust and terminate a number of Reference Units equal to the number obtained by dividing the credited dollar value of such performance units by the greater of the amounts referred to in subclauses (a) and (b) of Clause 1 above, and except as provided in the following sentence, such terminated Reference Units shall not be utilized for subsequent awards.

In the event that an award of performance units is forfeited or for any other reason the cash amount or the value of the shares of the Common Stock of the Company (as determined by the Committee in its sole judgment) ultimately delivered to a participant in payment for an award of performance units (other than amounts paid to the participant as earnings on the performance units) is less than the Reference Units originally exhausted and terminated upon the crediting of such

9

award, a number of Reference Units equal to the dollar amount of such shortfall divided by the value originally assigned to such Reference Units shall be restored and become available for subsequent awards under the Plan.

Nothing contained herein shall be deemed to limit the right of the Board of Directors or a duly appointed committee thereof to authorize the payment or award of compensation other than in stock to any employee otherwise than pursuant to the Plan, regardless of the fact that a particular form of compensation may be the same as or similar to that which the Committee may pay or award to participants under Section 9 of the Plan.

10. Tandem Awards

The Committee may, in its discretion, grant tandem awards to participating employees. A tandem award shall consist of a right of election by the employee among two or more of the following: (A) an option, which may include a stock appreciation right with respect thereto, (B) a performance unit award, and (C) a stock award. Subject to the provisions of Section 11, such right of election shall be upon such terms and conditions as the Committee may specify in the tandem award, which shall include the following:

(a) The number of shares of the Common Stock of the Company covered by the option, the number of shares covered by the stock award and the number of performance units covered by the performance unit award;

(b) Provisions establishing the number of shares and performance units which will remain subject to each portion of the tandem award upon the exercise of the right of election in whole or in part; and

(c) The date on which the right of election shall terminate unless earlier exercised or terminated pursuant to the terms of the tandem award.

11. Conditions Applicable to All Awards

(a) Recapitalization. In the event of any change in the number or kind of outstanding shares of Common Stock of the Company by reason of a recapitalization, merger, consolidation, reorganization, separation, liquidation, stock split, stock dividend, combination of shares or any other change in the corporate structure or shares of stock of the Company, an appropriate adjustment will be made automatically, in accordance with applicable provisions of the Internal Revenue Code and Treasury Department rulings and regulations thereunder, in the number and kind of shares and performance units subject to Sections 8, 9 and 10 and the maximum dollar value of performance units subject to Sections 9 and 10.

(b) Transferability. Each award to a participant under Section 8, 9 or 10 shall provide that neither the award nor any right or interest of a participant therein shall be transferable by the

10

participant other than by Will or the laws of descent and distribution, and that such award shall be exercisable, during the participant's lifetime, only by him.

(c) Surrender. The Committee may require the surrender of an option, stock appreciation right, stock award or performance unit award granted under this Plan as a condition precedent to a grant of a new option, stock appreciation right, stock award or performance unit award for the same or a different number of shares or having the same or a different initial value in Reference Units as the option, stock appreciation right, stock award or performance unit award surrendered; provided that a qualified option or incentive stock option which is so surrendered shall, solely for the provisions of Section 6(f) hereof, be deemed to be an outstanding qualified option or incentive stock option until such surrendered qualified option or incentive stock option would have expired by reason of the lapse of time, notwithstanding the fact that it had been surrendered and was no longer exercisable. Such new option, stock appreciation right, stock award or performance unit award shall be subject to the terms or conditions specified by the Committee at the time the new option, stock appreciation right, stock award or performance unit award is granted, all determined in accordance with the provisions of this Plan without regard to the price, period of exercise, or any other terms or conditions of the option, stock appreciation right, stock award or performance unit award surrendered.

(d) Leave of Absence. If approved by the Committee, an employee's absence or leave because of military or governmental service, disability or other reason shall not be considered an interruption of employment for any purpose of the Plan.

(e) Change of Control shall mean the occurrence of any of the following events: (a) at any time during the two-year period following the Effective Date, or the beginning of a renewal term as the case may be, at least a majority of the Company's Board of Directors shall cease to consist of "Continuing Directors" (meaning directors of the Company who either were directors at the beginning of such two-year period or who subsequently became directors and whose election, or nomination for election by the Company's stockholders, was approved by a majority of the then Continuing Directors); or (b) any "person" or "group" (as determined for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934), except any majority-owned subsidiary of the Company or any employee benefit plan of the Company or any trust or investment manager thereunder, shall have acquired "beneficial ownership" (as determined for purposes of Securities and Exchange Commission ("SEC") Regulation 13d-3) of shares of Common Stock of the Company having 20% or more of the voting power of all outstanding shares of capital stock of the Company, unless such acquisition is approved by a majority of the directors of the Company in office immediately preceding such acquisition; or (c) a merger or consolidation occurs to which the Company is a party, whether or not the Company is the surviving corporation, in which outstanding shares of Common Stock of the Company are converted into shares of another company (other than a conversion into shares of voting common stock of the successor corporation or a holding company thereof representing 80% of the voting power of all capital stock thereof outstanding immediately after the merger or consolidation) or other securities (of either the Company or another company) or cash or other property; or (d) the sale of all, or substantially all, of the Company's

11

assets occurs; or (e) the stockholders of the Company approve a plan of complete liquidation of the Company.

12. Definitions

(a) Company. The term "Company" shall mean Pfizer Inc, a Delaware corporation.

(b) Board of Directors. The term "Board of Directors" shall mean the Board of Directors of Pfizer Inc.

(c) Employee Compensation and Management Development Committee. The term "Employee Compensation and Management Development Committee" shall mean the Employee Compensation and Management Development Committee of Pfizer Inc as constituted by resolution of the Board of Directors.

(d) Executive Compensation and Management Development Committee. The term "Executive Compensation and Management Development Committee" shall mean the Executive Compensation and Management Development Committee of Pfizer Inc as constituted by resolution of the Board of Directors.

(e) Committee. The term "Committee" shall mean the Employee Compensation and Management Development Committee or such other committee referred to in the second proviso of the last sentence of Section 4 hereof, as may be appropriate.

(f) Subsidiary. The term "subsidiary" shall mean a subsidiary corporation of the Company as defined in Section 425(f) of the Internal Revenue Code of 1954.

(g) Common Stock. The term "Common Stock" shall mean the $.10 par value Common Stock of the Company, authorized but unissued, or issued and reacquired by the Company and held as Treasury Stock, or held by any trust established by the Company for the purpose of satisfying the Company's obligations for the issuance of Common Stock under the Plan.

(h) Tandem Options. A "Tandem Option" shall mean a qualified option or incentive stock option and a non-qualified option granted to an optionee, subject to the provision that the exercise of all or any part of either option will result in a reduction in the other option.

13. Reallocation of Unused Shares

Any shares which are not purchased or awarded under an option, performance unit award or right of election which has terminated or lapsed, either by its terms or pursuant to the exercise, in whole or in part, of an award or right granted under the Plan, or shares which are reacquired by the Company pursuant to Section 8 hereof, may be used for the further grant of options or, if such shares were authorized in 1975, stock awards under the Plan, or if such shares were authorized in 1980 or after, stock awards, performance unit awards or tandem awards under the Plan. For

12

purposes of this Section 13 the number of shares subject to a tandem award under
Section 10 hereof which shall be deemed not to have been purchased or awarded as of the time such award terminated or lapsed shall equal the excess, if any, of
(i) the maximum number of shares which the participant was entitled to receive under the tandem award over (ii) the number of shares which he in fact had received as of the time of such termination or lapse.

14. Use of Proceeds

The proceeds received by the Company from the sale of stock under the Plan shall be added to the general funds of the Company and shall be used for such corporate purposes as the Board of Directors shall direct.

15. Amendment and Revocation

The Board of Directors shall have the right to alter, amend or revoke the Plan or any part thereof at any time and from time to time, provided, however, that without the consent of the participants affected no change may be made in any option or award theretofore granted, which will impair the rights of participants under outstanding options or awards; and provided further, that the Board of Directors may not, without the approval of the holders of a majority of the outstanding Common Stock, make any alteration or amendment to the Plan which increases the maximum number of shares of Common Stock which may be issued under the Plan or the number of shares of such stock which may be issued to any one participant, extends the term of the Plan or of options granted thereunder, reduces the option price below that now provided for in the Plan, or changes the conditions of exercise of options specified in Sections 6(e) and 6(f). The Committee may make non-substantive administrative changes to the Plan so as to conform with or take advantage of governmental requirements, statutes or regulations.

16. Special Provisions Applicable to Employees in the United Kingdom

1. Administration; Operation and Effect

This Amendment to the Plan, which is effective as of June 26, 1986 sets forth the Employee Share Option (UK) Scheme (hereinafter referred to as "the Scheme"). In all respects, the Scheme will be administered by the Committee as provided in Section 2 of the Plan. No amendment to the Plan shall have effect in relation to the Scheme and no amendment to the Scheme shall have effect without the prior approval of the Board of Inland Revenue in the UK. The Committee shall be responsible for ensuring that all matters relating to the Scheme are in compliance with UK tax laws and codes.

2. Stock

Options granted under this Scheme shall be to purchase shares of the Company's authorized, but unissued or reacquired Common Stock (hereinafter referred to as "Scheme Shares") satisfying

13

the requirements of paragraphs 7 to 11 of Schedule 10 to the Finance Act of 1984 (hereinafter referred to as "Schedule 10"). The total number of such shares with respect to which options may be granted under the Scheme is subject to the limits set out in the Plan* and the limits set out below.

3. Eligibility

Persons eligible to receive options under the Scheme shall be salaried employees of the Company's UK subsidiaries who are employed at the time of the grant of the option and whom the Committee selects from time to time PROVIDED ALWAYS that:

(a) they are contracted to work not less than 20 hours (or, in the case of directors, 25 hours) per week excluding meal breaks for the Company's UK subsidiaries; and

(b) at the date of the grant or exercise of the option, they are not ineligible to participate in the Scheme by virtue of paragraph 4(1)(b) of Schedule 10.

An option holder may hold more than one option.

4. Terms and Conditions of Options

Options granted under the Scheme shall be evidenced by agreements with option holders in such form as the Committee may determine. Each such agreement shall be subject to the following terms and conditions:

(a) Grants of Options

Offers of options may be sent as soon as practicable after approval of the Scheme by the UK Board of Inland Revenue, and thereafter at any time. All offers of options shall be made on the basis that participation in the Scheme will be deemed to constitute acceptance of the provisions set forth or incorporated by reference in this Amendment to the Plan. The sum of one pound sterling shall be payable by the option holder as consideration for the grant of the option to him.

(b) Number of Shares

The number of Scheme Shares subject to each option shall be stated. Such number shall be determined by the Committee, but their aggregate Market Value, as that term is defined in Schedule 10, and number of Shares shall not at any time exceed either:

(i) the aggregate fair market value or the number of Shares as is determined for such option holder by the Committee in accordance with Section 3 of the Plan; or

(ii) in total with subsisting options over Scheme Shares granted under any scheme approved by the Board of Inland Revenue under Schedule 10 the greater of:

14

(a) (pound)100,000; and

(b) four times the amount of the eligible employee's Relevant Emoluments (as defined in Schedule 10, paragraph 5, sub-paragraph 5), for the current or preceding Year of Assessment (defined as commencing on April 6 and ending on the following April 5) whichever of those years gives the greater amount or, if there were no Relevant Emoluments for the preceding Year of Assessment, four times the amount of the Relevant Emoluments for the period of 12 months beginning with the first day during the current Year of Assessment in respect of which there are Relevant Emoluments.

In calculating the limits stated above and the Market Value, sums denominated in US dollars shall be converted to sterling at the rate of exchange published by the Company's bankers (being a United Kingdom clearing bank) at 11 o'clock a.m. on the date of the grant of the relevant option.

(c) Option Price and Payment of Option Price

(i) The option price per share shall be no less than the mean between the high and the low selling prices on the composite tape of the New York Stock Exchange as reported by the New York Times for the date the option is granted.

(ii) Upon the exercise of an option, the option price shall be payable in lawful money of the United States and may be paid in cash or by certified check or by bank draft.

(d) Terms and Exercise of Options

The times at which and the terms under which any option shall be exercisable shall (unless otherwise stated in accordance with the determination of the Committee and with prior approval of the Board of Inland Revenue) be as stated in Section 6(d), 6(e) and 6(g)** of the Plan provided that the reference to Section 11(c) in Section 6 of the Plan shall be replaced by a reference to Clause 4(f) of the Scheme and in no event may an option be exercised more than 12 months after an option holder's death.***

(e) Recapitalization

Section 6(h) of the Plan shall apply to the Scheme provided that any adjustments made pursuant to that Section shall be subject to the prior approval of the Board of Inland Revenue pursuant to Schedule 10 to the Finance Act 1984.

15

(f) Surrender

The Committee may require the surrender of an option granted under the Scheme as a condition precedent to a grant of a new option for the same or a different number of shares surrendered. Such new options shall be subject to the terms and conditions specified by the Committee at the time the new option is granted, determined in accordance with the provisions of the Plan and the Scheme without regard to the price, period of exercise or any other terms or conditions of the options surrendered.

(g) Transferability, Applicable Law and Leave of Absence

Sections 6(i), 6(j) and, subject to Clause 3 hereof, 11(d) of the Plan shall apply to the Scheme.

(h) Incorporation by Reference

The option agreement shall contain a provision that all the terms and conditions of the Scheme are incorporated by reference therein.

5. Reallocation of Unused Shares

Any shares which are not purchased under an option which has terminated or lapsed, either by its terms or pursuant to the exercise in whole or in part, may be used for the further grant of options, provided always that no options shall be granted to an employee at a time when his employment is interrupted.

6. Amendment and Revocation

Section 15 of the Plan shall apply to the Scheme but no amendment may be made so as to have effect with respect to the Scheme or the Scheme Shares without the prior approval of the Board of Inland Revenue.****

7. Definitions

(a) In the Scheme, the term the "Plan" shall mean the Company's Stock Option and Incentive Plan of 1965 as amended.

(b) Section 12 of the Plan other than sub-sections (d) and (h) shall apply to the Scheme.

16

Footnotes for UK Plan


* Section 3 of the Plan was amended by resolution of the shareholders on April 26, 1990 and has effect in relation to the Scheme with the approval of the Board of Inland Revenue in the UK given June 14, 1990.

** Section 6(e), 6(g) and 11 were amended with the approval of the shareholders on April 26, 1990. These amendments have effect in relation to the Scheme with the approval of the Board of Inland Revenue in the UK given on June 14, 1990 provided that the amendment to Section 6(e) to give the Board power to "make any options that are not yet exercisable immediately exercisable" shall not have effect with regard to subsisting options granted before June 14, 1990.

*** Section 6(e) was further amended with the approval of the shareholders on April 22, 1993 by the insertion of the following words "and further provided the Committee may in its discretion make any options that are not yet exercisable immediately exercisable in cases where (i) an optionee's employment is to be terminated due to a divestiture or downsizing of a business, (ii) in the case of a retiring optionee who holds options with extended vesting provisions, or (iii) otherwise, where the Committee determines that such action is appropriate to prevent inequities with respect to an optionee" at the end of the second sentence. The amendment has effect in relation to the Scheme with the approval of the Board of Inland Revenue in the UK given on August 5, 1993 provided that the discretionary power conferred on the Committee "to make any options that are not yet exercisable immediately exercisable" shall not have effect with regard to subsisting options granted before August 5, 1993.

**** Section 15 of the Plan was amended by resolution of the Board of Directors on December 18, 1989 and has effect in relation to the Scheme with the approval of the Board of Inland Revenue in the UK given June 14, 1990.

17

17. Special Provisions Applicable to Employees in the Republic of Ireland

1. Administration; Operation and Effect

This amendment to the Plan, which is effective as of June 25, 1987, sets forth the Employee Share Option (Republic of Ireland) Scheme (hereinafter referred to as "the Scheme"). The Scheme will be administered in all respects by the Committee, as provided for by Section 2 of the Plan.

No amendment to the Plan shall have effect in relation to the Scheme, and no amendment to the Scheme shall have effect without the prior approval of the Revenue Commissioners.

The Committee shall be responsible for ensuring that all matters relating to the Scheme comply with Irish Tax law and practice.

2. Stock

Options granted under the Scheme shall be to purchase shares of the Company's authorized, but unissued or re-acquired Common Stock (hereinafter referred to as "Scheme Shares") which satisfy the requirements of paragraphs 6 to 11 of the Second Schedule to the Finance Act, 1986.

The total number of such shares in respect of which options may be granted is subject to the limits set out in the Plan.

3. Eligibility

Persons eligible to receive options under the Scheme shall be salaried employees of any existing or future Irish subsidiaries and any existing or future Irish branches established by Pfizer Inc or by any of its subsidiaries or branches who are employed at the time of the grant and whom the Committee selects from time to time provided always that:

(a) the employee is contracted to work for not less than 20 hours per week for any of the Company's Irish branches or subsidiaries (as defined above) (or in the case of a director of an Irish subsidiary, is a full-time director of such subsidiary), and

(b) at the date of the grant or exercise of an option is not ineligible to participate in the Scheme by virtue of paragraph
5 (1) (b) of the Second Schedule to the Finance Act, 1986.

An option holder may hold more than one option.

4. Terms and Conditions of Options

18

An option granted in accordance with the Scheme shall be evidenced by an agreement with the option holder in such form as the Committee may determine. Each such agreement shall be subject to the following terms and conditions:

(a) Grant of an Option

An offer of an option may be issued at any time. All offers of options shall be made on the basis that participation in the Scheme will be deemed to constitute acceptance of the provisions set forth in, or incorporated by reference to this amendment to, the Plan.

The sum of one pound (IRL1) shall be payable by an option holder as consideration for the grant of an option to him.

(b) Number of Shares

The number of Scheme Shares subject to each option shall be stated. Such number shall be determined by the Committee.

(c) Option Price and Payment of Option Price

(i) The option price per share shall be the mean between the high and the low selling prices on the composite tape of The New York Stock Exchange as reported by the New York Times for the day on which the option is granted.

(ii) Upon the exercise of an option, the option price shall be payable in lawful money of the United States of America and may be paid in cash or by certified check or by bank draft.

(d) Terms and Exercise of Options

The times at which and the terms under which an option shall be exercisable shall (unless otherwise stated in accordance with a determination of the Committee and with the prior approval of the Revenue Commissioners) be as stated in Section 6(d), 6(e) and 6(g) of the Plan provided that the reference to
Section 11(c) in Section 6 of the Plan shall be replaced by a reference to clause 4(f) of the Scheme and in no event may an option be exercised more than 12 months after an option holder's death.

19

(e) Recapitalization

Section 6(h) of the Plan shall apply to the Scheme provided that any adjustment made pursuant to that Section shall be subject to the prior approval of the Revenue Commissioners pursuant to the Second Schedule to the Finance Act, 1986.

(f) Surrender

The Committee may require the surrender of an option granted under the Scheme as a condition precedent to a grant of a new option for the same or a different number of shares surrendered. Such new options shall be subject to the terms and conditions specified by the Committee at the time the new option is granted, determined in accordance with the provisions of the Plan and the Scheme without regard to the price, period of exercise or any other terms or conditions of the options surrendered.

(g) Transferability, Applicable Law and Leave of Absence

Sections 6(i), 6(j) and, subject to Clause 3 hereof, 11(d) of the Plan shall apply to the Scheme.

(h) Incorporation by Reference

The option agreement shall contain a provision that all the terms and conditions of the Scheme are incorporated by reference therein.

5. Reallocation of Unused Shares

Any shares which are not purchased under an option which has terminated or lapsed, either by its terms or pursuant to the exercise in whole or in part, may be used for the further grant of options, provided always that no options shall be granted to any employee at a time when his employment is interrupted.

6. Amendment and Revocation

Section 15 of the Plan shall apply to the Scheme but no amendment may be made so as to have effect with respect to the Scheme or the Scheme Shares without the prior approval of the Revenue Commissioners.

7. Definitions

(a) In the Scheme, the term Plan shall mean the Company's Stock and Incentive Plan.

(b) Section 12 of the Plan other than sub-sections (d) and (h) shall apply to the Scheme.

20

18. Compliance with Section 16

With respect to Members subject to Section 16 of the Securities Exchange Act of 1934, transactions under the Plan are intended to comply with all applicable conditions of Rule 16b-3 or its successors under the 1934 Act. To the extent that compliance with any Plan provision applicable solely to such Members is not required in order to bring a transaction by such Member into compliance with Rule 16b-3, it shall be deemed null and void as to such transaction, to the extent permitted by law and deemed advisable by the Plan administrators. To the extent any provision of the Plan or action by the Plan administrators involving such Members is deemed not to comply with an applicable condition of Rule 16b-3, it shall be deemed null and void as to such Members, to the extent permitted by law and deemed advisable by the Plan administrators.

21

EXHIBIT 10(ii)

PFIZER

RETIREMENT ANNUITY PLAN

(As Amended through 1/97)

SECTION 1
Definitions

Wherever used in this Plan:

"Anniversary Year" means 1) the twelve-month period following the date on which an employee first begins his employment with an employer, as well as successive twelve-month periods thereafter, and 2) the twelve-month period following the date on which an employee returns to the employ of the Company or an Associate Company after incurring a one-year break in service, as well as successive twelve-month periods thereafter. No anniversary year shall be credited for purposes of vesting unless in such anniversary year the employee has completed 1,000 or more hours of service for an employer.

"Annuitant" means a person receiving annuity payments under this Plan.

"Annuity trust fund" means the trust fund created by the Company to finance annuities under this Plan.

"Associate Company" means any corporation which adopts this Plan and executes the Trust Agreement pursuant to the provisions of Section 11 hereof and when action is required to be taken hereunder by an Associate Company such action shall be authorized by its Executive Committee or its Board of Directors.

"Career Earnings" means the member's aggregate earnings, excluding any severance payments, during his period of Creditable Service, except that

1) his earnings for each calendar year prior to 1995 shall be the average of the member's earnings during the five consecutive calendar years prior to 1995, during which he rendered Creditable Service, which yield the highest average provided his earnings are not reduced thereby; and

2) only his earnings during his last 35 calendar years of Creditable Service shall be counted; provided that, such a calculation shall not lessen said member's Career Earnings below the result of a prior calculation; and provided, further, that earnings attributable to severance payments shall be counted towards years of Creditable Service, for the purposes of this paragraph only, on the basis of one year, or part thereof, for each year of earnings, or part thereof, paid out as severance.

3) Notwithstanding the foregoing, effective January 1, 1989, the amount of earnings taken into account for any calendar year in determining an employee's career earnings shall not exceed

1

$200,000, adjusted in accordance with Section 401(a)(17) of the Internal Revenue Code and the regulations and other guidance issued thereunder, and effective January 1, 1994, the amount of earnings taken into account for any calendar year in determining an employee's career earnings shall not exceed $150,000, adjusted in accordance with Section 401(a)(17) of the Internal Revenue Code and the regulations and other guidance issued thereunder. Such dollar limitation shall be prorated if, and only to the extent, required by applicable regulations. The amount of any member's normal retirement benefit shall be determined after December 31, 1988 and before January 1, 1994 either by (i) applying the $200,000 limitation to all applicable calendar years (including calendar years beginning before January 1, 1989), provided that the member's normal retirement benefit is not less than his normal retirement benefit determined as of December 31, 1988, or (ii) by applying the $200,000 limitation only to calendar years commencing on and after January 1, 1989, and adding the amounts accrued during such post-1988 calendar years to the member's normal retirement benefit determined as of December 31, 1988, whichever method results in a higher normal retirement benefit to the member; and the amount of any member's normal retirement benefit shall be determined after December 31, 1993 either by (i) applying the $150,000 limitation to all applicable calendar years (including calendar years beginning before January 1, 1994), provided that the member's normal retirement benefit is not less than his normal retirement benefit determined as of December 31, 1993, or (ii) by applying the $150,000 limitation only to calendar years commencing on and after January 1, 1994, and adding the amounts accrued during such post-1993 calendar years to the member's normal retirement benefit determined as of December 31, 1993, whichever method results in a higher normal retirement benefit to the member. For purposes of the limitations under Section 401(a)(17) of the Internal Revenue Code, the family aggregation rules of Section 414(q)(6) of the Internal Revenue Code shall apply, except that in applying such rules, the term "family" shall include only the spouse of the employee and any lineal descendants of the employee that have not attained age 19 before the close of the applicable year.

"Company" means Pfizer Inc, a Delaware corporation, and any predecessor or successor corporation and when action is required to be taken hereunder by the Company, such action shall be authorized by the Executive Committee or the Board of Directors of the Company.

"Earnings" means the actual salary, wages, bonus, or other remuneration earned by an employee from an employer for his service with the employer, as determined by such employer, provided that no part of the cost of any employee benefit, including without limitation stock options, perquisites and group insurance, shall constitute earnings hereunder; and further provided that any remuneration received in the form of salary continuation by an employee while no longer performing services for the Company as an employee shall not be credited hereunder. No part of any bonus or other remuneration forming part of the compensation of any employee shall be used as a basis for a retirement annuity under this Plan, if such bonus should cause such annuity to become discriminatory under the applicable provisions of the Internal Revenue Code.

"Employee" means a person who is employed by an employer.

2

"Employer" means the Company or any Associate Company. For purposes of sections 410 and 411 of the Internal Revenue Code, "Employer" also shall mean any corporation or other trade or business that is treated under the first sentence of section 414(b) or under section 414(c), 414(m) or 414(o) of the Internal Revenue Code as constituting the same "employer" as the Company or an Associate Company, with respect to any period of such affiliated status.

"Disability Leave Status" means the status of a member who has been determined, pursuant to Section 4e. hereof, to be totally and permanently disabled and who has fully utilized his benefits under the employer's short-term disability program.

"Hours of Service" means all hours for which an employee is directly or indirectly paid, or entitled to payment (including back pay for periods for which such awards pertain), by the employer, or any company which is a member of the same control group of corporations as the Company at the time of such service within the meaning of section 1563(a) of the Internal Revenue Code for the performance of duties, or for reasons other than the performance of duties, such as vacation, accident, injury, sickness, short-term disability or authorized leave of absence. In the case of a payment which is made or due on account of a period during which an employee performs no duties, hours of service will be determined in accordance with Department of Labor regulations ss. 2530.200b-2(b) and (c).

"Leased Employee" means any person who is not an employee of the employer and who provides services to the employer if such services are provided pursuant to an agreement between the employer and another, such person has performed such services for the employer on a substantially full-time basis for a period of at least one year, and such services are of a type historically performed in the business field of the employer, by employees.

"Member" means an employee or former employee to whom an annuity is credited under the Plan.

"One-year break in service" shall be an anniversary year in which the member does not perform more than five hundred hours of service.

"Primary Social Security Benefit" means the annual amount available to the member at age 65 under the Old Age Insurance provisions of Title II of the Social Security Act in effect at the time of his termination of employment, without regard to any increases in the wage base or benefit levels that take effect after the date of termination of employment, subject to the following. If any employee terminates service prior to age 65, his Primary Social Security Benefit shall be estimated by assuming continuation of his earnings until age 65 at the same rate in effect at termination of employment; provided however, that, if the employee retires pursuant to Section 4d.(ii), his Primary Social Security Benefit shall be estimated by assuming that he will not receive any income after retirement which would be treated as wages for purposes of the Social Security Act. The Retirement Committee may adopt rules governing the computation of such amounts, and the fact that an employee does not actually receive such amount because of failure to apply or continuance of work, or for any other reason, shall be disregarded. Notwithstanding the foregoing, actual salary history will be used to calculate the Primary Social Security Benefit if this will result in a larger benefit under the Plan for the employee but only if documentation of such history is provided by the employee within two years after the later of his termination of employment or the date the employee receives notice of his benefits under the Plan.

3

"Retire" means to terminate service by a Member who is an Employee in the service of an Employer after meeting the requirements of Sections 4a., b. or
d., respectively, for normal retirement, late retirement or early retirement hereunder.

"Retirement Annuity" means the payments made pursuant to Section 4a.,
b. or d. of the Plan to retired members or their beneficiaries.

"Trustee" means the trustee appointed by the Company to hold and invest the annuity trust fund.

"Vest" means to acquire, in accordance with the express provisions of the Plan, an interest in an annuity under the Plan.

"Vested Annuity" means the payments made pursuant to Section 4c. of the Plan.

The masculine pronoun shall include the feminine pronoun and the feminine pronoun shall include the masculine.

SECTION 2
Eligibility for Membership

a. Employees of the Company: All persons who were in the regular service of the Company on January 1, 1943 shall be included in the membership of the Plan as of January 1, 1943. All persons who entered the regular service of the Company after January 1, 1943 and prior to September 1, 1961, became members of the Plan as of the date of employment. All employees who enter the service of the Company on or after September 1, 1961 become members of the Plan as of the date of their employment provided they are: (1) included in a group or class designated by the Company as eligible for membership in the Plan and (2) in the service of an employer within the United States of America or United States citizens in the service of an employer outside of the continental limits of the United States of America. An employee who is a United States citizen and who is employed outside the continental limits of the United States of America in the service of a foreign subsidiary (including foreign subsidiaries of such foreign subsidiary) of the Company shall be included in the membership of the Plan, provided that the Company has entered into an agreement under section 3121(1) of the Internal Revenue Code which applies to the foreign subsidiary of which such person is an employee and provided further, that contributions under a funded plan of deferred compensation (whether or not a plan described in section
401(a), 403(a), or 405(a), of said Code) are not provided by any other person with respect to the remuneration paid to such individual by the foreign subsidiary. The groups and classes designated by the Company are set forth in Schedule A.

b. Employees of Associate Companies: Wherever a corporation became an Associate Company prior to September 1, 1961, all persons, who were in the regular service of such corporation on the date it became an Associate Company, became members of the Plan as of such date. Subject to Section 2a. hereof, wherever a corporation becomes an Associate Company after September 1, 1961, all employees who are in the service of such corporation on the date it becomes an Associate Company become members of the Plan as of such date and all employees who enter the service of a corporation after it has become an Associate Company become members of the Plan as of the date of employment.

4

c. Leased Employees: No leased employee shall be eligible to become a member of the Plan. However, if a leased employee becomes an employee of the Company, all years of service completed while a leased employee shall be credited solely for purposes of vesting pursuant to Section 4c. of the Plan.

SECTION 3
Service Credited Under Plan

a. Prior Service: Service rendered by a person who is in the service of an employer, before the date on which he becomes a member (in the case of an employee becoming a member after December 12, 1951), who continues in service on and after the date he becomes a member shall be known as "Prior Service" except as provided in Section 4a. and Section 11.

b. Membership Service: Service rendered by an employee for an employer after the date he becomes a member shall be known as "Membership Service."

c. Special Service: Service rendered outside the United States, by a person employed by a corporation which is a subsidiary or affiliate of the Company, but not an Associate Company, at the time of such service (1) before the date on which he becomes a member, who continues in service on and after the date he becomes a member, or (2) during a period of interrupted Membership Service followed by a return to such Service, shall be known as "Special Service."

d. Creditable Service: Membership Service plus Prior Service and Special Service, if any, shall be known as "Creditable Service" under the Plan. A member shall be credited with a full year of Creditable Service under the Plan only if he completes at least 1,000 hours of service within an Anniversary Year and no fractional years will be credited under the Plan; provided, however, that for purposes only of 1) determining the Social Security calculation used in
Section 4a.2 and 2) determining a member's Career Earnings, and his eligibility for early retirement under clauses (i) and (ii) of Section 4d. below, the member's Creditable Service shall be determined on the basis of his number of months of Membership Service plus Prior Service and Special Service without regard to whether he completes at least 1,000 hours of service within an Anniversary Year.

e. Military Service: For the purpose of this Plan, those employees who were in the service of the Armed Forces of the United States, at the time they would have become eligible for membership under the Plan except for such service, or who subsequently enlisted in or were inducted into said Armed Forces, shall be credited with all the benefits under this Plan for service actually rendered to an employer prior to their entrance into said Armed Forces, and shall be credited with time spent on active duty in said Armed Forces for the purposes of computing length of service and benefits payable under the Plan; provided that such employees return to active service with an employer within the time limits provided by law after their separation or discharge from active duty from said Armed Forces, having satisfactorily completed their period of training and service.

f. Leave of Absence: Interruption of active service on account of leave of absence authorized by the employer, leave of absence taken under the Family and Medical Leave Act of 1993, as it may be amended from time to time, and any regulations and other official guidance issued thereunder ("FMLA"), or transfer

5

on Special Service shall not be considered termination of service. Time spent on authorized leave of absence shall be credited for the purpose of computing length of service and benefits payable under the Plan on the following basis:
members shall receive credit for each full year spent on authorized leave of absence for each full year of Creditable Service that they render to an employer following return to active service, except that time spent on authorized leave of absence for medical reasons or under the FMLA shall be credited without requirement of subsequent Creditable Service and time spent on Civic Leave shall be credited after the member has returned to active service for three (3) months. Notwithstanding the foregoing, in the case of Maternity/Paternity Leave, as defined below, up to 501 hours of service shall be credited in the anniversary year in which the Maternity/Paternity Leave begins, if the employee would otherwise have incurred a one-year break in service in that anniversary year, otherwise up to 501 hours of service shall be credited in the following anniversary year to prevent a one-year break in service. Maternity/Paternity Leave means an absence from work (1) by reason of the pregnancy of an employee,
(2) by reason of the birth of a child of an employee, (3) by reason of the placement of a child with the employee in connection with the adoption of the child, or (4) for the purposes of caring for the child during the period immediately following the birth or placement for adoption.

g. Termination of Service: On termination of service, and after he has subsequently incurred a one-year break in service, a person shall forfeit all credit for service previously credited under the Plan unless

(1) He is reemployed before incurring five consecutive one-year breaks in service; or

(2) He is reemployed after his termination of service and thereafter completes at least 24 consecutive months of Creditable Service; or

(3) He is eligible to receive a retirement benefit or a vested annuity under Section 4c.

If a reemployed employee does not forfeit his service credit as provided above, for purposes only of determining his "Career Earnings," the last calendar year in which he rendered Creditable Service shall be treated as being consecutive with the first calendar year in which he renders Creditable Service after his reemployment.

h. General: For the purpose of this Plan, length of service shall be computed in accordance with the employment records of the employer, or of a subsidiary or affiliated corporation of the Company, as the case may be. No employee may voluntarily terminate his status as an active participant in the Plan during his period of employment. The period over which an employee receives remuneration in the form of salary continuation while no longer performing services for the Company as an employee shall not be credited hereunder.

SECTION 4
Benefits to Employees

a. Normal Retirement: Each member who attains his normal retirement date, i.e., age 65, shall be eligible for normal retirement as of the first day

6

of the month following, and if permitted under the provisions of the Age Discrimination in Employment Act, as amended, and other applicable law, shall be retired as of the first day of the month following.

Upon normal retirement, a member shall receive a retirement annuity, subject to the provisions of and payable in the form described in Section 4f. hereof, which shall accrue and be equal to the greatest of:

1. 1.4 per cent of his Career Earnings; or

2. 1.75 per cent of his Career Earnings, less 1.50 per cent of his Primary Social Security Benefit multiplied by his years of Creditable Service, but in no event more than 35 years; or

3. The accrued benefit as of December 31, 1977 payable to him under the provisions of the Plan as of that date.

(1) In the case of any group or class which is designated as eligible for membership in the Plan commencing as of a date after September 1,1961, the employer may limit the Prior Service of persons included in such group or class to service rendered on and after a date to be determined by the employer.

(2) Except in the case of a person in the service of a corporation which becomes an Associate Company after September 1, 1961, the Prior Service benefits of any employee who is a member of the Plan, but who was absent from the employer during all or part of the calendar year next preceding the date he becomes a member, because of sickness, disability, service in the Armed Forces of the United States, or like reasons beyond his control, and who entered the service of the employer prior to such calendar year, shall be computed by crediting to him as earnings for such calendar year -

(i) All earnings actually received by such employee in such calendar year before or after the period of absence from the employer, and

(ii) The earnings he would have received in such calendar year during the period of absence based on a forty-hour week at his straight-time rate of pay at the time of leaving the employer and any increased rate to which he would have been entitled as a result of automatic length-of-service increases or a general increase, and any bonuses or other payments made in such calendar year during such period of absence to which he would normally have been entitled.

b. Late Retirement: In the event that a member remains in service after attainment of his normal retirement date, he may retire on his own application setting forth a date for retirement which shall be the first of the month not less than 30 days following the filing of the application.

c. Vesting: Upon the completion of 5 Anniversary Years of Creditable Service, a member shall acquire a vested interest in an annuity under the Plan. Upon termination of service such a member shall be entitled to receive a vested annuity at age 65, equal to the amount which his Creditable Service up to the date of his termination would then provide; or, at any time prior to age 65, such a member may elect to receive such an annuity on the first day of any month following such election, which shall be computed by applying the percentages set forth in Schedule B hereof to the amount of the annuity computed in accordance

7

with Section 4a., provided he is at least 55 years of age. Notwithstanding anything herein to the contrary, a member who is not otherwise vested, shall become vested upon attaining his normal retirement date, i.e., age 65.

d. Early Retirement: Any member may retire before the attainment of age 65 provided he has reached age 55 and (i) has 10 years or more of Creditable Service; or (ii) his attained age when added to his years of Creditable Service equals or exceeds 90. On early retirement, a member shall receive a retirement annuity commencing at age 65, equal to the annuity to which his Creditable Service up to the date of his retirement would then produce, or, at his election made at any time prior to age 65, a retirement annuity commencing on the first day of any month following his earlier retirement and prior to age 65, which shall be computed by applying the percentages set forth in Schedule C hereof to the amount of the annuity computed in accordance with Section 4a.; provided that, if a member's attained age when added to his years of Creditable Service equals or exceeds 90, his retirement annuity shall be computed by so applying the percentage set forth in Schedule D hereof.

e. Disability Leave Status: Upon total and permanent disability as determined on or after January 1, 1974 by a physician appointed by the employer, a member who has completed at least 5 years of Creditable Service will be eligible for Disability Leave Status. Such status may be terminated or suspended by the Retirement Committee if at any time before age 65 the member again engages in regular full-time employment, fails or refuses to undergo any medical examination ordered by the Retirement Committee, or the Retirement Committee determines on the basis of medical examination that the member has sufficiently recovered to engage in regular full-time employment. While on Disability Leave Status, a member will be credited with Membership Service, and with earnings at the same rate as he had earned in the calendar year prior to the calendar year in which he became totally and permanently disabled, until the member retires, or his Disability Leave Status is sooner terminated or suspended.

8

f. Form of Benefit Payments:

(1) Normal Form: If a member is married on the date his benefits commence, such member shall receive a benefit payable in the form of a joint and survivor annuity which shall provide for an amount actuarially reduced from the amount computed under Section 4a. to be paid to the member for his lifetime; and for an annuity in an amount equal to one-half of such reduced amount to be paid to the member's spouse to whom he was married on the date his benefits commence, for her lifetime, if surviving at the time of the member's death. The form of benefit shall also provide that if the member dies after retirement but prior to the date on which his benefit becomes payable, his surviving spouse will nevertheless be entitled to receive the lifetime annuity to which she would otherwise be entitled beginning at the date that the member's annuity would have become payable and under such circumstances, at her option, the surviving spouse may elect to have benefits commence prior to the date on which the member's annuity would have become payable on an appropriately reduced actuarial basis. The benefit payable to the member and his spouse shall have the equivalent actuarial value of the benefits determined under Section 4a. above. In lieu of such a joint and survivor annuity, such a member may, in accordance with section 417 of the Internal Revenue Code, elect in writing, with the consent of his spouse, at any time prior to the commencement of his benefits, to receive his benefits in the form of a single annuity payable for his lifetime as computed under Section 4a. above, or may revoke any such election previously made by him. Notwithstanding the foregoing, if a member becomes divorced from his spouse after his benefits commence, such member may elect in writing to cancel such joint and survivor annuity and to receive his benefits thereafter in any form permitted under the Plan; provided that, (1) the member obtains a valid written release from his former spouse releasing the Plan from any claim the former spouse may have against the Plan and (2) the member's benefit is adjusted actuarially, including, but not limited to, adjustments for the value of benefits previously paid and for the value of the protection provided by the canceled joint and survivor annuity while in was in effect.

A member who is not married at the time that his benefits commence will receive his benefits in the form of a single annuity payable for his lifetime as computed under Section 4a. above.

(2) Optional Forms: At any time within 90 days prior to the commencement of his retirement benefits, a member who is eligible for a retirement annuity under Section 4a., b., or d. of the Plan may, in accordance with section 417 of the Internal Revenue Code, elect, with the written and witnessed consent of his spouse in the case of a married member, to convert the benefits otherwise payable after retirement into a retirement benefit of equivalent actuarial value in accordance with one of the options named below, or may revoke any such election previously made by him; provided, however, that if one of the options named below shall be so elected and the other named person or persons shall die before the payment of any part of such benefit, then and in that event the benefit shall be restored to the amount of the retirement annuity as provided in Section 4a., b., or d. hereof, as if no such election had been made; and provided further, that if one of the options named below shall be so elected and the member shall die before the date of his retirement then the election shall be of no effect and no payments shall be due under the option.

Option 1: A reduced retirement annuity commencing at or after the member's retirement payable during his life, with the provision that after his death it shall continue during the life of and shall be paid to the person (including his spouse) nominated by him by written designation duly acknowledged

9

and filed with the Retirement Committee at the time such election is made, provided that if the member dies after retirement but prior to the date on which his benefit becomes payable, his surviving beneficiary will nevertheless be entitled to receive such a lifetime annuity beginning at the date that the member's annuity would have become payable and also provided that under such circumstances at his option, the surviving beneficiary may elect to have benefits commence prior to the date on which the member's annuity would have become payable on an appropriately reduced actuarial basis.

Option 2: A reduced retirement annuity commencing at or after the member's retirement payable during his life, with the provision that after his death an allowance of one-half the rate of his reduced allowance shall be continued during the life of, and it shall be paid to, the person [other than his spouse for whom this is the normal form of benefit provided in Section 4f.,
(1) above] nominated by him by written designation duly acknowledged and filed with the Retirement Committee at the time such election is made, provided that if the member dies after retirement but prior to the date his benefit becomes payable, his surviving beneficiary will nevertheless be entitled to receive such a lifetime annuity beginning at the date that the member's annuity would have become payable and also provided that under such circumstances, at his option, the surviving beneficiary may elect to have benefits commence prior to the date on which the member's annuity would have become payable on an appropriately reduced actuarial basis.

Option 3: A retirement benefit in a single lump sum that shall be the actuarial equivalent of the benefit which would otherwise be payable to him, provided that such benefit must be elected by the member prior to the date of receipt of his first benefit payment.

(3) A member may, at the time he elects one of the options described above, name a second person, who, in the event the first named person shall die before the commencement of the annuity to the member, shall acquire all the rights which the first named person would otherwise have had.

(4) Optional benefit payments shall commence at the end of the month following the month in which the last payment to the deceased annuitant was made.

(5) Notwithstanding any other provision of this Section 4f., an optional form of retirement benefit which provides for payments to any person other than the member may be elected by a member, and may be approved by the Retirement Committee, only if the payments to such other person will be merely incidental to the payment or payments made to the member.

(6) Where a member is entitled to or elects to receive a reduced retirement annuity commencing after the member's retirement under which an allowance would have been paid to such member's spouse or other beneficiary after the member's death, and, prior to the date his benefit becomes payable, the member elects any other form of benefit, then and in that event the benefit so payable on his account shall be reduced actuarially to reflect any cost attributable to the benefit earlier so provided to his spouse or other beneficiary as the case may be.

(7) Notwithstanding anything to the contrary in the Plan, effective January 1, 1989, in accordance with Section 401(a)(9) of the Internal Revenue Code and the regulations and other official guidance issued thereunder, the benefit of each member will be distributed or commence to be distributed to him

10

not later than April 1 of the calendar year next following the calendar year in which he attains age 70 1/2; provided, however, that if a member is not a 5% owner and shall have attained age 70 1/2 before January 1, 1988, his benefit shall be distributed or commence to be distributed not later than the April 1 following the later of the calendar year in which he retires. Payment shall be made as follows: If a member is married on the date his benefits commence, such member shall receive a benefit payable in the form of a joint and survivor annuity which shall provide for an amount actuarially reduced from the amount computed under Section 4a. to be paid to the member for his lifetime; and for an annuity in an amount equal to one-half of such reduced amount to be paid to the member's spouse to whom he was married on the date his benefits commence, for her lifetime, if surviving at the time of the member's death. A member who is not married at the time that his benefits commence will receive his benefits in the form of a single annuity payable for his lifetime as computed under Section 4a. above. The member's beneficiary shall receive benefits, if any, only to the extent provided under the applicable form of payment, and such beneficiary shall not be entitled to receive death benefits under Section 4h. As of each following January 1 the member's benefit shall be adjusted to reflect any additional benefits accrued as of the immediately preceding December 31; and further provided that any additional accruals for any twelve consecutive month period shall be offset (but not below zero) by the actuarial value (determined in accordance with applicable law) of benefits received by the member for such period. All distributions under this Plan shall comply with the incidental death benefit requirements of Section 401(a)(9)(G) of the Internal Revenue Code and the regulations (including Treas. Reg. ss.1.401(a)(9)-2) and other official guidance issued thereunder.

With respect to payments to a spouse of a member, the following distribution limitations shall apply:

(A) Where distribution has commenced to the member prior to his death, distribution to the surviving spouse shall be over a period that is no longer than the period under which the member was receiving benefits;

(B) Where distribution has not commenced to the member at the time of his death, distribution to the surviving spouse shall begin no later than the date upon which the member would have attained age 70 1/2, and shall be payable over the life of the surviving spouse or over a period not extending beyond the life expectancy of the surviving spouse. (If the surviving spouse dies before distribution of her benefit commences, the limitations applicable to the distribution of any benefit remaining payable under the Plan shall be determined hereunder as if the surviving spouse were the member.)

With respect to payments to a designated beneficiary of a member (other than the spouse), the following distribution limitations shall apply:

(A) Where distribution has commenced to the member prior to his death, distribution to the designated beneficiary shall be over a period that is no longer than the period under which the member was receiving benefits;

(B) Where distribution has not commenced to the member at the time of his death, distribution to the designated beneficiary shall begin no later than one year after the date of the member's death, or such later date as may be permitted by Treasury Regulations, and shall be payable over the life of the

11

designated beneficiary or over a period not extending beyond the life expectancy of the designated beneficiary.

In all other cases where distribution has not commenced to the member at the time of his death, no benefit remaining payable under the Plan shall be distributed over a period that exceeds five years after the member's death.

Nothing in this Section 4f.(7) shall affect the ability of a member, upon retirement, to select a form of benefit as provided otherwise by Section 4.

g. Adjustment For Federal Old Age Benefits: If a member who is eligible for a retirement annuity under Section 4a., b., or d. of the Plan retires before his Federal Old Age Benefit is payable, he may, at any time or from time to time, elect to have the retirement benefit otherwise payable after retirement to him for his lifetime under the normal form of benefit, or under an optional benefit payment, whichever is applicable, actuarially adjusted to provide, so far as practicable, a constant total retirement income inclusive of the estimated Federal Old Age Benefit, both before and after the Federal benefit is scheduled to begin.

h. Benefits To Surviving Spouse: In the event a member, who has performed at least one hour of service on or after January 1, 1976, dies on or after August 1, 1984, after having become vested under the Plan, leaving a surviving spouse to whom the member was legally married for one year or more prior to his death, an annuity at one-half the rate of the annuity which the member would have been entitled to receive under Section 4f.(1) had he retired and commenced receipt of benefits as of the first of the month following the date of his death, if the member was eligible for retirement at the time of his death, or an annuity at one-half the rate of the annuity which the member would have been entitled to receive under Section 4f.(1) had he retired and commenced receipt of benefits on the date he first would have been eligible to do so, if the member was not eligible for retirement at the time of his death, shall be paid to such spouse, commencing at the end of the month following the month in which the member would have attained his normal retirement date or earlier if the spouse so elects, but not earlier than the date the member first would have reached age 55, as the case may be, for the life of such spouse.

i. (1) All annuities shall be payable in monthly installments.
[Effective August 1, 1994, the previous sentence shall read as follows: All annuities shall be payable in monthly installments provided that any annuity which has an actuarially computed present value at the time of termination of service which is less than $3,500 shall be paid in a lump sum of equivalent actuarial value.] In determining the amount of a lump sum payment payable under this paragraph, (i) equivalent actuarial value shall mean a benefit, in the case of a lump sum benefit payable prior to a member's normal retirement date, of equivalent value to the benefit which would otherwise have been provided commencing at the member's normal retirement date, and (ii) the interest rate to be used shall be an interest rate no greater than that which would be used by the Pension Benefit Guaranty Corporation ("PBGC") for valuing lump sums for single employer plans that terminate three months preceding the date of termination. For this lump sum equivalent actuarial value, the PBGC mortality table shall be used. Monthly installment payments shall commence at the end of the month in which retirement occurs and continue until death. Full payment will be made for the month in which death occurs. In the event a member terminates employment at a time when he is not entitled to any retirement benefit or vested annuity, such member shall be deemed to have received a single sum payment of a zero accrued benefit, and his entire accrued benefit shall immediately be

12

forfeited. In the event such a member is restored to service as an employee, he shall be deemed to have immediately repaid to the Plan the amount which was deemed to have been distributed upon his prior termination.

(2) If any person to whom a retirement annuity, vested annuity or other benefit under this Plan is payable shall not have provided evidence satisfactory to the Retirement Committee of his continued life and address for a period of two years after or during which such annuity or other benefit is payable, the Retirement Committee shall send by registered mail a notice addressed to such person at his last address known to the Committee describing the annuity or other benefit payable to him and stating that unless he communicates with the Committee within 30 days from the date of such notice, the Retirement Committee may suspend payments of the annuity or other benefit to such person while it causes an investigation to be made as to the continued life and address of such person.

(3) If any person to whom a benefit is payable hereunder is an infant, or if the Retirement Committee determines that any person to whom a retirement annuity or other benefit is payable is incompetent by reason of physical or mental disability, the Committee shall have power to cause the payments becoming due to such person to be made to another for his benefit without responsibility of the Committee or the Trustee to see to the application of such payments. Payments made pursuant to such power shall operate as a complete discharge of the annuity trust fund, the Trustee and the Retirement Committee.

(4) Notwithstanding the other provisions of this Section, a member who retires or becomes entitled to a vested annuity shall receive an annuity computed as provided for under the provisions of the Plan in effect on the date of his termination of service or retirement, except that: (a) effective for payments made under Section 4a., b., or d. of the Plan on and after October 1, 1990, the Retirement Annuity of a member who retired or was eligible for normal or late retirement under the Plan prior to January 1, 1990 shall be increased by the greater of the increase attributable to paragraph (b) below or 10%, provided that any increase attributable to this paragraph (a) shall be a minimum of $35 per month for any eligible member who at retirement had either (i) completed at least 25 years of Creditable Service, or (ii) attained his normal retirement date and completed at least 10 years of Creditable Service; and (b) effective on and after January 1, 1981, except for those members who on and after January 2, 1994 elect a retirement benefit in a single lump sum as described in Option 3 under Section f.(2) hereof, any change in the years used in calculating Career Earnings under Section l of the Plan that would improve the benefits payable to a member who had retired prior to the effective date of such change or changes, but on or after January 1, 1981 shall be applied to calculate the Career Earnings of such member; and (c) effective for such payments made on and after July 1, 1994, the retirement annuity of a member who retired or was eligible for normal or late retirement under the Plan prior to January 1, 1994 shall be increased by the greater of $500 or the amount of increase attributable to the amendment to Section 1 adopted on May 26, 1994.

(5) The annual benefit for a calendar year shall be defined and adjusted as provided in section 415(b)(2) of the Internal Revenue Code and no annual annuity shall be payable in excess of the lesser of the maximum dollar amount permitted by section 415(b)(1)(A) of the Internal Revenue Code, or 100% of the average compensation of the member for the three consecutive calendar years which yield the highest average during which the participant was an active participant in the Plan, subject to the following conditions:

13

(a) For purposes of determining the percentage limitations in Section
4i.(5), the term "compensation" shall mean compensation as defined under Section 415(c)(3) of the Internal Revenue Code and the Treasury Regulations issued thereunder.

(b) If benefits begin prior to or following the social security retirement age (as defined in section 415(b)(8) of the Internal Revenue Code), the maximum annual dollar amount will be adjusted in accordance with Regulations issued by the Secretary of the Treasury.

(c) If the member has fewer than ten years of Creditable Service at retirement, the maximum benefit payable as a result of the compensation limitation hereunder shall be multiplied by a fraction, of which the numerator is his Creditable Service and the denominator is 10. If the member has fewer than ten years of participation in the Plan, the maximum benefit payable as a result of the dollar limitation hereunder shall be multiplied by a fraction, of which the numerator is his years of participation and the denominator is 10.

(d) Effective as of January 1 of each calendar year, the maximum annual dollar amount referred to in Section 4i.(5) shall increase to the maximum annual dollar amount as determined by the Commissioner of the Internal Revenue Service for such calendar year pursuant to section 415(d)(1)(A) of the Internal Revenue Code. Notwithstanding Section 4i.(4), such increased maximum dollar amount shall also be applicable to participants who have retired under Section 4a., b., or d. of the Plan regardless of whether they have actually begun to receive such benefits.

(e) With respect to a member who was a participant in the Plan before October 3, 1973, in lieu of the foregoing the maximum computed under this subsection shall be the annuity payable under the Plan provision in effect as of October 2, 1973 based upon (a) his aggregate creditable earnings on such date plus (b) his rate of earnings under the Plan in effect as of such date times his years of Creditable Service after such date.

(f) Notwithstanding the foregoing, in the case of an employee who participates in this Plan and in the Company's Savings and Investment Plan or any other defined contribution plan maintained by the employer, the sum of the defined benefit plan fraction and the defined contribution plan fraction for any year shall not exceed 1. In the event the sum of such fractions exceeds 1, the Retirement Committee shall reduce the pension provided under this Plan in order that none of the Plans shall be disqualified under the Internal Revenue Code. For purposes of applying the limitations of this Section, the following rules shall apply:

(I) The "defined benefit plan fraction" for any year shall mean the projected annual pension payable under this Plan (determined as of the close of the calendar year, and determined under the assumptions that his employment will continue until his normal retirement age (i.e., age 65) (or his current age, if greater), that his earnings will continue at the same rate as in effect in the calendar year under consideration, and that all other relevant factors used to determine benefits under the Plan will remain constant for all future years), over the lesser of (i) 1.25 multiplied by the maximum dollar limitation in effect under Section 415(b)(1)(A) of the Internal Revenue Code for such calendar year, or (ii) 1.4 multiplied by the projected annual benefit that would be payable to the member under the Plan (determined as of the close of the calendar year) if the Plan provided the maximum benefit allowable under section 415(b)(1)(B) of the Internal Revenue Code as adjusted by section 235(g)(4) of the Tax Equity and Fiscal Responsibility Act of 1982; provided, however, that

14

the defined benefit plan fraction with respect to a member whose pension is described in subsection 5(d) hereof shall never be deemed to exceed 1.

(II) The "defined contribution plan fraction" for any calendar year shall mean the actual aggregate annual additions, as hereinafter defined, to the defined contribution plan determined as of the close of the year, over the sum of the lesser of the following amounts determined for the calendar year under consideration and each prior year of service: (i) 1.25 multiplied by the maximum dollar limitation in effect under section 415(c)(1)(A) of the Internal Revenue Code (without regard to section 415(c)(6) of the Internal Revenue Code), or (ii) 1.4 multiplied by the maximum amount of annual additions which could have been credited to such member under section 415(c)(1)(B) of the Internal Revenue Code for such year, taking into account the transition rules for years ending before January 1, 1983 prescribed thereunder and under the Employee Retirement Income Security Act of 1974 and the Tax Equity and Fiscal Responsibility Act of 1982, including the rules of section 415(e)(3) of the Internal Revenue Code, as amended by the Tax Equity and Fiscal Responsibility Act of 1982, and as adjusted by section 235(g)(3) of the Tax Equity and Fiscal Responsibility Act of 1982, unless the Committee elects to apply the rules of section 415(e)(6) of the Internal Revenue Code, as added by the Tax Equity and Fiscal Responsibility Act of 1982; provided, however, that the defined contribution plan fraction shall never be deemed to exceed 1 with respect to years prior to January 1, 1976.

(III) The term "annual addition" shall mean for any calendar year the sum of the Company contributions, Qualified Deferred Earnings Contributions under the Company's Savings and Investment Plan, forfeitures, if any, and (a) for years prior to January 1, 1987, the lesser of employee contributions in excess of 6% of the member's compensation or one-half of the member's total contribution allocated to a member's account in the defined contributions plan, and (b) for years beginning after December 31, 1986, all employee contributions; provided, however, that in computing such annual addition for any year prior to January 1, 1976, the amount of a member's contributions taken into account for such year shall be deemed to be an amount equal to the excess of the aggregate of the member's contributions to the Plan prior to January 1, 1976 (without regard to contributions made on or after October 2, 1973, which exceed the rate of employee contributions prescribed under the terms of the Plan as of such date) over 10% of his aggregate compensation for each year of his participation in the defined contribution Plan prior to such date, multiplied by a fraction, the numerator of which is 1 and the denominator of which is the number of the member's years of participation prior to January 1, 1976.

(IV) The dollar limitation prescribed under Section 4i.(5) hereof shall not apply [and shall not be used in computing the denominator of the defined benefit plan fraction under Section 4i.(5)(e)(I)] in the case of any member who was a member in the Plan on December 31, 1982 and whose annual benefit accrued under the Plan as of such date determined in accordance with section 415(b)(2) of the Internal Revenue Code, exceeds such limitation. In lieu thereof, the member's annual accrued benefit as of December 31, 1982 shall be the applicable dollar limitation.

(g) The limitations of subsection (f) shall not apply with respect to any member who on September 2, 1974 participated in this Plan and a defined contribution plan maintained by an employer, if the following conditions are met:

(I) The defined benefit plan fraction with respect to the member is not increased, by amendment or otherwise, after September 2, 1974, and

15

(II) No contributions are made under the defined contribution plan after such date.

(h) The limitation of this Section with respect to any member who at any time has participated in any other defined benefit plan, or in more than one defined contribution plan, maintained by an employer or by a corporation which is a member of a controlled group of corporations [within the meaning of section 1563(a), determined without regard to section 1563(a)(4) and (e)(3)(C), and section 415(h) of the Internal Revenue Code], of which the employer is a member, shall apply as if the total benefits payable under all defined benefit plans in which the member has been a participant were payable from one plan, and as if the total annual additions made to all defined contribution plans in which the member has been a participant were made to one plan.

(6) The benefits provided under this Plan shall be reduced in the case of any member or beneficiary under uniform rules adopted by the Committee, by the amount of any benefits payable to such member or beneficiary under any other qualified non-government pension plan or program or any retirement or pension benefits payable to him under the laws of any foreign government, to the extent that the benefits payable under such other plan or program are based on service which is included in Prior Service, Membership Service or Special Service, hereunder, and are not attributable to contributions made to such other plan or program by the member.

(7) The benefits provided under this Plan shall be reduced, under uniform rules adopted by the Retirement Committee, in the case of any member reemployed by an employer to avoid duplication of any benefits previously paid by this Plan to such member after a prior termination of service and with respect to annuity payments, only to the extent prior to the member's attainment of age 65. Such reduction shall not apply to the extent that the member shall, upon reemployment, repay to the Trustee any amount received from the Trust with interest thereon compounded annually, at the rate to be determined by the Retirement Committee from the date or dates of receipt of such benefits to the date of repayment to the Trust.

(8) Whenever the amount of a benefit under this Plan is to be determined by an actuarial procedure, effective January 1, 1984, the following actuarial assumptions will be used: The interest rate assumption for annuity forms of benefit payments shall be 7 1/2% per annum and for the lump sum form of payment shall be the applicable Pension Benefit Guaranty Corporation discount rate for the month three months preceding the date of retirement if the election is made before retirement, or for the month following an election for the lump sum form of payment made after retirement. The mortality assumption for all forms of benefit payments except for the lump sum form of payment shall be based upon the latest Unisex Mortality Table prepared by the Plan's actuary and adopted by the Committee. For lump sum payments, the Pension Benefit Guaranty Corporation Immediate Annuity Lump Sum Factor shall be used.

j. Qualified Domestic Relations Order: Notwithstanding anything in the Plan to the contrary, the payment of any benefit to which a member may be entitled under this Section 4 shall be subject to a qualified domestic relations order within the meaning of section 414(p) of the Internal Revenue Code.

k. Special Rules For Certain Members Who Are Not Eligible To Retire Under Sections 4.a. or 4.d.: Notwithstanding anything to the contrary in Sections 4.c., 4.d., 4.f. or 4.h., this Section 4.k. provides special rules for a member who (i) terminates service or dies on or after January 1, 1994, (ii)

16

has completed at least 5 Anniversary Years of Creditable Service upon his termination from service or death, and (iii) has accrued a portion of his Plan benefit prior to January 1, 1994 (the "Pre-1994 benefit"). The otherwise applicable provisions of the Plan shall apply to such member except to the extent specifically modified herein.

(1) Except as provided below, a terminated member (other than a deceased member) described in this Section 4.k. may elect to receive his pre-1994 benefit at any time after his attainment of age 50 and on or before attainment of age 65, commencing on the first day of the month following such election. The member shall receive such benefit in the normal form provided under Section 4.f.(1). If the member elects commencement of his pre-1994 benefit before age 65, such benefit shall be reduced for early commencement by applying the percentages set forth in Schedule C.

(2) If a member (other than a deceased member) described in this Section
4.k. terminates service (A) between the ages 50 and 55 with at least 10 years of Creditable Service, and his attained age when added to his years of Creditable Service equals or exceeds 65, he may elect to receive his pre-1994 benefit before age 65, reduced for early commencement by applying the percentages set forth in Schedule C; or (B) when his attained age when added to his years of Creditable Service equals or exceeds 90, he may elect to receive his pre-1994 benefit before age 65, reduced for early commencement by applying the percentages set forth in Schedule D. Such a member shall receive his pre-1994 benefit in the normal form provided under Section 4.f.(1); provided, however, he may elect an optional form of payment in accordance with the provisions of Section 4f.(2) or 4g.

(3) The surviving spouse of a deceased member described in this Section
4.k., who is entitled to benefits under Section 4.h., may elect to have the amount attributable to the member's pre-1994 benefit commence prior to the end of the month following the month in which the member would have attained his normal retirement date, but not earlier than the date the member first would have reached age 50.

(4) If a member's pre-1994 benefit is paid or commences to be paid pursuant to (1), (2) or (3) above, the remaining portion of his benefit shall be equal to his benefit, determined under the provisions of Section 4.a. (taking into account all years of Creditable Service and all Career Earnings), and expressed in the form of a single life annuity payable at normal retirement date reduced by his pre-1994 benefit, expressed in the form of a single life annuity payable at normal retirement date. Such remaining benefit shall be payable under the otherwise applicable provisions of this Plan.

(5) If receipt of the pre-1994 benefit of a member described in this
Section 4.k. commences after the member attains, or would have attained, age 55, the remaining portion of his benefit shall commence at the same time.

l. Suspension of Benefit Rules: If a member terminates employment or retires and is reemployed by an employer before such member's normal retirement date, the payment of any benefits he is then receiving shall be suspended. If a member terminates employment or retires and is reemployed by an employer on or after such member's normal retirement date, or if a member continues in employment after the member's normal retirement date, payment of the member's pension shall be suspended in accordance with the following provisions:

17

(1) If the member is reemployed or continues in Suspendible Employment, the payment of any benefits he is then receiving or entitled to receive shall be suspended until his subsequent retirement. The Retirement Committee will notify the member of the suspension of benefits in the manner, form and at such time as is required by applicable law.

(2) If the member is reemployed, or continues in employment other than Suspendible Employment, the payment of any benefits he is then receiving shall be suspended, and the amount of his resumed benefit payments upon subsequent retirement shall be the amount in effect immediately before the suspension, increased actuarially to reflect the delayed commencement of payments, but only to the extent the value of such actuarial increase exceeds the value of any additional pension earned during the period employment after normal retirement date.

(3) For purposes of this Section 4.(l), "Suspendible Employment" means the completion of 40 or more hours of service with the employer during any calendar month (or four or five week payroll period).

m. Direct Rollover Rules: Effective for distributions under the Plan on or after January 1, 1993, at the written request of a distributee (which shall mean a member, a surviving spouse of a member, or a spouse or former spouse of a member that is an alternative payee under a Qualified Domestic Relations Order), and upon receipt of the written consent of the Retirement Committee, the Trustee shall effectuate a direct rollover distribution of the amount requested by the distributee in accordance with Section 401(a)(31) of the Internal Revenue Code, to an eligible retirement plan (as defined in Section 401(a)(31)(D) of the Internal Revenue Code). Such amount shall constitute all or part of any distribution otherwise to be made hereunder to the distributee, provided that such distribution constitutes an "eligible rollover distribution," as defined in
Section 402(c) of the Internal Revenue Code and the regulations and other guidance issued thereunder. All direct rollover distributions shall be made in accordance with the following:

(1) The term "eligible rollover distribution" means any distribution of all or any portion of the balance to the credit of the distributee, except that an eligible rollover distribution does not include: any distribution that is one of a series of substantially equal periodic payments (not less frequently than annually) made for the life (or life expectancy) of the distributee or for a specified period of ten years or more; or any distribution to the extent such distribution is required under Section 401(a)(9) of the Internal Revenue Code; or any distribution to the extent such distribution is not includible in gross income (determined without regard to the exclusion for net unrealized appreciation with respect to employer securities).

(2) The term "eligible retirement plan" means an individual retirement account described in Section 408(a) of the Internal Revenue Code, an individual retirement annuity described in
Section 408(b) of the Internal Revenue Code, or (to the extent provided in Section 401(a)(31)(D) of the Internal Revenue Code) a qualified trust described in Section 401(a) of the Internal Revenue Code that accepts the distributee's eligible rollover distribution. However, in the case of an eligible

18

rollover distribution to a surviving spouse, an eligible retirement plan is an individual retirement account or individual retirement annuity.

(3) A direct rollover distribution shall be made to only one eligible retirement plan; a distributee may not elect to have a direct rollover distribution apportioned between more than one eligible retirement plan.

(4) Direct rollover distributions shall be made in cash in the form of a check made payable to the trustee or custodian of the eligible retirement plan, in accordance with procedures established by the Retirement Committee.

(5) No direct rollover distribution shall be made unless the distributee furnishes the Retirement Committee with such information as the Committee shall require, including but not limited to: the name of the recipient eligible retirement plan, and any account number or other identifying information.

(6) A distributee may have a portion of an eligible rollover distribution distributed directly to him and a portion directly rolled over to an eligible retirement plan as such distributee may determine.

19

SECTION 5
Contributions

All of the retirement annuity payments provided under this Plan shall be financed entirely by means of contributions made by the Company and Associate Companies, subject to conditions set forth under Sections 9 and 12.

a. Service Contributions: Subject to the future financial needs and condition of the business as determined by its Board of Directors, it is the intention of the employer to continue the Plan and, within the time allowed by law for filing of its federal income tax return for each fiscal year, to make regular contributions each year in such amounts as are necessary to maintain the Plan on a sound actuarial basis, and to meet minimum funding standards prescribed by any applicable law. Upon transfer from Special Service to service with an employer, appropriate contributions shall be made with respect to each employee so transferred to provide the benefits for such Special Service.

b. Actuarial Calculations: The Company shall adopt from time to time, service and mortality tables and the rates of interest to be used in actuarial calculations required in connection with the Plan. As an aid to the Company in adopting such tables the actuary designated by the Company shall from time to time submit recommendations to the Company as to possible changes affecting such tables. The actuary shall, in addition, make annual valuations of the contingent assets and liabilities of the Plan and establish the rate of Company contributions payable to the Plan.

c. Continuation of Plan: The continuation of this Plan and the payment of contributions are not assumed as contractual obligations of the employer.

SECTION 6
Funding the Plan

a. Trust Fund: All contributions made by the employer to provide the benefits under this Plan shall be paid into a trust fund. The trust fund will be held and invested as described in the trust agreement, a brief description of the provisions of which is given in Section 7 hereof. No part of the fund may be used for, or diverted to, purposes other than for the exclusive benefit of employees or their beneficiaries, nor may any part of the fund be remitted to the Company, except as otherwise permitted under ERISA, provided, however, that the reasonable expenses of the Trustee in the administration of this trust as well as fees and other charges incurred for investment counseling and for actuarial services and expenses of the Retirement Committee and the Plan Assets Committee will be paid out of the trust fund.

b. Annuities: Notwithstanding anything herein to the contrary, if the Retirement Committee shall find that any benefit prescribed in this Plan can be provided with equal security to the members at the same or less cost, or at an increased cost, provided the Company shall approve, through the purchase of immediate or deferred annuities from any governmental agency or insurance company or companies, approved by the Company, the Retirement Committee is authorized and empowered to provide for the payment of such benefits by purchase thereof from such agency or company or companies.

20

SECTION 7
Administration of the Trust Fund - The Trust Agreement

The Company has entered into a Trust Agreement with The Northern Trust Company, providing for the administration of the annuity trust fund by that bank as Trustee thereof, which includes provisions with respect to the powers and authority of the Trustee (in its discretion and/or as directed by an Investment Adviser appointed by the Plan Assets Committee) as to the investment and reinvestment of the trust fund and the income therefrom provided, however, the Company specifically reserves unto itself or its delegate the Plan Assets Committee, through the Proxy Voting Committee, the right to vote any shares of securities held in the Trust Fund or, alternatively, may permit the Investment Adviser to exercise such responsibility and provisions with respect to the administration of the trust fund, the limitations on the liability of the Trustee, authority of the Company to settle the accounts of the Trustee and of the Retirement Committee on behalf of all persons having any interest in the trust fund, and from time to time, to appoint a new Trustee in place of any then acting Trustee to the trust fund, and that, with respect to any payments to or for the benefit of any employee or beneficiary under this Plan, the Trustee shall follow the directions of the Retirement Committee. The Trust Agreement further provides that the Company shall have the right, from time to time, to modify or amend the Trust Agreement in whole or in part, provided that no such amendment shall divert any part of the annuity trust fund to purposes other than the exclusive benefit of employees or their beneficiaries; provided, however, that the reasonable expenses of the Trustee in the administration of this trust as well as fees and other charges incurred for investment counseling (including any Investment Adviser) and for actuarial services and expenses of the Retirement Committee and of the Plan Assets Committee will be paid out of the trust fund. The Trust Agreement shall be deemed to form a part of this Plan, and any and all rights or benefits which may accrue to any person under this Plan shall be subject to all the terms and provisions of said Trust Agreement.

SECTION 8
Committees

a. (1) Retirement Committee: This Plan is administered by a Retirement Committee consisting of at least three persons appointed by the Board of Directors of the Company. Members of the Retirement Committee may resign at any time upon due notice in writing. The Board of Directors of the Company may remove any Retirement Committee members and appoint others in their places. The Retirement Committee may act by a majority of its members.

(2) The Retirement Committee shall be the Plan Administrator and shall have fiduciary responsibility under the Employee Retirement Income Security Act of 1974 for the general operation of the Plan, except that the Retirement Committee shall have no responsibility for or control over the investment of the Plan assets, other than the authority to provide for the purchase of annuities pursuant to Section 6b. of the Plan and to give written directions to the Trustee to retain cash as provided in Article II Section 2.1(a)i of the Trust Agreement to meet contemplated payments under the Plan. The Retirement Committee may appoint or employ such persons as it deems necessary to render advice with respect to any responsibility of the Retirement Committee under the Plan. The Retirement Committee may allocate to any one or more of its members any

21

responsibility it may have under the Plan and may designate any other person or persons to carry out any responsibility of the Retirement Committee under the Plan, other than its authority described above with respect to the retention of cash and the purchase of annuities. Any person may serve in more than one fiduciary capacity with respect to the Plan.

(3) Duties:

(a) The Retirement Committee will determine the names of annuitants and joint annuitants and the amounts that are payable to them from the trust fund in accordance with the provisions of this Plan.

(b) The Retirement Committee shall keep in convenient form such data as shall be necessary for actuarial valuations of the contingent assets and liabilities of the Plan and for checking the experience thereof.

(c) The Retirement Committee shall determine the manner in which the funds of the Plan shall be dispensed including the form of voucher or waiver to be used in making disbursements and the due notification of persons authorized to approve and sign the same.

(d) The Retirement Committee shall determine whether a judgment, decree or order, including approval of a property settlement agreement, made pursuant to a state domestic relations law, including a community property law, that relates to the provision of child support, alimony payments, or marital property rights of a spouse, former spouse, child, or other dependent of the member is a qualified domestic relations order within the meaning of section 414(p) of the Internal Revenue Code, and shall give the required notices and segregate any amounts that may be subject to such order if it is a qualified domestic relations order, and shall administer the distributions required by any such qualified domestic relations order.

(4) Administration of Plan: The Retirement Committee is authorized to make such rules and regulations as may be necessary to carry out the provisions of the Plan and will determine any questions arising in the administration, interpretation and application of the Plan, which determination shall be conclusive and binding on all parties. The Retirement Committee is also authorized to adopt such rules and regulations as in its opinion may be necessary to prevent inequities with respect to any employees whose total annual compensation did not exceed $7,500 in any year during which such inequity occurred and the determination of the Committee on such inequity and the correction thereof shall be conclusive and binding on all parties. The Retirement Committee is also authorized to provide for accelerated vesting and to purchase or arrange for payment of an appropriate annuity or any other form of payment or to permit the immediate distribution of Plan benefits in those cases involving groups of employees involuntarily terminated, including, but not limited to, cases involving groups of employees who involuntarily cease to render Creditable Service due to a liquidation, sale, or other means of terminating the parent-subsidiary or controlled group relationship with the Employer or the sale or other transfer to a third party of all or substantially all of the assets used by the Employer in a trade or business conducted by the Employer, when the Retirement Committee determines that such action is appropriate to prevent inequities with respect to such employees, and the determination of the Committee in such matters shall be conclusive and binding on all parties. For the purpose of the preceding sentence, Employer includes the definition of controlled group contained in Section 1c. hereof. Further, the Retirement Committee, upon the written request of the Company's Vice

22

President-Personnel, is authorized, with respect to a member of the Plan who has five or more years of Credited Service and who is transferred to the purchaser of a portion of the Company's operations, effective the day after the Closing Date of the Sale, to grant additional Creditable Service and additional credit for age under the Plan, in each case up to one percent for each year of Creditable Service, and to advance the date through which a member's earnings are calculated pursuant to Section 1q. hereof, so as to prevent hardship with respect to his participation in said purchaser's pension plan. The Retirement Committee, upon written request of the Company's Vice-President-Personnel, is also authorized to waive, either in whole or in part, the percentage reductions for early commencement of retirement benefits set forth in Section 4d. and/or to grant additional years of Creditable Service and additional credit for age under the Plan, or a combination thereof, up to a total of five (5), in those cases where groups of employees have terminated employment either as a result of a reduction in the work force or early retirement incentive programs or for similar economic reasons, and the determination of the Retirement Committee shall be conclusive and binding on all parties. The Retirement Committee is also authorized to adopt such rules and regulations as it may consider necessary or desirable for the conduct of its affairs and the transaction of its business, including, but not limited to, the power on the part of the Retirement Committee to act without formally convening and to provide that action of the Retirement Committee may be expressed by written instrument signed by a majority of its members. It shall elect a Secretary, who need not of necessity be a member of the Retirement Committee, who shall record the Minutes of its proceedings and shall perform such other duties as may from time to time be assigned to him. The Retirement Committee may retain legal counsel (who may be counsel for the Company) when and if it be found necessary to do so and may also employ such other assistants, clerical or otherwise, as may be requisite, and expend such monies as may be requisite in their work. All of these expenses of the Retirement Committee and the reasonable expenses of the Trustee in the administration of this trust as well as for actuarial services will be paid out of the trust fund.

b. (1) Plan Assets Committee: A Plan Assets Committee consisting of at least three persons appointed by the Board of Directors of the Company shall have exclusive authority and fiduciary responsibility under the Employee Retirement Income Security Act of 1974 (i) to appoint and remove Investment Advisers, if any, under the Plan and the Trust Agreement, (ii) to direct the segregation of assets of the Retirement Annuity Trust Fund into an Investment Adviser account or accounts at any time, and from time to time to add to or withdraw assets from such Investment Adviser account or accounts as it deems desirable or appropriate and also to direct the Company's contribution or any portion thereof into any of the accounts maintained under the trust, (iii) to direct the Trustee to enter into an agreement or agreements with an insurance company or companies designated by the Plan Assets Committee as provided in Article II Section 2.6 of the Trust Agreement, (iv) to establish investment guidelines for areas other than those set forth above and, within such guidelines, to direct the Trustee to purchase and sell securities or to enter into one or more agreements with one or more companies, partnerships or joint ventures and to transfer assets of the Retirement Annuity Trust Fund to such entities for purposes of investment therein; provided however, that, except as expressly set forth herein, the Plan Assets Committee shall have no responsibility for or control over the investment of the Plan assets held in the fund established hereunder. Notwithstanding the foregoing, the Company specifically reserves unto itself or its delegate, the Plan Assets Committee, through the Proxy Voting Committee, the right to vote any shares of securities held in the Trust Fund or, alternatively, may permit the Investment Adviser to exercise such responsibility. In addition, the Plan Assets Committee shall receive the reports and recommendations of the actuary designated by the Company under Section 5b. hereof concerning actuarial assumptions to be adopted on subjects including, but not limited to, employee turnover, rate of mortality,

23

disability rate, ages at actual retirement, rate of pay increases, investment income and size of participant group, and make such recommendations and determinations based upon such reports and recommendations as it may deem necessary or appropriate. The Plan Assets Committee may appoint or employ such persons as it deems necessary to render advice with respect to any responsibility of the Plan Assets Committee under the Plan. The Plan Assets Committee may allocate to any one or more of its members any responsibility that it may have under the Plan and may designate any other person or persons to carry out any responsibility of the Plan Assets Committee under the Plan. Any person may serve in more than one fiduciary capacity with respect to the Plan. Members of the Plan Assets Committee may resign at any time upon due notice in writing. The Board of Directors of the Company may remove any Plan Assets Committee members and appoint others in their places. The Plan Assets Committee may act by a majority of its members.

(2) The Plan Assets Committee is authorized to make such rules and regulations as may be necessary to carry out its duties under the Plan. The Plan Assets Committee is also authorized to adopt such rules and regulations as it may consider necessary or desirable for the conduct of its affairs and the transaction of its business, including, but not limited to, the power on the part of the Plan Assets Committee to act without formally convening and to provide that action of the Plan Assets Committee may be expressed by written instrument signed by a majority of its members. It shall elect a Secretary, who need not of necessity be a member of the Plan Assets Committee, who shall record the Minutes of its proceedings and shall perform such other duties as may from time to time be assigned to him. The Plan Assets Committee may retain legal counsel (who may be counsel for the Company) when and if it be found necessary to do so and may also employ such other assistants, clerical or otherwise, as may be requisite, and expend such monies as may be requisite in their work. All of these expenses of the Plan Assets Committee as well as expenses for investment counseling will be paid out of the trust fund.

c. To the extent permitted by law, the Retirement Committee, the Plan Assets Committee, the Trustee, the Boards of Directors of the employers, and the employers and their respective officers shall not be liable for the directions, actions or omissions of any agent, legal or other counsel, accountant or any other expert who has agreed to the performance of administrative duties in connection with the Plan or Trust. The Committees, the Trustee, the Boards of Directors of the employers, and the employers and their respective officers shall be entitled to rely upon all certificates, reports, data, statistics, analyses and opinions which may be made by such experts and shall be fully protected in respect to any action taken or suffered by them in good faith reliance upon any such certificates, reports, data, statistics, analyses or opinions; all action so taken or suffered shall be conclusive upon each of them and upon all persons having or claiming to have any interest in or under the Plan.

d. Indemnification: Each member of the Retirement Committee and each member of the Plan Assets Committee shall be indemnified by the Company against all costs and expenses (including counsel fees but excluding any amount representing a settlement unless such settlement be approved by the Board of Directors of the Company) reasonably incurred by or imposed upon him, in connection with or resulting from any action, suit or proceeding, to which he may be made a party by reason of his being or having been a member of the Retirement Committee or the Plan Assets Committee, as applicable (whether or not he continues to be a member of such Committee at the time when such cost or expense is incurred or imposed), to the full extent permitted by law. The foregoing rights of indemnification shall not be exclusive of other rights to which any member of the Retirement Committee or the Plan Assets Committee may be entitled as a matter of law.

24

SECTION 9
Amendments and Changes in Plan and Coverage

Because of the uncertainty as to future conditions, including the possibility that Federal Social Security Benefits may be extended and liberalized, the Company necessarily reserves the right, through its Board of Directors, at any time to modify, suspend or discontinue this Plan or the annuity trust fund and to change the Trustee. Any such amendment may effect a substantial change in the Plan, and may include (but shall not be limited to) provisions for disability pensions, provisions permitting or requiring employees to make contributions to the trust, provisions for the participation in the Plan of any corporation or any change deemed by the Company to be necessary or desirable to make the Plan conform to, or to obtain tax benefits under, any existing or future laws or rules or regulations thereunder, and a change in the class or classes of persons to whom any retirement annuity may be or become payable or in the amount of any such annuity. An employer may at any time, or from time to time, change the designation of a group or class of employees with respect to the eligibility or non-eligibility of such group or class for membership in the Plan, as well as change, modify, consolidate or redefine any and all groups or classes of employees for purposes of such designation. Any such amendment or change shall not reduce any retirement annuities which shall have already been granted and which are then in force and shall not so operate as to divert substantial amounts of trust funds from one group of employees to any other group of employees. No such amendment or change shall discriminate in favor of employees who are officers, stockholders, persons whose principal duties consist of supervising the work of other employees, or highly compensated employees or their beneficiaries, provided, however, that changes shall not be considered discriminatory, because of readjustment of the Plan to integrate benefits in accordance with present or future Social Security Laws of the United States or any State or States.

The Committee may make non-substantive administrative changes to the Plan so as to conform with or take advantage of governmental requirements, statutes or regulations.

SECTION 10
Non-Alienation of Benefits

No benefit payable under the provisions of the Plan shall be subject in any manner to anticipation, alienation, sale, transfer, assignment, pledge, encumbrance or charge, and any attempt so to anticipate, alienate, sell, transfer, assign, pledge, encumber or charge the same shall be void; nor shall any such benefits be in any manner liable for or subject to the debts, contracts, liabilities, engagements or torts of any member or beneficiary except as specifically provided in the Plan, or by a qualified domestic relations order within the meaning of section 414(p) of the Internal Revenue Code, or by any other applicable law.

SECTION 11
Associate Companies

25

a. Adoption of Plan: Any corporation, with the consent of the Company, by taking appropriate corporate action may become an Associate Company and secure the benefits of this Plan for its employees by adopting this Plan as its Retirement Annuity Plan and by executing the Trust Agreement. As a condition to such corporation becoming an Associate Company, the Company may require such corporation to modify or amend any pension plan which such corporation may then have so as to conform to the provisions of this Plan, or to limit Prior Service, as defined in Section 3, to service rendered for such corporation on and after a date to be determined by the Company. The Associate Company shall thereafter promptly deliver to the Trustee a certified copy of the resolutions or other documents evidencing its adoption of this Plan and also a written instrument showing the consent by the Company to such adoption.

b. Employee Transfers: Any employee who is transferred from one employer under this Plan to another employer under this Plan shall receive upon retirement a retirement annuity based on his Creditable Service with all such employers.

c. Withdrawal: The Company may upon thirty (30) days written notice request an Associate Company to withdraw from the Plan and upon the expiration of such thirty (30) day period, unless such Associate Company has taken the appropriate corporate action to accomplish such withdrawal, such Associate Company shall be deemed to have withdrawn from the Plan and the provisions of
Section 12 shall apply. The Retirement Committee shall give written notice to the Trustee of any such withdrawal.

SECTION 12
Withdrawal from Plan

Any employer may withdraw from the Plan by giving the Retirement Committee thirty (30) days written notice of its intention to withdraw. In the event any employer withdraws from the Plan, the Retirement Committee shall thereupon determine, on the basis of actuarial valuation, that portion of the annuity trust fund held on account of the employees of such employer not yet retired. The Retirement Committee shall thereupon instruct the Trustee to set aside such assets in the annuity trust fund, as the Retirement Committee shall specify, which equal in value that portion of the annuity trust fund so determined by the Retirement Committee. The Retirement Committee in its discretion shall direct the Trustee either (1) to hold such assets so set aside for the exclusive benefit of the employees of such withdrawing employer, who were members under this Plan on the date of such withdrawals; or (2) to deliver such assets to such trustee or trustees as shall be selected by such withdrawing employer; or (3) to use such assets to purchase an appropriate retirement annuity for each employee of such withdrawing employer who was a member on the date of such withdrawal.

SECTION 13
Termination of Plan

a. Application of Funds: Upon complete or partial termination of the Plan, the rights of all affected members to affected benefits accrued to the date of such termination, to the extent then funded, shall be non-forfeitable. If the Plan is terminated by an employer for any reason, the funds in the trust shall be used and applied by the Retirement Committee, after expenses, exclusively for the benefit of members and annuitants at the time of termination

26

in accordance with the formula set forth below by either purchasing or arranging for payment of an appropriate annuity or any other form of payment approved by the Retirement Committee, and for no other purpose, and when so used and applied the trust shall finally cease and be at an end. The funds shall be allocated for distribution in the following order:

(1) In the case of a benefit, payable as an annuity to a member or beneficiary, which was in pay status as of the beginning of the three-year period ending on the termination date of the Plan, to each such benefit, based on the provisions of the Plan (as in effect under the five-year period ending on such date) under which such benefit would be the least.

(2) In the case of a benefit, payable as an annuity to a participant or beneficiary, which would have been in pay status as of the beginning of such three-year period if the participant had retired prior to the beginning of the three-year period and if his benefits had commenced (in the normal form of annuity under the Plan) as of the beginning of such period, to each such benefit based on the provisions of the Plan (as in effect during the five-year period ending on such date) under which such benefit would be the least.

(3) To all other benefits, if any, of individuals under the Plan subject to the Pension Benefit Guaranty Corporation insurance guarantee and to any additional benefits to a substantial owner, as that term is defined in
Section 4022(b)(6)(A) of the Employee Retirement Income Security Act of 1974, which would be subject to the guarantee but for their "substantial owner" status.

(4) To all other non-forfeitable benefits under the Plan and, if the assets are not sufficient to cover all such remaining non-forfeitable benefits, then to the benefits resulting from the Plan as in effect five years prior to the date of termination, and if assets remain after satisfaction of such benefits, then to each increase in benefits resulting from amendments during the last five years in the order in which those amendments occurred.

(5) To all other benefits under the Plan.

(6) In the event that there remain additional funds available for distribution after the funds have been distributed as provided in said paragraphs (1), (2), (3), (4) and (5) above, any other provisions of this
Section 13 notwithstanding, any funds, remaining as a result of actuarial error may be reclaimed by the employer. Any of such funds remaining, but not as a result of actuarial error, and/or any of such funds remaining as a result of actuarial error, but not reclaimed by the employer, shall be distributed in such a manner that all the annuitants and members included in paragraphs (1), (2),
(3), (4) and (5) above shall receive an additional amount determined by multiplying the total value of these remaining assets in the trust fund by a percentage computed by dividing the value as of the date of termination of such annuitant's remaining benefits or such member's benefits, as the case may be, by the total value as of the date of termination of the remaining benefits, or the benefits of all such annuitants or members under the Plan, as the case may be.

b. In the event of the termination of the Plan, the benefit of any one of the twenty-five (25) most highly compensated employees (whether a current or former employee) is limited to a benefit that is nondiscriminatory under Section 401(a)(4) of the Internal Revenue Code.

27

c. Unless an escrow or similar agreement is permitted and established in accordance with IRS procedures, annual payments to any one of the twenty-five
(25) most highly compensated employees is restricted to the sum of:

(1) the amount that would be paid under a straight life annuity that is the actuarial equivalent of the employee's accrued benefit and other benefits to which the employee is entitled under the Plan; and

(2) the amount the employee is entitled to receive under a social security supplement.

However, none of the restrictions in this subsection (c) shall apply to any one of the twenty-five (25) most highly compensated employees if any of the conditions set forth in IRS Regulations Section 1.401(a)(4)-5(b)(3)(iv) are satisfied with respect to such employee.

d. Excess Reserves: Any excess reserves resulting from the application of the foregoing provisions of this Section shall be used and applied for the benefit of other members who are employees of such employer, in accordance with the provisions of the Plan.

e. Change in Law: In the event that it should subsequently be determined by statute, court decision administrative ruling, or otherwise, that the provisions of this Section applicable to the twenty-five (25) most highly compensated employees are no longer necessary to qualify the Plan under the Internal Revenue Code, such provisions shall be ineffective without the necessity of further amendment of the Plan.

28

SECTION 14
Plan Mergers and Consolidations

In the event of any merger or consolidation of the Plan with, or transfer in whole or in part of the assets and liabilities of the trust fund to another trust fund held under, any other plan of deferred compensation maintained or to be established for the benefit of all or some of the members of this Plan, the assets of the trust fund applicable to such members shall be transferred to the other trust fund only if:

a. Each member would, if either this Plan or the other plan were to terminate at such time, receive a benefit immediately after the merger, consolidation or transfer which is equal to or greater than the benefit he would have been entitled to receive immediately before the merger, consolidation or transfer if this Plan had then terminated;

b. The employer and any new or successor employer of the affected members shall authorize such transfer of assets; and

c. Such new or successor employer shall assume all liabilities with respect to such members' inclusion in the new employer's plan.

SECTION 15
Claims Procedure

Any request by a member or any other person for any benefit alleged to be due under the Plan shall be known as a "Claim" and the member or such other person making a Claim shall be known as a "Claimant."

A Claim shall be filed when a written statement has been made by the Claimant or his authorized representative and delivered to the Vice President-Personnel, Pfizer Inc, 235 East 42nd Street, New York, New York 10017. This statement shall include a general description of the benefit which the Claimant believes is due and the reasons that the Claimant believes such benefit to be due, to the extent this is within the knowledge of the Claimant. It shall not be necessary for the Claimant to cite any particular Section or Sections of the Plan, but only to set out the facts known to him which he believes constitute a basis for a Claim.

Within 90 days of the receipt of the Claim by the Plan, the Vice President-Personnel shall (i) notify the Claimant that the Claim has been approved, (ii) notify the Claimant that the Claim has been partially approved and partially denied, or (iii) notify the Claimant that the Claim has been denied. Notice of the decision shall be in writing and shall be delivered to the Claimant either personally or by first-class mail. Special circumstances may require an extension of time for processing the claim. In such event, written notice of the extension shall be furnished to the Claimant prior to the termination of the initial 90 day period but in no event shall the extension exceed a period of 90 days from the end of such initial period. The notice shall indicate the special circumstances requiring an extension of time and the date by which the Plan expects to render the final decision.

29

In the event a Claim is denied in whole or in part, the notice of denial shall set forth (i) the specific reason or reasons for the denial, (ii) specific reference to the pertinent Plan provisions on which the denial is based, (iii) a description of any additional material or information necessary for the Claimant to perfect the Claim and an explanation of why such material or information is necessary, and (iv) an explanation of the Plan's claims review procedure.

Within 60 days of the receipt of a notice of denial of a Claim in whole or in part, a Claimant or his duly authorized representative (i) may request a review upon written application to the Retirement Committee, (ii) may review documents pertinent to the Claim, and (iii) may submit issues and comments in writing to the Retirement Committee.

It shall be the duty of the Retirement Committee to review a Claim for which a request for review has been made and to render a decision not later than 60 days after receipt of a request for review; provided, however, that if special circumstances require an extension of time for processing, a decision shall be rendered no later than 120 days after receipt of a request for review. Written notice of any such extension shall be furnished to the Claimant within 60 days after receipt of request for review. The decision shall be in writing and shall include the specific reasons for the decision and specific references to the pertinent Plan provisions on which the decision is based. The decision shall be delivered to the Claimant either personally or by first-class mail. If the decision on review is not furnished within such time, the Claim shall be deemed denied on review.

SECTION 16

Top-Heavy Rule

a. Notwithstanding any provision in the Plan to the contrary, if the Plan is determined by the Retirement Committee to be top-heavy, as that term is defined in section 416 of the Internal Revenue Code, in any calendar year, commencing on or after January 1, 1984, then for that calendar year the vesting schedule and minimum benefit rules, as set forth below, shall be applicable. Determination of whether the Plan is top-heavy shall be made in accordance with section 416(g)(2)(B) of the Internal Revenue Code.

b. Definitions solely applicable to this Section 16.

(1) "Compensation" shall mean the amount reportable by the employer for federal income tax purposes as wages paid to the member for such period.

(2) "Determination Date," the date for determining whether the Plan is top-heavy, shall be the December 31 of the preceding year.

(3) "Key Employee" shall have the same meaning as in section 416(i)(1) of the Internal Revenue Code.

(4) "Non-Key Employee" shall mean an employee other than a Key Employee as defined in subsection b.(3) above.

30

(5) "Testing Period" shall mean the period of consecutive years, not exceeding five (5), during which a member had the greatest aggregate compensation from the employer, but not including years beginning before January 1, 1984 or years in which this Plan was determined not to be top-heavy.

(6) "Valuation Date," for minimum funding purposes, shall be a date within the twelve-month period ending on the Determination Date, regardless of whether a valuation for minimum funding purposes is performed in that year.

c. For the purpose of determining whether this Plan is top-heavy, this Plan, the Company's Savings and Investment Plan, and the Company's Employee Stock Ownership Plan shall be aggregated, as provided in section 416(g)(2)(A) of the Internal Revenue Code.

d. Vesting Schedule: Employees shall acquire a vested interest in an annuity under the Plan in accordance with the following schedule:

20% of the accrued benefit under Section 4a. after two (2) Anniversary Years of Creditable Service; 40% of the accrued benefit under Section 4a. after three (3) Anniversary Years of Creditable Service; 60% of the accrued benefit under Section 4a. after four (4) Anniversary Years of Creditable Service; 80% of the accrued benefit under Section 4a. after five (5) Anniversary Years of Creditable Service; and 100% of the accrued benefit under Section 4a. after six (6) Anniversary Years of Creditable Service.

e. Minimum Benefit Rule: A Non-Key Employee's benefit shall not be less than the lesser of: 2% of his average compensation during the testing period, not exceeding the compensation limitation under section 416(d) of the Internal Revenue Code and applicable regulations, multiplied by those years of service with the employer on or after January 1, 1984 in which this Plan is determined to be top-heavy or 20% of his average compensation during the testing period; provided, however, that any minimum benefit provided under this Section 16 shall be offset by the actuarial equivalent of the value of the employer's contributions to the Company's Savings and Investment Plan and the Company's Employee Stock Ownership Plan on the Non-Key Employee's behalf. Such actuarial equivalent shall be calculated using the Pension Benefit Guaranty Corporation immediate annuity lump sum factor, with male and female factors equally weighted, in effect three (3) months prior to termination of employment. All accruals derived from employer contributions, whether or not attributable to years in which the Plan is top-heavy, may be used in determining whether the minimum accrued benefit requirements for a Non-Key Employee has been satisfied.

f. If the Plan becomes subject to the adjustments pursuant to section 416(h) of the Internal Revenue Code, the defined benefit plan fraction described in section 415(e)(2)(B) and the defined contribution fraction described in section 415(e)(3)(B) shall be applied by substituting 1.0 for 1.25 in the denominator of each fraction.

g. If the Plan becomes top-heavy and in a subsequent year ceases to be top-heavy, the vesting schedule under Section 16d. shall revert to the vesting schedule under Section 4c. of the Plan provided, however, that any employee who has completed at least five (5) or more years of Creditable Service at the time

31

the Plan ceases to be top-heavy and who had at least one (1) hour of service while the Plan was a top-heavy plan, shall be entitled to elect, within a reasonable period (such period to be determined by the Retirement Committee when relevant but in no event no earlier than 60 days following the latest of (i) the date upon which the reversion to the prior vesting schedule became effective, or
(ii) the day the employee is issued written notice by the Retirement Committee that the prior schedule is applicable), whether the vesting schedule in Section
16d. or in Section 4c. is applicable to his benefit.

32

SCHEDULE A

List of Eligible Groups or Classes

Groups or Classes eligible for participation in the Retirement Annuity Plan (except in each case employees covered by a collective bargaining agreement that does not provide for coverage of such employees under the Plan):

1. All employees in the service of Pfizer Inc at the following locations:

New York Headquarters, New York, New York Brooklyn Plant, Brooklyn, New York
Groton Plant and Research Laboratories, Groton, Connecticut Vigo Plant and Research Laboratories, Terre Haute, Indiana Washington Office, Washington, D.C. Atlanta Branch, Doraville, Georgia
Chicago Branch, Hoffman Estates, Illinois Clifton Branch, Clifton, New Jersey
Dallas Branch, Dallas, Texas
Parsippany Plant, Parsippany, New Jersey Irvine Branch, Irvine, California
Lee's Summit Plant, Lee's Summit, Missouri Aviation Department, West Trenton, New Jersey Lincoln, Nebraska
West Chester, Pennsylvania
Exton, Pennsylvania
Miami, Florida
Omaha, Nebraska
White Hall, Illinois
Albany, New York
Arlington, Texas
Ashland, Virginia
Englewood, Colorado
Marietta, Georgia
Olive Branch, Mississippi
Orlando, Florida
Sacramento, California
South Bend, Indiana
Memphis, Tennessee

2. Headquarters Foreign Residents in the service of a foreign subsidiary (as defined in section 3121(1)(8) of the Internal Revenue Code) of Pfizer Inc who are United States citizens employed outside the continental limits of the United States.

3. All Field Sales Personnel in the service of the following groups or divisions of Pfizer Inc:

33

Pfizer Laboratories
Animal Health Group
Roerig
Consumer Health Care Group
Pratt
National Health Care Operations Specialty
Powers Rx
Pfizer Corporation Carolina

4. All employees in the service of the following Associate Companies:

Pfizer International Inc.
Howmedica, Inc.
Howmedica Management and Technical Services, Ltd. Pfizer Pharmaceuticals, Inc.
Shiley Heart Valve Research Center Valleylab, Inc.
Strato/Infusaid, Inc.
Schneider (USA) Inc., a Pfizer Company American Medical Systems, Inc.
NAMIC USA Corporation
Corvita Corporation
Howmedica Leibinger Inc.

5. All employees employed in Puerto Rico by Pfizer Corporation, an Associate Company.

34

SCHEDULE B

Vested Benefit Table

The following table sets forth the percentages which will apply at the ages indicated in the computation of vested benefits:

Age                                 Percentage
----------------------------------------------
65                                         100
64                                          94
63                                          88
62                                          82
61                                          76
60                                          70
59                                          64
58                                          58
57                                          52
56                                          46
55                                          40

35

SCHEDULE C

Early Retirement Table

The following table sets forth the percentages which will apply at the ages indicated in the computation of early retirement benefits:

 Age                                 Percentage
------------------------------------------------
 65                                         100
 64                                          96
 63                                          92
 62                                          88
 61                                          84
 60                                          80
 59                                          76
 58                                          72
 57                                          68
 56                                          64
 55                                          60

36

SCHEDULE D

Alternate Early Retirement Table

The following table sets forth the percentages which will apply at the ages indicated in the computation of early retirement benefits:

Age                Service          Percentage
----------------------------------------------
64                   26                    100
63                   27                    100
62                   28                    100
61                   29                    100
60                   30                    100
59                   31                     96
58                   32                     92
57                   33                     88
56                   34                     84
55                   35                     80


EXHIBIT 10(iv)

PFIZER INC
NONFUNDED DEFERRED
COMPENSATION AND SUPPLEMENTAL
SAVINGS PLAN
(As amended through 1/97)

1. Each employee who is a Member of the Pfizer Inc Savings and Investment Plan and who is prevented, because of the restrictions of Section 415(c)(1)(A) or
Section 401(a)(17) of the Internal Revenue Code, from contributing further to the Savings and Investment Plan may elect on or before the last day of any calendar month, beginning with the following calendar month, to defer payment of future compensation, in whole percents, at a rate not to exceed the greater of 6% or the rate of pre-tax contribution permitted under the Savings and Investment Plan to "highly compensated employees," as that term is defined under
Section 414(q) of the Internal Revenue Code, until he ceases to be an employee of the Company, unless before such time he dies or becomes totally disabled, as determined by the Employee Compensation and Management Development Committee or the Executive Compensation Committee, as appropriate, in which case all amounts credited to his account shall become payable as soon as practicable thereafter in a single sum payment. Notwithstanding the preceding sentence, an employee cannot defer compensation under this Plan at a rate in excess of the employee's combined rate of pre-tax and post-tax contribution under the Company's Savings and Investment Plan. The deferrals by such employee under this Plan shall be matched by the Company in accordance with the formula for Company matching contributions under the Company's Savings and Investment Plan.

If the restrictions of Section 415 or Section 401(a)(17) of the Internal Revenue Code prevent an employee from receiving any Company matching contributions or employee forfeitures, any amount that would have been contributed on the employee's behalf to the Company's Savings and Investment Plan by the Company as a matching contribution and any amount that would have been credited to the employee by way of forfeitures if it were not for such restrictions, shall be credited to the employee hereunder.

Any election to defer shall be made by written notice directed to the Vice President-Personnel of the Company. Any such election may be terminated, or may be modified as to the amount of deferral (in whole percents of compensation only) or as to the form of deferral (whether interest or units) with regard to future compensation, commencing with the following calendar month, upon written notice directed to the Vice President-Personnel of the Company on or before the last day of the calendar month preceding the calendar month in which such compensation would otherwise be payable. Switching the form of deferral of monies previously deferred may be done, as of the first day of any calendar month, by notice in writing to the Vice President-Personnel of the Company before such date. With respect to a Member subject to Section 16 of the Securities Exchange Act of 1934, an election to transfer into, or out of, the unit account shall be permitted only if the Member has not elected to transfer out of, or into, the unit account within this Plan, Fund C within the Pfizer


Savings and Investment Plan or the unit account within the Pfizer Inc Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors during the prior six months.

2. All compensation deferred by the employee hereunder shall be held in the general funds of the Company and shall be credited to the employee's account, and, at the employee's election, the account shall be credited with (a) interest at a rate equal to the rate of return for Fund A in the Savings and Investment Plan, compounded monthly, (b) a number of units, calculated to the nearest thousandth of a unit, produced by dividing the amount of compensation deferred, on the date such compensation would otherwise have been paid, by the closing market price of the Company's Common Stock as reported on the Consolidated Tape of the New York Stock Exchange on the last business day prior to the date such compensation would otherwise have been paid, or (c) a combination of (a) and (b).

Company matching contributions and/or forfeitures shall be held in the general funds of the Company and shall be credited to the employee's account in the form of units only.

Whenever a dividend is declared, the number of units in the employee's account shall be increased by the result of the following calculations: 1) the number of units in the employee's account multiplied by any cash dividend declared by the Company on a share of its Common Stock, divided by the closing market price of such Common Stock on the related dividend record date; and/or 2) the number of units in the employee's account multiplied by any stock dividend declared by the Company on a share of its Common Stock. In the event of any change in the number or kind of outstanding shares of Common Stock of the Company including a stock split or splits, other than a stock dividend as provided above, an appropriate adjustment shall be made in the number of units credited to the employee's account.

3. At least ninety days before he ceases to be an employee of the Company, an employee may elect, or may modify an election that he had previously made, to receive payment of the balance credited to his account in a lump sum or in annual installments, and he may elect the time that such payment or payments are to be made; provided however, that no payments shall be made prior to the employee's next taxable year following his termination of employment; and further provided that, solely for the purposes of this subsection 3, in the case of an employee who is transferring to a company which is at least 30% owned by the Company, the employee shall not be deemed to cease to be an employee of the Company until he ceases to be an employee of said company. In the absence of an election, such payments will begin with the first month of the employee's next taxable year following his termination of employment and will be made in five annual installments, provided however that if the amount of the payment is less than 10%, or such smaller percentage established by the Savings Plan Committee of the Savings and Investment Plan (the "Committee"), of the employee's total benefit from the Savings and Investment Plan and this supplemental plan, such payment shall be made in a lump sum, unless at least ninety days before the employee ceases to be an employee of the Company, the employee elects another form of payment as provided in this subsection 3.

To the extent that the employee's account has been credited with units calculated as provided in Section 2, the amount payable to the employee in each instance shall be determined by multiplying the number of units by the closing market price of the Company's Common Stock on the day prior to the date for payment or the last business day prior to that date, if the day prior to the date for payment is not a business day.

Where the employee receives the balance of his account in annual installments of deferred compensation, the first installment shall be a fraction of the value of the balance of the amount deferred and credited to the employee's account by way

2

of interest and/or units calculated under Section 2 hereof, as the case may be, on the date of such payment, the numerator of which is one (1) and the denominator of which is the total number of installments remaining to be paid at that time. Each subsequent installment shall be calculated in the same manner, except that the denominator shall be reduced by the number of installments that have been paid previously.

4. If an employee should become totally disabled, as determined by the Employee Compensation and Management Development Committee or the Executive Compensation Committee, as appropriate, before full payment of all amounts credited to his account, such amounts shall be paid to him in a single sum payment to be made as soon as practicable after such event. If an employee should die before full payment of all amounts credited to his account, such amounts shall be paid to his beneficiary or beneficiaries designated under the Savings and Investment Plan in accordance with the participant's payment election on file at the time of death or if no beneficiary or beneficiaries are named under that Plan or the named beneficiary or beneficiaries have predeceased him, to his estate in a single sum payment to be made as soon as practicable after his death. If an employee wishes to designate a different beneficiary or beneficiaries than are provided for by the method set forth above he may do so by written notice to the Senior Vice President-Employee Resources of the Company. At any time, and from time to time, any such designation may be changed or canceled by the employee without the consent of any beneficiary. Any such designation, change or cancellation must be by written notice filed with the Senior Vice President-Employee Resources of the Company and shall not be effective until received by the Senior Vice President-Employee Resources of the Company. If an employee designates more than one beneficiary, any payments to such beneficiaries shall be made in equal shares unless the employee has designated otherwise.

5. An employee's election to defer receipt of his compensation shall continue until he ceases to be an employee unless he earlier terminates such election with respect to future compensation by written notice delivered to the Vice President-Personnel of the Company. Any such notice shall become effective as of the end of the calendar month in which such notice is received by the Vice President-Personnel. Amounts credited to the account of an employee prior to the effective date of such notice shall not be affected thereby and shall be paid to him in accordance with Section 1, Section 3 or Section 4, as appropriate.

6. The right of an employee to any amounts credited to his account shall not be subject to assignment by him. If an employee does assign his right to any amounts credited to his account, the Company may disregard such assignment and discharge its obligation hereunder by making payment as though no such assignment had been made.

7. Notwithstanding anything contained in Section 1 or Section 5 to the contrary, an employee who receives a hardship distribution under the Company's Savings and Investment Plan shall not defer compensation hereunder for the period of 12 months commencing after receipt of the hardship distribution.

8. The Savings and Investment Plan Committee may make non-substantive administrative changes to this Plan so as to conform with or take advantage of governmental requirements, statutes or regulations.

3

EXHIBIT 10(vii)

PFIZER INC.
NONFUNDED SUPPLEMENTAL
RETIREMENT PLAN
(As amended through 1/96)

1. The Company shall make payments supplementing the amounts payable under the Pfizer Retirement Annuity Plan (the Plan) to retiring employees whose benefits under the Plan are limited, by reason of Section 415 and, on and after January 1, 1989, Section 401(a)(17) of the Internal Revenue Code, to amounts less than would be payable under the provisions of said Plan if calculated without reference to the limitations imposed by Section 415 and, on and after January 1, 1989, Section 401(a)(17) of the Internal Revenue Code.

2. To the extent practicable, such supplemental payments by the Company shall, in the case of each such employee, be substantially equal to the difference between the benefits payable under the Plan and the benefits that would be payable under the provisions of the Plan if calculated without reference to the limitations imposed by Section 415 and, on and after January 1, 1989, Section 401(a)(17) of the Internal Revenue Code, and further the Company shall make payments supplementing the amounts payable under the Plan for employees who elect to defer income under the "Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan" by treating such deferred amounts as though they were a part of the employee's Creditable Earnings under the Plan.

3. At least ninety days before an employee ceases to be an employee of the Company, the employee may elect, or may modify an election that the employee had previously made, to receive payment of such supplemental payments by the Company in a lump sum or in monthly or annual installments, and the employee may elect the time that such lump sum payment or installments are to be made, except that no payment or payments shall be made prior to the employee's next taxable year following termination of employment, and provided that in the absence of an election, such supplemental payments by the Company shall be made in ten annual installments commencing with the first month of the employee's next taxable year following termination of employment, further provided that if the amount of the supplemental payment is less than 10%, or such smaller percentage established by the Retirement Committee of the Retirement Annuity Plan (the "Committee"), of the employee's total retirement benefit from the Retirement Annuity Plan and this supplemental plan, such payment shall be made in a lump sum, unless at least ninety days before the employee ceases to be an employee of the Company, the employee elects another form of payment as provided in this subsection 3., and still further provided that, solely for the purposes of this subsection 3., in the case of an employee who is transferring to a company which is at least 30% owned by the Company, the employee shall not be deemed to cease to be an employee of the Company until he ceases to be an employee of said company.

4. An employee's right to supplemental payments hereunder may not be assigned. If an employee does assign such right, the Company may disregard such assignment and discharge its obligation by making payment as though no such assignment had been made.

5. The Committee may make non-substantive administrative changes to this Plan so as to conform with or take advantage of governmental requirements, statutes or regulations.


AGREEMENT

This Agreement, made and entered into as of the ____ day of _______, 199_ ("Agreement"), by and between Pfizer Inc. a Delaware corporation ("Company"), and [INSERT NAME] ("Indemnitee"):

WHEREAS, highly competent persons are becoming more reluctant to serve publicly-held corporations as directors or in other capacities unless they are provided with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of the corporation; and

WHEREAS, the current impracticability of obtaining adequate insurance and the uncertainties relating to indemnification have increased the difficulty of attracting and retaining such persons;

WHEREAS, the Board of Directors of the Company (the "Board") has determined that the inability to attract and retain such persons is detrimental to the best interests of the Company's stockholders and that the Company should act to assure such persons that there will be increased certainty of such protection in the future; and

WHEREAS, it is reasonable, prudent and necessary for the Company contractually to obligate itself to indemnify such persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified; and

1

WHEREAS, Indemnitee is willing to serve, continue to serve and to take on additional service for or on behalf of the Company on the condition that he be so indemnified;

NOW, THEREFORE, in consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree as follows:

Section 1. Services by Indemnitee. Indemnitee agrees to serve as a director of the Company. Indemnitee may at any time and for any reason resign from such position (subject to any other contractual obligation or any obligation imposed by operation of law), in which event the Company shall have no obligation under this Agreement to continue Indemnitee in any such position.

Section 2. Indemnification - General. The Company shall indemnify, and advance Expenses (as hereinafter defined) to Indemnitee as provided in this Agreement and to the fullest extent permitted by applicable law in effect on the date hereof and to such greater extent as applicable law may thereafter from time to time permit. The rights of Indemnitee provided under the preceding sentence shall include, but shall not be limited to, the rights set forth in the other Sections of this Agreement.

Section 3. Proceedings Other Than Proceedings by or in the Right of the Company. Indemnitee shall be entitled to the rights of indemnification provided in this Section 3 if, by reason of his Corporate Status (as hereinafter defined), he is, or is threatened to be made, a party to any threatened, pending, or completed Proceeding (as hereinafter defined), other than a Proceeding by or in the right of the Company. Pursuant to this Section 3, Indemnitee shall be indemnified against Expenses, judgments, penalties, fines and amounts paid in settlement actually and reasonably incurred by him or on his behalf in connection with such Proceeding or any claim, issue or matter therein, if he acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Company, and, with respect to any criminal Proceeding, had no reasonable cause to believe his conduct was unlawful.

Section 4. Proceedings by or in the Right of the Company. Indemnitee shall be entitled to the rights of indemnification provided in this
Section 4 if, by reason of his Corporate Status, he is, or is threatened to be made, a party to any threatened, pending or completed Proceeding brought by or in the right of the Company to procure a judgment in its favor. Pursuant to this Section, Indemnitee shall be indemnified against Expenses actually and reasonably incurred by him or on his behalf in connection with such Proceeding if he acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Company. Notwithstanding the foregoing, no indemnification against such Expenses shall be made in respect of any claim, issue or matter in such Proceeding as to which Indemnitee shall have been adjudged to be liable to the Company if applicable law prohibits such indemnification; provided, however, that, if applicable law so permits, indemnification against Expenses shall nevertheless be made by the Company in such event if and only to the extent that the Court of Chancery of the State of Delaware, or the Court in which such Proceeding shall have been brought or is pending, shall determine.

2

Section 5. Indemnification for Expenses of a Party Who is Wholly or Partly Successful. Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by reason of his Corporate Status, a party to and is successful, on the merits or otherwise, in any Proceeding, he shall be indemnified against all Expenses actually and reasonably incurred by him or on his behalf in connection therewith. If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by him or on his behalf in connection with each successfully resolved claim, issue or matter. For purposes of this Section and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.

Section 6. Indemnification for Expenses of a Witness. Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by reason of his Corporate Status, a witness in any Proceeding, he shall be indemnified against all Expenses actually and reasonably incurred by him or on his behalf in connection therewith.

Section 7. Advancement of Expenses. The Company shall advance all reasonable Expenses incurred by or on behalf of Indemnitee in connection with any Proceeding within twenty days after the receipt by the Company of a statement or statements from Indemnitee requesting such advance or advances from time to time, whether prior to or after final disposition of such Proceeding. Such statement or statements shall reasonably evidence the Expenses incurred by Indemnitee and shall include or be preceded or accompanied by an undertaking by or on behalf of Indemnitee to repay any Expenses advanced if it shall ultimately be determined that Indemnitee is not entitled to be indemnified against such Expenses.

3

Section 8. Procedure for Determination of Entitlement to Indemnification.

(a) To obtain indemnification under this Agreement, Indemnitee shall submit to the Company a written request, including therein or therewith such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification. The Secretary of the Company shall, promptly upon receipt of such a request for indemnification, advise the Board of Directors in writing that Indemnitee has requested indemnification.

(b) Upon written request by Indemnitee for indemnification pursuant to the first sentence of Section 8(a) hereof, a determination, if required by applicable law, with respect to Indemnitee's entitlement thereto shall be made in the specific case: (i) if a Change in Control (as hereinafter defined) shall have occurred, by Independent Counsel (as hereinafter defined) (unless Indemnitee shall request that such determination be made by the Board of Directors or the stockholders, in which case by the person or persons or in the manner provided for in clauses (ii) or (iii) of this
Section 8(b)) in a written opinion to the Board of Directors, a copy of which shall be delivered to Indemnitee; (ii) if a Change of Control shall not have occurred, (A) by the Board of Directors by a majority vote of a quorum consisting of Disinterested Directors (as hereinafter defined), or (B) if a quorum of the Board of Directors consisting of Disinterested Directors is not obtainable or, even if obtainable, such quorum of Disinterested Directors so directs, by Independent Counsel in a written opinion to the Board of Directors, a copy of which shall be delivered to Indemnitee or (C) by the stockholders of the Company; or (iii) as provided in Section 9(b) of this Agreement; and, if it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within ten (10) days after such determination. Indemnitee shall cooperate with the person, persons or entity making such determination with respect to Indemnitee's entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination. Any costs or expenses (including attorneys' fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons or entity making such determination shall be borne by the Company (irrespective of the determination as to Indemnitee's entitlement to indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom.

4

(c) In the event the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 8(b) hereof, the Independent Counsel shall be selected as provided in this Section
8(c). If a Change of Control shall not have occurred, the Independent Counsel shall be selected by the Board of Directors, and the Company shall give written notice to Indemnitee advising him of the identity of the Independent Counsel so selected. If a Change of Control shall have occurred, the Independent Counsel shall be selected by Indemnitee (unless Indemnitee shall request that such selection be made by the Board of Directors, in which event the preceding sentence shall apply), and Indemnitee shall give written notice to the Company advising it of the identity of the Independent Counsel so selected. In either event, Indemnitee or the Company, as the case may be, may, within 7 days after such written notice of selection shall have been given, deliver to the Company or to Indemnitee, as the case may be, a written objection to such selection. Such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of "Independent Counsel" as defined in Section 17 of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion. If such written objection is made, the Independent Counsel so selected may not serve as Independent Counsel unless and until a court has determined that such objection is without merit. If, within 20 days after submission by Indemnitee of a written request for indemnification pursuant to Section 8(a) hereof, no Independent Counsel shall have been selected and not objected to, either the Company or Indemnitee may petition the Court of Chancery of the State of Delaware or other court of competent jurisdiction for resolution of any objection which shall have been made by the Company or Indemnitee to the other's selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by the Court or by such other person as the Court shall designate, and the person with respect to whom an objection is so resolved or the person so appointed shall act as Independent Counsel under Section 8(b) hereof. The Company shall pay any and all reasonable fees and expenses of Independent Counsel incurred by such Independent Counsel in connection with acting pursuant to Section 8(b) hereof, and the Company shall pay all reasonable fees and expenses incident to the procedures of this Section 8(c), regardless of the manner in which such Independent Counsel was selected or appointed. Upon the due commencement of any judicial proceeding or arbitration pursuant to Section 10(a)(iii) of this Agreement, Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing).

Section 9. Presumptions and Effect of Certain Proceedings.

(a) If a Change of Control shall have occurred, in making a determination with respect to entitlement to indemnification hereunder, the person or persons or entity making such determination shall presume that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with Section 8(a) of this Agreement, and the Company shall have the burden of proof to overcome that presumption in connection with the making by any person, persons or entity of any determination contrary to that presumption.

5

(b) If the person, persons or entity empowered or selected under Section 8 of this Agreement to determine whether Indemnitee is entitled to indemnification shall not have made a determination within 60 days after receipt by the Company of the request therefor, the requisite determination of entitlement to indemnification shall be deemed to have been made and Indemnitee shall be entitled to such indemnification, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee's statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law; provided, however, that such 60-day period may be extended for a reasonable time, not to exceed an additional 30 days, if the person, persons or entity making the determination with respect to entitlement to indemnification in good faith requires such additional time for the obtaining or evaluating of documentation and/or information relating thereto; and provided, further, that the foregoing provisions of this Section 9(b) shall not apply (i) if the determination of entitlement to indemnification is to be made by the stockholders pursuant to Section 8(b) of this Agreement and if (A) within 15 days after receipt by the Company of the request for such determination the Board of Directors has resolved to submit such determination to the stockholders for their consideration at an annual meeting thereof to be held within 75 days after such receipt and such determination is made thereat, or (B) a special meeting of stockholders is called within 15 days after such receipt for the purpose of making such determination, such meeting is held for such purpose within 60 days after having been so called and such determination is made thereat, or (ii) if the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 8(b) of this Agreement.

(c) The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of nolo contendere or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his conduct was unlawful.

Section 10. Remedies of Indemnitee.

(a) In the event that (i) a determination is made pursuant to Section 8 of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii) advancement of Expenses is not timely made pursuant to Section 7 of this Agreement, (iii) the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to
Section 8(b) of this Agreement and such determination shall not have been made and delivered in a written opinion within 90 days after receipt by the Company of the request for indemnification, or (iv) payment of indemnification is not made pursuant to Section 6 of this Agreement within ten (10) days after receipt by the Company of a written request therefor, or (v) payment of indemnification is not made within ten (10) days after a determination has been made that Indemnitee is entitled to indemnification or such determination is deemed to have been made pursuant to Section 8 or 9 of this Agreement, Indemnitee shall be entitled to an adjudication in an appropriate court of the State of Delaware, or in any other court of competent jurisdiction, of his entitlement to such indemnification or advancement of Expenses. Alternatively, Indemnitee, at his option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the rules of the American Arbitration Association. Indemnitee shall commence such proceeding seeking an adjudication or an award in arbitration within 180 days following the date on which Indemnitee first has the right to commence such proceeding pursuant to this Section 10(a). The Company shall not oppose Indemnitee's right to seek any such adjudication or award in arbitration.

6

(b) In the event that a determination shall have been made pursuant to Section 8 of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to this Section 10 shall be conducted in all respects as a de novo trial, or arbitration, on the merits and Indemnitee shall not be prejudiced by reason of that adverse determination. If a Change of Control shall have occurred, in any judicial proceeding or arbitration commenced pursuant to this
Section 10 the Company shall have the burden of proving that Indemnitee is not entitled to indemnification or advancement of Expenses, as the case may be.

(c) If a determination shall have been made or deemed to have been made pursuant to Section 8 or 9 of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this Section 10, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee's statement not materially misleading, in connection with the request for indemnification, or
(ii) a prohibition of such indemnification under applicable law.

(d) The Company shall be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this Section 10 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement.

(e) In the event that Indemnitee, pursuant to this
Section 10, seeks a judicial adjudication of or an award in arbitration to enforce his rights under, or to recover damages for breach of, this Agreement, Indemnitee shall be entitled to recover from the Company, and shall be indemnified by the Company against, any and all expenses (of the types described in the definition of Expenses in Section 17 of this Agreement) actually and reasonably incurred by him in such judicial adjudication or arbitration, but only if he prevails therein. If it shall be determined in said judicial adjudication or arbitration that Indemnitee is entitled to receive part but not all of the indemnification or advancement or expenses sought, the expenses incurred by Indemnitee in connection with such judicial adjudication or arbitration shall be appropriately prorated.

Section 11. Non-Exclusivity; Survival of Rights; Insurance; Subrogation.

(a) The rights of indemnification and to receive advancement of Expenses as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Certificate of Incorporation, the By-Laws, any agreement, a vote of stockholders or a resolution of directors, or otherwise. No amendment, alteration or termination of this Agreement or any provision hereof shall be effective as to any Indemnitee with respect to any action taken or omitted by such Indemnitee in his Corporate Status prior to such amendment, alteration or termination.

7

(b) To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, officers, employees, agents or fiduciaries of the Company or of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise which such person serves at the request of the Company, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any such director, officer, employee or agent under such policy or policies.

(c) In the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.

(d) The Company shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable hereunder if and to the extent that Indemnitee has otherwise actually received such payment under any insurance policy, contract, agreement or otherwise.

Section 12. Duration of Agreement. This Agreement shall continue until and terminate upon the later of: (a) 10 years after the date that Indemnitee shall have ceased to serve as a director, or (b) the final termination of all pending Proceedings in respect of which Indemnitee is granted rights of indemnification or advancement of Expenses hereunder and of any proceeding commenced by Indemnitee pursuant to Section 10 of this Agreement relating thereto. This Agreement shall be binding upon the Company and its successors and assigns and shall inure to the benefit of Indemnitee and his heirs, executors and administrators.

Section 13. Severability. If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a) the validity, legality and enforceability of the remaining provisions of this Agreement (including without limitation, each portion of any Section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby; and (b) to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any Section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested by the provision held invalid, illegal or unenforceable.

Section 14. Exception to Right of Indemnification or Advancement of Expenses. Notwithstanding any other provision of this Agreement, Indemnitee shall not be entitled to indemnification or advancement of Expenses under this Agreement with respect to any Proceeding, or any claim therein, brought or made by him against the Company.

8

Section 15. Identical Counterparts. This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement.

Section 16. Headings. The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.

Section 17. Definitions. For purposes of this Agreement:

(a) "Change in Control" means a change in control of the Company occurring after the Effective Date of a nature that would be required to be reported in response to Item 5(f) of Schedule 14A of Regulation 14A (or in response to any similar item on any similar schedule or form) promulgated under the Securities Exchange Act of 1934 (the "Act"), whether or not the Company is then subject to such reporting requirement; provided, however, that, without limitation, such a Change in Control shall be deemed to have occurred if after the Effective Date (i) any "person" (as such term is used in Sections 13(d) and 14(d) of the Act) is or becomes the "beneficial owner" (as defined in Rule 13d-3 under the Act), directly or indirectly, of securities of the Company representing 25% or more of the combined voting power of the Company's then outstanding securities without the prior approval of at least two-thirds of the members of the Board of Directors in office immediately prior to such person attaining such percentage interest; (ii) the Company is a party to a merger, consolidation, sale of assets or other reorganization, or a proxy contest, as a consequence of which members of the Board of Directors in office immediately prior to such transaction or event constitute less than a majority of the Board thereafter; or (iii) during any period of two consecutive years, individuals who at the beginning of such period constituted the Board of Directors (including for this purpose any new director whose election or nomination for election by the Company's stockholders was approved by a vote of at least two-thirds of the directors then still in office who were directors at the beginning of such period) cease for any reason to constitute at least a majority of the Board of Directors.

(b) "Corporate Status" describes the status of a person who is or was a director, officer, employee, agent or fiduciary of the Company or of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise which such person is or was serving at the request of the Company.

(c) "Disinterested Director" means a director of the Company who is not and was not a party to the Proceeding in respect of which indemnification is sought by Indemnitee.

(d) "Effective Date" means May 23, 1996.

9

(e) "Expenses" shall include all reasonable attorneys' fees, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, or being or preparing to be a witness in a Proceeding.

(f) "Independent Counsel" means a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past five years has been, retained to represent: (i) the Company or Indemnitee in any matter material to either such party, or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term "Independent Counsel" shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee's rights under this Agreement.

(g) "Proceeding" includes any action, suit, arbitration, alternate dispute resolution mechanism, investigation, administrative hearing or any other proceeding whether civil, criminal, administrative or investigative, except one initiated by an Indemnitee pursuant to Section 10 of this Agreement to enforce his rights under this Agreement.

Section 18. Modification and Waiver. No supplement, modification or amendment of this Agreement shall be binding unless executed in writing by both of the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions hereof (whether or not similar) nor shall such waiver constitute a continuing waiver.

Section 19. Notice by Indemnitee. Indemnitee agrees promptly to notify the Company in writing upon being served with any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification or advancement of Expenses covered hereunder.

10

Section 20. Notices. All notices, requests, demands and other communications hereunder shall be in writing and shall be deemed to have been duly given if (i) delivered by hand and receipted for by the party to whom said notice or other communication shall have been directed, or (ii) mailed by certified or registered mail with postage prepaid, on the third business day after the date on which it is so mailed:

(a) If to Indemnitee, to:

[INSERT NAME]
Pfizer Inc.
235 East 42nd Street
New York, NY 10017

(b) If to the Company to:

Pfizer Inc.
235 East 42nd Street New York, New York 10017 Attn: Office of the Secretary

or such other address as may have been furnished to Indemnitee by the Company or to the Company by Indemnitee, as the case may be.

Section 21. Governing Law. The parties agree that this Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware.

Section 22. Miscellaneous. Use of the masculine pronoun shall be deemed to include usage of the feminine pronoun where appropriate.

11

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.

ATTEST:                                                     PFIZER INC.

By                                     By
   -----------------------------            ---------------------------------

INDEMNITEE


Address:             [INSERT NAME]
                     Pfizer Inc.
                     235 East 42nd Street
                     New York, NY 10017

12

AGREEMENT

This Agreement, made and entered into as of the ____ day of _______, 199_ ("Agreement"), by and between Pfizer Inc. a Delaware corporation ("Company"), and [INSERT NAME] ("Indemnitee"):

WHEREAS, highly competent persons are becoming more reluctant to serve publicly-held corporations as directors or in other capacities unless they are provided with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of the corporation; and

WHEREAS, the current impracticability of obtaining adequate insurance and the uncertainties relating to indemnification have increased the difficulty of attracting and retaining such persons;

WHEREAS, the Board of Directors of the Company (the "Board") has determined that the inability to attract and retain such persons is detrimental to the best interests of the Company's stockholders and that the Company should act to assure such persons that there will be increased certainty of such protection in the future; and

WHEREAS, it is reasonable, prudent and necessary for the Company contractually to obligate itself to indemnify such persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified; and

1

WHEREAS, Indemnitee is willing to serve, continue to serve and to take on additional service for or on behalf of the Company on the condition that he be so indemnified;

NOW, THEREFORE, in consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree as follows:

Section 1. Services by Indemnitee. Indemnitee agrees to serve as a director of the Company. Indemnitee may at any time and for any reason resign from such position (subject to any other contractual obligation or any obligation imposed by operation of law), in which event the Company shall have no obligation under this Agreement to continue Indemnitee in any such position.

Section 2. Indemnification - General. The Company shall indemnify, and advance Expenses (as hereinafter defined) to Indemnitee as provided in this Agreement and to the fullest extent permitted by applicable law in effect on the date hereof and to such greater extent as applicable law may thereafter from time to time permit. The rights of Indemnitee provided under the preceding sentence shall include, but shall not be limited to, the rights set forth in the other Sections of this Agreement.

Section 3. Proceedings Other Than Proceedings by or in the Right of the Company. Indemnitee shall be entitled to the rights of indemnification provided in this Section 3 if, by reason of his Corporate Status (as hereinafter defined), he is, or is threatened to be made, a party to any threatened, pending, or completed Proceeding (as hereinafter defined), other than a Proceeding by or in the right of the Company. Pursuant to this Section 3, Indemnitee shall be indemnified against Expenses, judgments, penalties, fines and amounts paid in settlement actually and reasonably incurred by him or on his behalf in connection with such Proceeding or any claim, issue or matter therein, if he acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Company, and, with respect to any criminal Proceeding, had no reasonable cause to believe his conduct was unlawful.

Section 4. Proceedings by or in the Right of the Company. Indemnitee shall be entitled to the rights of indemnification provided in this
Section 4 if, by reason of his Corporate Status, he is, or is threatened to be made, a party to any threatened, pending or completed Proceeding brought by or in the right of the Company to procure a judgment in its favor. Pursuant to this Section, Indemnitee shall be indemnified against Expenses actually and reasonably incurred by him or on his behalf in connection with such Proceeding if he acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Company. Notwithstanding the foregoing, no indemnification against such Expenses shall be made in respect of any claim, issue or matter in such Proceeding as to which Indemnitee shall have been adjudged to be liable to the Company if applicable law prohibits such indemnification; provided, however, that, if applicable law so permits, indemnification against Expenses shall nevertheless be made by the Company in such event if and only to the extent that the Court of Chancery of the State of Delaware, or the Court in which such Proceeding shall have been brought or is pending, shall determine.

2

Section 5. Indemnification for Expenses of a Party Who is Wholly or Partly Successful. Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by reason of his Corporate Status, a party to and is successful, on the merits or otherwise, in any Proceeding, he shall be indemnified against all Expenses actually and reasonably incurred by him or on his behalf in connection therewith. If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by him or on his behalf in connection with each successfully resolved claim, issue or matter. For purposes of this Section and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.

Section 6. Indemnification for Expenses of a Witness. Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by reason of his Corporate Status, a witness in any Proceeding, he shall be indemnified against all Expenses actually and reasonably incurred by him or on his behalf in connection therewith.

Section 7. Advancement of Expenses. The Company shall advance all reasonable Expenses incurred by or on behalf of Indemnitee in connection with any Proceeding within twenty days after the receipt by the Company of a statement or statements from Indemnitee requesting such advance or advances from time to time, whether prior to or after final disposition of such Proceeding. Such statement or statements shall reasonably evidence the Expenses incurred by Indemnitee and shall include or be preceded or accompanied by an undertaking by or on behalf of Indemnitee to repay any Expenses advanced if it shall ultimately be determined that Indemnitee is not entitled to be indemnified against such Expenses.

3

Section 8. Procedure for Determination of Entitlement to Indemnification.

(a) To obtain indemnification under this Agreement, Indemnitee shall submit to the Company a written request, including therein or therewith such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification. The Secretary of the Company shall, promptly upon receipt of such a request for indemnification, advise the Board of Directors in writing that Indemnitee has requested indemnification.

(b) Upon written request by Indemnitee for indemnification pursuant to the first sentence of Section 8(a) hereof, a determination, if required by applicable law, with respect to Indemnitee's entitlement thereto shall be made in the specific case: (i) if a Change in Control (as hereinafter defined) shall have occurred, by Independent Counsel (as hereinafter defined) (unless Indemnitee shall request that such determination be made by the Board of Directors or the stockholders, in which case by the person or persons or in the manner provided for in clauses (ii) or (iii) of this
Section 8(b)) in a written opinion to the Board of Directors, a copy of which shall be delivered to Indemnitee; (ii) if a Change of Control shall not have occurred, (A) by the Board of Directors by a majority vote of a quorum consisting of Disinterested Directors (as hereinafter defined), or (B) if a quorum of the Board of Directors consisting of Disinterested Directors is not obtainable or, even if obtainable, such quorum of Disinterested Directors so directs, by Independent Counsel in a written opinion to the Board of Directors, a copy of which shall be delivered to Indemnitee or (C) by the stockholders of the Company; or (iii) as provided in Section 9(b) of this Agreement; and, if it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within ten (10) days after such determination. Indemnitee shall cooperate with the person, persons or entity making such determination with respect to Indemnitee's entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination. Any costs or expenses (including attorneys' fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons or entity making such determination shall be borne by the Company (irrespective of the determination as to Indemnitee's entitlement to indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom.

4

(c) In the event the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 8(b) hereof, the Independent Counsel shall be selected as provided in this Section
8(c). If a Change of Control shall not have occurred, the Independent Counsel shall be selected by the Board of Directors, and the Company shall give written notice to Indemnitee advising him of the identity of the Independent Counsel so selected. If a Change of Control shall have occurred, the Independent Counsel shall be selected by Indemnitee (unless Indemnitee shall request that such selection be made by the Board of Directors, in which event the preceding sentence shall apply), and Indemnitee shall give written notice to the Company advising it of the identity of the Independent Counsel so selected. In either event, Indemnitee or the Company, as the case may be, may, within 7 days after such written notice of selection shall have been given, deliver to the Company or to Indemnitee, as the case may be, a written objection to such selection. Such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of "Independent Counsel" as defined in Section 17 of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion. If such written objection is made, the Independent Counsel so selected may not serve as Independent Counsel unless and until a court has determined that such objection is without merit. If, within 20 days after submission by Indemnitee of a written request for indemnification pursuant to Section 8(a) hereof, no Independent Counsel shall have been selected and not objected to, either the Company or Indemnitee may petition the Court of Chancery of the State of Delaware or other court of competent jurisdiction for resolution of any objection which shall have been made by the Company or Indemnitee to the other's selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by the Court or by such other person as the Court shall designate, and the person with respect to whom an objection is so resolved or the person so appointed shall act as Independent Counsel under Section 8(b) hereof. The Company shall pay any and all reasonable fees and expenses of Independent Counsel incurred by such Independent Counsel in connection with acting pursuant to Section 8(b) hereof, and the Company shall pay all reasonable fees and expenses incident to the procedures of this Section 8(c), regardless of the manner in which such Independent Counsel was selected or appointed. Upon the due commencement of any judicial proceeding or arbitration pursuant to Section 10(a)(iii) of this Agreement, Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing).

Section 9. Presumptions and Effect of Certain Proceedings.

(a) If a Change of Control shall have occurred, in making a determination with respect to entitlement to indemnification hereunder, the person or persons or entity making such determination shall presume that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with Section 8(a) of this Agreement, and the Company shall have the burden of proof to overcome that presumption in connection with the making by any person, persons or entity of any determination contrary to that presumption.

5

(b) If the person, persons or entity empowered or selected under Section 8 of this Agreement to determine whether Indemnitee is entitled to indemnification shall not have made a determination within 60 days after receipt by the Company of the request therefor, the requisite determination of entitlement to indemnification shall be deemed to have been made and Indemnitee shall be entitled to such indemnification, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee's statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law; provided, however, that such 60-day period may be extended for a reasonable time, not to exceed an additional 30 days, if the person, persons or entity making the determination with respect to entitlement to indemnification in good faith requires such additional time for the obtaining or evaluating of documentation and/or information relating thereto; and provided, further, that the foregoing provisions of this Section 9(b) shall not apply (i) if the determination of entitlement to indemnification is to be made by the stockholders pursuant to Section 8(b) of this Agreement and if (A) within 15 days after receipt by the Company of the request for such determination the Board of Directors has resolved to submit such determination to the stockholders for their consideration at an annual meeting thereof to be held within 75 days after such receipt and such determination is made thereat, or (B) a special meeting of stockholders is called within 15 days after such receipt for the purpose of making such determination, such meeting is held for such purpose within 60 days after having been so called and such determination is made thereat, or (ii) if the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 8(b) of this Agreement.

(c) The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of nolo contendere or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his conduct was unlawful.

Section 10. Remedies of Indemnitee.

(a) In the event that (i) a determination is made pursuant to Section 8 of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii) advancement of Expenses is not timely made pursuant to Section 7 of this Agreement, (iii) the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to
Section 8(b) of this Agreement and such determination shall not have been made and delivered in a written opinion within 90 days after receipt by the Company of the request for indemnification, or (iv) payment of indemnification is not made pursuant to Section 6 of this Agreement within ten (10) days after receipt by the Company of a written request therefor, or (v) payment of indemnification is not made within ten (10) days after a determination has been made that Indemnitee is entitled to indemnification or such determination is deemed to have been made pursuant to Section 8 or 9 of this Agreement, Indemnitee shall be entitled to an adjudication in an appropriate court of the State of Delaware, or in any other court of competent jurisdiction, of his entitlement to such indemnification or advancement of Expenses. Alternatively, Indemnitee, at his option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the rules of the American Arbitration Association. Indemnitee shall commence such proceeding seeking an adjudication or an award in arbitration within 180 days following the date on which Indemnitee first has the right to commence such proceeding pursuant to this Section 10(a). The Company shall not oppose Indemnitee's right to seek any such adjudication or award in arbitration.

6

(b) In the event that a determination shall have been made pursuant to Section 8 of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to this Section 10 shall be conducted in all respects as a de novo trial, or arbitration, on the merits and Indemnitee shall not be prejudiced by reason of that adverse determination. If a Change of Control shall have occurred, in any judicial proceeding or arbitration commenced pursuant to this
Section 10 the Company shall have the burden of proving that Indemnitee is not entitled to indemnification or advancement of Expenses, as the case may be.

(c) If a determination shall have been made or deemed to have been made pursuant to Section 8 or 9 of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this Section 10, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee's statement not materially misleading, in connection with the request for indemnification, or
(ii) a prohibition of such indemnification under applicable law.

(d) The Company shall be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this Section 10 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement.

(e) In the event that Indemnitee, pursuant to this
Section 10, seeks a judicial adjudication of or an award in arbitration to enforce his rights under, or to recover damages for breach of, this Agreement, Indemnitee shall be entitled to recover from the Company, and shall be indemnified by the Company against, any and all expenses (of the types described in the definition of Expenses in Section 17 of this Agreement) actually and reasonably incurred by him in such judicial adjudication or arbitration, but only if he prevails therein. If it shall be determined in said judicial adjudication or arbitration that Indemnitee is entitled to receive part but not all of the indemnification or advancement or expenses sought, the expenses incurred by Indemnitee in connection with such judicial adjudication or arbitration shall be appropriately prorated.

Section 11. Non-Exclusivity; Survival of Rights; Insurance; Subrogation.

(a) The rights of indemnification and to receive advancement of Expenses as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Certificate of Incorporation, the By-Laws, any agreement, a vote of stockholders or a resolution of directors, or otherwise. No amendment, alteration or termination of this Agreement or any provision hereof shall be effective as to any Indemnitee with respect to any action taken or omitted by such Indemnitee in his Corporate Status prior to such amendment, alteration or termination.

7

(b) To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, officers, employees, agents or fiduciaries of the Company or of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise which such person serves at the request of the Company, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any such director, officer, employee or agent under such policy or policies.

(c) In the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.

(d) The Company shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable hereunder if and to the extent that Indemnitee has otherwise actually received such payment under any insurance policy, contract, agreement or otherwise.

Section 12. Duration of Agreement. This Agreement shall continue until and terminate upon the later of: (a) 10 years after the date that Indemnitee shall have ceased to serve as a director, or (b) the final termination of all pending Proceedings in respect of which Indemnitee is granted rights of indemnification or advancement of Expenses hereunder and of any proceeding commenced by Indemnitee pursuant to Section 10 of this Agreement relating thereto. This Agreement shall be binding upon the Company and its successors and assigns and shall inure to the benefit of Indemnitee and his heirs, executors and administrators.

Section 13. Severability. If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a) the validity, legality and enforceability of the remaining provisions of this Agreement (including without limitation, each portion of any Section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby; and (b) to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any Section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested by the provision held invalid, illegal or unenforceable.

Section 14. Exception to Right of Indemnification or Advancement of Expenses. Notwithstanding any other provision of this Agreement, Indemnitee shall not be entitled to indemnification or advancement of Expenses under this Agreement with respect to any Proceeding, or any claim therein, brought or made by him against the Company.

8

Section 15. Identical Counterparts. This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement.

Section 16. Headings. The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.

Section 17. Definitions. For purposes of this Agreement:

(a) "Change in Control" means a change in control of the Company occurring after the Effective Date of a nature that would be required to be reported in response to Item 5(f) of Schedule 14A of Regulation 14A (or in response to any similar item on any similar schedule or form) promulgated under the Securities Exchange Act of 1934 (the "Act"), whether or not the Company is then subject to such reporting requirement; provided, however, that, without limitation, such a Change in Control shall be deemed to have occurred if after the Effective Date (i) any "person" (as such term is used in Sections 13(d) and 14(d) of the Act) is or becomes the "beneficial owner" (as defined in Rule 13d-3 under the Act), directly or indirectly, of securities of the Company representing 25% or more of the combined voting power of the Company's then outstanding securities without the prior approval of at least two-thirds of the members of the Board of Directors in office immediately prior to such person attaining such percentage interest; (ii) the Company is a party to a merger, consolidation, sale of assets or other reorganization, or a proxy contest, as a consequence of which members of the Board of Directors in office immediately prior to such transaction or event constitute less than a majority of the Board thereafter; or (iii) during any period of two consecutive years, individuals who at the beginning of such period constituted the Board of Directors (including for this purpose any new director whose election or nomination for election by the Company's stockholders was approved by a vote of at least two-thirds of the directors then still in office who were directors at the beginning of such period) cease for any reason to constitute at least a majority of the Board of Directors.

(b) "Corporate Status" describes the status of a person who is or was a director, officer, employee, agent or fiduciary of the Company or of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise which such person is or was serving at the request of the Company.

(c) "Disinterested Director" means a director of the Company who is not and was not a party to the Proceeding in respect of which indemnification is sought by Indemnitee.

(d) "Effective Date" means May 23, 1996.

9

(e) "Expenses" shall include all reasonable attorneys' fees, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, or being or preparing to be a witness in a Proceeding.

(f) "Independent Counsel" means a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past five years has been, retained to represent: (i) the Company or Indemnitee in any matter material to either such party, or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term "Independent Counsel" shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee's rights under this Agreement.

(g) "Proceeding" includes any action, suit, arbitration, alternate dispute resolution mechanism, investigation, administrative hearing or any other proceeding whether civil, criminal, administrative or investigative, except one initiated by an Indemnitee pursuant to Section 10 of this Agreement to enforce his rights under this Agreement.

Section 18. Modification and Waiver. No supplement, modification or amendment of this Agreement shall be binding unless executed in writing by both of the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions hereof (whether or not similar) nor shall such waiver constitute a continuing waiver.

Section 19. Notice by Indemnitee. Indemnitee agrees promptly to notify the Company in writing upon being served with any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification or advancement of Expenses covered hereunder.

10

Section 20. Notices. All notices, requests, demands and other communications hereunder shall be in writing and shall be deemed to have been duly given if (i) delivered by hand and receipted for by the party to whom said notice or other communication shall have been directed, or (ii) mailed by certified or registered mail with postage prepaid, on the third business day after the date on which it is so mailed:

(a) If to Indemnitee, to:

[INSERT NAME]
Pfizer Inc.
235 East 42nd Street
New York, NY 10017

(b) If to the Company to:

Pfizer Inc.
235 East 42nd Street New York, New York 10017 Attn: Office of the Secretary

or such other address as may have been furnished to Indemnitee by the Company or to the Company by Indemnitee, as the case may be.

Section 21. Governing Law. The parties agree that this Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware.

Section 22. Miscellaneous. Use of the masculine pronoun shall be deemed to include usage of the feminine pronoun where appropriate.

11

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.

ATTEST:                                                     PFIZER INC.

By                                     By
   -----------------------------            ---------------------------------

INDEMNITEE


Address:             [INSERT NAME]
                     Pfizer Inc.
                     235 East 42nd Street
                     New York, NY 10017

12

EXHIBIT 10(x)

PFIZER INC.
RETIREMENT PLAN FOR
NON-EMPLOYEE DIRECTORS
(Frozen as of October 1996)

Non-employee directors of the Company who satisfy the following requirements will receive a pension after retirement from the Board:

(i) the directors must be at least sixty years of age at the time of retirement,
(ii) the directors must have served a minimum of five years on the Board and
(iii) the director must have years of service on the Board that, when added to his or her age at the time of retirement, equal at least 70,

provided, however, that the foregoing requirements set forth in clauses (ii) and
(iii) shall not apply to any non-employee Director who leaves the Board to accept a position with, or provide services to, a governmental, charitable or educational institution the policies of which prohibit continued services as a Director. The pension is an annuity equal to the director's annual cash retainer at the time of the retirement. Payments will be made in monthly installments for a period of time equal to the period that the director served on the board. A survivor benefit is payable to the director's spouse after the director's death until the full benefit is paid.


EXHIBIT 10(xiii)

PFIZER INC.
RESTRICTED STOCK PLAN
FOR NON-EMPLOYEE DIRECTORS
(As amended through 6/94)

1. Purpose and Effective Date of Plan

This plan shall be known as the Pfizer, Inc Restricted Stock Plan for Non-Employee Directors. The purpose of this Plan is to enable Pfizer Inc ("the Company") to attract and retain persons of outstanding competence to serve as directors of the Company by paying such persons a portion of their compensation in stock of the Company pursuant to the terms of this Plan. The Plan shall become effective as of October 1, 1989, subject to the approval of the shareholders of the Company.

2. Stock Available for the Plan

An aggregate of 50,000 shares of common stock of $0.10 par value of the Company shall be available for delivery, pursuant to the provisions of this Plan. Such shares shall be either previously unissued shares or reacquired shares. Any restricted shares awarded under this Plan which become forfeited for any reason shall again be available for other restricted awards under the Plan.

3. Eligibility for Participation in Plan

Participation in this Plan is limited to persons who serve as directors of the Company and who are not "employees" of the Company (or its subsidiaries) within the meaning of the Employee Retirement Income Security Act of 1974, as amended. It is intended that all non-employee directors of the Company will be participants to the Plan.

4. Awards of Restricted Common Stock Under the Plan

Upon the effective date of the Plan, each participant in the Plan shall receive an award of 100 restricted shares of common stock. Thereafter, awards consisting of 100 restricted shares of common stock will be made to each participant, who is elected or who continues as a director, each year, effective as of the date of the Annual Meeting of Shareholders. Upon the election of a director to fill a vacancy, the director so elected shall be awarded 100 restricted shares of common stock.


Each award of restricted shares under this Plan shall be immediately registered in the name of the participant but shall be expressly subject to the restrictions, the service provisions, and the other, terms and conditions set forth in Section 5 of this Plan.

5. Restrictions, Removal of Restrictions, and Terms and Conditions of Awards of Restricted Shares

(a) Each participant shall have the right to receive all dividends and other distributions made with respect to restricted shares registered in his or her name and shall have the right to vote or execute proxies with respect to such registered restricted shares, unless and until such shares are forfeited pursuant to the provisions of this Plan. Each participant shall have the right to defer receipt of said dividends or other such distributions.

Possession of the certificates of restricted shares shall be retained by the Treasurer of the Company for the benefit of participants, but subject to the restrictions of this Plan, until the provisions of the Plan relating to removal of the restrictions have been satisfied.

(b) Shares of restricted stock may not be sold, assigned, pledged or otherwise transferred by the participant unless and until all of the restrictions imposed by this Plan have been removed pursuant to the provisions of this Plan. Where the restrictions are removed from such shares within less than six months of the date of grant, the participant shall not dispose of such shares until six months have elapsed from the date of grant.

(c) None of the shares of restricted stock awarded under this Plan shall become free of restrictions and non-forfeitable until the termination of the participant's service as a director of the Company at the earliest of the participant's:

(i) death or disability;

(ii) retirement-from the Board within one year of attaining age 70;

(iii) failure to be re-elected after being duly nominated; or

(iv) resignation to enter government service.

Subject to Section 5(d) below, any involuntary termination for cause effected by Board or shareholder action, shall result in forfeiture of the restricted shares.

(d) In the event of a "change of control" of the Company (as defined below), the Board will accelerate the removal of all restrictions relating to all or a portion of the outstanding restricted shares. Involuntary termination of Board service, except for cause, following a change of control will result in immediate lapse of the forfeiture provisions relating to all of the affected director's restricted shares. In any situation involving acceleration of the removal of restrictions relating to the awarded shares upon a change of control, the Board will repurchase all such shares which were awarded more than six months prior to the change of control at the then fair market price instead of

2

releasing the shares to the participant owning such shares. For purposes of this Plan, a "change of control" of the Company shall mean a change of control of a nature that would be required to be reported in response to item 1(a) of Form 8-K promulgated under the Securities Exchange Act of 1934, as amended ("Exchange Act"); provided that, without limitation, such a change of control shall be deemed to have occurred if (a) any "person" (as such term is used in Sections 13(d) and 14(d)(2) of the Exchange Act) is or becomes the beneficial owner, directly or indirectly, of securities of the Company representing 20% or more of the combined voting power of the Company's then outstanding securities, or (b) during any period of two consecutive years, individuals who at the beginning of such period constitute the Board of Directors of the Company cease for any reason to constitute at least a majority thereof unless the election, or the nomination for election by shareholders of each new director was approved by a vote of at least two-thirds of the directors then still in office who were directors at the beginning of the period.

(e) All shares with respect to which the restrictions are not removed in accordance with the provisions of this Plan shall be forfeited and shall revert to the Treasury of the Company. All awarded shares shall remain subject to the Plan's restrictions prohibiting sale or transfer of such shares during the period of time while the participant continues to serve as a director of the Company, and for a period of six (6) months thereafter. Notwithstanding any other provision of this Plan, the issuance or delivery of any shares may be postponed for such period as may be required to comply with any applicable requirements of any national securities exchange or any requirements under any other law or regulation applicable to the issuance or delivery of such shares, and the Company shall not be obligated to issue or deliver any such shares if the issuance or delivery thereof shall constitute a violation of any provision of any law or of any regulation of any governmental authority or any national securities exchange.

6. Amendment or Termination of Plan

The Company reserves the right to amend, modify or terminate this Plan at any time by action of its Board of Directors, provided that such action shall not adversely affect any participant's rights under the provisions of this Plan with respect to awards of restricted stock which were made prior to such action, and further provided that any change in eligibility under the Plan or in the number of shares available for grant under the Plan will be subject to the approval of the shareholders of the Company. In no event, however, shall the provision of
Section 5 be amended more than once every six months, other than to comport with changes in the Internal Revenue Code, the Employee Retirement Income Security Act, or the rules thereunder.

7. Administration of Plan

This Plan shall be administered by the Employee Compensation and Management Development, Committee (hereinafter referred to as the "'Administrator") . All decisions which are made by the Administrator with respect to interpretation of the terms of the Plan, or with respect: to any questions or disputes arising under this Plan, shall be final and binding on the Company and on the participants and their heirs or beneficiaries.

3

8. Recapitalization

In the event of any change in the number or kind of outstanding shares of common stock of the Company by reason of a recapitalization, merger, consolidation, dividend, combination of shares or any other change in the corporate structure or shares of stock of the Company, the Board of Directors of the Company will make appropriate adjustments in the number of shares available for delivery pursuant to the provisions of this Plan and the number of shares to be awarded to each participant under this Plan.

9. Compliance with Section 16

Transactions under the Plan are intended to comply with all applicable conditions of Rule 16b-3 or its successors under the 1934 Act. To the extent any provision of the plan or action by the plan administrators is deemed not to comply with an applicable condition of Rule 16b-3, it shall be deemed null and void, to the extent permitted by law and deemed advisable by the Plan administrators.

10. Cessation of Awards

Notwithstanding any other provision of the Plan, no further awards of restricted stock shall be made under the Plan after June 23, 1994.

4

EXHIBIT 11

PFIZER INC. AND SUBSIDIARY COMPANIES

COMPUTATION OF EARNINGS PER COMMON SHARE
(Unaudited)

                                                                                                      Year Ended December 31,
                                                                                                      -----------------------
                                                                                                      1996         1995       1994
                                                                                                     ------       ------     ------
                                                                                                   (millions, except per share data)
Earnings:
   Income from continuing operations........................................................         $1,929       $1,554     $1,276
   Discontinued operations..................................................................              -           19         22
                                                                                                     ------       ------     ------
   Net income...............................................................................         $1,929       $1,573     $1,298
                                                                                                     ======       ======     ======

Primary:
  Weighted average shares:
        Weighted average number of common shares outstanding................................            624          615        611
        Common share equivalents (a)........................................................             20           15          9
                                                                                                     ------       ------     ------
        Weighted average number of common shares and common share equivalents...............            644          630        620
                                                                                                     ======       ======     ======


  Earnings per common share:
        Income from continuing operations...................................................          $2.99        $2.47      $2.05
        Discontinued operations.............................................................              -          .03        .04
                                                                                                     ------       ------     ------
        Net income per common share.........................................................          $2.99        $2.50      $2.09
                                                                                                     ======       ======     ======


Fully Diluted:
  Weighted average shares:
        Weighted average number of common shares outstanding................................            624          615        611
        Common share equivalents and other dilutive securities..............................             21           16         10
                                                                                                     ------       ------     ------
        Weighted average number of common shares and common share equivalents...............            645          631        621
                                                                                                     ======       ======     ======


  Earnings per common share:
        Income from continuing operations...................................................          $2.99        $2.46      $2.05
        Discontinued operations.............................................................              -          .03        .04
                                                                                                     ------       ------     ------
        Net income per common share.........................................................          $2.99        $2.49      $2.09
                                                                                                     ======       ======     ======


(a) Common share equivalents applicable to stock options under the Stock and Incentive Plan.


EXHIBIT 12

PFIZER INC. AND SUBSIDIARY COMPANIES
COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES

                                                                                          Year Ended December 31,
                                                                                           -----------------------
                                                                             1996       1995         1994       1993        1992
                                                                            ------     ------       ------     ------      ------
                                                                                    (millions of dollars, except ratios)

Determination of Earnings:
   Income from continuing operations before provision for taxes on          $2,804     $2,299       $1,830      $835       $1,541
      income, minority interests and cumulative effect of
      accounting changes.........................................
  Less:
      Minority interests.........................................                6          7            5         2            3
      Undistributed earnings/(losses) of unconsolidated
        subsidiaries.............................................                0          0          (1)         1            8
                                                                            ------     ------       ------      ----       ------
  Adjusted income                                                            2,798      2,292        1,826       832        1,530
      Fixed charges..............................................              206        232          158       136          130
                                                                            ------     ------       ------      ----       ------
        Total earnings as defined................................           $3,004     $2,524       $1,984      $968       $1,660
                                                                            ======     ======       ======      ====       ======

Fixed charges
   Interest expense (a)..........................................             $165       $192         $127      $107         $103
   Rents (b).....................................................               41         40           31        29           27
                                                                            ------     ------       ------      ----       ------
      Fixed charges..............................................              206        232          158       136          130
   Capitalized interest..........................................                5         13           15        14           12
                                                                            ------     ------       ------      ----       ------

      Total fixed charges........................................             $211       $245         $173      $150         $142
                                                                            ======     ======       ======      ====       ======

Ratio of earnings to fixed charges...............................             14.2       10.3         11.5       6.5         11.7
                                                                            ======     ======       ======      ====       ======


(a) Interest expense includes amortization of debt discount and expenses.

(b) Rents included in the computation consist of one-third of rental expense, which the Company believes to be a conservative estimate of an interest factor in its leases, which are not material.


Major Pfizer Products and Selected Candidates in Development


Cardiovascular Diseases -- Cardiovascular diseases are the leading cause of death in most developed countries. About 64 million Americans suffer from different forms of heart disease such as atherosclerosis, hypertension, angina, congestive heart failure, and stroke. Many cardiovascular drugs are available to treat these conditions. Catheters and stents are increasingly used in interventional procedures to treat blocked arteries caused by atherosclerosis.

Central Nervous System Disorders -- More than 100 million people worldwide suffer from psychiatric and neurological disorders. Central nervous system disorders include anxiety, depression, panic disorder, post-traumatic stress disorder, schizophrenia, sleep disorders, migraine, and Alzheimer's disease and other neuro-degenerative disorders. A common disease in the growing elderly population, Alzheimer's is expected to be a major public health concern in the next century.

Infectious Diseases -- Infectious diseases remain a leading cause of disability and death worldwide. Routine infections are not always appropriately treated, and resistant organisms are becoming more common. Aggressive treatment and research into more powerful anti- infectives will improve care while reducing cost. Today, novel antifungal drugs are especially important in the fight against infections.

Arthritis/Inflammation -- Some form of arthritis and inflammation, from simple but painful "tennis elbow" to severe rheumatoid arthritis, afflicts about 30 percent of the world's population. Although a growing health problem, these conditions can be alleviated with medication. Today, joint replacement is also available to help people suffering from diseased or trauma-damaged joints enjoy more normal mobility.

Metabolic Diseases -- Diabetes, the most common metabolic illness, afflicts 16 million people in the U.S. and 30 million worldwide. It can result in heart disease, kidney disease, blindness, and amputations. Osteoporosis, a common metabolic bone disease often leading to debilitating fractures, affects about 25 million people in the U.S. By the year 2000, more than 14 million patients in Europe, Canada, and Latin America will be treated for osteoporosis.

Allergic Disease -- Allergic diseases, including seasonal and year-round allergies and urticaria (itching and hives), cause much discomfort. Allergic rhinitis, which is common in children, affects approximately 50 million people in the United States.

Cancer -- The incidence of cancer is on the rise. It is the second-leading cause of death in the U.S. where about 185,000 new cases of breast cancer will be diagnosed this year. Outside the U.S., the prevalence of advanced/metastatic breast cancer is about 85,000 patients. Special drug-delivery devices offer improved chemotherapeutic regimens.

Urogenital Disorders -- Worldwide, benign prostatic hyperplasia occurs in more than half the male population over the age of 60. Inplants can alleviate some problems caused by urogenital disorders. Promising drugs are also now in development for incontinence, and for erectile dysfunction, a condition affecting more than 40 million men in Australia, Canada, Europe and the United States.

Surgery/Interventional -- Advances in surgical techniques, which include sophisticated instrumentation and minimally invasive interventional procedures such as laparoscopic surgery, have revolutionized medicine. State-of-the-art instruments and implants give trauma victims better treatment outcomes. Stent endoprostheses are used to keep blood vessels, ducts, and passageways open, improving quality of life and survival prospects for patients with debilitating and life-threatening diseases. Other advances include electrosurgical and ultrasonic surgical systems -- innovations that make surgery less invasive and recovery faster and easier.
Consumer Health/OTC -- The quality and value of familiar consumer health care products help people everywhere feel better as they go about their daily tasks. Many of these products, such as lotions that protect skin from the damaging rays of the sun, also provide health benefits. In addition, drugs that previously were only available by prescription are becoming increasingly available as over-the-counter (OTC) products, giving consumers the option to take medications with proven clinical effectiveness for their health problems.

Animal Health -- Livestock and companion animals are subject to many of the health problems affilicting humans, including bacterial infections, viruses, and parasitic diseases. Keeping animals healthy requires a dedication to the research and development that will produce anti-infectives, antiparasitics, anticoccidials, and vaccines to improve the quality of life both for animals and for their human owners. New products to treat animals include medications to restore mobility to older, arthritic dogs, and new vaccines to protect livestock and companion animals from disease.


Current Products
===================================================================================================================================
Cardiovascular Diseases
- -----------------------
Cardura                                      Diagnostic angiography catheters                 Shortgoose, Mystic
Lipitor (atorvastatin)(1)                    Guidewires: C-Thru, Forte 18, Forte 30,          Magnarail probing catheter
 (for lowering cholesterol)                    Clyde [I], Hannibal [I], Magnum Meier          Morse Manifold and other fluid
Minipress                                    PTA catheters: Match 35, Smash [I],              Management products
Minipress XL/Alpress [I]                       Total Cross                                    NAMIC cath lab accessories
Norvasc                                      PTCA catheters: Goldie, Asuka, Magical           Schneider Guider guiding catheter
Procardia [U.S.]                               Speedy [I], Speedflow, Speedflow, Jr. [I]      Magic Wallstent [I]
Procardia XL [U.S.]                            Bonnie, Takumi [I], Chubby, MC Rail,           Wallstent [I] coronary stent
- -----------------------------------------------------------------------------------------------------------------------------------
Central Nervous System Disorders
- --------------------------------
Aricept (donepezil)(2)
 (for Alzheimer's disease)
Atarax/Vistaril
Navane
Sinequan
Zoloft
 (for depression and OCD)
- -----------------------------------------------------------------------------------------------------------------------------------
Infectious Diseases
- -------------------
Bacacil/Spectrobid                           streptomycin                                     Zithromax
Cefobid                                      Sulperazon [I]                                   Zithromax POS (for pediatric use)
Diflucan                                     Terramycin                                       Zithromax SDP (for Chlamydia)
Diflucan [I] (for onychomycosis)             Trosyd [I]                                       Zithromax 600 for MAC
Diflucan (for pediatric use)                 Unasyn IM/IV                                      (for prevention of Mycobacterium
Diflucan VC (for vaginal candidiasis)        Unasyn Oral [I]                                    avium complex [AIDS related])
Fasigyn [I]                                  Vibramycin
- -----------------------------------------------------------------------------------------------------------------------------------
Arthritis/Inflammation
- ----------------------
Feldene                                      Duracon, Interax [I], Kinemax                    Duration Polyethylene
Feldene FDDF [I]                              total knees                                     Simplex P bone cement
Flucam [I]                                   Exeter total hip
                                             Hydroxyapatite coatings for orthopedic
Command hip and Monogram knee                 implants
 instrument systems                          Partnership and ABG [I], total hips
- -----------------------------------------------------------------------------------------------------------------------------------
Metabolic Diseases
- ------------------
Diabinese
Glucotrol
Glucotrol XL
- -----------------------------------------------------------------------------------------------------------------------------------

[I] -- International only (in at least one country)
(1) Codeveloped and copromoted by Warner-Lambert and Pfizer; trademark of Warner-Lambert
(2) Copromoted by Eisai and Pfizer; trademark of Eisai
[US] -- U.S. only NO KEY-- Both U.S. and at least one other country


Current Products (cont.)
===================================================================================================================================
Allergic Disease
- ----------------
Reactine [I](3)
Zyrtec [U.S.](3) (tablets and syrup)
- -----------------------------------------------------------------------------------------------------------------------------------
Cancer
- ------
Infuse-a-Port, Life-Port, PeriPort
 implantable infusion ports
M400, M550 [I] constant flow
 implantable infusion pumps
- -----------------------------------------------------------------------------------------------------------------------------------
Urogenital disorders
- --------------------
Cardura                                      UroLume Endoprosthesis
 (for benign prostatic hyperplasia)           (to treat recurrent bulbous urethral
                                               stricture)
AMS 600, AMS 650, AMS 700CX                  UroLume Endoprosthesis [I]
700 Ultrex, Dynaflex, Ambicor penile            (to treat urethral obstruction caused by
 implants                                        benign prostatic hyperplasia [BPH])
AMS 800 urinary sphincter
- -----------------------------------------------------------------------------------------------------------------------------------

Surgery/Interventional
- ----------------------
Alta, Gamma Nail,                             Electroshield Monitoring System                 Edge Costed ES Blade and Needle
BoneSource bone substitute                    Force GSU, Force Argon Systems                   Electrodes
Extra-Drive power systems                     Force 30, 40 electrosurgical systems            NS 2000 Bipolar Neurosurgical
Hoffmann, Monotube external                   Force FX, Force 300 [I] electrosurgical          System, including instrumentation
 trauma products                               systems                                        Electrosurgical Laparoscopic
Leibinger/Fischer RM, ZD stereotaxy           Permalume [U.S.] covered stent                   Handset
 systems                                      Wellstent endoprosthesis (biliary, iliac,       REM Polyhesive patient return pads
Luhr, Leibinger internal fixation products     esophageal, tracheobronchial,                  Vesta DUB [l] Endometrial
Mainstay soft-tissue anchor                    TIPS [venous shunt]                              ablation device
AirForce smoke evacuation system              CUSA Ultrasonic Aspiration System
Accuvac smoke evacuation attachment           Electrosurgical pencils and electrodes
- -----------------------------------------------------------------------------------------------------------------------------------
Consumer Health/OTC
- -------------------
Aludrox [I]          BenGay            DentSure [U.S.]           Isogel [I]            PLT [I]            Terra-Cortril [I]
Analock [I]          Bonine/           Desitin/Daily             Juscoat [I]           Rappell [I]        Terramycin [I]
Aneton [I]            Bonamine [I]      Care [U.S.]              Liqufruta [I]         Reactine (OTC)[I]  TCP [I]
Antiminth [U.S.]     Buttercup [I]     Diflucan One              Lucilla [I]           Rectinol [I]       Trosyd AF [I]
Aquasun [I]          Choats [I]         (OTC) [I]                Migraleve [I]         Rheaban [U.S.]     Unisom
Atarax-P [I]         Combantrin [I]    Galaflax [I]              OcuHist [U.S.]        Rid                Vanart
Bain de Soleil       Corex [I]         Galloways [I]             Ondaflex [I]          Stoppers [I]       Visine/
Banlice [I]          Cortisone         GyneCure [I]              Pacquin               Straitus [I]         Visaclean
Barbasol/Pure Silk   Dabaways [I]      Hemorid                   Plax                  Taizer [I]         Wart-Off
- -----------------------------------------------------------------------------------------------------------------------------------
Animal Health
- -------------                                                    Companion
Livestock            Dectomax          Peracef [I]               Animals               Leukocell          Vanguard
- ---------            FarrowSure        RespiSure                 ---------             Mycodex            Vanguard puppy
Advocin Inj.[I]/     Fortress          Rispoval [I]              Adams Line [U.S.]      Line [U.S.]       Vibravet [I]
Soluble Powder [I]   Imuresp [I]       Rumatel [U.S.]            Amoxi/Clamoxyl        Nemex
Atrobac/PR-Vac       LitterGuard       ScourGuard                Clavamox/             Pet Tabs
Avaix/Coxistac [I]   Mecadox           ScourShield               Synulox               Primor [U.S.]
Banminth             Neo Terramycin    Stafac/V-Max              Defensor              Primucell
BoviShield           One Shot          Terramycin/LA             Domitor/Antisedan     Rescamune [I]
CattleMaster         Paratect Flex [I] Ultrabac                  Felocell              Rimadyl [U.S.]
Clamoxyl [I]         Pathozone         Valbazen                  Filaribits            Strongid
===================================================================================================================================

Key: [U.S.] -- U.S. only [I] -- International only (in at least one country) No Key -- Both U.S. and at least one other country
[3] -- Copromoted by UCB and Pfizer


Extensions/
Additional                             Supplemental Filings
Indications                            Under Regulatory                               Undergoing Regulatory
(last 12 months)                       Review                                         Review
=======================                ============================                   =======================
Cardiovascular Diseases
- -----------------------
Norvasc                                                                               Cardura XL [I]
 (safety label changes for
 use in congestive heart                                                              Clyde [U.S.]
 failure [CHF])                                                                       freeFLOW [U.S.] perfusion catheter
                                                                                      Hannibal [U.S.]
                                                                                      Unistep Plus [U.S.]
- -----------------------                ----------------------------                   --------------------------------------
Central Nervous System Disorders
- --------------------------------
Zoloft [U.S.]                          Zoloft [U.S.]
 (for OCD)                              (for panic disorder)
Zoloft [I]                             Zoloft [U.S.]
 (for panic disorder)                   (for pediatric OCD)
- -----------------------                ----------------------------                   --------------------------------------
Infectious Diseases
- -------------------
Unasyn [U.S.]                          Diflucan [U.S.]                                E5 [I]
 (for pediatric use)                    (for onychomycosis)                           Trovan (trovafloxacin)
Zithromax [U.S.]                                                                       (for bacterial infections)
 (for pediatric lower respiratory                                                     Trovan IV (alatrofloxacin)
 tract infections; atypical                                                            (IV form of trovafloxacin)
 pneumonia; gonorrhea and
 chancroid: PID; IV form for
 pneumonia)
- -----------------------                ----------------------------                   --------------------------------------
Arthritis/Inflammation
- ----------------------

- -----------------------                ----------------------------                   --------------------------------------
Metabolic Diseases
- ------------------

- -----------------------                ----------------------------                   --------------------------------------

(1) Codeveloped and copromoted by Warner-Lambert and Pfizer; trademark of Warner-Lambert
(2) Copromoted by Eisai and Pfizer; trademark of Eisai
(3) Copromoted by UCB and Pfizer
[I] -- International only (in at least one country)
[US] -- U.S. only NO KEY-- Both U.S. and at least one other country


Extensions/
Additional                             Supplemental Filings
Indications                            Under Regulatory                               Undergoing Regulatory
(last 12 months)                       Review                                         Review
=======================                ============================                   =======================
Allergic Disease
- ----------------
Zyrtec [U.S.](3)
 (syrup; for pediatric use,
 ages 6-11)
- -----------------------                ----------------------------                   --------------------------------------
Cancer
- ------

- -----------------------                ----------------------------                   --------------------------------------
Urogenital Disorders                    UroLume Endoprosthesis [U.S.]
- --------------------                    (to treat urethral obstruction caused
                                        by BPH)
- -----------------------                ----------------------------                   --------------------------------------
Surgery/Interventional
- ----------------------

- -----------------------                ----------------------------                   --------------------------------------
Consumber Health/OTC
- --------------------

Bain de Soleil                         BenGay
Rid                                    Desitin
                                       Feldene Topical
                                       OcuHist
                                       Unisom
                                        (in process of registration in various
                                         international markets)
- -----------------------                ----------------------------                   --------------------------------------
Animal Health
- -------------
Companion Animals                      Livestock                                      Livestock               Companion
- -----------------                      ---------                                      ---------                Animals
                                                                                                               --------
Vanguard puppy CPV/CV [U.S.]           Dectomax Inj-Sheep [I]                         Aviax cross
                                       Dectomax Inj-Swine                              clearances              Rimadyl [I]
                                       Stafac-Sows                                    Dectomax pour-on
                                                                                      Rispoval 4 [I]
                                                                                      Rispoval pasteurella [I]
                                                                                      ScourGuard 5
========================               =============================                  ======================================

(1) Codeveloped and copromoted by Warner-Lambert and Pfizer; trademark of Warner-Lambert
(2) Copromoted by Eisai and Pfizer; trademark of Eisai
(3) Copromoted by UCB and Pfizer
[I] -- International only (in at least one country)
[US] -- U.S. only NO KEY-- Both U.S. and at least one other country


In Late-Stage                                                   In Early-Stage
Development                                                     Development
=========================================================       ========================================
Cardiovascular Diseases
- -----------------------
Cardura XL                       Bonnie [U.S.]
 (GITS extended-release          Takumi [U.S.]
 formulation)                    Magic Wallstent [U.S.]
candoxatril [I]                 Wallstent [U.S.]
 (for CHF, Phase III)             coronary stent
Xelide (dofetilide)              Wallstent [U.S.]
 (antiarrhythmic agent,            carotid stent
 Phase III)
- ---------------------------------------------------------       ----------------------------------------
Central Nervous System Disorders
- --------------------------------
eletriptan                                                      sunepitron (CP-93,393)
 (for migraine, Phase III)                                       (for anxiety and depression, Phase II)
Zeldox (ziprasidone)                                            CP-400,092 (NGD-91-1)
 (for schizophrenia, Phase III)                                  (for anxiety disorder)
- ---------------------------------------------------------       ----------------------------------------
Infectious Diseases
- -------------------
E5 [U.S.] (Phase III)                                           Zithromax
voriconazole                                                     (for treatment and prevention of
 (for serious fungal infections, Phase III)                       malaria and typhoid)
Zithromax
 (for gastric ulcers caused by H. pylori, Phase III)
Zithromax 600 for MAC
 (for treatment of Mycobacterium avium complex
 [AIDS related], Phase III)
- ---------------------------------------------------------       ----------------------------------------
Arthritis/Inflammation
                                                                tenidap (OA)
                                                                 (for osteoarthritis, Phase II)

                                                                New total hip and knee designs
                                                                Total Shoulder
- ---------------------------------------------------------       ----------------------------------------
Metabolic Diseases
Alond (zopolrestat)                                             CP-422,935 (NGD-95-1)
 (for prevention of diabetic neuropathy, Phase III)              (for obesity)
                                                                droloxifene
                                                                 (for prevention and treatment of
                                                                 osteoporosis, Phase II)
                                                                inhaled insulin
                                                                 (novel delivery system; for diabetes, Phase II)
- ---------------------------------------------------------       ----------------------------------------

(1) Codeveloped and copromoted by Warner-Lambert and Pfizer; trademark of Warner-Lambert
(2) Copromoted by Eisai and Pfizer; trademark of Eisai
(3) Copromoted by UCB and Pfizer
[I] -- International only (in at least one country)
[US] -- U.S. only NO KEY-- Both U.S. and at least one other country


In Late-Stage                                                   In Early-Stage
Development                                                     Development
=========================================================       ========================================
Allergic Disease
- ----------------
- ---------------------------------------------------------       ----------------------------------------
Cancer
- ------
droloxifene
 (for advanced breast cancer, Phase III)
TLC D-99 (liposomal doxorubicin)
 (for late-stage breast cancer, Phase III)
- ---------------------------------------------------------       ----------------------------------------
Urogenital Disorders
- --------------------
Cardura XL [I]                                                  darifenacin
Viagra (sildenafil)                                              (for urinary urge incontinence and irritable
 (for erectile dysfunction, Phase III)                           bowel syndrome, Phase II)
Coaguloop (to treat BPH)
Cartilage/Autologous Cells
 (for pediatric vesicoureteral reflux and stress
 incontinence)
- ---------------------------------------------------------       ----------------------------------------
Surgery/Interventional
- ----------------------
Advanced bipolar instrumentation                                Next-generation fracture fixation designs
Dri-Polar Suction Coagulator                                    Next-generation ultrasonic aspiration system
Force EZ [U.S.] electrosurgical generator
Trigger Switch and Cord                                         Corvita Corethane Endoluminal Graft
Vesta DUB [U.S.] endometrial ablation device                     (for peripheral applications)

Bioresorbable fracture fixation devices

Easy Wallstent, Flamingo Wallstent [I]
Wallgraft PET [U.S.] endoprosthesis
Corvita Corethane Endoluminal Graft
 (for occlusive disease)
- ---------------------------------------------------------       ----------------------------------------
Consumer Health/OTC
- -------------------

- ---------------------------------------------------------       ----------------------------------------
Animal Health
- -------------
Livestock                             Companion                 Livestock                  Companion
- ---------                             ---------                 ---------                  ---------
                                       Animals                                              Animals
Adjuvanted BoviShield                  -------                  BHV-1 gD vaccine [I]        -------
Advocin 18%                           Zenoquin                  Erysipelas vaccine         azithromycin
Atrophic rhinitis vaccine              (marbofloxacin)                                     doramectin-horse
CattleMaster Plus                                                                          UK-124,114
=========================================================       ========================================

(1) Codeveloped and copromoted by Warner-Lambert and Pfizer; trademark of Warner-Lambert
(2) Copromoted by Eisai and Pfizer; trademark of Eisai
(3) Copromoted by UCB and Pfizer
[I] -- International only (in at least one country)
[US] -- U.S. only NO KEY-- Both U.S. and at least one other country


Financial Contents

30 Financial Review

38 Management's Report

38 Audit Committe's Report

38 Independent Auditors' Report

Financial Statements

39 Segment Information

40 Geographic Data

41 Consolidated Statement of Income

42 Consolidated Statement of Shareholders' Equity

43 Consolidated Balance Sheet

44 Consolidated Statement of Cash Flows

45 Notes to Consolidated Financial Statements

59 Quarterly Consolidated Statement of Income

(Unaudited)

60 Financial Summary (1986-1996)


Earnings Per Common Share
(dollars)

- --------------------------------$2.99--

- --------------------------$2.50--------

$2.09

$1.20

- -----------$1.03-----------------------



92 93 94 95 96

The 1996 increase in earnings per common share reflects strong worldwide sales growth, complemented by continuing improvements in operating efficiencies. Earnings per common share have increased at a compound annual growth rate of almost 12% over the past 10 years.

Earnings per common share in 1993 would have been $1.85 excluding after-tax net charges for divestitures, restructuring and unusual items.

Market Value Per Common
Share (December 31)(dollars)

$83.00


$63.00


$38.63
$36.25
$34.50



92 93 94 95 96

Market value per common share of the Company's stock has increased at a compound annual growth rate of more than 18% over the past 10 years.


Financial Review

Significant Events Affecting Comparability The Company entered into various strategic transactions to better position itself as a research-based, global health care company. The Company's financial statements include the financial position, results of operations and cash flows for the following acquisitions subsequent to the respective dates of acquisition:
o Corvita Corporation, which develops, manufactures and markets self-expanding endovascular stent grafts and synthetic vascular grafts used in the treatment of severely diseased arteries, was acquired in June 1996.
o Cortizone, an anti-itching product and Hemorid, a hemorrhoid treatment, were purchased from Thompson Medical Co., Inc. in April 1996.
o The Leibinger Companies, leaders in the manufacture of specialty instruments and implantable devices used in skull, jaw, facial, hand and foot surgery, were acquired in January 1996.
o Bain de Soleil sun-related skin care products were acquired from the Procter & Gamble Company in August 1995.
o NAMIC U.S.A. Corporation (NAMIC), a manufacturer of accessories for angioplasty procedures, was acquired in March 1995.
o SmithKline Beecham's animal health business (SBAH), a manufacturer of animal vaccines as well as livestock and companion animal health products, was acquired in January 1995. See the footnote "Acquisitions" beginning on page 53.

Overview of Consolidated Operating Results Net income in 1996 was $1,929 million, or $2.99 per share, compared with $1,573 million, or $2.50 per share in 1995. These results reflected strong operating leverage. Sales grew 13%, while net income increased 23% and earnings per share increased 20%.
The 1996 net sales of $11,306 million reflected continued strong demand for the Company's innovative new products. Cost of sales increased from 1995 by 1%, while selling expenses increased by double digit rates in support of both existing and newly launched products. Research and development (R&D) expenditures increased by 17% as an unprecedented number of new chemical entities continued to advance in late stages of clinical development. The growth in net income was also aided by a decrease in the Company's effective tax rate from 32.1% to 31.0%.

Net Sales
Consolidated net sales increased $1,285 and $2,044 million, or 13% and 26% in 1996 and 1995, respectively. Excluding the effect of the SBAH acquisition, net sales for 1995 increased 18% compared with 1994. The net sales growth in 1996 and 1995 was primarily driven by volume increases.


Net Sales by Business Segment
(% of consolidated net sales)      (millions of dollars)        % Change*
- ---------------------------------------------------------------------------
1996                                                               96/95
                                                                   -----

         85%       o Health Care              $ 9,630               15
         11%       o Animal Health              1,222                0
          4%       o Consumer
                     Health Care                  454               15
                     --------------------------------
                         Total                $11,306               13
- ---------------------------------------------------------------------------
1995                                                               95/94
                                                                   -----

         84%       o Health Care              $ 8,409               21
         12%       o Animal Health              1,219              101
          4%       o Consumer
                     Health Care                  393               (4)
                     ---------------------------------------------------
                         Total                $10,021               26
- ---------------------------------------------------------------------------
1994                                                               94/93
                                                                   -----

         87%       o Health Care              $ 6,963               12
          8%       o Animal Health                605                5
          5%       o Consumer
                     Health Care                  409               10
                     ---------------------------------------------------
                         Total                $ 7,977               11
- ---------------------------------------------------------------------------

*Percentages may reflect rounding adjustments.

The health care segment is comprised of pharmaceuticals and hospital products.
Pharmaceutical net sales were $8,188 million in 1996 and $7,072 million in 1995, reflecting increases of 16% and 22%, respectively. The 1996 increase in worldwide pharmaceutical net sales reflected growth of 21% in the U.S. and 11% overseas, while the 1995 increase reflected growth of 17% in the U.S. and 27% overseas. Foreign exchange fluctuations, principally the relative strengthening of the dollar as compared with the Japanese yen in 1996 versus 1995, decreased worldwide pharmaceutical net sales by 3%. Foreign exchange fluctuations, principally the relative weakening of the dollar as compared with the yen and major European currencies in 1995 versus 1994, increased worldwide pharmaceutical net sales by 3%.
In 1996, three products--Norvasc, Zoloft and Procardia XL--had sales in excess of $1 billion. The Company's portfolio of seven key products introduced in the U.S. during the 1990s--Norvasc, Zoloft, Diflucan, Cardura, Zithromax, Glucotrol XL and Zyrtec--accounted for 67% of worldwide pharmaceutical net sales and grew 34% in 1996. U.S. basic patent protection for these products extends into the next century, ranging from the year 2000 for Cardura to 2007 for Norvasc.
Reflecting the product's maturity and the Company's increasing emphasis on Norvasc, net sales of Procardia XL declined.


Composition of Net Sales
Growth
o Volume
o Price
o Currency
24%


15%

11%


3%

0% 0% 0%
(1)% (2)%


94 95 96

Volume has been the major contributor to net sales growth in each of the last three years.

The 1990 Omnibus Budget Reconciliation Act included a provision requiring pharmaceutical companies to rebate a portion of revenues from pharmaceutical products dispensed to state Medicaid recipients. Medicaid rebates and related state programs reduced net sales by $92, $85 and $74 million in 1996, 1995 and 1994, respectively. In addition, the Company provided approximately $87, $80 and $56 million in legislatively mandated discounts to the federal government in 1996, 1995 and 1994, respectively. Net sales growth in the U.S. was reduced by performance-based contracts with several customers. This decrease was more than offset by volume increases in all three years.

Percentage Change in Net Sales
                                                   Analysis of Change
                                      Total %  ----------------------------
                                      Change   Volume     Price    Currency
- ---------------------------------------------------------------------------
    Health Care
         1996 vs. 1995                 15        17         0         (2)
         1995 vs. 1994                 21        19        (1)         3
    Animal Health
         1996 vs. 1995                 0          2         0         (2)
         1995 vs. 1994                101       102        (1)         0
    Consumer Health Care
         1996 vs. 1995                 15        15         5         (5)
         1995 vs. 1994                 (4)       (2)        4         (6)
    Consolidated
         1996 vs. 1995                 13        15         0         (2)
         1995 vs. 1994                 26        24        (1)         3
- ----------------------------------------------------------------------------

Net Sales--Major Pharmaceuticals                                    % Change*
                                                                 ------------
   (millions of dollars)              1996     1995      1994    96/95  95/94
- -----------------------------------------------------------------------------
    CARDIOVASCULAR DISEASES:        $3,486   $2,981    $2,428     17     23
        Norvasc                      1,795    1,265       768     42     65
        Procardia XL                 1,005    1,133     1,177    (11)    (4)
        Cardura                        533      413       313     29     32

    INFECTIOUS DISEASES:             2,332    2,153     1,751      8     23
        Diflucan                       910      878       721      4     22
        Zithromax                      619      406       206     53     97
        Unasyn                         326      333       290     (2)    15
        Sulperazon                     139      160       126    (13)    27

    CENTRAL NERVOUS SYSTEM
        DISORDERS:                   1,382    1,092       775     27     41
        Zoloft                       1,337    1,037       718     29     44

    ALLERGY:                           156       21        11    633     91
        Zyrtec/Reactine                146       10        11     **     (9)
- -----------------------------------------------------------------------------

*Percentages may reflect rounding adjustments. **Calculation not meaningful.

Hospital products net sales were $1,442 million in 1996 and $1,337 million in 1995, representing increases of 8% and 16%, respectively. Net sales growth for 1996 reflected incremental sales of stents and the acquisitions of Leibinger and Corvita, partially offset by unfavorable foreign exchange effects. Together, these acquisitions contributed 4 percentage points to hospital products net sales growth in 1996. For the year, stent sales exceeded $100 million. Growth in 1995 net sales was attributable to the launch of new angioplasty and angiography catheters, strong demand for stents, the NAMIC acquisition and favorable foreign exchange effects.
Animal health net sales of $1,222 million in 1996 were comparable to the 1995 net sales of $1,219 million. Adverse conditions in the U.S. and European livestock markets, heightened competition for companion animal products and the impact of foreign exchange tempered sales performance in the year. Despite this environment, sales of Dectomax, the novel antiparasitic for livestock, increased 36% worldwide to $95 million, reflecting successful introductions in the U.S., Japan and other major markets. Animal health net sales increased 101% in 1995 due to the sales volume contribution of the SBAH acquisition.
Consumer health care net sales increased 15% in 1996 to $454 million, primarily due to recently acquired brands, including Bain de Soleil, Cortizone and Hemorid. Sales of over-the-counter products previously available only by prescription also contributed to growth. These included the 1995 introductions of Reactine (an anti-allergy medication) in Canada and Diflucan One (for treatment of vaginal candidiasis) in the U.K. and the early 1996 introduction of OcuHist (an antihistamine eye drop) in the United States. Consumer health care net sales declined 4% in 1995 as compared with 1994 due to increased private-label competition in the U.S. for existing brands and the impact of the devaluation of the Mexican peso. These factors were partially offset by launches of over-the-counter products in a number of countries.


Financial Review continued

Changes in Geographic Net Sales by Business

                                              % Change in Net Sales
                                          -------------------------------
                                               U.S.        International
                                          -------------   ---------------
                                          96/95   95/94   96/95     95/94
- --------------------------------------------------------------------------
    Health Care                            18      17      10        25
    Animal Health                          (8)    148       5        82
    Consumer Health Care                   22      (9)      4         7
    Total Operations                       16      21       9        31
- --------------------------------------------------------------------------

Net Sales by Geographic Area
(% of consolidated net sales)         (millions of dollars)      % Change
- ---------------------------------------------------------------------------
1996                                                               96/95
                                                                   -----
         53%       o United States            $ 5,941               16
         24%       o Europe                     2,773               13
         14%       o Asia                       1,598                4
          7%       o Canada
                     Latin America                750                8
          2%       o Africa/Middle East           244                6
                     --------------------------------
                         Total                $11,306               13
- ---------------------------------------------------------------------------
1995                                                               95/94
                                                                   -----
         51%       o United States            $ 5,113               21
         25%       o Europe                     2,444               39
         15%       o Asia                       1,538               28
          7%       o Canada
                     Latin America                696               16
          2%       o Africa/Middle East           230               26
                     --------------------------------
                         Total                $10,021               26
- ---------------------------------------------------------------------------
1994                                                               94/93
                                                                   -----
         53%       o United States            $ 4,237               11
         22%       o Europe                     1,759               11
         15%       o Asia                       1,201               12
          8%       o Canada
                     Latin America                598               19
          2%       o Africa/Middle East           182                3
                     --------------------------------
                         Total                $ 7,977               11
- ---------------------------------------------------------------------------

In 1996, the Company had net sales in excess of $10 million in each of 45 countries outside the U.S., with no single country, other than the U.S., contributing more than 10% to total net sales.

Product Developments
The Company continues to invest in R&D to develop both new products and additional uses for existing products. Following are certain significant regulatory actions that occurred in 1996:
In December:
o The U.S. Food and Drug Administration (FDA) approved the antibiotic Zithromax for the treatment of atypical pneumonia and pediatric lower respiratory tract infections.
o Warner-Lambert received FDA approval for the drug Lipitor, which was discovered and developed by its Parke-Davis Research Division. Warner-Lambert and Pfizer have signed a collaborative agreement to copromote and continue the


development of Lipitor in the U.S. and international markets. Lipitor, a
cholesterol-lowering product, received marketing approval in the U.K. and
Germany in November and was launched in the U.S. during February 1997.
        In November:
        o The FDA approved specific dosage forms of Zithromax for the treatment
of certain sexually transmitted diseases.
        o The Company received an approvable letter from the FDA for the use of
Zoloft, the Company's antidepressant, in the treatment of panic disorder.
        o Eisai Co., Ltd., the company that discovered and developed Aricept and
with whom the Company will be copromoting the product, received FDA approval for
the drug. Aricept, a once-daily treatment for mild to moderate Alzheimer's
disease, was launched in the U.S. during February 1997.
        In October:
        o The FDA approved Zoloft for the treatment of patients with
obsessive-compulsive disorder (OCD).
        In September:
        o The FDA approved the use of a syrup formulation of the antihistamine
Zyrtec for the treatment of children 6 to 11 years of age.
        In June:
        o The FDA approved the use of Norvasc in treating angina or hypertensive
patients who also have congestive heart failure.
        o The FDA approved Zithromax for the prevention of disseminated
Mycobacterium avium complex, a common disease in people with advanced HIV
infection.
        The table below lists the Company's pending New Drug Applications
(NDAs) and the related filing dates with the FDA:

Product        Indication(s)                              Date Filed
- -------------------------------------------------------------------------------
Trovan         Respiratory, surgical, urological, skin    December 1996
               and sexually transmitted infections
Zoloft         OCD--pediatric                             December 1996
Diflucan       Nail infections                            November 1996
Zithromax*     Community-acquired pneumonia               February 1996
               and pelvic inflammatory disease--
               intravenous use
Zoloft**       Panic disorder                             December 1995
Unasyn*        Injectable antibiotic--pediatric           November 1993
- -------------------------------------------------------------------------------

*Approved in 1997.
**Approvable letter received in 1996.

Apparently following the advice of an Advisory Committee, the FDA did not approve the use of tenidap in the U.S. for the treatment of either osteoarthritis or rheumatoid arthritis, pending further evaluation of the drug's safety profile. In September 1996, the Company indicated that, in spite of tenidap's potentially unique role in the treatment of rheumatoid arthritis, it has decided not to pursue its commercialization of tenidap 120 mg. for rheumatoid arthritis. Tenidap has been shown to be an effective agent against the symptoms of osteoarthritis at lower doses in clinical trials. A decision to undertake the extensive clinical development program needed to establish tenidap as a disease modifying osteoarthritis agent will be made after the results of current clinical studies are completed and after discussions about such a program are held with appropriate regulators.


        The Company currently has 13 new chemical entities in late-stage
development or under regulatory review and 53 other compounds in early- or
mid-stage development.

Components of Net Income
The components of net income are reflected in the following table:

Analysis of the Consolidated Statement of Income
                                                                    % Change*
                                                                  -------------
(millions of dollars)              1996      1995      1994       96/95   95/94
- -------------------------------------------------------------------------------
Net sales                        $11,306   $10,021   $ 7,977       13      26
Cost of sales                    $ 2,176   $ 2,164   $ 1,722        1      26
  % of net sales                   19.3%     21.6%     21.6%

Selling, informational and
 administrative expenses         $ 4,366   $ 3,855   $ 3,184       13      21
  % of net sales                   38.6%     38.5%     39.9%

R&D expenses                     $ 1,684   $ 1,442   $ 1,126       17      28
  % of net sales                   14.9%     14.4%     14.1%

Other deductions--net            $   276   $   261   $   115        6     128
  % of net sales                    2.4%      2.6%      1.5%
- -------------------------------------------------------------------------------
Income from continuing
 operations before taxes
 and minority interests          $ 2,804   $ 2,299   $ 1,830       22      26
  % of net sales                   24.8%     22.9%     22.9%

  Taxes on income                $   869   $   738   $   549       18      34
  Effective tax rate               31.0%     32.1%     30.0%
  Minority interests             $     6   $     7   $     5      (14)     52
- -------------------------------------------------------------------------------
Income from continuing
 operations                      $ 1,929   $ 1,554   $ 1,276       24      22
  % of net sales                   17.1%     15.5%     16.0%

Discontinued operations--net     $   --    $    19   $    22       --     (14)
  % of net sales                     --%       .2%       .3%
- -------------------------------------------------------------------------------
Net income                       $ 1,929   $ 1,573   $ 1,298       23      21
  % of net sales                   17.1%     15.7%     16.3%
- -------------------------------------------------------------------------------

*Percentages may reflect rounding adjustments.

Cost of sales increased by only 1% in 1996 as compared with 1995 and declined as a percentage of net sales primarily due to an improved business and product sales mix, the favorable impact of hedging programs, improvement in manufacturing efficiencies and, in 1995, the impact of purchase accounting relating to SBAH inventories.
Expressed as a percentage of net sales, cost of sales was the same in 1995 and 1994. The 1995 results were primarily attributable to favorable product mix as well as the benefit of reengineering of manufacturing operations, including the shutdown of a number of overseas plants, offset by the impact of purchase accounting related to SBAH and its higher production costs.


Research and Development
Expenses (millions of dollars)

$1,684


$1,442


$1,126

$961

$851



92 93 94 95 96

Research and development expenses have increased at a compound annual growth rate of almost 18% over the past 10 years. The Company now has 13 new chemical entities in late-stage development.

Selling, informational and administrative expenses (SI&A), as a percentage of net sales, remained relatively constant in 1996. Selling expenses in 1996 and 1995 increased versus the prior years due to the rollout of new products and support for newly launched products. Additionally, in 1996, the Company made substantial global investments in infrastructure and personnel, including the creation of a new sales force in the U.S. and personnel increases in key international markets. SI&A, as a percentage of net sales, declined in 1995 due to the beneficial impact of the Company's continuous improvement and restructuring programs.
In response to the changes in the health care environment, the Company adopted a strategy in 1994 that focuses on the diverse needs of managed care customers and decision makers. SI&A expenses reflect costs of communicating scientific, medical and clinical information about the Company's various products to the medical community and others. Health care information is communicated by field representatives, by means of medical symposia and conventions as well as through distribution of literature concerning the Company's products.
R&D expenses reflected a 21% compound annual growth rate over the past three years. The increase in 1996 as compared with 1995 was due to the support of new health care products at all stages of development. The increase in 1995 as compared to 1994 reflected, in large part, the rapid advancement of a number of drug candidates in late-stage development. Health care R&D expenses, expressed as a percentage of health care net sales, were 15.8%, 15.4% and 14.9% for 1996, 1995 and 1994, respectively. In 1997, the Company plans to spend about $2 billion on R&D.


Financial Review continued

Income from Continuing
Operations (millions of dollars)
$1,929

$1,554

$1,276


$1,098

$645



92 93 94 95 96

The strong growth in income from continuing operations of 24% in 1996 was achieved while continuing to invest aggressively in research and development and new product support.

Income from continuing operations in 1993 would have been $1,163 million excluding after-tax net charges for divestitures, restructuring and unusual items.

Other deductions--net increased $15 million in 1996 due, in part, to higher amortization of intangibles related to acquisition activity, partially offset by lower net interest expense. In 1996, other deductions--net included income of $48 million related to revised royalty arrangements covering sales of Procardia XL, an $18 million write-off of in-process R&D in connection with the Corvita acquisition and payments totaling $45 million related to the purchase of certain product licensing rights.

The 1995 increase of $146 million in other deductions--net was primarily due to the amortization of goodwill and other intangibles resulting from the SBAH acquisition, additional interest expense on borrowings following the acquisition, a provision for various litigation issues, the impact of unfavorable changes in foreign exchange in hyperinflationary markets and changes resulting from decisions to withdraw from a product line and to modify certain distribution relationships in the hospital products business. Partially offsetting these events was the recognition of income from a judgment following the completion of all appeals in a patent infringement case with SciMed Life Systems, Inc. For further details, see the footnote "Other Deductions--Net" on page 49.
The Company experienced steady increases in income from continuing operations before taxes and other deductions--net, expressed as a percentage of net sales, in the years 1994 through 1996. Profit margin increased 2.8 percentage points during this time due to the Company's focus on its core health care businesses, strong acceptance of its broad array of new products and numerous productivity improvement initiatives.


        The effective tax rate decreased from 32.1% in 1995 to 31.0% in 1996.
This decrease is mainly due to changes in the mix of income by country,
partially offset by the continuing reduction of tax benefits from the Company's
operations in Puerto Rico as a result of the enactment of the Omnibus Budget
Reconciliation Act of 1993 and the elimination of the tax exemption on certain
Puerto Rican investment income. The effective tax rate increased from 30.0% in
1994 to 32.1% in 1995 due to the reduction of the tax benefit from the Company's
operations in Puerto Rico, the expiration of the R&D tax credit during 1995 and
changes in the mix of income by country.
        The Company has received and is protesting assessments from the U.S.
and Belgian tax authorities. For additional details, see the footnote "Taxes
on Income" beginning on page 49.

Segment Profit

                                                                   % Change*
                                                                --------------
(millions of dollars)               1996     1995      1994      96/95  95/94
- ------------------------------------------------------------------------------
Health Care                        $3,090   $2,548    $1,977      21     29
Animal Health                         101       97        47       4    104
Consumer Health Care                   36       36        34      --      6
- ------------------------------------------------------------
    Total                          $3,227   $2,681    $2,058      20     30
- ------------------------------------------------------------------------------
* Percentages may reflect rounding adjustments.

        For further details, see segment information on page 39.

Liquidity and Capital Resources
Company operations in 1996 provided significant positive cash flows which,
supplemented by the ability to issue commercial paper as well as to maintain
other worldwide credit facilities, provided adequate liquidity to meet the
Company's operational needs. Cash and cash equivalents and short-term loans
and investments, which are principal measures of liquidity, amounted to $2.0,
$1.8 and $2.4 billion at December 31, 1996, 1995 and 1994, respectively.

Selected Measures of Liquidity and Capital Resources
                                                   1996      1995        1994
- --------------------------------------------------------------------------------
Working capital (millions of dollars)            $   828    $   965    $   962
Current ratio                                     1.15:1     1.19:1     1.20:1
Shareholders' equity per
 common share*                                   $ 11.08    $  8.90    $  7.10
Debt to total capitalization                         30%        34%        40%
Days of sales outstanding                             56         60         60
Months of inventory on hand                          8.9        9.2        8.6
- -------------------------------------------------------------------------------

*Represents shareholders' equity divided by the actual number of common shares outstanding.

Working capital decreased by $137 million in 1996 versus 1995. Contributing to this decline was the fact that the working capital provided by operations as well as proceeds from the sale of the food science business and stock option transactions were utilized primarily for long-term investments,


additions to property, plant and equipment, business acquisitions, payment of
dividends and the net repayment of long-term debt during 1996. Additionally, the
6-1/2% notes due in 1997 were reclassified from Long-term debt to Short-term
borrowings in 1996.

        The increase in shareholders' equity per common share and decrease in
the percentage of debt to total capitalization for 1996 and 1995 were
primarily due to higher shareholders' equity resulting principally from
growth in net income.

Net Financial Asset (Debt) Position

(millions of dollars)                            1996        1995      1994
- -------------------------------------------------------------------------------
Financial assets*                               $3,154      $2,346    $3,208
Short-term borrowings
 and long-term debt                              2,922       2,869     2,824
- -------------------------------------------------------------------------------
Net financial assets (debt)                     $  232      $ (523)   $  384
- -------------------------------------------------------------------------------
*Consists of cash and cash equivalents, short-term loans and investments and
 long-term loans and investments.

        The net financial debt position at December 31, 1995 resulted
primarily from higher debt levels following the SBAH acquisition.

Summary of Cash Flows

(millions of dollars)                           1996        1995      1994
- -------------------------------------------------------------------------------
Cash provided by/(used in):
  Operating activities                         $2,067     $ 1,821    $1,488
  Investing activities                           (937)     (2,343)     (840)
  Financing activities                           (382)       (519)       62
Effect of exchange rate changes on
 cash and cash equivalents                         (1)        (14)       19
- -------------------------------------------------------------------------------
Net increase/(decrease) in cash
 and cash equivalents                          $  747     $(1,055)   $  729
- -------------------------------------------------------------------------------

Operating Activities
The increases in cash flows from operations in both 1996 and 1995 primarily reflected growth in income generated by the continued rollout of new pharmaceutical products and additional indications for existing pharmaceutical products.
In 1993, the Company initiated a worldwide restructuring program that included the consolidation of manufacturing facilities, the demolition of buildings resulting from the consolidation, reconfiguration and rehabilitation of remaining facilities and the consolidation of distribution and administrative organizations and infrastructures. At December 31, 1996, this program was completed and its objectives of workforce reduction, facility closings and annual cost savings substantially achieved. Cash outlays for 1996, 1995 and 1994 related to the restructuring totaled $176, $121 and $88 million, respectively. For additional information, see the "Restructuring Program" footnote on page 49.

Investing Activities
Cash used in investing activities was lower in 1996 than in 1995, as less cash was utilized for acquisitions, proceeds were received from the disposal of the food science business and redemptions of short-term investments exceeded purchases. An offsetting factor in 1996 was the increase in the long-term investment portfolio.


Cash Dividends Paid Per
Common Share (dollars)

$1.20

$1.04
$0.94

$0.84

$0.74



92 93 94 95 96

The 1996 cash dividends paid represented the 29th consecutive year of dividend increases.

Cash used in investing activities increased in 1995 primarily due to the acquisition of SBAH, which absorbed available cash resources causing the Company to turn to commercial paper for operating activities. Additionally, an increase in the purchases of short-term investments was largely offset by a decrease in the loan portfolio of the Company's banking operation.
Capital expenditures were $774, $696 and $672 million for 1996, 1995 and 1994, respectively. In 1997, the Company anticipates capital expenditures will be approximately $800 million, including approximately $250 million for research and development projects.

Financing Activities
The lower level of cash used in financing activities in 1996 as compared with 1995 reflected higher levels of short-term borrowings used to fund working capital needs as well as certain investment opportunities, a decrease in purchases of its common stock and an increase in proceeds from stock option transactions. These factors were partially offset by the net repayment of long-term debt and a higher 1996 dividend payout as compared to 1995. Cash dividends paid to shareholders in 1996 were $771 million as compared with $659 million in 1995, reflecting a 15% increase in the annual dividend rate from $1.04 to $1.20 per common share.
In 1996, the Company issued a series of unsecured notes with an aggregate principal amount of $636 million. The proceeds from these notes were used to repay short-term borrowings. In 1996, the repayment of a repurchase agreement obligation entered into in 1995 was funded through short-term borrowings and cash provided by operations.
Cash used in financing activities increased in 1995 as compared with 1994. This increase was principally related to a decrease in short-term


Financial Review continued

borrowings versus an increase in 1994, as well as higher dividends. This change was partially offset by an increase in the proceeds from long-term debt, primarily resulting from a sale-and-repurchase financing, a decrease in the Company's purchases of its common stock and an increase in proceeds from stock option transactions.
In September 1996, the Company announced a program to purchase up to $2 billion of its common stock over the next 18 to 24 months in the open market or in privately negotiated transactions. Under this program, approximately 300,000 shares were repurchased during 1996 in the open market at a cost of approximately $27 million. These shares will be available for general corporate purposes. In 1995, the Company completed its plan to purchase up to 4.5 million shares of its common stock in order to fund the NAMIC acquisition.
The Company has available lines of credit and revolving-credit agreements with a select group of banks and other financial intermediaries. Its major unused lines of credit totaled approximately $1.2 billion at December 31, 1996.
An indicator of the Company's financial strength is that its senior debt has been rated Aaa by Moody's Investors Services (Moody's) and AAA by Standard and Poor's (S&P), their highest ratings, for the past 11 years. Moody's and S&P are the major corporate debt rating organizations.

Banking Operation
The Company's international banking operation, Pfizer International Bank Europe (PIBE), operates under a full banking license from the Central Bank of Ireland. PIBE extends credit to financially strong borrowers largely through U.S. dollar loans made primarily for the short and medium term, with floating interest rates. Generally, loans are made on an unsecured basis. When deemed appropriate, guarantees and certain covenants may be obtained as a condition to the extension of credit. To reduce credit risk, PIBE has established credit approval guidelines, borrowing limits and monitoring procedures. Credit risk is further reduced through an active policy of diversification with respect to borrower, industry and geographic location. PIBE continues to have S&P's highest short-term rating of A1+.
The net income of PIBE is affected by fluctuations in market interest rates because of repricing and maturity mismatches between its interest-sensitive assets and liabilities. When PIBE is asset sensitive (more assets than liabilities repricing in a given period), net income would benefit in a period of increasing interest rates. PIBE's asset and liability management reflects its liquidity, interest-rate outlook and general market conditions. The interest-rate sensitivity of PIBE's largely U.S. dollar-denominated floating-rate asset portfolio is largely offset by the corresponding interest-rate sensitivity inherent in the Company's U.S. dollar-denominated short-term debt. PIBE enters into interest-rate swaps, currency swaps and forward-exchange agreements as vehicles to manage the interest-rate sensitivity of its portfolio. For further details regarding the Company's interest-rate contracts, see the footnote "Financial Instruments and Risk Management" beginning on page 46.
For further information regarding the Company's banking operation, see the footnote "Financial Subsidiaries" on page 46.


Prospective Information and Factors That May Affect Future Results
The Securities and Exchange Commission encourages companies to disclose forward-looking information so that investors can better understand a company's future prospects and make informed investment decisions. This annual report contains such forward-looking statements that set out anticipated results based on management's plans and assumptions. Words such as "anticipate," "estimate," "expects," "projects," and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify these forward-looking statements.
The Company cannot guarantee that any forward-looking statement will be realized, although it believes it has been prudent in its plans and assumptions. Achievement of future results are subject to risks, uncertainties and inaccurate assumptions. Should known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results could vary materially from those anticipated, estimated or projected. Investors should bear this in mind as they consider forward-looking statements. Discussion of certain risks, uncertainties and assumptions follow and are discussed under the heading entitled "Cautionary Factors That May Affect Future Results" in Item 1 of the Company's annual report on Form 10-K for the year ended December 31, 1996, which will be filed at the end of March 1997. Prior to the filing of the Form 10-K, reference should be made to Exhibit 99 in the Company's quarterly report on Form 10-Q for the quarter ended September 29, 1996.

Competition and the Health Care Environment In the U.S., many of the Company's pharmaceutical products are subject to increasing price pressures as managed care groups, institutions and government agencies seek price discounts. Federal and state government efforts to reduce Medicare and Medicaid expenses are expected to increase the use of managed care and to offer incentives to beneficiaries to join these plans. This may result in managed care influencing prescription decisions for a larger segment of the population. International operations are also subject to increasing degrees of government regulations. It is expected that pressures on pricing and operating results will continue in 1997 as a result of market competition and changes in the health care environment.
Feldene and Glucotrol have been subject to generic competition since 1992 and 1994, respectively. The combined U.S. net sales of these products were $59, $95 and $203 million in 1996, 1995 and 1994, respectively.
In mid-1993, the FDA approved an NDA for a competitor's sustained-release form of nifedipine for the treatment of hypertension. This product uses a different delivery system from the patented technology used in Procardia XL, the Company's product, which is approved for the treatment of hypertension and angina and which has a delivery system that is patent-protected until 2003. Other forms of sustained-release nifedipine have been reported to be in various stages of development by other companies. It is not possible to predict the timing and impact of possible future competition on sales of Procardia XL.


Calcium Channel Blockers
During 1995, the authors of several nonclinical studies questioned the safety of calcium channel blockers, including the Company's immediate-release nifedipine capsules. Although the clinical evidence supported the safety of these medications, the FDA convened an advisory panel to review their safety. In January 1996, the advisory panel recommended that labeling for immediate-release nifedipine capsules--approved only to treat a form of angina--be clarified. However, the advisory panel specifically noted that there were no data which questioned the safety of the newer sustained-release and intrinsically long-acting calcium channel blockers (such as the Company's Procardia XL and Norvasc) which are approved for both hypertension and angina and are prescribed for the vast majority of American patients on calcium channel blockers. The safety and effectiveness of these new long-acting calcium channel blockers in lowering blood pressure and controlling angina are supported by a large body of data from numerous studies and the daily clinical experiences of physicians around the world.
It is not possible for the Company to predict the impact, if any, of these nonclinical studies or the FDA panel's findings and recommendations on its future sales, but the Company does not believe that it will have a material, adverse effect on its financial position or results of operations.

Foreign Exchange
Sales and earnings growth in 1997 could be impacted by changes in foreign exchange rates. The Company manages its foreign exchange risk through a variety of techniques. For further details, see the footnote "Financial Instruments and Risk Management" beginning on page 46.
In 1997, in accordance with generally accepted accounting principles, the Company will change the functional currency of its Mexican operations to the U.S. dollar since the cumulative rate of Mexico's inflation exceeded 100% for the three-year period ending December 31, 1996. This change will not have a material effect on the Company's financial position or results of operations.

Tax Legislation
Pursuant to the Small Jobs Protection Act of 1996 (the Act), Section 936 of the Internal Revenue Code (the possessions corporation income tax credit) was repealed for tax years beginning after December 31, 1995. The Act provided that existing credit claimants, such as the Company, are eligible to continue using the credit against the tax arising from manufacturing income earned in a U.S. possession for an additional ten-year period. The amount of manufacturing income eligible for the credit during this additional period is subject to a cap based on prior years' income earned by the Company in the possession. This ten-year extension period does not apply to investment income earned in a possession, the credit on which expired as of July 1, 1996. This legislation does not affect the amendments made to Section 936 by the Omnibus Budget Reconciliation Act of 1993 which provided for a five-year phase-down of the possession tax credit from 100% to 40%. In addition, the 1996 Act extended the R&D tax credit for 11 months effective July 1, 1996.


Recently Issued Accounting Standards
In October 1996, the Accounting Standards Executive Committee of the American Institute of Certified Public Accountants issued Statement of Position (SOP) 96-1, Environmental Remediation Liabilities, which will be effective in 1997. SOP 96-1 provides guidance on accounting for the recognition, measurement, display and disclosure of environmental liabilities. The Company's adoption of SOP 96-1 is not expected to have a material impact on its financial position and results of operations, nor will it affect the Company's cash flows.
In July 1996, the Emerging Issues Task Force of the Financial Accounting Standards Board reached a consensus on Issue 96-14, Accounting for the Costs Associated with Modifying Computer Software for the Year 2000, which provides that costs associated with modifying computer software for the year 2000 be expensed as incurred. The Company is assessing the extent of the necessary modifications to its computer software.

Litigation, Tax and Environmental Matters Claims have been brought against the Company and its subsidiaries for various legal and tax matters. In addition, the Company's operations are subject to international, federal, state and local environmental laws and regulations. For further details, see the footnotes "Litigation" beginning on page 54 and "Taxes on Income" beginning on page 49.

Dividend Growth
The dividend payout ratio amounted to 40.1%, 41.6% and 45.0% in 1996, 1995 and 1994, respectively. In January 1997, the Board of Directors declared a first-quarter 1997 dividend of $.34, an increase of 13% over the $.30 dividend declared in each quarter of 1996. This marked the 30th consecutive year of quarterly dividend increases.

Proposed Stock Split
In January 1997, the Company announced that on April 24, 1997, its Board of Directors would vote on a two-for-one stock split in the form of a stock dividend, provided shareholders approve an increase in the number of authorized shares at the Company's annual meeting earlier that day.


Management's Report
Pfizer Inc and Subsidiary Companies

The financial statements that appear on pages 39 through 59 were prepared by and are the responsibility of the Company's management. These financial statements are in conformity with generally accepted accounting principles and, therefore, include amounts based upon informed judgments and estimates. Management also accepts responsibility for the preparation of other financial information included in this document.
The Company's management has designed a system of internal control to safeguard its assets, ensure that transactions are properly authorized and provide reasonable assurance, at reasonable cost, as to the integrity, objectivity and reliability of financial information. Even an effective internal control system, regardless of how well designed, has inherent limitations and, therefore, can provide only reasonable assurance with respect to financial statement preparation. The system is built on a business ethics policy that requires all employees to maintain the highest ethical standards in conducting Company affairs. The system of internal control includes careful selection, training and development of financial managers, an organizational structure that segregates responsibilities and a communications program which ensures that Company policies and procedures are well understood throughout the organization. The Company also has an extensive program of internal audits, with prompt follow-up, including reviews of separate Company operations and functions around the world.
The Company's independent certified public accountants, KPMG Peat Marwick LLP, have audited the annual financial statements in accordance with generally accepted auditing standards. The independent auditors' report expresses an informed judgment as to the fair presentation of the Company's reported operating results, financial position and cash flows. This judgment is based on the results of auditing procedures performed and such other tests that they deemed necessary, including consideration of the Company's internal control structure.
Recommendations made by KPMG Peat Marwick LLP and the Company's internal auditors are considered and appropriate action taken with respect to these recommendations. The Company believes that its system of internal control is effective and adequate to accomplish the objectives discussed above.

/s/ W. C. Steere, Jr.
- ----------------------------
W. C. Steere, Jr.
Principal Executive Officer


/s/ D. L. Shedlarz
- ----------------------------
D. L. Shedlarz
Principal Financial Officer


/s/ H. V. Ryan
- ----------------------------
H. V. Ryan
Principal Accounting Officer
February 27, 1997


Audit Committee's Report
Pfizer Inc and Subsidiary Companies

The Board of Directors reviews the audit function, internal controls and the financial statements largely through its Audit Committee, which consists solely of directors who are not Company employees. In 1996, the Audit Committee met six times with management, the independent auditors and internal auditors concerning their respective responsibilities. Among its various duties, the Audit Committee recommends the appointment of the Company's independent auditors. Both KPMG Peat Marwick LLP and the internal auditors have full access to the Audit Committee and meet with it, without management present, to discuss the scope and results of their examinations including internal control, audit and financial reporting matters.

/s/ S. O. Ikenberry, Ph.D.
- -----------------------------
S. O. Ikenberry, Ph.D.
Chair, Audit Committee
February 27, 1997

Independent Auditors' Report

KPMG Peat Marwick LLP
Certified Public Accountants

To the Shareholders and Board of Directors of Pfizer Inc:

We have audited the accompanying consolidated balance sheet of Pfizer Inc and subsidiary companies as of December 31, 1996, 1995 and 1994 and the related consolidated statements of income, shareholders' equity and cash flows for each of the years then ended. These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.
We conducted our audits in accordance with generally accepted auditing standards. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall consolidated financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to abov e present fairly, in all material respects, the financial position of Pfizer Inc and subsidiary companies at December 31, 1996, 1995 and 1994, and the results of their operations and their cash flows for each of the years then ended, in conformity with generally accepted accounting principles.

/s/ KPMG Peat Marwick LLP
- ----------------------------
KPMG Peat Marwick LLP

New York, NY
February 27, 1997


Segment Information Pfizer Inc and Subsidiary Companies

                                                                                    Consumer     Corporate/
                                                                Health      Animal    Health      Financial
(millions of dollars)                                             Care      Health      Care   Subsidiaries(a)   Consolidated
- ------------------------------------------------------------------------------------------------------------------------------
1996

Net sales                                                       $9,630      $1,222      $454         $   --           $11,306
- ------------------------------------------------------------------------------------------------------------------------------
Segment profit                                                  $3,090      $  101      $ 36         $   --           $ 3,227
Net interest and corporate expenses                                                                    (423)             (423)
- ------------------------------------------------------------------------------------------------------------------------------
Income before provision for taxes
  on income and minority interests                                                                                    $ 2,804
- ------------------------------------------------------------------------------------------------------------------------------
Identifiable assets                                             $6,686      $2,243      $473         $5,265           $14,667
- ------------------------------------------------------------------------------------------------------------------------------
Capital additions                                               $  594      $   87      $ 22         $   71           $   774
- ------------------------------------------------------------------------------------------------------------------------------
Depreciation and amortization                                   $  319      $   82      $ 15         $   14           $   430
- ------------------------------------------------------------------------------------------------------------------------------

1995
Net sales                                                        8,409      $1,219      $393         $   --           $10,021
- ------------------------------------------------------------------------------------------------------------------------------
Segment profit                                                   2,548      $   97      $ 36         $   --           $ 2,681
Net interest and corporate expenses                                                                    (382)             (382)
- ------------------------------------------------------------------------------------------------------------------------------
Income from continuing operations before provision for taxes
 on income and minority interests                                                                                     $ 2,299
- ------------------------------------------------------------------------------------------------------------------------------
Identifiable assets                                             $5,557      $2,069      $307         $4,796(b)        $12,729
- ------------------------------------------------------------------------------------------------------------------------------
Capital additions                                               $  515      $   74      $ 28         $   79(b)        $   696
- ------------------------------------------------------------------------------------------------------------------------------
Depreciation and amortization                                   $  271      $   57      $ 12         $   34(b)        $   374
- ------------------------------------------------------------------------------------------------------------------------------

1994
Net sales                                                       $6,963      $  605      $409         $   --           $ 7,977
- ------------------------------------------------------------------------------------------------------------------------------
Segment profit                                                  $1,977      $   47      $ 34         $   --           $ 2,058
Net interest and corporate expenses                                                                    (228)             (228)
- ------------------------------------------------------------------------------------------------------------------------------
Income from continuing operations before provision for taxes
 on income and minority interests                                                                                     $ 1,830
- ------------------------------------------------------------------------------------------------------------------------------
Identifiable assets                                             $5,388      $  502      $206         $5,003(b)        $11,099
- ------------------------------------------------------------------------------------------------------------------------------
Capital additions                                               $  483      $   46      $ 16         $  127(b)        $   672
- ------------------------------------------------------------------------------------------------------------------------------
Depreciation and amortization                                   $  229      $   17      $ 10         $   36(b)        $   292
==============================================================================================================================

(a) Net interest and corporate expenses include amounts that relate to the operations of the Company's financial subsidiaries. Segment information for the financial subsidiaries can be found in the "Financial Subsidiaries" footnote on page 46.

(b) Includes amounts related to the food science business which was sold in 1996.

Various segments use common production facilities. Allocation among these segments of property, plant and equipment, as well as capital additions and depreciation, is based principally on physical production. Corporate assets consist primarily of cash, short-term investments and long-term marketable securities.

See Notes to Consolidated Financial Statements which are an integral part of these statements.


Geographic Data Pfizer Inc and Subsidiary Companies

                                                                     Canada/     Africa/    Corporate/
                                    United                            Latin      Middle     Financial   Adjustments/
    (millions of dollars)           States(a)  Europe       Asia    America        East  Subsidiaries   Eliminations   Consolidated
- -----------------------------------------------------------------------------------------------------------------------------------
1996
Net sales                          $ 5,941    $ 2,773    $ 1,598     $   750     $   244      $    --        $    --        $11,306
Intercompany sales                     197        813         84          35           9           --         (1,138)            --
- -----------------------------------------------------------------------------------------------------------------------------------
Total                              $ 6,138    $ 3,586    $ 1,682     $   785     $   253      $    --        $(1,138)       $11,306
- -----------------------------------------------------------------------------------------------------------------------------------
Geographic profit/(loss)           $ 2,018    $ 1,013    $   250     $    29     $    (5)     $    --        $   (78)       $ 3,227
- -----------------------------------------------------------------------------------------------------------------------------------
Net interest and
     corporate expenses                                                                          (423)                         (423)
- -----------------------------------------------------------------------------------------------------------------------------------
Income before provision
     for taxes on income
     and minority interests                                                                                                 $ 2,804
- -----------------------------------------------------------------------------------------------------------------------------------
Identifiable assets                $ 4,424    $ 4,072    $ 1,278     $   606     $   174      $ 5,265        $(1,152)       $14,667
- -----------------------------------------------------------------------------------------------------------------------------------

1995
Net sales                          $ 5,113    $ 2,444    $ 1,538     $   696     $   230      $    --        $    --        $10,021
Intercompany sales                     175        692         75          29          10           --           (981)            --
- -----------------------------------------------------------------------------------------------------------------------------------
Total                              $ 5,288    $ 3,136    $ 1,613     $   725     $   240      $    --        $  (981)       $10,021
- -----------------------------------------------------------------------------------------------------------------------------------
Geographic profit                  $ 1,628    $   778    $   261     $    49     $    12      $    --        $   (47)       $ 2,681
- -----------------------------------------------------------------------------------------------------------------------------------
Net interest and
     corporate expenses                                                                          (382)                         (382)
- -----------------------------------------------------------------------------------------------------------------------------------
Income from continuing
     operations before provision
     for taxes on income
     and minority interests                                                                                                 $ 2,299
- -----------------------------------------------------------------------------------------------------------------------------------
Identifiable assets                $ 3,199    $ 3,647    $ 1,243     $   612     $   193      $ 4,796(b)    $  (961)        $12,729
- -----------------------------------------------------------------------------------------------------------------------------------

1994
Net sales                          $ 4,237    $ 1,759    $ 1,201     $   598     $   182      $    --       $    --         $ 7,977
Intercompany sales                     140        439         43           9           5           --          (636)             --
- -----------------------------------------------------------------------------------------------------------------------------------
Total                              $ 4,377    $ 2,198    $ 1,244     $   607     $   187      $    --       $  (636)        $ 7,977
- -----------------------------------------------------------------------------------------------------------------------------------
Geographic profit                  $ 1,410    $   531    $   109     $    41     $    12      $    --       $   (45)        $ 2,058
- -----------------------------------------------------------------------------------------------------------------------------------
Net interest and
     corporate expenses                                                                          (228)                         (228)
- -----------------------------------------------------------------------------------------------------------------------------------
Income from continuing
     operations before provision
     for taxes on income
     and minority interests                                                                                                 $ 1,830
- -----------------------------------------------------------------------------------------------------------------------------------
Identifiable assets                $ 2,402    $ 2,386    $ 1,277     $   470     $   139      $ 5,003(b)    $  (578)        $11,099
===================================================================================================================================

(a) The Company's manufacturing operations in Puerto Rico are included in the United States.

(b) Includes identifiable assets of the food science business which was sold in 1996.

Products are transferred between geographic areas for additional processing, as well as for ultimate sale, on a basis intended to recognize economic and competitive circumstances in the market of end use. The assets physically located in one area are considered assets of that area even though they provide goods and/or services to other areas.

See Notes to Consolidated Financial Statements which are an integral part of these statements.


Consolidated Statement of Income Pfizer Inc and Subsidiary Companies

                                                                             Year ended December 31
                                                                       ---------------------------------------
(millions, except per share data)                                      1996             1995            1994
- --------------------------------------------------------------------------------------------------------------
Net sales                                                            $11,306          $10,021           $7,977
Costs and expenses
  Cost of sales                                                        2,176            2,164            1,722
  Selling, informational and administrative expenses                   4,366            3,855            3,184
  Research and development expenses                                    1,684            1,442            1,126
  Other deductions--net                                                  276              261              115
- --------------------------------------------------------------------------------------------------------------
Income from continuing operations before provision for
 taxes on income and minority interests                                2,804            2,299            1,830
Provision for taxes on income                                            869              738              549
Minority interests                                                         6                7                5
- --------------------------------------------------------------------------------------------------------------
Income from continuing operations                                      1,929            1,554            1,276
Discontinued operations--net of taxes on income                           --               19               22
- --------------------------------------------------------------------------------------------------------------
Net income                                                           $ 1,929          $ 1,573           $1,298
- --------------------------------------------------------------------------------------------------------------
Earnings per common share
  Income from continuing operations                                  $  2.99          $  2.47           $ 2.05
  Discontinued operations--net of taxes on income                         --              .03              .04
- --------------------------------------------------------------------------------------------------------------
  Net income                                                         $  2.99          $  2.50           $ 2.09
- --------------------------------------------------------------------------------------------------------------
Weighted average shares used to calculate per share amounts              644              630              620
==============================================================================================================

See Notes to Consolidated Financial Statements which are an integral part of these statements.


Consolidated Statement of Shareholders' Equity Pfizer Inc and Subsidiary Companies

                                                                               Currency
                                    Common Stock    Additional               Translation    Employee      Treasury Stock
                                 -----------------     Paid-In      Retained  Adjustment     Benefit    -----------------
(millions)                       Shares  Par Value     Capital      Earnings   and Other       Trust     Shares    Cost      Total
- ----------------------------------------------------------------------------------------------------------------------------------
Balance January 1, 1994             677        $34    $  492       $ 5,241        $ 32     $  (690)      (35)   $(1,243)   $ 3,866
Net income                                                           1,298                                                   1,298
Cash dividends declared                                               (594)                                                   (594)
Currency translation
    adjustment                                                                     162                                         162
Stock option transactions             3         --        63                                              --          1         64
Purchases of common stock                                                                                (17)      (511)      (511)
Employee benefit trust
    transactions--net                                     83                                   (59)                             24
Other                                 1         --        13                         2                                          15
- ----------------------------------------------------------------------------------------------------------------------------------
Balance December 31, 1994           681         34       651         5,945         196        (749)      (52)    (1,753)     4,324
Net income                                                           1,573                                                   1,573
Cash dividends declared                                               (659)                                                   (659)
Currency translation
    adjustment                                                                      12                                          12
Stock option transactions             4         --       126                                               2         79        205
Purchases of common stock                                                                                 (2)      (108)      (108)
Employee benefit trust
    transactions--net                                    440                                  (421)                             19
Unrealized net gain on available-
    for-sale securities--net                                                        23                                          23
Minimum pension liability--net                                                     (68)                                        (68)
Treasury stock utilized for
    the NAMIC acquisition                                                                                  4        167        167
Other                                --         --        18                                                                    18
- ----------------------------------------------------------------------------------------------------------------------------------
Balance December 31, 1995           685         34     1,235         6,859         163      (1,170)      (48)    (1,615)     5,506
Net income                                                           1,929                                                   1,929
Cash dividends declared                                               (771)                                                   (771)
Currency translation
    adjustment                                                                     (32)                                        (32)
Stock option transactions             4         --       124                                               4        156        280
Purchases of common stock                                                                                 --        (27)       (27)
Employee benefit trust
    transactions--net                                    341                                  (318)                             23
Unrealized net gain on available-
    for-sale securities--net                                                        15                                          15
Other                                --         --        28                        (1)                   --          4         31
- ----------------------------------------------------------------------------------------------------------------------------------
Balance December 31, 1996           689        $34    $1,728       $ 8,017        $145     $(1,488)      (44)   $(1,482)   $ 6,954
==================================================================================================================================
See Notes to Consolidated Financial Statements which are an integral part of
these statements.

Consolidated Balance Sheet                 Pfizer Inc and Subsidiary Companies

                                                                                        December 31
                                                                           --------------------------------------
(millions, except per share data)                                             1996          1995            1994
- -----------------------------------------------------------------------------------------------------------------
Assets
Current Assets
Cash and cash equivalents                                                  $  1,150       $    403       $  1,458
Short-term investments                                                          487          1,109            560
Accounts receivable, less allowances for doubtful accounts:
  1996--$58; 1995--$61; 1994--$44                                             2,252          2,024          1,665
Short-term loans                                                                354            289            361
Inventories
    Finished goods                                                              617            564            528
    Work in process                                                             695            579            535
    Raw materials and supplies                                                  277            241            202
- -----------------------------------------------------------------------------------------------------------------
      Total inventories                                                       1,589          1,384          1,265
- -----------------------------------------------------------------------------------------------------------------
Prepaid expenses, taxes and other assets                                        636            943            479
- -----------------------------------------------------------------------------------------------------------------
      Total current assets                                                    6,468          6,152          5,788
Long-term loans and investments                                               1,163            545            829
Property, plant and equipment, less accumulated depreciation                  3,850          3,473          3,073
Goodwill, less accumulated amortization:
    1996--$115; 1995--$79; 1994--$48                                          1,424          1,243            326
Other assets, deferred taxes and deferred charges                             1,762          1,316          1,083
- -----------------------------------------------------------------------------------------------------------------
      Total assets                                                         $ 14,667       $ 12,729       $ 11,099
- -----------------------------------------------------------------------------------------------------------------
Liabilities and Shareholders' Equity
Current Liabilities
Short-term borrowings, including current portion of long-term debt         $  2,235       $  2,036       $  2,220
Accounts payable                                                                913            715            525
Income taxes payable                                                            892            822            731
Accrued compensation and related items                                          436            421            419
Other current liabilities                                                     1,164          1,193            931
- -----------------------------------------------------------------------------------------------------------------
      Total current liabilities                                               5,640          5,187          4,826
Long-term debt                                                                  687            833            604
Postretirement benefit obligation other than pension plans                      412            426            433
Deferred taxes on income                                                        253            166            212
Other noncurrent liabilities                                                    671            564            661
Minority interests                                                               50             47             39
- -----------------------------------------------------------------------------------------------------------------
      Total liabilities                                                       7,713          7,223          6,775
- -----------------------------------------------------------------------------------------------------------------
Shareholders' Equity
Preferred stock, without par value; 12 shares authorized, none issued            --             --             --
Common stock, $.05 par value; 1,500 shares authorized;
    issued: 1996--689; 1995--685; 1994--681                                      34             34             34
Additional paid-in capital                                                    1,728          1,235            651
Retained earnings                                                             8,017          6,859          5,945
Currency translation adjustment and other                                       145            163            196
Employee benefit trust                                                       (1,488)        (1,170)          (749)
Treasury stock, at cost:
    1996--44; 1995--48; 1994--52                                             (1,482)        (1,615)        (1,753)
- -----------------------------------------------------------------------------------------------------------------
      Total shareholders' equity                                              6,954          5,506          4,324
- -----------------------------------------------------------------------------------------------------------------
      Total liabilities and shareholders' equity                           $ 14,667       $ 12,729       $ 11,099
=================================================================================================================

See Notes to Consolidated Financial Statements which are an integral part of these statements.


Consolidated Statement of Cash Flows Pfizer Inc and Subsidiary Companies

                                                                                              Year ended December 31
                                                                                       ------------------------------------
(millions of dollars)                                                                    1996          1995          1994
- ---------------------------------------------------------------------------------------------------------------------------
Operating Activities
 Net income                                                                            $ 1,929       $ 1,573       $ 1,298
 Adjustments to reconcile net income to net cash provided by operating
  activities:
    Depreciation and amortization of intangibles                                           430           374           292
    Deferred taxes                                                                          75           (12)           32
    Other                                                                                   14            76            (5)
      Changes in assets and liabilities, net of effect of businesses acquired and
       divested:
        Accounts receivable                                                               (255)         (290)         (160)
        Inventories                                                                       (149)          (25)         (111)
        Prepaid and other assets                                                          (208)         (171)          (12)
        Accounts payable and accrued liabilities                                            66           320           168
        Income taxes payable                                                                23            88           121
        Other deferred items                                                               142          (112)         (135)
- ---------------------------------------------------------------------------------------------------------------------------
Net cash provided by operating activities                                                2,067         1,821         1,488
- ---------------------------------------------------------------------------------------------------------------------------
Investing Activities
 Acquisitions, net of cash acquired                                                       (451)       (1,521)           --
 Purchases of property, plant and equipment                                               (774)         (696)         (672)
 Proceeds from the sale of a business                                                      353            --            --
 Purchases of short-term investments                                                    (2,851)       (2,611)       (1,356)
 Proceeds from redemptions of short-term investments                                     3,490         2,185         1,245
 Purchases of long-term investments                                                       (820)         (151)         (162)
 Purchases and redemptions of short-term investments by financial subsidiaries             (11)          (30)           44
 Decrease in loans and long-term investments by financial subsidiaries                      52           330            21
 Other investing activities                                                                 75           151            40
- ---------------------------------------------------------------------------------------------------------------------------
Net cash used in investing activities                                                     (937)       (2,343)         (840)
- ---------------------------------------------------------------------------------------------------------------------------
Financing Activities
 Proceeds from issuances of long-term debt                                                 636           502            40
 Repayments of long-term debt                                                             (804)          (52)           (4)
 Increase/(decrease) in short-term debt                                                    259          (444)        1,030
 Stock option transactions                                                                 280           205            64
 Purchases of common stock                                                                 (27)         (108)         (511)
 Cash dividends paid                                                                      (771)         (659)         (594)
 Other financing activities                                                                 45            37            37
- ---------------------------------------------------------------------------------------------------------------------------
Net cash (used in)/provided by financing activities                                       (382)         (519)           62
- ---------------------------------------------------------------------------------------------------------------------------
Effect of exchange rate changes on cash and cash equivalents                                (1)          (14)           19
- ---------------------------------------------------------------------------------------------------------------------------
Net increase/(decrease) in cash and cash equivalents                                       747        (1,055)          729
Cash and cash equivalents at beginning of year                                             403         1,458           729
- ---------------------------------------------------------------------------------------------------------------------------
Cash and cash equivalents at end of year                                               $ 1,150       $   403       $ 1,458
- ---------------------------------------------------------------------------------------------------------------------------
Supplemental Cash Flow Information
 Cash paid during the period for:
  Income taxes                                                                         $   709       $   646       $   414
  Interest                                                                                 139           175           107
===========================================================================================================================

See Notes to Consolidated Financial Statements which are an integral part of these statements.


Notes to Consolidated Financial Statements Pfizer Inc and Subsidiary Companies

Significant Accounting Policies
The consolidated financial statements include the accounts of Pfizer Inc and all significant subsidiaries (the Company). Material intercompany transactions are eliminated. Certain reclassifications have been made to the 1995 and 1994 financial statements to conform to the 1996 presentation.
The preparation of the consolidated financial statements requires that management make estimates and assumptions affecting reported amounts and disclosures. Actual results could differ from those estimates.
The Company is subject to certain risks and uncertainties as a result of changes in the health care environment, competition, foreign exchange, tax legislation and other factors as discussed in "Prospective Information and Factors That May Affect Future Results" beginning on page 36.
Cash equivalents consist primarily of demand deposits, certificates of deposit and certain time deposits with maturities of three months or less at the date of purchase. Certain items which meet the definition of cash equivalents, but are part of a larger pool of investments, are included in Short-term investments.
Inventories are valued at cost or market, whichever is lower. Except as noted below, raw materials and supplies are valued at average or latest actual costs and finished goods and work in process at average actual costs. Inventories valued utilizing the last-in, first-out (LIFO) method represent approximately 13% of worldwide inventories at December 31, 1996 and consist of substantially all of the Company's U.S.-sourced pharmaceuticals, as well as a portion of the animal health inventories. The estimated replacement cost for these inventories is not materially different from the LIFO value.
Long-lived assets consist of property, plant and equipment, identifiable intangibles and goodwill.
Property, plant and equipment are recorded at cost. Significant improvements are capitalized. In general, the straight-line method of depreciation is used for financial reporting purposes and accelerated methods are used for U.S. and certain foreign tax reporting purposes.
Goodwill and other intangibles are recorded at cost. Amounts arising from acquisitions accounted for as purchases subsequent to 1970 are amortized over various periods not exceeding 40 years. Other intangibles are included in Other assets, deferred taxes and deferred charges in the Consolidated Balance Sheet.
Effective January 1, 1996, the Company adopted Statement of Financial Accounting Standards (SFAS) No. 121, Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed Of. In accordance with SFAS No. 121, the Company reviews long-lived assets for impairment whenever events or changes in business circumstances occur that indicate that the carrying amount of the assets may not be recoverable. The Company assesses the recoverability of long-lived assets held and to be used based on undiscounted cash flows and measures the impairment, if any, using discounted cash flows. Adoption of SFAS No. 121 did not have a material impact on the Company's consolidated financial position, operating results or cash flows.


Foreign currency translation into U.S. dollars for the assets and liabilities of most of the Company's international subsidiaries is performed using current exchange rates. The resulting translation adjustments are recorded in Shareholders' equity. Exchange gains and losses on hedges of foreign currency-denominated net investments and on intercompany balances of a long-term investment nature are also recorded in Shareholders' equity. International subsidiaries and branches operating in highly inflationary economies translate nonmonetary assets at historical rates, while net monetary assets are translated at current rates, with the resulting translation adjustments included in net income.
Employee stock options are granted with an exercise price equal to the market price. Compensation cost generally is not recognized for the issuance of employee stock options. Effective January 1, 1996, the Company adopted the disclosure provisions of SFAS No. 123, Accounting for Stock-Based Compensation. For the fair value of the employee stock options issued in 1996 and 1995, see the footnote "Stock Option Plan and Performance Awards" beginning on page 52.
Advertising production costs are expensed as incurred, while costs related to radio time, television time and space in publications are deferred and expensed when the advertising initially occurs. Advertising expenses were $778, $688 and $609 million for 1996, 1995 and 1994, respectively.
The provision for taxes on income does not include a provision for U.S. income taxes on international subsidiaries' unremitted earnings which, for the most part, are expected to be reinvested overseas. As part of its overall planning, the Company may remit a portion of future periodic earnings. To the extent that the parent company receives such foreign earnings as dividends, foreign taxes paid on those earnings may generate tax credits which could substantially offset the related U.S. income taxes.
Earnings per common share are computed by dividing net income by the weighted average number of common shares and common share equivalents outstanding for the period. For 1996, 1995 and 1994, common share equivalents, which consisted of common shares issuable upon the exercise of outstanding stock options, were 20, 15 and 9 million, respectively. Earnings per common share, assuming full dilution, were not materially different from the primary amounts.

Consolidated International Subsidiaries
Subsidiaries operating outside the U.S. generally are included in the consolidated financial statements on a fiscal year basis ending November 30. Substantially all the international subsidiaries' unremitted earnings are free from legal or contractual restrictions. Additional information is shown on page 40.

Net exchange losses included in Other deductions--net were $3, $14 and $2 million in 1996, 1995 and 1994, respectively. The currency translation adjustment amounts included in shareholders' equity at December 31, 1996, 1995 and 1994 were $174, $206 and $194 million, respectively.


Financial Subsidiaries
Combined financial data/segment information as of November 30, 1996, 1995 and 1994 applicable to the Company's financial subsidiaries, consisting of Pfizer International Bank Europe (PIBE) and a small captive insurance company, were as follows:

Condensed Balance Sheet
(millions of dollars)                         1996        1995        1994
- ---------------------------------------------------------------------------
Cash and interest-bearing deposits           $   78      $   13      $  285
Eurosecurities and securities purchased
     under resale agreements                     45          34           4
Loans, net                                      381         433         767
Other assets                                      8           8          13
- ---------------------------------------------------------------------------
     Total assets                            $  512      $  488      $1,069
- ---------------------------------------------------------------------------
Certificates of deposit and
     other liabilities                       $   87      $   85      $  198
Shareholders' equity                            425         403         871
- ---------------------------------------------------------------------------
  Total liabilities and shareholders'
     equity                                  $  512      $  488      $1,069
===========================================================================
Condensed Statement of Income
(millions of dollars)                          1996        1995        1994
- ---------------------------------------------------------------------------
Interest income                                $ 28        $ 44        $ 49
Interest expense                                 (3)         (3)         (4)
Other income/(expense)net                         2          (6)        (12)
- ---------------------------------------------------------------------------
Net income                                     $ 27        $ 35        $ 33
===========================================================================

The 1995 data reflect a reduction in PIBE's loan portfolio to bring PIBE's balance sheet into line with its business needs. PIBE continues to have S&P's highest short-term rating of A1+.

Investments in Debt and Equity Securities
Investments in debt and equity securities are summarized in the following
tables:

                                                     Amortized Cost
                                      -------------------------------------
(millions of dollars)                        1996         1995        1994
- ---------------------------------------------------------------------------
Held-to-maturity:
    Certificates of deposit                 $  657       $  350      $  235
    Corporate debt                             602          682         381
    Municipals                                  29          222          89
    Other                                       81          186         204
- ----------------------------------------------------------------------------
      Total                                 $1,369       $1,440      $  909
============================================================================


As of December 31, 1996, 1995 and 1994, the aggregate fair value of held-to-maturity securities was substantially the same as the amortized cost and gross unrealized gains and losses by type of security were not material.

Gross Unrealized Amortized ---------------- Fair (millions of dollars) Cost Gains Losses Value
Available-for-sale:
Debt and equity securities
     1996                      $717       $ 73       $ (8)       $782
     1995                        68         50         (8)        110
     1994                        57         18        (15)         60
=====================================================================

In 1996, the available-for-sale securities included certificates of deposit and corporate debt with a cost of $636 million, which approximates fair value.
These securities are reflected in the Consolidated Balance Sheet as follows:

(millions of dollars)                        1996        1995      1994
- ------------------------------------------------------------------------
Cash and cash equivalents                  $  640      $  153      $ 90
Short-term investments                        487       1,109       560
Long-term loans and investments             1,024         288       319
========================================================================

The contractual maturities of the held-to-maturity and available-for-sale securities as of December 31, 1996 were as follows:

                                              Years
                             --------------------------------------
                                         Over 1    Over 5
(millions of dollars)        Within 1      to 5     to 10   Over 10      Total
- ------------------------------------------------------------------------------
Held-to-maturity:
    Certificates of deposit    $  640      $ 17       $ 0       $ 0     $  657
    Corporate debt                425       157        15         5        602
    Municipals                      9        20         0         0         29
    Other                          53         0        13        15         81
Available-for-sale:
    Certificates of deposit         0        95       350         0        445
    Corporate debt                  0        41       150         0        191
- ------------------------------------------------------------------------------
    Total                      $1,127      $330      $528       $20     $2,005
==============================================================================

Financial Instruments and Risk Management Changes in the value of the U.S. dollar and other currencies affect the Company's financial position and results of operations since the Company has manufacturing operations in many countries and sells its products on a worldwide basis. Changes in interest rates affect the Company's financial position and results of operations because of its investments and borrowings. The Company manages its foreign-exchange and interest-rate risks through a variety of techniques, including the use of foreign-currency and interest-rate contracts.


Generally, gains and losses arising from contracts used for foreign-exchange and interest-rate risk management are recognized in income simultaneously with the net income effect of the related transactions generating such risks.
The aggregate notional amounts of the Company's foreign-currency and interest-rate contracts were as follows:

(millions of dollars)                  1996             1995             1994
- ------------------------------------------------------------------------------
Foreign-currency contracts:
     Forward-exchange                 $2,844           $1,888           $  750
     Purchased options                   367              497              150
     Written options                      --               74               --
     Swaps                                45              559               90
Interest-rate contracts:
     Swaps                             1,360              874              275
==============================================================================

The Company enters into certain forward-exchange contracts to match local market short-term assets and liabilities denominated in currencies other than the functional currency. The Company's contracts generally have maturities of six months or less. Changes in the fair value of forward-exchange contracts are included in Other deductions--net, together with foreign exchange gains and losses.
The Company also enters into other forward-exchange sale contracts to hedge its foreign currency-denominated net investments in Japan and Switzerland. These contracts have maturities of three months. Changes in the fair value of these forward-exchange contracts are included in the Currency translation adjustment and other account in Shareholders' equity. Discounts on currencies sold are amortized on a straight-line basis and are included in Other deductions--net.
The Company purchases currency options to hedge anticipated inventory purchases and sales. The currency options are reported at cost, which is amortized to operations on a straight-line basis through the expected inventory delivery date. Unrealized gains at that date are deferred as a reduction of inventory cost and recognized in net income as the inventory is sold. These options have maturities of up to one year in 1996 and up to two years in 1995 and 1994.


The U.S. dollar equivalent notional amounts of the significant foreign currency forward contracts and purchased options were as follows:

(millions of dollars)                            1996      1995      1994
- -------------------------------------------------------------------------
Commitments to sell foreign currencies:
    U.K. pounds                                  $564      $645      $ 61
    French francs                                 193       238        34
    German marks                                  131        67        29
    Irish punt                                    112       104        49
    Japanese yen                                   94        40       107
    Belgian francs                                 67       114         8
    Net investment hedges:
     Japanese yen                                 615        --        --
     Swiss francs                                 342        --        --
Commitments to purchase foreign currencies:
    Swiss francs                                  154         1         4
    U.K. pounds                                   128       283       132
    German marks                                   54        79        55
    Irish punt                                     21        35        92
    Japanese yen                                    7        39        --
Purchased options:
    Japanese yen                                  221       231       150
    French francs                                  35        87        --
    German marks                                   28       104        --
    Belgian francs                                 25        56        --
- -------------------------------------------------------------------------

The commitments to sell and purchase foreign currencies and purchased options are primarily in exchange for U.S. dollars.
During 1995, the Company wrote Japanese yen put options with terms identical to previously purchased put options. Both options are reported at market value and any market value changes are reported in Other deductions--net. Due to the fact that these positions effectively offset, there was no net impact on earnings.
Interest-rate swap contracts are used to manage interest-rate risk on assets and liabilities and to lower the Company's borrowing cost. The differential to be paid or received under the contracts is accrued over the lives of the contracts as interest rates change. Such amounts are included in Other deductions--net.
At December 31, 1996 and 1995, the interest-rate swap contracts included Japanese yen-denominated contracts with aggregate notional principal amounts of $932 and $350 million, respectively. These contracts are in place to effectively convert short-term floating-rate debt (based on the yen London Interbank Offered Rate [LIBOR]--0.5% in 1996 and 1995) into fixed-rate debt (0.7% in 1996 and 1.3% in 1995). The contracts outstanding at December 31, 1996 mature in December 1997.


At December 31, 1996, the Company had other interest-rate swap contracts with a notional amount of $428 million that mature in December 1997. These contracts are in place to effectively convert short-term floating rate debt (based on Swiss franc LIBOR--2.1% in 1996) into 2.1% fixed-rate debt.
At December 31, 1994, PIBE had contracts of $200 million to effectively convert certain floating-rate assets to fixed-rate assets. The Company sold the right to receive the fixed-rate payments under the contracts totaling $200 million in order to reduce counterparty credit risk. Income on this transaction was deferred and amortized over the life of the swap contracts, all of which expired in 1995. Additionally, a contract of $50 million that matured early in 1995 effectively converted certain fixed-rate assets of PIBE into floating-rate assets based on U.S. dollar LIBOR.
Currency-swap contracts are used to manage foreign-exchange risk on foreign currency denominated assets and liabilities with the differential to be paid or received under the agreements accrued over the lives of the contracts as foreign exchange gains and losses. Such amounts are included in Other deductions--net. Currency-swap contracts are reported net in the Consolidated Balance Sheet.
In 1995, in connection with a sale-and-repurchase financing, the Company entered into an interest-rate swap and a currency swap to effectively convert a U.K. pound liability from fixed rate to U.S. dollar variable rate for a period of five years. The notional amount of the U.K. pound denominated interest-rate swap was $499 million. In December 1996, the financing was repaid and the swaps were terminated.
At December 31, 1996, 1995 and 1994, the Company had other currency-swap contracts with notional amounts of approximately $45, $60 and $90 million outstanding, respectively, maturing through 1997. Such contracts effectively convert certain PIBE fixed-rate (6.2% in 1996, 6.8% in 1995 and 6.4% in 1994) foreign currency assets into floating-rate (based on U.S. dollar LIBOR--6.0% in 1996, 6.0% in 1995 and 5.8% in 1994) U.S. dollar-denominated assets.
The Company periodically reviews the credit quality of financial institutions which are counterparties to its foreign-currency and interest-rate contracts and does not expect any loss from the failure of such institutions to perform under the contracts. The Company generally requires no collateral from its customers and performs ongoing credit evaluations of its customers' financial condition.
At December 31, 1996, the Company had no significant concentrations of credit risk related to financial instruments.

Fair Value of Financial Instruments
The following methods and assumptions were used to estimate the fair value of financial instruments:
For short-term financial instruments, the carrying amount approximates fair value because of the short maturities of those instruments. For loans, the carrying amount approximates fair value because of the short reset period.


Quoted market prices or dealer quotes for the same or similar instruments were used for certain long-term interest-bearing deposits and investments, long-term debt, forward-exchange contracts and currency options.
Interest-rate and currency-swap agreements have been valued by using an estimated amount that the Company would receive or pay to terminate the swap agreements at the reporting date based on broker quotes, taking into account current interest rates and the current creditworthiness of the swap counterparties.
The difference between fair and carrying values of the Company's financial instruments was not material.

Property, Plant and Equipment
The major categories of property, plant and equipment follow:

(millions of dollars)                   1996           1995           1994
- ---------------------------------------------------------------------------
Land                                   $  119         $   95         $   85
Buildings                               1,597          1,406          1,219
Machinery and equipment                 2,511          2,345          2,108
Furniture, fixtures and other           1,291          1,100            940
Construction in progress                  487            517            641
- ---------------------------------------------------------------------------
                                        6,005          5,463          4,993
Less: accumulated depreciation          2,155          1,990          1,920
- ---------------------------------------------------------------------------
                                       $3,850         $3,473         $3,073
===========================================================================

Long-Term Debt
Long-term debt, exclusive of current maturities of $261, $277 and $7 million in 1996, 1995 and 1994, respectively, is summarized below:

(millions of dollars)                    1996           1995           1994
- ---------------------------------------------------------------------------
Floating-rate unsecured notes            $636           $ --           $ --
Repurchase agreement obligation            --            499             --
7-1\8% Notes due 1996                      --             --            250
6-1\2% Notes due 1997                      --            250            250
Other borrowings and mortgages             51             84            104
- ---------------------------------------------------------------------------
                                         $687           $833           $604
===========================================================================

In 1996, the Company issued a series of unsecured notes in the aggregate principal amount of $636 million maturing on various dates from the year 2001 through 2005. The notes bear interest at a defined variable rate (weighted-average rate of 5.7% at December 31, 1996) based on the commercial paper rate. The notes enable the Company to minimize credit risk exposures of certain of its long-term investments by providing, in part, that the Company may satisfy the notes at maturity by delivery of the specified long-term investments, which had a fair value of $636 million at December 31, 1996.


In 1995, the Company sold securities for $499 million with an obligation to repay the same principal amount pursuant to a repurchase agreement maturing in December 2000. In 1996, this obligation was terminated in accordance with the agreement, the principal repaid and the related swaps terminated.
Long-term debt maturities for the years 1998 through 2001 are $4, $3, $1 and $136 million, respectively. At December 31, 1996, the Company had approximately $1.2 billion in major unused lines of credit.
The effective weighted average interest rate on short-term borrowings outstanding as of December 31, 1996, 1995 and 1994 was 5.0%, 5.2% and 5.8%, respectively.
During 1996, 1995 and 1994, respectively, the Company incurred interest costs of $170, $205 and $142 million, including $5, $13 and $15 million that were capitalized.

Other Deductions -- Net
Other deductions--net are summarized below:

(millions of dollars)               1996           1995           1994
- ----------------------------------------------------------------------
Interest income                    $(135)         $(158)         $(123)
Interest expense                     165            192            127
Amortization of goodwill
  and other intangibles               66             46             14
Other, net                           180            181             97
- ----------------------------------------------------------------------
Other deductions--net              $ 276          $ 261          $ 115
======================================================================

Other, net for 1996 included income of $48 million related to revised royalty arrangements covering sales of Procardia XL, an $18 million write-off of in-process R&D in connection with the Corvita acquisition and payments totaling $45 million related to the purchase of certain product licensing rights.
In 1995, Other, net included approximately $57 million of net pre-tax income related to the completion of all appeals in a patent infringement case with SciMed Life Systems, Inc., a provision for various litigation issues and pre-tax charges of approximately $53 million that resulted from decisions to withdraw from a product line and to modify certain distribution relationships.

Restructuring Program
In 1993, the Company initiated a worldwide restructuring program which included the consolidation of manufacturing facilities, the demolition of buildings resulting from the consolidation, reconfiguration and rehabilitation of remaining facilities and the consolidation of distribution and administrative organizations and infrastructures. As a result, the Company recorded restructuring charges of $679 million. The restructuring reserve was utilized in the amounts of $217, $157, $149 and $146 million in 1996, 1995, 1994 and 1993, respectively. As of December 31, 1996, this program was completed.


Taxes on Income
Income from continuing operations before taxes consisted of the following:

(millions of dollars)                 1996           1995           1994
- -------------------------------------------------------------------------
United States                        $1,065         $1,041         $1,057
International                         1,739          1,258            773
- -------------------------------------------------------------------------
Total income from continuing
  operations before taxes            $2,804         $2,299         $1,830
==========================================================================

The classification of items presented in the table above differs from that in the geographic data table on page 40. The geographic data table displays information by management organization, exclusive of financial subsidiaries, net interest and corporate expenses. Income from continuing operations before taxes in the above table is classified based on the location of the operations of the Company.
The provision for taxes on income consisted of the following:

(millions of dollars)                       1996          1995           1994
- ------------------------------------------------------------------------------
United States
  Taxes currently payable
    Federal                                 $ 332         $ 341          $ 238
    State and local                            54            41             15
  Deferred income taxes                        10           (22)            35
- ------------------------------------------------------------------------------
Tax provision                                 396           360            288
- ------------------------------------------------------------------------------
International
    Taxes currently payable                   408           368            264
    Deferred income taxes                      65            10             (3)
- ------------------------------------------------------------------------------
Tax provision                                 473           378            261
- ------------------------------------------------------------------------------
Total provision for taxes on income         $ 869         $ 738          $ 549
==============================================================================

The provision for taxes on income in the above table is classified based on the location of the taxing authority. A provision for U.S. income taxes which would approximate $880 million has not been made on approximately $3.9 billion of international subsidiaries' unremitted earnings as of December 31, 1996, which, for the most part, are expected to be reinvested overseas.
The earnings of the Company's pharmaceutical subsidiary operating in Puerto Rico are subject to taxes pursuant to an incentive grant effective through December 31, 2002. Under this grant, the Company is partially exempt from income, property and municipal taxes. Tax legislation in 1993 and 1996 has limited the tax incentives available to the Company from its operations in Puerto Rico. For further information, see "Tax Legislation" on page 37. In addition, the 1996 Act extended the R&D tax credit for 11 months effective July 1, 1996. As a result, taxes have been provided to the extent required by these changes in law.


The major elements contributing to the difference between the U.S. statutory tax rate and the consolidated effective tax rate were as follows:

(percentages)                             1996          1995          1994
- ---------------------------------------------------------------------------
U.S. statutory tax rate                   35.0          35.0          35.0
Effect of partially tax-exempt
  operations in Puerto Rico               (3.5)         (5.8)         (9.9)
Effect of foreign operations              (2.9)          1.6          (2.3)
All other--net                             2.4           1.3           7.2
- ---------------------------------------------------------------------------
Consolidated effective tax rate           31.0          32.1          30.0
===========================================================================

Deferred tax assets and liabilities, netted by jurisdiction, are included in the Consolidated Balance Sheet as follows:

(millions of dollars)                       1996        1995        1994
- -------------------------------------------------------------------------
Current assets--Prepaid expenses,
   taxes and other assets                   $ 425       $ 469       $ 374
Noncurrent assets--Other assets,
   deferred taxes and deferred charges        297         255         336
Noncurrent liabilities--Deferred
   taxes on income                           (253)       (166)       (212)
- -------------------------------------------------------------------------
Net deferred tax asset                      $ 469       $ 558       $ 498
=========================================================================

The income tax effects of the principal temporary differences which give rise to a significant portion of deferred tax assets and liabilities were as follows:

                                      1996                      1995                     1994
                                   Deferred Tax             Deferred Tax             Deferred Tax
                            ------------------------   ----------------------     ---------------------
(millions of dollars)        Assets         Liabs.      Assets        Liabs.      Assets         Liabs.
- -------------------------------------------------------------------------------------------------------
Prepaid/deferred items      $   242       $   156      $   236       $   193      $   158       $   150
Inventories                     263            98          245            71          186            67
Property, plant and
  equipment                      32           414           43           372           32           322
Employee benefits               241           105          277           100          207           128
Restructurings and
  special charge                157            --          215            --          280            --
Foreign tax credit
  carryforwards                  65            --          110            --          165            --
Other carryforwards             251            --          153            --          117            --
All other                       106            87          106            61           76            28
- -------------------------------------------------------------------------------------------------------
Subtotal                      1,357           860        1,385           797        1,221           695
Valuation allowance             (28)           --          (30)           --          (28)           --
- -------------------------------------------------------------------------------------------------------
Total deferred taxes        $ 1,329       $   860      $ 1,355       $   797      $ 1,193       $   695
- -------------------------------------------------------------------------------------------------------
Net deferred tax asset      $   469                    $   558                    $   498
=======================================================================================================

In 1994, foreign tax credit carryforwards arose from dividends received by the Company from foreign subsidiaries. These carryforwards expire through 1999.
A valuation allowance is provided when it is likely that some portion of the deferred tax assets will not be realized. The major component of the valuation allowance relates to the uncertainty of realizing certain foreign deferred tax assets.


The Internal Revenue Service (IRS) has completed its examination of the Company's federal income tax returns for the years 1987 through 1989. The Company has filed a response protesting proposed adjustments and has begun interacting with the IRS Appeals Office. The proposed adjustments relate primarily to the tax accounting treatment of certain swaps and related transactions undertaken by the Company in 1987 and 1988. These transactions resulted in the receipt of cash in those years, which the Company duly reported as income for tax purposes. In 1989 (in Notice 89-21), the IRS announced that it believed cash received in certain swap transactions should be reported as income for tax purposes over the life of the swaps, rather than when received. In the case of the Company, this would cause some of the income to be reported in years subject to the Tax Reform Act of 1986. The IRS proposed adjustment involves approximately $72 million in federal taxes for the years 1987 through 1989, plus interest. If the proposed adjustment is carried through to the maturity of the transactions in 1992, an additional tax deficiency of approximately $86 million, plus interest, would result. The Company disagrees with the proposed adjustment and continues to believe that its tax accounting treatment for the transactions in question was proper. While it is impossible to determine the final disposition, the Company is of the opinion that the ultimate resolution of this matter should not have a material adverse effect on the financial position or the results of operations of the Company.
In November 1994, Belgian tax authorities notified Pfizer Research and Development Company N.V./S.A. (PRDCO), an indirect, wholly owned subsidiary of the Company, of a proposed adjustment to the taxable income of PRDCO for fiscal year 1992. The proposed adjustment arises from an assertion by the Belgian tax authorities of jurisdiction with respect to income resulting primarily from certain transfers of property by non-Belgian subsidiaries of the Company to the Irish branch of PRDCO. In January 1995, PRDCO received an assessment from the tax authorities for additional taxes and interest of approximately $432 million and $97 million, respectively, relating to these matters. In January 1996, PRDCO received an assessment from the tax authorities, for fiscal year 1993, for additional taxes and interest of approximately $86 million and $18 million, respectively. The new assessment arises from the same assertion by the Belgian tax authorities of jurisdiction with respect to all income of the Irish branch of PRDCO. Based upon the relevant facts regarding the Irish branch of PRDCO and the provisions of the Belgian tax laws and the written opinions of outside counsel, the Company believes that the assessments are without merit.
The Company believes that its accrued tax liabilities are adequate for all open years.


Pension Plans
The Company and its subsidiaries have pension plans covering most employees worldwide. Those pension plans are reflected in the tables below. The components of net periodic pension cost were as follows:

(percentages)                            1996       1995            1994
- ------------------------------------------------------------------------
Assumptions:
 Expected long-term rate of return
  on plan assets:
    U.S. plans                           10.0        10.0            9.0
    International plans                   7.8         8.1            8.1

(millions of dollars)
- ------------------------------------------------------------------------
Expected return on plan assets:
  Actual return                         $(325)      $(415)         $ (33)
  Deferred return                         133         245           (119)
- ------------------------------------------------------------------------
  Net                                    (192)       (170)          (152)
Service cost -- benefits earned
 during the period                         93          81             79
Interest cost on projected
 benefit obligations                      139         131            116
Net amortization and deferral              30          46             31
- ------------------------------------------------------------------------
Net periodic pension cost               $  70       $  88          $  74
========================================================================
         As of December 31, the funded status of the Company's pension plans was

as follows:

(percentages)                                 1996          1995          1994
- --------------------------------------------------------------------------------
Assumptions:
 U.S. plans:
  Discount rate                                 7.5           7.5           8.5
  Rate of increase in salary levels             4.5           5.5           5.5
 International plans:
  Discount rate                                 6.5           6.4           7.1
  Rate of increase in salary levels             4.2           4.3           4.6

(millions of dollars)
- --------------------------------------------------------------------------------
Actuarial present value of accumulated
 benefit obligations:
   Vested                                   $(1,606)      $(1,558)      $(1,312)
   Non-vested                                  (242)         (216)         (133)
- --------------------------------------------------------------------------------
   Total                                     (1,848)       (1,774)       (1,445)
Effect of future salary increases              (282)         (288)         (259)
- --------------------------------------------------------------------------------
Projected benefit obligations                (2,130)       (2,062)       (1,704)
Plan assets at fair value                     2,410         2,168         1,773
- --------------------------------------------------------------------------------
Plan assets in excess of projected
 benefit obligations                            280           106            69
Unrecognized overfunding at date
 of adoption                                    (15)          (18)          (27)
Unrecognized net (gains)/losses                 (14)          129           163
Unrecognized prior service costs                 70            95           118
Minimum liability adjustment                   (159)         (180)          (36)
- --------------------------------------------------------------------------------
Net pension asset included in
 Consolidated Balance Sheet                 $   162       $   132       $   287
================================================================================


In 1996, there was no change in the U.S. discount rate. There was, however, a $129 million net increase in the projected benefit obligation due to a reduction in the discount rate to 7.5% from 8.5% in the U.S. in 1995.
For 1996, 1995 and 1994, accumulated benefit obligations of $615, $620 and $173 million, respectively, and assets at fair value of $319, $326 and $6 million, respectively, primarily related to partially funded international plans are reflected in the preceding table. The funding policy for the international plans conforms to local governmental and tax requirements. In 1995, a previously fully funded international plan became, and currently is, partially funded due primarily to a decrease in the discount rate.
Benefits under defined benefit plans generally are based on years of service and employee career earnings. Participants become fully vested after as few as five years of employment.
The Company's funding policy for U.S. plans generally is to contribute annually into trust funds at a rate intended to remain at a level percentage of compensation for covered employees. Since the major U.S. plan is overfunded, the Company's last contribution to this plan was in 1992.
The plans' assets are invested primarily in stocks, bonds and short-term investments. At December 31, 1996, the major U.S. plan held approximately 2.8 million shares of the Company's common stock with a fair value of approximately $235 million. Dividends of approximately $4 million were paid on such shares in 1996.

Savings and Investment Plans
The Company maintains voluntary savings and investment plans for most employees in the U.S., Puerto Rico, the U.K. and Ireland. Within prescribed limits, the Company bases its contributions to the plans on employee contributions. For 1996, 1995 and 1994, Company contributions amounted to $36, $33 and $30 million, respectively.

Postretirement Benefits Other Than Pensions The Company has postretirement plans that provide medical and life insurance benefits primarily for U.S. retirees and their eligible dependents. Employees become eligible for these benefits if they meet minimum age and service requirements and are eligible for retirement benefits. The Company reserves the right to modify or terminate these plans. The plans are not funded.
The components of the 1996, 1995 and 1994 expense were as follows:

(millions of dollars)                      1996         1995        1994
- -------------------------------------------------------------------------
Service cost--benefits earned
  during the period                        $  6         $  5         $  6
Interest cost on the accumulated
  obligation                                 20           22           21
Net amortization and deferral               (24)         (24)         (24)
- --------------------------------------------------------------------------
Net periodic postretirement expense        $  2         $  3         $  3
==========================================================================


The accumulated postretirement benefit obligation recognized in the Consolidated Balance Sheet consists of:

(millions of dollars)                         1996        1995        1994
- ---------------------------------------------------------------------------
Retirees                                     $(188)      $(197)      $(192)
Fully eligible active plan participants        (33)        (32)        (35)
Other active plan participants                 (64)        (61)        (53)
- ---------------------------------------------------------------------------
Accumulated postretirement benefit
 obligation                                   (285)       (290)       (280)
Unrecognized prior service cost (gain)        (108)       (133)       (157)
Unrecognized net (gain)/loss                   (19)         (3)          4
- ---------------------------------------------------------------------------
Recorded obligation                          $(412)      $(426)      $(433)
===========================================================================

An average increase of 9.1% in the cost of covered health care benefits was assumed for 1997 and is projected to decrease to 5.2% after eight years and to then remain at that level. A 1% increase in the health care cost trend rate would have increased the accumulated postretirement benefit obligation as of December 31, 1996 by $15 million and the total of service and interest cost by $1 million. The discount rates used to estimate the accumulated postretirement benefit obligation were 7.5%, 7.5% and 8.5% at December 31, 1996, 1995 and 1994, respectively.

Common Stock
In September 1996, the Board of Directors authorized the Company to repurchase up to $2 billion of its currently issued common stock over the next 18 to 24 months in open-market or private transactions. Stock purchased under the program will be held in the Company treasury and will be available for general corporate purposes. Under the 1996 program, approximately 300,000 shares were purchased in the open market at an average cost of approximately $88 per share.
In June 1995, the Company effected a two-for-one stock split in the form of a 100% stock dividend on its common stock. The par value decreased from $.10 to $.05 a share. The 1994 share and per share data were retroactively restated to reflect the two-for-one stock split. The stock split followed a vote by the shareholders to increase the Company's authorized common shares to 1.5 billion shares from 750 million.

Preferred Stock Purchase Rights
Preferred Stock Purchase Rights were granted in 1987 and are scheduled to expire October 5, 1997 unless they are extended or replaced. The rights are not exercisable unless certain change-in-control events transpire. These include an Acquiring Person acquiring or obtaining the right to acquire beneficial ownership of 15% or more of the outstanding common stock of the Company, or an announcement of a tender offer for at least 30% of the Company's common stock. The rights are evidenced by the Company's corresponding common stock certificates and automatically trade in tandem with the common stock until an event transpires that makes them exercisable. If the rights become exercisable, separate certificates evidencing the rights will be distributed and each right will entitle the holder to purchase from the Company a new series of preferred stock at a predefined price. The preferred stock, in addition to a preferred dividend and liquidation right, will entitle the holder to vote with the Company's common stock.


The rights are redeemable by the Company at a fixed price until 10 days, or longer as determined by the Board, after certain defined events, or at any time prior to the expiration of the rights.
Through December 31, 1996, the Company had reserved 1.9 million preferred shares issuable pursuant to these rights. At the present time, the rights have no dilutive effect on the earnings per common share calculation.

Employee Benefit Trust
In 1993, the Company sold 20 million shares of treasury stock to the Pfizer Inc. Grantor Trust (the Trust) in exchange for a promissory note of approximately $600 million. The Trust is being used primarily to fund future obligations for approved Company benefit plans over its 15-year term. The amount recorded on the Consolidated Balance Sheet representing unearned employee benefits is recorded as a deduction from shareholders' equity and is reduced as employee benefits are satisfied.
In 1996, 1995 and 1994, approximately 630,000, 830,000 and 600,000 shares, respectively, were released from the Trust to satisfy exercised employee stock options and the Company's obligation under other employee benefit plans. Compensation costs related to the other employee benefit plans are recorded at fair market value of the shares at the date of release.

Lease Commitments
Rent expense, net of sublease rentals, for the years ended December 31, 1996, 1995 and 1994 amounted to approximately $122, $118 and $94 million, respectively. Total future minimum rental commitments under all noncancellable leases for the years 1997 through 2001 and thereafter are approximately $44, $39, $32, $17, $16 and $217 million, respectively.
Under the more significant lease agreements, the Company must either pay directly for taxes, insurance, maintenance and other operating expenses or pay higher rentals when such expenses increase.

Stock Option Plan and Performance Awards Under the Stock and Incentive Plan (the Plan), the Company may grant options to any employee, including officers, to purchase common stock at the market price on the date an option is granted. All options are granted with a term of 10 years and may be exercised subject to continued employment and certain other conditions. The options generally vest ratably over terms of from one to five years. The Plan also provides for stock appreciation rights, stock awards and/or performance unit awards.
In 1996, shareholders approved amendments to the Plan to increase the number of shares of common stock available under the Plan by an additional 23 million shares and to extend the term of the Plan to December 31, 2005.


The following table summarizes the stock option activity for the Plan:

                                                               Under Option
                                                        ---------------------------
                                     Shares                                Weighted
                              Available for                        Average Exercise
(thousands of shares)                 Grant             Shares      Price Per Share
- -----------------------------------------------------------------------------------
Balance January 1, 1994              19,006             38,589            $   30.85
     Granted                         (9,918)             9,918                34.27
     Exercised                         --               (3,562)               17.18
     Cancelled                          697               (703)               35.80
- -----------------------------------------------------------------------------------
Balance December 31,1994              9,785             44,242                32.26
     Granted                         (7,052)             7,052                49.00
     Exercised                         --               (7,548)               28.01
     Cancelled                          842               (842)               37.69
- -----------------------------------------------------------------------------------
Balance December 31, 1995             3,575             42,904                36.74
     Authorized                      23,000               --                --
     Granted                         (9,410)             9,410                74.50
     Exercised                         --               (8,733)               26.87
     Cancelled                          342               (367)               48.00
- -----------------------------------------------------------------------------------
Balance December 31, 1996            17,507             43,214                43.24
===================================================================================

The weighted-average fair value per option at the date of grant for options granted during 1996 and 1995 was $21.80 and $12.92, respectively. The fair value was estimated using the Black-Scholes option pricing model, modified for dividends and based on the following assumptions:

                                               1996       1995
- ---------------------------------------------------------------
Expected dividend yield                        1.97%      2.85%
Risk-free interest rate                        6.38%      6.26%
Expected stock price volatility               25.45%     26.00%
Expected term until exercise (years)           5.25       5.25
- ---------------------------------------------------------------

Pro forma net income and earnings per share reflecting compensation cost for the fair value of stock options awarded in 1996 and 1995 were as follows:

(millions of dollars, except per share data)          1996         1995
- ------------------------------------------------------------------------
Net income:
     As reported                                     $1,929       $1,573
     Pro forma                                        1,860        1,559
Earnings per share:
     As reported                                     $ 2.99       $ 2.50
     Pro forma                                         2.89         2.48
========================================================================

The pro forma effects on net income and earnings per share for 1996 and 1995 may not be representative of the pro forma effects in future years since compensation cost is allocated on a straight-line basis over the vesting periods of the grants, which extends beyond the reported years.


The following table summarizes information concerning options outstanding under the Plan at December 31, 1996:

(thousands
of shares
under option)              Options Outstanding                           Options Exercisable
- ------------------------------------------------------------------   ---------------------------
                                        Weighted
                                         Average          Weighted                      Weighted
                           Number      Remaining           Average        Number         Average
       Range of       Outstanding    Contractual          Exercise   Exercisable        Exercise
Exercise Prices       at 12/31/96    Term (Years)            Price   at 12/31/96           Price
- ------------------------------------------------------------------------------------------------
       $10--$20             5,564            2.4         $   15.34         5,564       $   15.34
        30-- 40            15,430            6.7             33.11        13,223           32.97
        40-- 50            12,874            7.1             44.76         8,417           42.54
        70-- 80             9,346            9.6             74.50            --              --
================================================================================================

The Performance-Contingent Share Award Program (the Program), established in 1993, provides executives and other key employees with the right to earn awards payable in shares of the Company's common stock with the actual payout determined using two performance criteria. Actual issuance of shares occurs when the performance period is completed and the criteria measured. The Program provides for up to 20 million shares to be awarded. In 1996 and 1995, approximately 160 and 46 thousand shares, respectively, were issued under the Program. At December 31, 1996, executives and other key employees had the right to earn up to approximately 2.3 million shares. Compensation cost related to the Program amounted to $31, $15 and $8 million in 1996, 1995 and 1994, respectively.

Acquisitions
In 1996, the Company acquired:
o Vesta Medical Inc., a development-stage company, which has designed a proprietary system to treat abnormal uterine bleeding.
o Certain cosmetic, dietetic and other over-the-counter products from the Formenti group through the acquisition of three Italian companies: Ircafarm S.r.l., Farkemo S.r.l and Blue Cross S.r.l.
o All of Corvita Corporation's outstanding shares of common stock. Corvita develops, manufactures and markets self-expanding endovascular stent grafts and synthetic vascular grafts used in the treatment of severely diseased arteries.
o Cortizone, an anti-itching product and Hemorid, a hemorrhoid treatment, from Thompson Medical Co., Inc.
o Bioindustria Farmaceutici S.p.A., an Italian company engaged in the production and distribution of prescription and over-the-counter pharmaceutical products.


o The Leibinger Companies, leaders in the manufacture of specialty instruments and implantable devices used in skull, jaw, facial, hand and foot surgery.

In 1995, the Company acquired:
o SmithKline Beecham plc subsidiaries operating solely in the animal health business and certain net assets used in the animal health business from other SmithKline Beecham plc subsidiaries (collectively, SBAH) for approximately $1.5 billion, including direct costs of the acquisition. The Company's results of operations for 1995 include 12 months of SBAH's activity in the U.S. and 11 months in international markets. The excess of the purchase price over the estimated fair value of the tangible net assets acquired was allocated to identifiable intangibles of approximately $285 million and goodwill of approximately $790 million. The goodwill and identifiable intangibles are being amortized on a straight-line basis over periods of 10 to 40 years.
o NAMIC U.S.A. Corporation for approximately 4.4 million shares of the Company's common shares in a stock transaction valued at approximately $170 million, including direct costs of acquisition.
o Bain de Soleil sun-related skin care products from the Procter & Gamble Company.

In 1994, the Company acquired:
o Certain assets of Flavor Technology Inc., a specialty flavors business, for approximately $32 million.
o Restiva Italiana S.p.A. for approximately $26 million. Restiva produces and sells health and skin care products.
o Rovifarma, S.A. for approximately $24 million. Rovifarma is a Spanish producer and distributor of over-the-counter products.

All acquisitions were recorded under the purchase method of accounting. The results of operations of these acquired businesses have been included subsequent to the respective dates of acquisition. Pro forma results of operations that reflect the 1996 acquisitions as if they had occurred at the beginning of the periods presented would not be materially different from the reported amounts.

Discontinued Operations
In January 1996, the Company sold substantially all the net assets of its food science business to Cultor Ltd., a publicly held international nutrition company based in Finland, for approximately $353 million in cash. In October 1996, the Company completed the disposition of this business with the sale of its Chy-Max product line to Chr. Hansen A/S, a Danish company. The food science business has been reported as a discontinued operation.


Below is a summary of its operating results:

(millions of dollars)                   1996           1995           1994
- ---------------------------------------------------------------------------
Net sales                               $ 47           $328           $304
- ---------------------------------------------------------------------------
Income before provision for
 taxes on income                        $ --           $ 31           $ 31
Provision for taxes on income             --              9              9
- ---------------------------------------------------------------------------
Net income                              $ --           $ 22           $ 22
===========================================================================

At December 31, 1995, net assets of the food science business of approximately $330 million were included in Prepaid expenses, taxes and other assets in the Consolidated Balance Sheet.

Insurance
The Company believes it maintains insurance coverage adequate for its needs. Under its insurance contracts, the Company usually accepts self-insured retentions appropriate for the specific risks of its business.

Litigation
The Company is involved in a number of claims and litigations, including product liability claims and litigations considered normal in the nature of its businesses. These include suits involving various pharmaceutical and hospital products that allege either reaction to or injury from use of the product.
As previously disclosed, numerous claims have been brought against the Company and Shiley Incorporated, a wholly owned subsidiary, alleging either personal injury from fracture of 60 degree or 70 degree Shiley Convexo Concave (C/C) heart valves, or anxiety that properly functioning implanted valves might fracture in the future or personal injury from a prophylactic replacement of a functioning valve.
In an attempt to resolve all claims alleging anxiety that properly functioning valves might fracture in the future, the Company entered into a settlement agreement in January 1992 in Bowling v. Shiley, et al., a case brought in the United States District Court for the Southern District of Ohio, that establishes a worldwide settlement class of people with C/C heart valves and their spouses, except those who elect to exclude themselves. The settlement provides for a Consultation Fund of $90 to $140 million (depending on the number of claims filed) from which valve recipients who make claims will receive payments that are intended to cover their cost of consultation with cardiologists or other health care providers with respect to their valves . The settlement agreement establishes a second fund of at least $75 million to support C/C valve-related research, including the development of techniques to identify valve recipients who may have significant risk of fracture, and to cover the unreimbursed medical expenses that valve recipients may incur for certain procedures related to the valves. The Company's obligation as to coverage of these unreimbursed medical expenses is not subject to any dollar limitation. Following a hearing on the fairness of the settlement, it was approved by the court on August 19, 1992. An appeal of the court's approval of the settlement was dismissed on December 21, 1993 by the United States Court of Appeals for the Sixth Circuit. A motion for rehearing en banc was denied on March 4, 1994, and the U.S. Supreme Court denied a writ of certiorari on October 3, 1994. On August 8, 1994, the Sixth Circuit dismissed an appeal from the


denial of a motion by the same appellants to vacate the judgment approving the settlement, and the U.S. Supreme Court denied a writ of certiorari on January 9, 1995. Another appeal to the Sixth Circuit by the same appellants regarding the denial of their earlier motion to intervene affirmed the denial and all judgments entered by the District Court, and denied all pending motions, on December 16, 1996. A motion for a rehearing en banc before the Sixth Circuit was filed by the same appellants. It is expected that most of the costs arising from the Bowling class settlement will be covered by insurance and the proceeds of the sale of certain product lines of the Shiley businesses in 1992. Of approximately 900 implantees (and spouses of some of them) who opted out of the Bowling settlement class, eight have cases pending; approximately 792 have been resolved; and approximately 100 have never filed a case or claim.
Several claims relating to elective reoperations of valve recipients are currently pending. Some of these claims relate to elective reoperations covered by the Bowling class settlement described above, and, therefore, the claimants are entitled to certain benefits in accordance with the settlement. Such claimants, if they irrevocably waive all of the benefits of the settlement, may pursue separate litigation to recover damages in spite of the class settlement. The Company is defending these claims.
Generally, the plaintiffs in all of the pending heart valve litigations discussed above seek money damages. Based on the experience of the Company in defending these claims to date, including available insurance and reserves, the Company is of the opinion that these actions should not have a material adverse effect on the financial position or the results of operations of the Company.
On September 30, 1993, Dairyland Insurance Co., a carrier providing excess liability coverage (excess carrier) in the early 1980s, commenced an action in the California Superior Court in Orange County, seeking a declaratory judgment that it was not obligated to provide insurance coverage for Shiley heart valve liability claims. On October 8, 1993, the Company filed cross-complaints against Dairyland and filed third-party complaints against 73 other excess carriers who sold excess liability policies covering periods from 1979 to 1985, seeking damages and declaratory judgments that they are obligated to pay for defense and indemnity to the extent not paid by other carriers. A significant portion of such claims have been resolved and the remainder are involved in pretrial discovery. On April 26, 1996, the trial court entered an order stating that implanting an allegedly defective heart valve is not an appropriate trigger of insurance coverage in at least one and perhaps all working valve lawsuits. This decision, even if it is applied to all claims alleging anxiety that properly functioning valves might fracture in the future, does not deal with fracture claims, which are also part of the Company's claims.
The Company's operations are subject to federal, state, local and foreign environmental laws and regulations. Under the Comprehensive Environmental Response Compensation and Liability Act of 1980, as amended (CERCLA or Superfund), the Company has been designated as a potentially responsible party by the United States Environmental Protection Agency with respect to certain waste sites with which the Company may have had direct or indirect involvement. Similar designations have been made by some state environmental agencies under applicable state superfund laws. Such designations are made regardless of the extent of the Company's involvement. There are also


claims that the Company may be a responsible party or participant with respect to several waste site matters in foreign jurisdictions. Such claims have been made by the filing of a complaint, the issuance of an administrative directive or order, or the issuance of a notice or demand letter. These claims are in various stages of administrative or judicial proceedings. They include demands for recovery of past governmental costs and for future investigative or remedial actions. In many cases, the dollar amount of the claim is not specified. In most cases, claims have been asserted against a number of other entities for the same recovery or other relief as was asserted against the Company. The Company is currently participating in remedial action at a number of sites under federal, state, local and foreign laws.
To the extent possible with the limited amount of information available at this time, the Company has evaluated its responsibility for costs and related liability with respect to the above sites and is of the opinion that the Company's liability with respect to these sites should not have a material adverse effect on the financial position or the results of operations of the Company. In arriving at this conclusion, the Company has considered, among other things, the payments that have been made with respect to the sites in the past; the factors, such as volume and relative toxicity, ordinarily applied to allocate defense and remedial costs at such sites; the probable costs to be paid by the other potentially responsible parties; total projected remedial costs for a site, if known; existing technology; and the currently enacted laws and regulations. The Company anticipates that a portion of these costs and related liability will be covered by available insurance.
Through the early 1970s, Pfizer Inc. (Minerals Division) and Quigley Company, Inc. (Quigley), a wholly owned subsidiary, sold a minimal amount of one construction product and several refractory products containing some asbestos. These sales were discontinued thereafter. Although these sales represented a minor market share, the Company has been named as one of a number of defendants in numerous lawsuits. These actions, and actions related to the Company's sale of talc products in the past, claim personal injury resulting from exposure to asbestos-containing products, and nearly all seek general and punitive damages. In these actions, the Company or Quigley is typically one of a number of defendants, and both are members of the Center for Claims Resolution (the CCR), a joint defense organization of 20 defendants that is defending these claims. The Company and Quigley are responsible for varying percentages of defense and liability payments for all members of the CCR. Prior to September 1990, the cases involving talc products were defended by the CCR, but the Company is now overseeing its own defense of these actions. A number of cases alleging property damage from asbestos-containing products installed in buildings have also been brought against the Company.
On January 15, 1993, a class action complaint and settlement agreement were filed in the United States District Court for the Eastern District of Pennsylvania involving all personal injury claims by persons who have been exposed to asbestos-containing products but who have not yet filed a personal injury action against the members of the CCR (Future Claims Settlement). The Future Claims Settlement agreement establishes a claims-processing mechanism that will provide historic settlement values upon proof of impaired medical condition as well as claims-processing rates over 10 years. In addition, the


shares allocated to the CCR members eliminate joint and several liability. The court has determined that the Future Claims Settlement is fair and reasonable. Subsequently, the court entered an injunction enforcing its determination. Plaintiffs filed an appeal from that injunction in the United States Court of Appeals for the Third Circuit and on May 10, 1996, a panel of the Third Circuit reversed the order of the District Court and directed that the preliminary injunction be vacated. Although the Third Circuit subsequently denied the motion of the CCR members including the Company and Quigley, for rehearing of that determination, it agreed to stay its mandate while review is sought in the United States Supreme Court. On November 1, 1996, the United States Supreme Court granted a writ of certiorari to hear the appeal. In the event that the Future Claims Settlement is not upheld, it is not expected to have a material impact on the Company's exposure or on the availability of insurance for the vast majority of such cases. It is expected, too, that the CCR will attempt to resolve such cases outside of the Future Claims Settlement in the same manner as heretofore.
At approximately the time it filed the Future Claims Settlement class action, the CCR settled approximately 16,360 personal injury cases on behalf of its members, including the Company and Quigley. The CCR has continued to settle remaining and opt-out cases and claims on a similar basis to past settlements. The total pending number of active personal injury claims, exclusive of those covered by the Future Claims Settlement preliminary injunction and those which are inactive or have been settled in principle as of December 28, 1996, is 11,415 asbestos cases against Quigley; 3,882 asbestos cases against the Company; and 68 talc cases against the Company.
Costs incurred by the Company in defending the asbestos personal injury claims and the property damage claims, as well as settlements and damage awards in connection therewith, are largely insured against under policies issued by several primary insurance carriers and a number of excess carriers.
The Company believes that its costs incurred in defending and ultimately disposing of the asbestos personal injury claims, whether or not the Future Claims Settlement is eventually upheld, as well as the property damage claims, will be largely covered by insurance policies issued by carriers that have agreed to provide coverage, subject to deductibles, exclusions, retentions and policy limits. In connection with the Future Claims Settlement, the defendants commenced a third-party action against their respective excess insurance carriers that have not agreed to provide coverage seeking a declaratory judgment that (a) the Future Claims Settlement is fair and reasonable as to the carriers;
(b) the carriers had adequate notice of the Future Claims Settlement; and (c) the carriers are obligated to provide coverage for asbestos personal injury claims. Even if the Future Claims Settlement is not eventually upheld, it is expected that the insurance coverage action against the insurance carriers that have not agreed to provide coverage for asbestos personal injury claims will be pursued. Based on the Company's experience in defending the claims to date and the amount of insurance coverage available, the Company is of the opinion that the actions should not ultimately have a material adverse effect on the financial position or the results of operations of the Company.
The United States Environmental Protection Agency--Region I and the Department of Justice have informed the Company that the federal government is


contemplating an enforcement action arising primarily out of a December 1993 multimedia environmental inspection, as well as certain state inspections, of the Company's Groton, Connecticut facility. The Company is engaged in discussions with the governmental agencies and does not believe that an enforcement action, if brought, will have a material adverse effect on the financial position or the results of operations of the Company.
The Company has been named, together with numerous other manufacturers of brand name prescription drugs and certain companies that distribute brand name prescription drugs, in suits in federal and state courts brought by various groups of retail pharmacy companies. The federal cases consist principally of a class action by retail pharmacies (including approximately 30 named plaintiffs)(the Federal Class Action), as well as additional actions by approximately 3,500 individual retail pharmacies and a group of chain and supermarket pharmacies (the individual actions). These cases, which have been transferred to the United States District Court for the Northern District of Illinois and coordinated for pretrial purposes, allege that the defendant drug manufacturers violated the Sherman Act by unlawfully agreeing with each other (and, as alleged in some cases, with wholesalers) not to extend to retail pharmacy companies the same discounts allegedly extended to mail order pharmacies, managed care companies and certain other customers, and by unlawfully discriminating against retail pharmacy companies by not extending them such discounts. On November 15, 1994, the federal court certified a class (the Federal Class Action) consisting of all persons or entities who, since October 15, 1989, bought brand name prescription drugs from any manufacturer or wholesaler defendant, but specifically excluding government entities, mail order pharmacies, HMOs, hospitals, clinics and nursing homes. Fifteen manufacturer defendants, including the Company, agreed to settle the Federal Class Action subject to court approval. The Company's share pursuant to an Agreement as of January 31, 1996, was $31.25 million, payable in four annual installments without interest. The Company continues to believe that there was no conspiracy and specifically denied liability in the Settlement Agreement, but had agreed to settle to avoid the monetary and other costs of litigation. The settlement was filed with the Court on February 9, 1996 and went through preliminary and final fairness hearings. By orders of April 4, 1996, the Court: (1) rejected the settlement; (2) denied the motions of the manufacturers (including the Company) for summary judgment; (3) granted the motions of the wholesalers for summary judgment; and (4) denied the motion to exclude purchases by other than direct purchasers. The decision on the wholesalers has been made final, and been appealed. The decision on the indirect purchasers has been certified, and accepted, for appeal. The Court has put off setting a trial date while these matters are pending.
In May 1996, 13 manufacturer defendants, including the Company, entered into an Amendment to the Settlement Agreement which was filed with the Court on May 6, 1996. The Company's financial obligations under the Settlement Agreement will not be increased. The Settlement Agreement, as amended, received final approval June 21, 1996. An appeal of that approval is pending.
In addition, consumer class actions have been filed in state courts and the District of Columbia, alleging injury to consumers as well as retail pharmacies from the failure to give discounts to retail pharmacy companies. Both


a consumer class and a retailer class have been certified in separate California actions. Consumer class actions filed in Colorado, New York and Washington have been dismissed; Washington and New York are now on appeal. The Company was dismissed from a consumer class action in Wisconsin. Consumer class actions are also pending in Alabama, Arizona, Florida, Kansas, Maine, Michigan, Minnesota and the District of Columbia. On February 3, 1997, the District Court for the District of Columbia certified a limited consumer class. Retailer class actions are also pending in Alabama and Minnesota.
The Company believes that these brand name prescription drug antitrust cases, which generally seek damages and certain injunctive relief, are without merit, and has moved to have them dismissed.
The Federal Trade Commission is conducting an investigation focusing on the pricing practices at issue in the above pharmacy antitrust litigation. In July 1996, the Commission issued a subpoena for documents to the Company, among others, to which the Company has responded.
Schneider (USA) Inc. and Schneider (Europe) AG have been named, together with Advanced Cardiovascular Systems, Inc., in a federal antitrust action brought on January 2, 1996, by Boston Scientific Corporation and SciMed Life Systems, Inc. (a subsidiary of Boston Scientific) in the U.S. District Court, District of Massachusetts. The suit alleges that the defendants unlawfully obtained and enforced certain patents covering rapid exchange angioplasty catheters and conspired against the plaintiffs by, among other allegations, their settlement of patent infringement litigation in December of 1991. The suit seeks unspecified treble damages and injunctive relief. The Company believes that the case is without merit, and has moved to have it dismissed.
FDA administrative proceedings relating to Plax are pending, principally an industry-wide call for data on all anti-plaque products by the FDA. The call for data notice specified that products that have been marketed for a material time and to a material extent may remain on the market pending FDA review of the data, provided the manufacturer has a good faith belief that the product is generally recognized as safe and effective and is not misbranded. The Company believes that Plax satisfied these requirements and prepared a response to the FDA's request, which was filed on June 17, 1991. This filing, as well as the filings of other manufacturers, is still under review and is currently being considered by an FDA Advisory Committee.
On January 15, 1997, an action was filed in Circuit Court, Chambers County, Alabama, and certified by an ex parte order as a class action, purportedly on behalf of a class of consumers, variously defined by the laws or types of laws governing their rights and encompassing residents of up to 47 states. The complaint alleges that the Company's claims for Plax were untrue, entitling them to a refund of their purchase price for purchases since 1988. The action is in the earliest stages. The Company believes the complaint is without merit.
In April 1996, the Company received a Warning Letter from the FDA relating to the timeliness and completeness of required post marketing reports for pharmaceutical products. The letter did not raise any safety issue about Pfizer drugs. The Company has been implementing remedial actions designed to remedy the issues raised in the letter.


In August 1996, the Company received a Warning Letter from the FDA relating to certain promotional materials used in the marketing of Zoloft. The Company has been in communication with the FDA on this matter and the discussions are proceeding. Two purported consumer class actions involving Zoloft were filed, in Circuit Court, Dallas County, Texas, on December 3, and in Superior Court, San Diego County, California, on December 26, 1996. Each complaint alleges that Pfizer's promotional materials improperly implied that the FDA had approved Zoloft as safe and effective for certain indications, and that patients for whom Zoloft was prescribed as a result of the promotion were entitled to a refund of their purchase price. Both suits have been removed to federal court; the plaintiffs in the Texas suit have moved to remand the case to state court. The Company believes the suits are without merit.
A consolidated class action on behalf of persons who allegedly purchased Pfizer common stock during the March 24, 1989 through February 26, 1990 period is pending in the United States District Court for the Southern District of New York. This lawsuit, which commenced on July 13, 1990, alleges that the Company and certain officers and former directors and officers violated federal securities law by failing to disclose potential liability arising out of personal injury suits involving Shiley heart valves and seeks damages in an unspecified amount. Even though it is believed that this suit is without merit, in order to avoid the monetary and other costs of litigation, the Company has entered into an agreement to settle this action for $9.75 million, subject to a court determination of the fairness of the settlement. Following a fairness hearing held December 13, 1996, the court affirmed the settlement and dismissed the action. A derivative action commenced on April 2, 1990 against certain directors and officers and former directors and officers alleging breaches of fiduciary duty and other common law violations in connection with the manufacture and distribution of Shiley heart valves is pending in the Superior Court, Orange County, California. The complaint seeks, among other forms of relief, damages in an unspecified amount. Even though it is believed that the suit is without merit, in order to avoid the monetary and other costs of litigation, the Company has entered into an agreement to settle this action by way of a $15 million payment by the Company's insurance carrier to the Company with an attorneys' fee to be paid by the Company out of the proceeds of the settlement to the shareholders' attorneys who brought the case. The settlement is subject to court approval and a fairness hearing is scheduled for April 11, 1997.
A purported class action entitled Bradshaw v. Pfizer Inc. and Howmedica Inc. is pending in the U.S. District Court, Northern District of Ohio. The action sought monetary and injunctive relief, including medical monitoring, on behalf of patients implanted with the Howmedica P.C.A. one-piece acetabular hip component, which was manufactured by Howmedica from 1983 to 1990. The complaint alleges that the prostheses were defectively designed and manufactured and posed undisclosed risks to implantees. The federal magistrate judge has recommended that the district court deny the plaintiffs' motion to certify the case as a class action. The Company believes that the suit is without merit. On February 4, 1997, the Company was served with 15 separate actions in the United States District Court for the District of New Jersey, brought by some of the same individuals previously identified as members of the purported class in the


Notes to Consolidated Financial Statements continued

Bradshaw action, represented by the same lawyers, and making the same allegations. The Company believes that most if not all of these cases are without merit.
The Company and/or Howmedica, along with other device manufacturers and numerous orthopedic surgeons, have been named as defendants in approximately 700 cases (among over 1,600 pending) in numerous state and federal courts seeking damages relating to alleged improper design, manufacture, and/or promotion of bone screws for unapproved use in spinal pedicles. Neither Howmedica nor the Company manufactured or sold pedicle screws in the U.S., but the claims allege a conspiracy among all of the defendants to over-promote the devices. The federal cases have been consolidated by the Multidistrict Panel in the U.S. District Court in Philadelphia, which ruled on April 8, 1996 that all claims against the manufacturers except express warranty and improper promotion are preempted. The recent decisions of the United States Supreme Court in Lohr v. Medtronic may impact the availability of the pre-emption defense in this case (and in other medical device cases). The Company believes the cases are without merit and during the fourth quarter over 150 of the cases against Howmedica and/or the Company have been dismissed, leaving a year-end total of 617.
From 1994 to 1995, seven purported class actions were filed against American Medical Systems (AMS) in federal courts in South Carolina (subsequently transferred to Minnesota), California, Minnesota (2), Indiana, Ohio and Louisiana. The California, Ohio and Indiana suits and one Minnesota suit also name Pfizer Inc. as a defendant, based on its ownership of AMS. The suits seek monetary and injunctive relief on the basis of allegations that implantable penile prostheses are prone to unreasonably high rates of mechanical failure and/or various autoimmune diseases as a result of silicone materials. On September 30, 1994, the federal Judicial Panel on Multidistrict Litigation denied the various plaintiffs' motions to consolidate or coordinate the cases for pretrial proceedings. On February 28, 1995, the Court in the Ohio suit conditionally granted plaintiffs' motion for class certification; on March 3, 1995, the court in the California suit denied plaintiffs' motion for class certification; and on October 25, 1995, the court in the Indiana suit denied plaintiffs' motion for class certification; on February 15, 1996, the United States Court of Appeals for the Sixth Circuit reversed the Ohio Court's conditional certification; on May 15, 1996, the purported Minnesota class actions were dismissed without prejudice (following which plaintiffs' counsel have filed several actions in Minnesota State Court on behalf of over 200 individuals); and a motion to strike the class allegations in the Louisiana case was granted by the Court on July 23, 1996. The Company believes the suits are without merit.
During late 1996, over 300 individual suits alleging injuries from penile implants were filed in Circuit Court in Minneapolis by individuals who were allegedly members of one or more of the discontinued purported class actions described above and/or who are represented by the same lawyers. The Company believes that most if not all of these cases are without merit.
In June 1993, the Ministry of Justice of the State of Sao Paulo, Brazil commenced a civil public action against the Company's Brazilian subsidiary, Laboratorios Pfizer Ltda. (Pfizer Brazil) asserting that during a period in 1991, Pfizer Brazil withheld sale of the pharmaceutical product Diabinese in


violation of antitrust and consumer protection laws. The action seeks the award of moral, economic and personal damages to individuals and the payment to a public reserve fund. On February 8, 1996, the trial court issued a decision holding Pfizer Brazil liable. The award of damages to individuals and the payment into the public reserve fund will be determined in a subsequent phase of the proceedings. The trial court's opinion sets out a formula for calculating the payment into the public reserve fund which could result in a sum of approximately $88 million. The total amount of damages payable to eligible individuals under the decision would depend on the number of persons eventually making claims. Pfizer Brazil is appealing this decision. The Company believes that this action is without merit and should not have a material adverse effect on the financial position or the results of operations of the Company.
For information on income tax adjustments proposed by the U.S. and Belgian tax authorities, see the footnote "Taxes on Income" beginning on page 49.

Segment Information and Geographic Data
The Company is a research-based, global health care company. In 1996, the Company had net sales in excess of $10 million in each of 45 countries outside the U.S., with no single country, other than the U.S., contributing more than 10% to total net sales. Segment information (including major product groups) and geographic data as of and for the years ended December 31, 1996, 1995 and 1994 are shown on pages 39 and 40, respectively, and in the footnote "Financial Subsidiaries" on page 46 and are incorporated in this footnote.
The Company's operations consist of three business segments and a financial subsidiaries group:
Health care: a broad line of pharmaceutical products (including cardiovascular diseases, infectious diseases, central nervous system disorders, diabetes, arthritis/inflammation and allergy) as well as hospital products (including bone and joint prostheses, specialty instruments and implantable devices, diagnostic and therapeutic products used in the treatment of cardiovascular disease, electrosurgical and ultrasonic surgical devices and implantable urological devices). Health care products are sold to wholesale and retail outlets, public and private hospitals, managed care organizations, government and the medical profession.
Animal health: products for livestock and companion animals including antibiotic and feed supplements, animal vaccines and other veterinary items. Animal health products are sold through drug wholesalers, distributors, retail outlets and directly to users, including feed manufacturers, animal producers and veterinarians.
Consumer health care: over-the-counter health care items and oral care products. Consumer products are sold to wholesalers and retailers.
Financial subsidiaries: a banking operation that makes loans and accepts deposits in international markets and a small captive insurance operation that reinsures certain assets, inland transport and marine cargo of the Company's subsidiaries.


Quarterly Consolidated Statement of Income Pfizer Inc and Subsidiary Companies
(Unaudited)

                                                                                Quarter
                                                           -------------------------------------------------
(millions of dollars, except per share data)                First        Second         Third        Fourth           Year
- ---------------------------------------------------------------------------------------------------------------------------
1996
Net sales                                                  $ 2,682       $ 2,661       $ 2,803       $ 3,160        $11,306
Costs and expenses
  Cost of sales                                                513           521           522           620          2,176
  Selling, informational and administrative expenses           994         1,083         1,040         1,249          4,366
  Research and development expenses                            366           422           406           490          1,684
  Other deductions--net                                         57            61            86            72            276
- ---------------------------------------------------------------------------------------------------------------------------
Income before provision for taxes on income
 and minority interests                                        752           574           749           729          2,804
Provision for taxes on income                                  233           178           232           226            869
Minority interests                                               2             2             3            (1)             6
- ---------------------------------------------------------------------------------------------------------------------------
Net income                                                 $   517       $   394       $   514       $   504        $ 1,929
- ---------------------------------------------------------------------------------------------------------------------------
Earnings per common share                                  $   .81       $   .61       $   .80       $   .77        $  2.99
- ---------------------------------------------------------------------------------------------------------------------------
Cash dividends paid per common share                       $   .30       $   .30       $   .30       $   .30        $  1.20
- ---------------------------------------------------------------------------------------------------------------------------
Stock prices*
  High                                                     $70-3\4       $ 77-3\8      $79-1\2       $ 91-1\4       $91-1\4
  Low                                                      $60-1\8       $ 62-7\8      $65-5\8       $ 77-1\2       $60-1\8
- ---------------------------------------------------------------------------------------------------------------------------
1995
Net sales                                                  $ 2,338       $ 2,401       $ 2,538       $ 2,744        $10,021
Costs and expenses
  Cost of sales                                                509           552           536           567          2,164
  Selling, informational and administrative expenses           849           967           960         1,079          3,855
  Research and development expenses                            313           354           351           424          1,442
  Other deductions--net                                         39            60            65            97            261
- ---------------------------------------------------------------------------------------------------------------------------
Income from continuing operations before provision
 for taxes on income and minority interests                    628           468           626           577          2,299
Provision for taxes on income                                  207           155           206           170            738
Minority interests                                               2             2             1             2              7
- ---------------------------------------------------------------------------------------------------------------------------
Income from continuing operations                              419           311           419           405          1,554
Discontinued operations--net                                     1             6             6             6             19
- ---------------------------------------------------------------------------------------------------------------------------
Net income                                                 $   420       $   317       $   425       $   411        $ 1,573
- ---------------------------------------------------------------------------------------------------------------------------
Earnings per common share:
  Continuing operations                                    $   .68       $   .49       $   .66       $   .64        $  2.47
  Discontinued operations--net                                 .00           .01           .01           .01            .03
- ---------------------------------------------------------------------------------------------------------------------------
  Net income                                               $   .68       $   .50       $   .67       $   .65        $  2.50
- ---------------------------------------------------------------------------------------------------------------------------
  Cash dividends paid per common share                     $   .26       $   .26       $   .26       $   .26        $  1.04
- ---------------------------------------------------------------------------------------------------------------------------
Stock prices*
  High                                                     $45           $ 47-1\2      $ 54-1\4      $ 66-7\8       $66-7\8
  Low                                                      $37-1\4       $ 40-1\4      $ 43-1\2      $ 52-5\8       $37-1\4
- ---------------------------------------------------------------------------------------------------------------------------

*As reported in The Wall Street Journal. The first two quarters of 1995 have been adjusted for the second quarter 1995 two-for-one stock split in the form of a 100 percent stock dividend.

As of January 31, 1997, there were approximately 65,338 holders of the Company's common stock (symbol PFE).

59

Financial Summary Pfizer Inc and Subsidiary Companies

                                                                             Year Ended December 31
                                                        ---------------------------------------------------------------------------
(millions, except per share data)                  1996   1995   1994   1993    1992   1991  1990   1989   1988   1987    1986
- ----------------------------------------------------------------------------------------------------------------------------------
Net sales                                        $11,306 10,021  7,977  7,162  6,871  6,580 5,859  5,162  4,873  4,406   4,060
Cost of sales                                      2,176  2,164  1,722  1,559  1,766  1,930 1,815  1,671  1,634  1,518   1,409
Selling, informational and administrative          4,366  3,855  3,184  3,006  2,838  2,680 2,384  2,043  1,818  1,627   1,412
Research and development                           1,684  1,442  1,126    961    851    745   627    519    459    386     322
Divestitures, restructuring and unusual items*      --      --     --     741   (141)   300    --     --     --    --     --
Other (income)/deductions--net                       276    261    115     60     16     12   (42)    51    (93)   (66)    (7)
- ------------------------------------------------------------------------------------------------------------------------------
Income from continuing operations
  before provision for taxes on income             2,804  2,299  1,830    835  1,541    913 1,075    878  1,055    941    924
Provision for taxes on income                        869    738    549    188    440    211   290    222    296    295    288
Minority interests                                     6      7      5      2      3      3     5      4      3      3      4
- ------------------------------------------------------------------------------------------------------------------------------
Income from continuing operations before
  cumulative effect of accounting changes          1,929  1,554  1,276    645  1,098    699   780    652    756    643    632
Discontinued operations--net                         --      19     22     13     (4)    23    21     29     35     47     28
Cumulative effect of accounting changes              --      --     --     --   (283)**  --    --     --     --     --     --
- ------------------------------------------------------------------------------------------------------------------------------
    Net income                                    $1,929  1,573  1,298    658    811    722   801    681    791    690    660
- ------------------------------------------------------------------------------------------------------------------------------
Effective tax rate                                  31.0%  32.1%  30.0%  22.5%  28.6%  23.1% 27.0%  25.2%  28.0%  31.4%  31.2%
Depreciation                                        $361    321    275    241    243    218   200    184    177    162    147
Capital additions                                    774    696    672    634    674    594   548    457    344    258    196
Cash dividends paid                                  771    659    594    536    487    437   397    364    330    297    270
- ------------------------------------------------------------------------------------------------------------------------------
As of December 31
- ------------------------------------------------------------------------------------------------------------------------------
Working capital                                     $828    965    962  1,290  2,167  1,388 1,319  1,593  1,751  2,144  1,729
Property, plant and equipment--net                 3,850  3,473  3,073  2,633  2,305  2,381 2,110  1,784  1,655  1,506  1,352
Total assets                                      14,667 12,729 11,099  9,331  9,590  9,635 9,052  8,325  7,593  6,872  5,179
Long-term debt                                       687    833    604    571    571    397   193    191    227    249    285
Long-term capital***                               7,944  6,552  5,179  4,665  5,472  5,742 5,666  5,062  4,866  4,471  3,926
Shareholders' equity                               6,954  5,506  4,324  3,866  4,719  5,026 5,092  4,536  4,301  3,882  3,415
- ------------------------------------------------------------------------------------------------------------------------------
Per common share data:
    Income from continuing operations
      before effect of accounting changes          $2.99   2.47   2.05   1.01   1.63   1.03  1.16    .97   1.13    .95    .93
    Discontinued operations -- net                    --    .03    .04    .02   (.01)   .03   .03    .04    .05    .07    .04
    Cumulative effect of accounting changes           --     --     --     --   (.42)**  --    --     --     --     --     --
- ------------------------------------------------------------------------------------------------------------------------------
    Net income                                     $2.99   2.50   2.09   1.03   1.20   1.06  1.19   1.01   1.18   1.02    .97
- ------------------------------------------------------------------------------------------------------------------------------
    Market value (December 31)                    $83.00  63.00  38.63  34.50  36.25  42.00 20.19  17.38  14.50  11.66  15.25
    Cash dividends paid                             1.20   1.04    .94    .84    .74    .66   .60    .55    .50    .45    .41
    Shareholders' equity                           11.08   8.90   7.10   6.22   7.26   7.63  7.71   6.86   6.50   5.90   5.18
- ------------------------------------------------------------------------------------------------------------------------------
Weighted average shares used to
  calculate earnings per share amounts               644    630    620    641    673    679   674    679    678    682    683
Number of employees (thousands)                       47     44     40     40     40     43    42     41     40     39     39
- ------------------------------------------------------------------------------------------------------------------------------
Net sales per employee (thousands)                  $243    229    198    179    172    152   141    127    123    112    105
- ------------------------------------------------------------------------------------------------------------------------------

The results of operations of the food science business, which was sold in 1996, have been reported as a discontinued operation.

Common share data for the years 1986-1994 and 1986-1990 have been restated for the 1995 and 1991 two-for-one stock splits, respectively.

*Divestitures, restructuring and unusual items--net include the following:

1993--Pre-tax charges of approximately $745 million and $56 million to cover worldwide restructuring programs, as well as unusual items and a gain of approximately $60 million realized on the sale of the Company's remaining interest in Minerals Technologies Inc.

1992--Pre-tax gain of $259 million on the sale of a business, offset by pre-tax charges of $175 million for restructuring, consolidating and streamlining. In addition, it includes pre-tax curtailment gains of $57 million associated with postretirement benefits other than pensions of divested operations.

1991--A pre-tax charge of $300 million for potential future Shiley C/C heart valve fracture claims.

**Accounting changes adopted January 1, 1992: SFAS No. 106--$313 million or $.46 per share; SFAS No. 109--credit of $30 million or $.04 per share.

***Defined as long-term debt, deferred taxes on income, minority interests and shareholders' equity.

66


SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 11-K

FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS

AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

(Mark One)

|X| ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (FEE REQUIRED)

For the fiscal year ended December 31, 1996

OR

[ ] TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (NO FEE REQUIRED)

For the transition period from ... to ...

Commission file number 1-3619

A. Full title of the Plan and the address of the Plan, if different from that of the issuer named below:

PFIZER SAVINGS AND INVESTMENT PLAN

B. Name of issuer of the securities held pursuant to the Plan and the address of its principal executive offices:

PFIZER INC.

235 EAST 42ND STREET

NEW YORK, NEW YORK 10017



PFIZER SAVINGS AND INVESTMENT PLAN
STATEMENT OF NET ASSETS AVAILABLE
FOR PLAN BENEFITS
December 31, 1996
(thousands of dollars except unit values)

                                                  Non-Participant
                                                    Directed                             Participant Directed
                                                 -----------------------------------------------------------------------------------
                                                     Company Common
                                          Total        Stock Fund          Fund A      Fund B      Fund C       Fund D    Loan Fund
                                    ------------------------------------------------------------------------------------------------
Investments, at fair value:
  Pfizer Inc. common stock:
    Company Common Stock
    Fund, 9,845,884 shares,
    cost $138,298; Fund C,
    9,809,675 shares,
    cost $206,233.................    $1,631,412       $817,208      $      --    $      --      $814,204       $   --       $   --
  Intermediate Treasury Bond Fund,
    The Northern Trust Company,
    cost $170,673.................       170,580             --        170,580           --            --           --           --
  Collective Stock Index Fund, The
    Northern Trust Company,  cost
    $72,820.......................       147,468             --             --      147,468            --           --           --
Other investments, at cost which
  approximates fair value:
    Loans to participants.........        39,385             --             --           --            --           --       39,385
    Cash and short-term securities        28,602             92            592           26            45       27,847           --
                                    ------------------------------------------------------------------------------------------------
  Total investments...............     2,017,447        817,300        171,172      147,494       814,249       27,847       39,385

Interest receivable...............         3,406              2          3,281           --             1          122           --
Contributions receivable from
  employers, including amounts
  collected from employees........         9,154          2,698          1,362           21         4,992           81           --
                                    ------------------------------------------------------------------------------------------------

Net assets available for plan
  benefits --Note 8...............    $2,030,007       $820,000       $175,815     $147,515      $819,242      $28,050      $39,385
                                    ================================================================================================


Number of units outstanding at end
  of year.........................                   32,067,445     14,665,944    8,883,551    32,219,343    2,478,547
Unit Value--Note 1................                       $25.38         $11.86       $16.49        $25.32       $11.27

See Notes to Financial Statements which are an integral part of these financial statements.

1

PFIZER SAVINGS AND INVESTMENT PLAN
STATEMENT OF NET ASSETS AVAILABLE
FOR PLAN BENEFITS
December 31, 1995
(thousands of dollars except unit values)

                                                  Non-Participant
                                                    Directed                             Participant Directed
                                                 -----------------------------------------------------------------------------------
                                                     Company Common
                                          Total        Stock Fund          Fund A      Fund B      Fund C       Fund D    Loan Fund
                                    ------------------------------------------------------------------------------------------------
Investments, at fair value:
  Pfizer Inc. common stock:
    Company Common Stock
    Fund, 10,451,382 shares,
    cost $132,164; Fund C,
    10,048,630 shares,
    cost $180,795.................    $1,291,501       $658,437   $         --  $        --      $633,064    $      --   $       --
  Intermediate Treasury Bond Fund,
    The Northern Trust Company,
    cost $137,223.................       140,002             --        140,002           --            --           --           --
  Collective Stock Index Fund, The
    Northern Trust Company,  cost
    $59,403.......................       110,014             --             --      110,014            --           --           --
Investment contracts with
  insurance companies, at contract
  value..........................         41,089             --         41,089           --            --           --           --
Other investments, at cost which
  approximates fair value:
    Loans to participants.........        31,707             --             --           --            --           --       31,707
    Cash and short-term securities        16,056             90             94           --            69       15,803           --
                                    ------------------------------------------------------------------------------------------------
  Total investments...............     1,630,369        658,527        181,185      110,014       633,133       15,803       31,707

Interest receivable...............         2,608              2          2,525            1             1           79           --
Contributions receivable from
  employers, including amounts
  collected from employees........         8,338          2,554          1,788        1,492         2,143          361           --
                                    ------------------------------------------------------------------------------------------------
                                       1,641,315        661,083        185,498      111,507       635,277       16,243       31,707
Payables arising from securities
  purchased.......................          (54)             --            (1)         (40)          (13)           --           --
                                    ------------------------------------------------------------------------------------------------

Net assets available for plan
  benefits --Note 8...............    $1,641,261       $661,083       $185,497     $111,467      $635,264      $16,243      $31,707
                                    ================================================================================================


Number of units outstanding at end
  of year.........................                   34,575,800     16,345,905    8,249,272    33,396,661    1,472,371
Unit Value--Note 1................                       $18.96         $11.29       $13.40        $18.91       $10.69

See Notes to Financial Statements which are an integral part of these financial statements.

2

PFIZER SAVINGS AND INVESTMENT PLAN
STATEMENT OF CHANGES IN NET ASSETS AVAILABLE
FOR PLAN BENEFITS
Year Ended December 31, 1996
(thousands of dollars)

                                                  Non-Participant
                                                    Directed                             Participant Directed
                                                 -----------------------------------------------------------------------------------
                                                     Company Common
                                              Total         Stock Fund     Fund A       Fund B     Fund C     Fund D      Loan Fund
                                    ------------------------------------------------------------------------------------------------
Net investment income
  Cash dividends:
    Pfizer Inc. common stock......           $24,240          $12,184     $    --     $     --    $12,056    $     --       $   --
    Other marketable
      securities..................             2,758               --          --        2,758         --         --            --
  Interest........................            16,518               49      12,352           11         28      1,002          3,076
                                        --------------------------------------------------------------------------------------------
                                              43,516           12,233      12,352        2,769     12,084      1,002          3,076
Investment management fees--
  Note 4..........................              (103)              --         (58)         (45)        --         --            --
                                        --------------------------------------------------------------------------------------------
                                              43,413           12,233      12,294        2,724     12,084      1,002          3,076
                                        --------------------------------------------------------------------------------------------
Realized gains (losses) on
  investments, net-- Note 5
    Pfizer Inc. common stock......            92,482           48,444          --           --     44,038         --            --
    Other securities..............              (932)               --     (1,174)         242         --         --            --
                                        --------------------------------------------------------------------------------------------
                                              91,550           48,444      (1,174)         242     44,038        --             --
                                        --------------------------------------------------------------------------------------------
Unrealized appreciation (depreciation)
  of investments,
  net-- Note 6....................           329,504          152,637      (2,872)      24,037    155,702         --            --
                                        --------------------------------------------------------------------------------------------
                                             464,467          213,314       8,248       27,003    211,824      1,002          3,076
                                        --------------------------------------------------------------------------------------------
Contributions
  Employees.......................            77,921               --      11,612       14,987     50,537        785            --
  Employers.......................            34,486           34,486          --           --         --         --            --
Withdrawals --Note 8..............          (188,128)         (85,169)    (26,090)      (9,912)   (63,769)    (3,188)           --
Loan transaction
  transfers, net..................                --           (3,714)      1,841        1,810     (5,221)       682          4,602
Transfers at fair
  value, net......................                --               --      (5,293)       2,160     (9,393)    12,526            --
                                        --------------------------------------------------------------------------------------------
                                             (75,721)         (54,397)    (17,930)       9,045    (27,846)    10,805          4,602
                                        --------------------------------------------------------------------------------------------
Net increase (decrease)...........           388,746          158,917      (9,682)      36,048    183,978     11,807          7,678
Net assets available for plan
  benefits--Note 8:
  Beginning of year...............         1,641,261          661,083     185,497      111,467    635,264     16,243         31,707
                                        --------------------------------------------------------------------------------------------

  End of year.....................        $2,030,007         $820,000    $175,815     $147,515   $819,242    $28,050        $39,385
                                        ============================================================================================

See Notes to Financial Statements which are an integral part of these financial statements.

3

PFIZER SAVINGS AND INVESTMENT PLAN
STATEMENT OF CHANGES IN NET ASSETS AVAILABLE
FOR PLAN BENEFITS
Year Ended December 31, 1995
(thousands of dollars)

                                                  Non-Participant
                                                    Directed                             Participant Directed
                                                 -----------------------------------------------------------------------------------
                                                        Company Common
                                            Total         Stock Fund        Fund A      Fund B     Fund C      Fund D      Loan Fund
                                    ------------------------------------------------------------------------------------------------
Net investment income
  Cash dividends:
    Pfizer Inc. common stock......         $21,180          $10,919     $       --   $      --    $10,261  $      --     $      --
    Other marketable
      securities..................           2,333               --             --       2,333         --         --            --
  Interest........................          15,605               38         12,351          29         86        939         2,162
                                       ------------------------------ -------------------------------------------------------------
                                            39,118           10,957         12,351       2,362     10,347        939         2,162
Investment management fees--
  Note 4..........................             (90)              --            (57)        (33)        --         --            --
                                       ------------------------------ -------------------------------------------------------------
                                            39,028           10,957         12,294       2,329     10,347        939         2,162
                                       ------------------------------ -------------------------------------------------------------
Realized gains (losses) on
  investments, net-- Note 5
    Pfizer Inc. common stock......          40,853           20,137             --          --     20,716         --            --
    Other securities..............             379               --           (638)      1,017         --         --            --
                                       ------------------------------ -------------------------------------------------------------
                                            41,232           20,137           (638)      1,017     20,716         --            --
                                       ------------------------------ -------------------------------------------------------------
Unrealized appreciation of
  investments, net-- Note 6.......         488,494          235,218          8,840      24,431    220,005         --            --
                                       ------------------------------ -------------------------------------------------------------
                                           568,754          266,312         20,496      27,777    251,068        939         2,162
                                       ------------------------------ -------------------------------------------------------------
Contributions --Note 7
  Employees.......................         132,035               --         13,942      13,281     41,807     63,005            --
  Employers.......................          32,068           32,068             --          --         --         --            --
Withdrawals --Note 8..............        (126,875)         (51,631)       (20,772)     (8,374)   (42,046)    (4,052)           --
Loan transaction
  transfers, net..................              --             (753)          (970)       (545)    (2,605)      (144)        5,017
Transfers at fair
  value, net......................              --               --         15,806      11,572     21,559    (48,937)           --
                                       ------------------------------ -------------------------------------------------------------
                                            37,228          (20,316)         8,006      15,934     18,715      9,872         5,017
                                       ------------------------------ -------------------------------------------------------------
Net increase......................         605,982          245,996         28,502      43,711    269,783     10,811         7,179
Net assets available for plan
  benefits--Note 8:
  Beginning of year...............       1,035,279          415,087        156,995      67,756    365,481      5,432        24,528
                                       --------------------------------------------------------------------------------------------
  End of year.....................      $1,641,261         $661,083       $185,497    $111,467   $635,264    $16,243       $31,707
                                       ============================================================================================

See Notes to Financial Statements which are an integral part of these financial statements.

4

PFIZER SAVINGS AND INVESTMENT PLAN

NOTES TO FINANCIAL STATEMENTS
December 31, 1996 and 1995

Note 1 -- Summary Plan Description

General -- The Pfizer Savings and Investment Plan (the "Plan") is a defined contribution plan which was originally adopted by Pfizer Inc. (the "Company") in 1965 as the Pfizer Savings Plan and has been amended from time to time since that date. Participation in the Plan is open to all eligible employees of the Company and any corporation which, with the consent of the Company, adopts the Plan ("Associate Companies"). The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974.

Effective December 31, 1992, all new contributions, in excess of withdrawals and transfers, directed to Fund A of the Plan are invested in an intermediate U.S. Treasury bond fund. In addition, as the investment contracts with insurance companies in Fund A matured, the contracts' proceeds were invested in an intermediate U.S. Treasury bond fund. As of June 3, 1996, all investment contracts with insurance companies had matured and the proceeds were invested in the bond fund.

Effective January 1, 1995, the Plan was amended to accept a rollover contribution by a participant in certain instances (as defined in the Plan) and to value a deceased participant's account as of the valuation date subsequent to the receipt of the distribution election rather than the valuation date preceding the decedent's death. Effective January 1, 1997, participants are permitted to roll over into the Plan eligible distributions from other qualified employer sponsored savings plans and conduit IRA's.

The following is a general description of certain provisions of the Plan. Refer to the Plan agreement for a complete description.

Contributions -- Each participant may make contributions on an after-tax basis and/or on a before-tax basis (that is, choose to reduce his or her compensation and have the Company contribute on his or her behalf). Before-tax contributions are subject to certain restrictions under the Internal Revenue Code of 1986, as amended. Contributions of up to 2% of compensation are matched 100% by the Company and the next 4% is matched 50%. Employee contributions in excess of 6% are not matched.

Effective February 1, 1997, the definition of earnings eligible for contributions was expanded to include overtime pay, premium pay and shift differentials.

Investment options -- Each participant in the Plan elects to have his or her contribution invested in any one or any combination of four investment funds. These funds are comprised of the following:

Fund A --     Intermediate U.S. Treasury bonds and, prior to
              June 3, 1996, investment contracts with insurance
              companies (see General caption above for a
              description of Fund A investments effective December
              31, 1992).

Fund B --     An index fund of corporate common stocks.

Fund C --     Common stock of the Company.

Fund D --     U.S. Treasury and government agency money market
              investments with maturities of less than one year.

5

PFIZER SAVINGS AND INVESTMENT PLAN
NOTES TO FINANCIAL STATEMENTS (Continued)
December 31, 1996 and 1995

Note 1 -- Summary Plan Description (Continued)

At December 31, 1996 and 1995, respectively, there were 13,476 and 13,033 employees participating in the Plan, some of whom had investments in more than one employee investment fund. On the basis of allocations by the employees of their contributions at December 31, 1996 and 1995, respectively, Fund A had 4,441 and 5,218 participating employees; Fund B, 5,044 and 4,802, Fund C, 11,535 and 10,828 and Fund D, 428 and 291.

All Company matching contributions are invested by the Trustee in a fifth fund designated the "Company Common Stock Fund," which consists primarily of common stock of the Company. These contributions are non-participant directed.

The Plan's trust agreement provides that any portion of any of the five funds may, pending its permanent investment or distribution, be invested in short-term investments.

The net assets used to calculate the unit values disclosed on the Statement of Net Assets Available for Plan Benefits as of December 31, 1996 and 1995, have been reduced by benefits payable as of that date. (See Note 8.)

Eligibility and Vesting -- Substantially all the domestic employees of the Company, except those covered by a collective bargaining agreement, are eligible to participate in the Plan beginning on the January 1 following their date of employment, or the beginning of any month thereafter. A Participant is immediately vested in the full value of his or her account (i.e., participants' and employers' contributions).

Effective January 1, 1997, employees are immediately eligible to enroll in the Plan.

Payment of Benefits -- Upon separation from service, retirement or disability, a participant may elect to receive a lump sum distribution immediately or at any time up to the later of 13 months from separation or age 65, subject to the provisions of the Plan. In the event of a participant's death, a spouse beneficiary may elect payment immediately or defer payments until the later of when the participant would have reached age 65 or 13 months from date of death. A nonspouse beneficiary may defer payment up until 13 months from the date of death.

Withdrawals -- A participant in the Plan may withdraw all or part of his or her account balance subject to the provisions of the Plan.

Loans --Plan participants are permitted to borrow against their vested balance. The minimum amount a participant may borrow is $1,000 and the maximum amount is the lesser of 50% of the vested account balance reduced by any current outstanding loan balance or $50,000 reduced by the highest outstanding loan balance in the preceding 12 months.

Under the terms of the Plan, loans must be repaid within five years, unless the funds are used to purchase a primary residence. Primary residence loans must be repaid over 10 or 15 years at the participant's option. The interest rate on all loans is based on the prime rate plus 1%. Interest paid by the participant is credited to the participant's account.

6

PFIZER SAVINGS AND INVESTMENT PLAN
NOTES TO FINANCIAL STATEMENTS (Continued)
December 31, 1996 and 1995

Note 1 -- Summary Plan Description (Continued)

Termination -- The Company expects to continue the Plan indefinitely, but necessarily reserves the right to amend, suspend or discontinue it in whole or in part at any time by action of the Company's Board of Directors. In the event of termination of the Plan, each participant shall receive the full value of his or her account balance as though he or she had retired as of the date of such termination. No part of the assets in the investment funds established pursuant to the Plan will at any time revert to the Company.

Note 2 -- Summary of Significant Accounting Policies

Basis of Accounting -- The financial statements of the Plan are prepared on the accrual basis of accounting. For treatment of benefits payable, refer to Note 8.

Investment Valuation -- Pfizer Inc. common stock is valued at the closing market price on the last business day of the year. The investments in the index fund of corporate common stocks and intermediate U.S. Treasury bond fund are recorded at fair value based on the closing market prices of the underlying investments of the respective fund as of the last business day of the year. Loans to participants and cash and short-term securities are recorded at cost which approximates fair value and the investment contracts with insurance companies are recorded at contract value.

Security Transactions -- Purchases and sales of securities are reflected on a trade-date basis. Realized gains and losses on sales of investments represent the difference between the net proceeds received and the cost of the investments (average cost if less than the entire investment is sold).

Unrealized Appreciation (Depreciation) of Investments -- Unrealized appreciation (depreciation) of investments for the year represents the difference between the cost of the investments and their fair value at the end of the year. Additionally, it reflects the reversal of the unrealized appreciation (depreciation) as of the end of the prior year.

Dividend Recognition -- Dividend income is recorded on the ex-dividend date. Income from other investments is recorded as earned.

Note 3 -- Income Taxes

The Internal Revenue Service has determined and informed the Company that the Plan and related trust as of May 26, 1994 were designed in accordance with the applicable sections of the Internal Revenue Code. The Plan has been amended since receiving the determination letter. The Plan administrator and the Plan's legal and tax counsel believe that the Plan is designed and is currently being operated in compliance with all the applicable requirements. Therefore, no provision has been made for Federal income taxes.

Contributions made to the Plan by the Company, including before-tax contributions made on the employee's behalf by the Company and the appreciation on all funds in the employee's account, are not taxable to the employee under Federal income tax law while these amounts remain in the Plan.

Note 4 -- Administrative Costs

Except for certain member transfer costs and the investment management fees (Fund A and Fund B), all costs and expenses of administering the Plan are borne by the Company.

7

PFIZER SAVINGS AND INVESTMENT PLAN
NOTES TO FINANCIAL STATEMENTS (Continued)
December 31, 1996 and 1995

Note 5 -- Realized Gains (Losses) on Investments

The aggregate net proceeds and carrying value used in the calculation of the realized gains (losses) on investments are as follows:

                                     Net Proceeds                          Realized Gains
                                   and Withdrawals           Cost             (Losses)
                                   -----------------    -------------    ------------------
Pfizer Inc. Common Stock                           (thousands of dollars)
         1996                           $119,840           $27,358            $92,482
         1995                             58,802            17,949             40,853

Other Securities

         1996                             95,543            96,475               (932)
         1995                             31,833            31,454                379

Realized gains from the disposal of Pfizer Inc. common stock include $62,371,000 in 1996 and $19,664,000 in 1995 related to shares distributed in kind to participants who withdrew from the Plan on retirement or termination.

In addition, the 1996 net proceeds and withdrawal amounts include $25,904,000 relating to the transfer of Plan assets of the former employees of the Pfizer Food Science Group to the Cultor Food Science Retirement and Savings Plan.

Note 6 -- Unrealized Appreciation (Depreciation) of Investments

The change in the amount of unrealized appreciation (depreciation) was as follows:

                                                 Aggregate Unrealized
                                           ---------------------------------
                                            December 31,      December 31,
                                                1996              1995          Change During 1996
                                           ---------------   ---------------   ---------------------
                                                            (thousands of dollars)
Company Common Stock Fund...............        $678,910          $526,273                $152,637
Fund A..................................             (93)            2,779                  (2,872)
Fund B..................................          74,648            50,611                  24,037
Fund C..................................         607,971           452,269                 155,702
                                           ---------------   ---------------   ---------------------
                                              $1,361,436        $1,031,932                $329,504
                                           ===============   ===============   =====================

                                                 Aggregate Unrealized
                                          ---------------------------------
                                            December 31,      December 31,
                                                1995              1994          Change During 1995
                                           ---------------   ---------------   ---------------------
                                                            (thousands of dollars)

Company Common Stock Fund...............        $526,273          $291,055                $235,218
Fund A..................................           2,779            (6,061)                  8,840
Fund B..................................          50,611            26,180                  24,431
Fund C..................................         452,269           232,264                 220,005
                                           ---------------   ---------------   ---------------------
                                              $1,031,932          $543,438                $488,494
                                           ===============   ===============   =====================

9

Note 7 -- Contributions

In 1995, contributions by participating employees of Pfizer Inc. includes rollover contributions of $62,260,000 from the employees of the former SmithKline Beecham animal health business that was acquired by the Company in January 1995.

Note 8 -- Withdrawals and Reconciliation with Form 5500

For financial statement purposes, participant withdrawals and distributions are recorded when paid rather than when processed and approved for payment. Therefore, the net assets available for Plan benefits as of December 31, 1996 and 1995 do not reflect a reduction for the following benefits payable to participants who had requested withdrawals as of December 31, but which were not distributed until the subsequent year:

                                                  1996          1995
                                               ------------  ------------
                                                (thousands of dollars)

Company Common Stock Fund.....................      $6,364        $5,471
Fund A........................................       1,933           871
Fund B........................................       1,063           933
Fund C........................................       3,580         3,735
Fund D........................................         120           508
                                               ------------  ------------

                                                   $13,060       $11,518

                                               ============  ============

For the purposes of Form 5500, such withdrawals and distributions are recorded when processed and approved for payment. Therefore, benefits payable to participants who have requested withdrawals have been reported as benefit expense on Form 5500 for those years.

9

SCHEDULE 1
PFIZER SAVINGS AND INVESTMENT PLAN

ITEM 27a -- SCHEDULE OF ASSETS HELD FOR INVESTMENT PURPOSES
December 31, 1996


(thousands of dollars)

                                                                                       Number of
                                                         Interest       Maturity       Shares or
                                                           Rate           Date           Units          Cost        Fair Value
                                                      --------------  -------------  --------------  ------------  -------------
FUND A:
The Northern Trust Company, Intermediate
  Treasury Bond Fund.................................      --              --          165,600,000      $170,673       $170,580

The Northern Trust Company, Short-Term Investment
  Fund...............................................    Various        Various            591,920           592            592
                                                                                                     ============  =============
    Total of Fund A..................................                                                   $171,265       $171,172
                                                                                                     ============  =============

FUND B:
The Northern Trust Company, Collective
  Stock Index Fund...................................      --              --            2,416,774       $72,820       $147,468

The Northern Trust Company, Short-Term Investment
  Fund...............................................    Various        Various                               26             26
                                                                                                     ------------  -------------
    Total of Fund B..................................                                                    $72,846       $147,494
                                                                                                     ============  =============
FUND C:
Pfizer Inc. Common Stock.............................      --              --            9,809,675      $206,233       $814,204

The Northern Trust Company, Short-Term Investment
  Fund...............................................    Various        Various             45,252            45             45
                                                                                                     ============  =============
    Total of Fund C..................................                                                   $206,278       $814,249
                                                                                                     ============  =============

FUND D:
The Northern Trust Company, Government Short-Term
  Investment Fund....................................    Various        Various         27,847,462       $27,847        $27,847
                                                                                                     ============  =============

COMPANY COMMON STOCK FUND:
Pfizer Inc. Common Stock.............................      --              --            9,845,884      $138,298       $817,208

The Northern Trust Company, Short-Term Investment
  Fund...............................................    Various        Various             92,168            92             92
                                                                                                     ------------  -------------
    Total of Company Stock Fund......................                                                   $138,390       $817,300
                                                                                                     ============  =============

LOAN FUND:
Loans to participants                                    Various        Various                 --       $39,385        $39,385
                                                                                                     ============  =============

10

SCHEDULE 2
PFIZER SAVINGS AND INVESTMENT PLAN

ITEM 27d -- SCHEDULE OF REPORTABLE TRANSACTIONS

Year Ended December 31, 1996

(thousands of dollars)

FUND C AND COMPANY
COMMON STOCK FUND:

                                               Number of        Number of
                                             Transactions         Shares          Cost
                                            ---------------  --------------  ------------
Securities Purchased
Pfizer Inc. common stock...................       33            819,318        $58,966



Securities Disposed*                                                                        Fair Value
                                              Number of        Number of                    of Disposed     Realized
                                             Transactions       Shares          Cost          Shares          Gains
                                            ---------------  --------------  ------------  --------------  ------------
Pfizer Inc. common stock...................      392             1,663,771     $27,358        $119,840       $92,482


* Dispositions represent sales of stock and shares distributed in kind to members who withdrew from the Plan on retirement or termination.

11

INDEPENDENT AUDITORS' REPORT

To the Savings and Investment Plan Committee Pfizer Savings and Investment Plan:

We have audited the accompanying statements of net assets available for plan benefits of the Pfizer Savings and Investment Plan (the Plan) as of December 31, 1996 and 1995 and the related statements of changes in net assets available for plan benefits for the years then ended. These financial statements are the responsibility of the Plan's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with generally accepted auditing standards. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the net assets available for plan benefits of the Plan as of December 31, 1996 and 1995 and the changes in net assets available for plan benefits for the years then ended, in conformity with generally accepted accounting principles.

Our audits were performed for the purpose of forming an opinion on the basic financial statements taken as a whole. The supplemental schedules of (1) assets held for investment purposes and (2) reportable transactions, as of and for the year ended December 31, 1996 are presented for the purpose of additional analysis and are not a required part of the basic financial statements but are supplementary information required by the Department of Labor's Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. The Fund Information in the statements of net assets available for plan benefits and the statements of changes in net assets available for plan benefits is presented for purposes of additional analysis rather than to present the net assets available for plan benefits and changes in net assets available for plan benefits of each fund. The supplemental schedules and Fund Information have been subjected to the auditing procedures applied in the audits of the basic financial statements and, in our opinion, are fairly stated in all material respects in relation to the basic financial statements taken as a whole.

                            /s/ KPMG Peat Marwick LLP

                              KPMG PEAT MARWICK LLP

New York, New York
March 17, 1997

12

SIGNATURES

The Plan. Pursuant to the requirements of the Securities Exchange Act of 1934, the members of the Savings and Investment Plan Committee have duly caused this annual report to be signed on its behalf by the undersigned thereunto duly authorized.

PFIZER SAVINGS AND INVESTMENT PLAN

                                   By:        /s/ David L. Shedlarz

                                   David L. Shedlarz
                                            Senior Vice President and
                                            Chief Financial Officer
                                            Chair, Savings and Investment
                                            Plan Committee

Date: March 27, 1997

13

EXHIBIT 23

CONSENT OF INDEPENDENT AUDITORS

To the Savings and Investment Plan Committee Pfizer Savings and Investment Plan:

We consent to the use of our report dated March 17, 1997 included herein and incorporated herein by reference in the Registration Statement on Form S-8 dated January 24, 1991 (File No. 33-38708) which report relates to the statements of net assets available for plan benefits of the Pfizer Savings and Investment Plan as of December 31, 1996 and 1995, and the related statements of changes in net assets available for plan benefits for the years then ended, and appears in the December 31, 1996 annual report on Form 11-K of the Pfizer Savings and Investment Plan.

                            /s/ KPMG Peat Marwick LLP

                            KPMG PEAT MARWICK LLP


New York, New York
March 27, 1997



SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 11-K

FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS

AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

(Mark One)

|X| ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (FEE REQUIRED)

For the fiscal year ended December 31, 1996

OR

[ ] TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (NO FEE REQUIRED)

For the transition period from ... to ...

Commission file number 1-3619

A. Full title of the Plan and the address of the Plan, if different from that of the issuer named below:

PFIZER SAVINGS AND INVESTMENT PLAN

FOR EMPLOYEES RESIDENT IN PUERTO RICO

B. Name of issuer of the securities held pursuant to the Plan and the address of its principal executive offices:

PFIZER INC.

235 EAST 42ND STREET

NEW YORK, NEW YORK 10017



PFIZER SAVINGS AND INVESTMENT PLAN
FOR EMPLOYEES RESIDENT IN PUERTO RICO

STATEMENT OF NET ASSETS
AVAILABLE FOR PLAN BENEFITS

December 31, 1996

                                                                     Non-Participant
                                                                        Directed                 Participant Directed
                                                                   --------------------------------------------------------------
                                                                      Pfizer Inc.
                                                        Total      Common Stock Fund     Fund A        Fund B         Fund C
                                                    -----------------------------------------------------------------------------
                      ASSETS
Investments, at fair value:
  Pfizer Inc. common stock:
    Pfizer Inc. Common Stock Fund, 91,400  shares,
      cost $2,894,428 Fund C, 79,736 shares; cost
      $2,874,537.................................      $14,204,288         $7,586,187  $        --      $      --     $6,618,101
  Other marketable securities:
    Fund A, cost $1,841,468; Fund B, cost $362,310       2,440,730                 --    1,851,482        589,248             --
Interest-bearing deposits, at cost which
  approximates fair value........................          139,863                 46      139,454             66            297
                                                    -----------------------------------------------------------------------------
             Total investments...................       16,784,881          7,586,233    1,990,936        589,314      6,618,398

Due (to)/from other funds........................               --                 --      (20,969)      (28,596)         49,565
Interest and misc. receivable....................           31,054                659       25,924           799           3,672
Contributions receivable:
  Employees......................................          370,028                 --       93,327         17,645        259,056
  Employers......................................          178,847            178,847           --             --             --
                                                    -----------------------------------------------------------------------------
      Net assets available for plan
        benefits - Note 7........................      $17,364,810         $7,765,739   $2,089,218       $579,162     $6,930,691
                                                    =============================================================================

Number of units outstanding at end of year.......                           1,489,150    1,370,474        250,509      1,374,653
Unit value.......................................                               $5.21        $1.52          $2.31          $5.04

See Notes to Financial Statements which are an integral part of these financial statements.

1

PFIZER SAVINGS AND INVESTMENT PLAN
FOR EMPLOYEES RESIDENT IN PUERTO RICO

STATEMENT OF NET ASSETS
AVAILABLE FOR PLAN BENEFITS

December 31, 1995

                                                                     Non-Participant
                                                                        Directed                 Participant Directed
                                                                   --------------------------------------------------------------
                                                                      Pfizer Inc.
                                                        Total      Common Stock Fund     Fund A        Fund B         Fund C
                                                    -----------------------------------------------------------------------------
                      ASSETS
Investments, at fair value:
  Pfizer Inc. common stock:
    Pfizer Inc. Common Stock Fund, 87,517  shares,
      cost $2,596,932; Fund C, 71,818 shares; cost
      $2,271,405.................................      $10,037,703         $5,513,160    $        --     $    --      $4,524,543

  Other marketable securities:
    Fund A, cost $1,806,318; Fund B, cost $278,353       2,292,532                 --      1,876,876      415,656             --
Interest-bearing deposits, at cost which
  approximates fair value........................          210,494             57,834        115,476       13,387         23,797
                                                    -----------------------------------------------------------------------------
             Total investments...................       12,540,729          5,570,994      1,992,352      429,043      4,548,340

Interest receivable..............................           32,630                155         32,379           34             62

Contributions receivable:
  Employees......................................          300,316                 --        103,983       13,772        182,561
  Employers......................................          157,502            157,502             --           --             --
                                                    -----------------------------------------------------------------------------
      Net assets available for plan
        benefits - Note 7........................      $13,031,177         $5,728,651     $2,128,714     $442,849     $4,730,963
                                                    =============================================================================

Number of units outstanding at end of year.......                           1,461,391      1,438,320      231,858      1,238,472
Unit value.......................................                               $3.92          $1.48        $1.91          $3.82

See Notes to Financial Statements which are an integral part of these financial statements.

2

PFIZER SAVINGS AND INVESTMENT PLAN
FOR EMPLOYEES RESIDENT IN PUERTO RICO

STATEMENT OF CHANGES IN NET ASSETS
AVAILABLE FOR PLAN BENEFITS

Year Ended December 31, 1996

                                                                     Non-Participant
                                                                        Directed                 Participant Directed
                                                                   --------------------------------------------------------------
                                                                      Pfizer Inc.
                                                        Total      Common Stock Fund     Fund A        Fund B         Fund C
                                                    -----------------------------------------------------------------------------
Net investment income:
  Cash dividends:
    Pfizer Inc. common stock......................         $199,071          $108,820      $       --    $     --         $90,251
    Other marketable securities...................           11,809                --              --      11,809              --
  Interest........................................          139,013             2,294         132,505         440           3,774
                                                    -------------------------------------------------------------------------------
                                                            349,893           111,114         132,505      12,249          94,025
Investment management fees - Note 4...............           (2,136)               --              --      (2,136)             --
                                                    -------------------------------------------------------------------------------
                                                            347,757           111,114         132,505      10,113          94,025
Realized gains/(losses) on investments, net - Note 5:
  Pfizer Inc. common stock........................           71,731            45,704              --          --          26,027
  Other marketable securities.....................           (5,043)               --          (8,077)      3,034              --
                                                    -------------------------------------------------------------------------------
                                                             66,688            45,704          (8,077)      3,034          26,027
                                                    -------------------------------------------------------------------------------
Miscellaneous income/(expense)....................            1,103               482          (3,500)        737           3,384
Unrealized appreciation/(depreciation) of
  investments net - Note 6........................        3,295,048         1,775,531         (60,544)     89,635       1,490,426
                                                    -------------------------------------------------------------------------------
                                                          3,710,596         1,932,831          60,384     103,519       1,613,862
                                                    -------------------------------------------------------------------------------
Contributions
  Employees.......................................        2,802,387                --         735,237     166,109       1,901,041
  Employers.......................................        1,376,512         1,376,512              --          --              --
Withdrawals - Note 7..............................       (3,555,862)       (1,265,817)       (646,612)    (93,034)     (1,550,399)
Transfers between funds - net.....................               --            (6,438)       (188,505)    (40,281)        235,224
                                                    -------------------------------------------------------------------------------
                                                            623,037           104,257         (99,880)     32,794         585,866
                                                    -------------------------------------------------------------------------------
Net increase/(decrease) - Note 3..................        4,333,633         2,037,088         (39,496)    136,313       2,199,728
Net assets available for plan benefits - Note 7:
  Beginning of year...............................       13,031,177         5,728,651       2,128,714     442,849       4,730,963
                                                    -------------------------------------------------------------------------------
  End of year.....................................      $17,364,810        $7,765,739      $2,089,218    $579,162      $6,930,691
                                                    ===============================================================================

See Notes to Financial Statements which are an integral part of these financial statements.

3

PFIZER SAVINGS AND INVESTMENT PLAN
FOR EMPLOYEES RESIDENT IN PUERTO RICO

STATEMENT OF CHANGES IN NET ASSETS
AVAILABLE FOR PLAN BENEFITS

Year Ended December 31, 1995

                                                                     Non-Participant
                                                                        Directed                 Participant Directed
                                                                   --------------------------------------------------------------
                                                                      Pfizer Inc.
                                                        Total      Common Stock Fund     Fund A        Fund B         Fund C
                                                    -----------------------------------------------------------------------------
Net investment income:
  Cash dividends:
    Pfizer Inc. common stock......................     $  159,945          $   86,696      $       --      $     --      $   73,249
    Other marketable securities...................          4,898                  --              --         4,898              --
  Interest........................................        129,556               3,825         119,267         4,196           2,268
                                                    --------------------------------------------------------------------------------
                                                          294,399              90,521         119,267         9,094          75,517
Investment management fees - Note 4...............         (5,129)                 --              --        (5,129)             --
                                                    --------------------------------------------------------------------------------
                                                          289,270              90,521         119,267         3,965          75,517
Realized gains on investments, net - Note 5:
  Pfizer Inc. common stock........................         60,220              29,373              --            --          30,847
  Other marketable securities.....................          5,614                  --             156         5,458              --
                                                    --------------------------------------------------------------------------------
                                                           65,834              29,373             156         5,458          30,847
                                                    --------------------------------------------------------------------------------
Unrealized appreciation of investments - net
  Note 6..........................................      3,945,688           2,023,731         129,776       103,206       1,688,975
                                                    --------------------------------------------------------------------------------
                                                        4,300,792           2,143,625         249,199       112,629       1,795,339
                                                    --------------------------------------------------------------------------------
Contributions
  Employees.......................................      2,340,054                  --         846,905       136,407       1,356,742
  Employers.......................................      1,231,787           1,231,787              --            --              --
Withdrawals - Note 7..............................     (2,607,599)           (788,809)       (526,514)      (77,333)     (1,214,943)
Transfers between funds - net.....................             --              11,301         (37,166)      (10,698)         36,563
                                                    --------------------------------------------------------------------------------
                                                          964,242             454,279         283,225        48,376         178,362
                                                    --------------------------------------------------------------------------------
Net increase - Note 3.............................      5,265,034           2,597,904         532,424       161,005       1,973,701
Net assets available for plan benefits - Note 7:
  Beginning of year...............................      7,766,143           3,130,747       1,596,290       281,844       2,757,262
                                                    --------------------------------------------------------------------------------
  End of year.....................................    $13,031,177          $5,728,651      $2,128,714      $442,849      $4,730,963
                                                    ================================================================================

See Notes to Financial Statements which are an integral part of these financial statements.

4

PFIZER SAVINGS AND INVESTMENT PLAN FOR
EMPLOYEES RESIDENT IN PUERTO RICO

NOTES TO FINANCIAL STATEMENTS
December 31, 1996 and 1995

Note 1 -- Summary Plan Description

General -- The Pfizer Savings and Investment Plan for Employees Resident in Puerto Rico (the "Plan") is a defined contribution savings plan which was adopted on February 1, 1990. Participation in the Plan is open to all eligible employees of the Puerto Rico branches of Pfizer Pharmaceuticals, Inc., a subsidiary of Pfizer Inc., and Pfizer Corporation, an indirect wholly-owned subsidiary of Pfizer Inc., (individually and collectively, the "Companies"). The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974.

Effective January 1, 1997, NAMIC CARIBE, INC., an affiliate of the Companies, and all its eligible employees entered into the Plan as sponsor and participants, respectively, under the same conditions stated in the provisions of the Plan.

The following is a general description of certain provisions of the Plan. Refer to the Plan agreement for a complete description of the Plan.

Contributions -- Each participant may make contributions on an after-tax basis and/or on a before-tax basis (that is, choose to reduce his or her compensation and have the Companies contribute on his or her behalf). Before-tax contributions are subject to certain restrictions under the Puerto Rico Income Tax Act of 1954, as amended. Contributions of up to 2% of compensation are matched 100% by the Companies and the next 4% is matched 50%. Employee contributions in excess of 6% are not matched.

Investment Options -- Each participant in the Plan elects to have his or her contributions invested in any one or any combination of the three investment funds. These funds are described below:

Fund A -- Fixed income securities.
Fund B -- An index fund of corporate common stocks. Fund C -- Common stock of Pfizer Inc.

At December 31, 1996 and 1995, there were 1,037 and 1,015 employees, respectively, participating in the Plan, some of whom had investments in more than one employee investment fund. On the basis of allocations by the employees of their contributions at December 31, 1996 and 1995, respectively, Fund A had 531 and 566 participating employees, Fund B, 171 and 160 and Fund C, 860 and 763.

All matching contributions are invested by the Plan's trustee in a fourth fund designated the "Pfizer Inc. Common Stock Fund," which consists primarily of common stock of Pfizer Inc. These contributions are non-participant directed.

The Plan's trust agreement provides that any portion of any of the funds may, pending its permanent investment or distribution, be invested in short-term investments.

Eligibility and Vesting -- Substantially all employees of the Companies who are resident in Puerto Rico are eligible to participate in the Plan beginning on the January 1 following their date of employment, or the beginning of any month or payroll period thereafter. A participant is immediately vested in the full value of his or her accounts (i.e., participant and employer contributions).

5

PFIZER SAVINGS AND INVESTMENT PLAN FOR
EMPLOYEES RESIDENT IN PUERTO RICO
NOTES TO FINANCIAL STATEMENTS
December 31, 1996 and 1995

Note 1 -- Summary Plan Description (Continued)

Payment of Benefits -- Upon separation from service, retirement, disability or death, a participant will receive the value of his or her account as a lump-sum distribution.

Withdrawals -- A participant in the Plan may withdraw all or part of his or her account balance subject to the provisions of the Plan.

Termination -- The Companies expect to continue the Plan indefinitely, but necessarily reserve the right to amend, suspend or discontinue it in whole or in part, at any time, by action of the Companies' Boards of Directors. In the event of termination of the Plan, each participant shall receive the full value of his or her account balance as though he or she had retired as of the date of such termination. No part of the assets in the investment funds established pursuant to the Plan will at any time revert to the Companies.

Note 2 -- Summary of Significant Accounting Policies

Basis of Accounting -- The financial statements of the Plan are prepared on the accrual basis of accounting. For treatment of benefits payable, refer to Note 7.

Investment Valuation -- Pfizer Inc. common stock is valued at the closing market price on the last business day of the year. Other marketable securities are valued at fair value based on the closing market price of the security on the last business day of the year except for investments in the index fund of corporate common stocks, which are recorded at fair value based on the closing market price of the underlying investments held by the fund on the last business day of the year. Interest-bearing deposits are recorded at cost, which approximates fair value.

Security Transactions -- Purchases and sales of securities are reflected on a trade-date basis. Realized gains and losses on sales of investments represent the difference between the net proceeds received and the cost of the investments (average cost if less than the entire investment is sold).

Unrealized Appreciation/(Depreciation) Of Investments -- Unrealized appreciation (depreciation) of investments for the year represents the difference between the cost of the investments and the fair value at the end of the year. Additionally, it includes the reversal of the unrealized appreciation (depreciation) as of the end of the prior year.

Dividend Recognition -- Dividend income is recorded on the ex-dividend date. Income from other investments is recorded as earned.

Note 3 -- Income Taxes

No provision has been made for Puerto Rico income tax in reliance upon a determination letter issued by the Puerto Rico Department of Treasury, which states that the Plan meets the requirements of Section 165(a) of the Puerto Rico Income Tax Act of 1954 and that the trust established thereunder is entitled to exemption.

Contributions made to the Plan by the Companies, including before-tax contributions made on the employee's behalf by the Companies and the appreciation on all funds in the employee's account, are not taxable to the employee under Puerto Rico income tax law while these amounts remain in the Plan.

6

PFIZER SAVINGS AND INVESTMENT PLAN FOR
EMPLOYEES RESIDENT IN PUERTO RICO
NOTES TO FINANCIAL STATEMENTS
December 31, 1996 and 1995

Note 4 -- Administrative Costs

Except for certain investment management fees (Fund B), all costs and expenses of administering the Plan are borne by the Companies.

Note 5 -- Realized Gains(Losses) on Investments

The aggregate net proceeds and carrying value used in the calculation of the realized gains (losses) on investments are as follows:

                                               Net Proceeds                        Realized Gains
                                              and Withdrawals         Cost            (Losses)
                                             ------------------  ---------------  -----------------
Pfizer Inc. Common Stock:
  1996......................................      $193,865          $122,134           $71,731
  1995......................................       183,217           122,997            60,220

Other Marketable Securities:
  1996......................................       381,238           386,281            (5,043)
  1995......................................        65,012            59,398             5,614

Note 6 -- Unrealized Appreciation (Depreciation) of Investments

The change in the amount of unrealized appreciation (depreciation) was as follows:

                                                          Aggregate Unrealized
                                                     --------------------------------
                                                      December 31,     December 31,      Change During
                                                          1996             1995              1996
                                                     --------------------------------  ------------------
Pfizer Inc. Common Stock Fund.......................     $4,691,759      $2,916,228          $1,775,531
Fund A..............................................         10,014          70,558             (60,544)
Fund B..............................................        226,938         137,303              89,635
Fund C..............................................      3,743,564       2,253,138           1,490,426
                                                     ---------------  ---------------  ------------------
                                                         $8,672,275      $5,377,227          $3,295,048
                                                     ===============  ===============  ==================

                                                          Aggregate Unrealized
                                                     --------------------------------
                                                      December 31,     December 31,      Change During
                                                          1995             1994              1995
                                                     --------------------------------  ------------------
Pfizer Inc. Common Stock Fund.......................     $2,916,228      $  892,497          $2,023,731
Fund A..............................................         70,558         (59,218)            129,776
Fund B..............................................        137,303          34,097             103,206
Fund C..............................................      2,253,138         564,163           1,688,975
                                                     ---------------  ---------------  ------------------
                                                         $5,377,227      $1,431,539          $3,945,688
                                                     ===============  ===============  ==================

7

PFIZER SAVINGS AND INVESTMENT PLAN FOR
EMPLOYEES RESIDENT IN PUERTO RICO
NOTES TO FINANCIAL STATEMENTS
December 31, 1996 and 1995

Note 7 -- Withdrawals and Reconciliation with Form 5500

For financial statement purposes, participant withdrawals and distributions are recorded when paid rather than when processed and approved for payment. Therefore, the net assets available for Plan benefits as of December 31, 1996 and 1995 do not reflect a reduction for the following benefits payable to participants who had requested withdrawals as of December 31, but which were not distributed until the subsequent year:

                                                   1996             1995
                                              ---------------   --------------
Pfizer Inc. Common Stock Fund........           $  90,028         $ 62,751
Fund A...............................              45,089           27,423
Fund B...............................                 963            3,822
Fund C...............................             105,224           89,894
                                              ---------------   --------------
                                                 $241,304         $183,890
                                              ===============   ==============

For the purposes of Form 5500, such withdrawals and distributions are recorded when processed and approved for payment. Therefore, benefits payable to participants who have requested withdrawals have been reported as benefit expense on Form 5500 for those years.

8

PFIZER SAVINGS AND INVESTMENT PLAN
FOR EMPLOYEES RESIDENT IN PUERTO RICO

ITEM 27a -- SCHEDULE OF ASSETS HELD FOR INVESTMENT PURPOSES

December 31, 1996

                                                            Interest Rate      Maturity         Cost         Fair Value
                                                           -----------------  ------------  --------------  --------------
FUND A:
U.S. Government Securities
U.S. Treasury Notes                                              7.87%      08/15/01        $111,035        $118,319

Equity Mutual Funds
Fidelity Investment Intermediate Fund                                -             -         100,406          99,620

Other Marketable Securities
Federal Home Loan Bank                                           9.15%      03/25/97          43,168          42,308
Federal Home Loan Bank Medium Term Note                          6.97%      11/20/97          75,000          75,762
Federal National Mortgage Association                            8.80%      07/25/97          49,406          50,899
Federal National Mortgage Association                            7.85%      09/10/98          25,969          25,754
Federal Farm Credit Bank Bond                                    6.05%      04/21/03          29,822          29,353
Federal Home Loan Mortgage Corporation                           6.35%      03/07/01          26,758          27,659
Federal National Mortgage Association Term Note                  7.90%      04/10/02          44,944          45,204
Federal National Mortgage Association Term Note                  5.80%      12/10/03           8,937           9,592
SLMA Medium Term Note                                            5.50%      07/08/02          57,213          57,440
Federal Home Loan Mortgage Term Note                             7.03%      10/19/05          60,355          59,194
                                                                                       ------------------------------
                                                                                             421,572         423,165
                                                                                       ------------------------------
Corporate Debentures
World Bank Medium Term Note                                      9.19%      06/23/98          42,807          41,824
Tennessee Valley Authority                                 zero coupon      07/15/03          87,554          97,350
Tennessee Valley Authority                                       6.12%      07/15/03          76,641          72,680
Tennessee Valley Authority                                       6.37%      06/15/05         117,188         118,106
Citicorp                                                         9.00%      04/15/99          51,213          52,693
Dean Witter Discover Bond                                        6.25%      03/15/00          22,810          23,845
Exxon Bond                                                       7.87%      08/15/97          57,520          55,718
Lehman Brothers Holdings, Inc. Note                              8.37%      04/01/97         100,409         100,599
Merrill Lynch                                                    6.37%      03/30/99          31,920          32,051
Shell Oil Co. Bond                                               6.95%      12/15/98          50,406          50,754
AT&T Corporate Bond                                              6.75%      04/01/04          50,676          50,406
New Jersey Bell Corporate Bond                                   5.87%      02/01/04          39,048          38,280
Bell South Telephone                                             6.37%      06/15/04          40,000          40,000
Dean Witter Discover & Co.                                       6.87%      03/01/03          25,499          27,013
General Telephone Co. Florida                                    8.00%      03/01/01          39,684          40,581
Georgia Power First Mortgage Bond                                6.62%      04/01/03          29,888          29,623
IBM Corporate Bond                                               7.25%      11/01/02          29,737          30,600
J.P. Morgan Corporate Bond                                       6.25%      12/15/05          66,707          67,050
New Jersey Bell Telephone                                        7.25%      06/01/02           9,882          10,290
Wal-Mart Stores                                                  6.75%      05/15/02          90,675          90,391
Wal-Mart Corporate Bond                                          5.87%      10/15/05         148,191         140,524
                                                                                       ------------------------------
                                                                                           1,208,455       1,210,378
                                                                                       ------------------------------
   Total marketable securities                                                             1,841,468       1,851,482

Interest-Bearing Deposit
Banco Popular de Puerto Rico Time Deposit(1)                     4.88%                       139,454         139,454
                                                                                       ------------------------------
   Total of Fund A                                                                        $1,980,922      $1,990,936
                                                                                       ==============================

(1)Banco Popular de Puerto Rico is a "party in interest" of the Plan.

9

PFIZER SAVINGS AND INVESTMENT PLAN
FOR EMPLOYEES RESIDENT IN PUERTO RICO

ITEM 27a -- SCHEDULE OF ASSETS HELD FOR INVESTMENT PURPOSES
(Continued)

December 31, 1996

                                                                      Number of        Interest
                                                                   Shares or Units       Rate           Cost          Fair Value
                                                                   -----------------  -----------  ---------------  ---------------
FUND B:
Other Marketable Securities
The Northern Trust Company, Collective Stock
  Index Fund.....................................................         9,032                          $362,310         $589,248

Interest-Bearing Deposit
The Northern Trust Company, Short-term
  Investment Fund................................................            66            4.56%               66               66
                                                                                                   --------------------------------
    Total of Fund B..............................................                                        $362,376         $589,314
                                                                                                   ================================

FUND C:
Pfizer Inc. Common Stock.........................................        79,736                        $2,874,537       $6,618,101

Interest-bearing Deposit
Banco Popular de Puerto Rico Time Deposit(1).....................                          4.88%              297              297
                                                                                                   --------------------------------
    Total of Fund C...............................................                                     $2,874,834       $6,618,398
                                                                                                   ================================

PFIZER INC. COMMON STOCK FUND:
Pfizer Inc. Common Stock ........................................        91,400                        $2,894,428       $7,586,187

Interest-Bearing Deposit
Banco Popular de Puerto Rico, Time Deposit(1)....................                          4.88%               46               46
                                                                                                   --------------------------------
    Total Pfizer Inc. Common Stock Fund..........................                                      $2,894,474       $7,586,233
                                                                                                   ================================

(1)Banco Popular de Puerto Rico is a "party in interest" of the Plan.

See accompanying independent auditors' report

10

PFIZER SAVINGS AND INVESTMENT PLAN FOR
EMPLOYEES RESIDENT IN PUERTO RICO

ITEM 27d -- SCHEDULE OF
REPORTABLE TRANSACTIONS

December 31, 1996

Funds A, B, C and Pfizer Inc. Common Stock Fund:

                                          Number of        Number of
Investments Purchased                    Transactions        Shares           Cost
                                       -----------------  -------------   --------------
Pfizer Inc. Common Stock..............          23            13,924         $1,022,762

Interest-bearing Deposits: Banco
  Popular de Puerto Rico(1),
    Time Deposits.....................         191             --             4,056,881

                                          Number of        Number of                                          Realized
Investments Disposed(2)                  Transactions        Shares           Cost           Fair Value      Gain/(Loss)
                                       -----------------  -------------   --------------   ---------------  --------------
Pfizer Inc. Common Stock..............           1             2,123          $122,134         $193,865        $71,731

Interest-bearing Deposits: Banco
  Popular de Puerto Rico(1),
    Time Deposits.....................         143             --           $4,127,509         $4,127,509        --

(1)Banco Popular de Puerto Rico is a "party in interest" of the Plan.

(2)Dispositions include sales of stock (665 shares) and shares distributed in kind to participants who withdrew from the Plan on retirement or termination (1,458 shares).

See accompanying independent auditors' report

11

INDEPENDENT AUDITORS' REPORT

To the Administrative Committee
Pfizer Savings and Investment Plan for
Employees Resident in Puerto Rico:

We have audited the accompanying statements of net assets available for plan benefits of the Pfizer Savings and Investment Plan for Employees Resident in Puerto Rico (the Plan) as of December 31, 1996 and 1995, and the related statements of changes in net assets available for plan benefits for the years then ended. These financial statements are the responsibility of the Plan's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with generally accepted auditing standards. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the net assets available for plan benefits of the Plan as of December 31, 1996 and 1995, and the changes in net assets available for plan benefits for the years then ended, in conformity with generally accepted accounting principles.

Our audits were performed for the purpose of forming an opinion on the basic financial statements taken as a whole. The supplemental schedules of
(1) assets held for investment purposes and (2) reportable transactions, as of and for the year ended December 31, 1996, are presented for the purpose of additional analysis and are not a required part of the basic financial statements but are supplementary information required by the Department of Labor's Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. The Fund Information in the statements of net assets available for plan benefits and the statements of changes in net assets available for plan benefits is presented for purposes of additional analysis rather than to present the net assets available for plan benefits and changes in net assets available for plan benefits of each Fund. The supplemental schedules and Fund Information have been subjected to the auditing procedures applied in the audits of the basic financial statements and, in our opinion, are fairly stated in all material respects in relation to the basic financial statements taken as a whole.

                                                   /s/ KPMG Peat Marwick LLP

                                                   KPMG Peat Marwick LLP

February 11, 1997

Stamp No. 1354305 Puerto Rico
Society of Certified Public Accountants was affixed to the record copy of this report.

12

SIGNATURES

The Plan. Pursuant to the requirements of the Securities Exchange Act of 1934, the members of the Savings and Investment Plan Committee have duly caused this annual report to be signed on its behalf by the undersigned thereunto duly authorized.

PFIZER SAVINGS AND INVESTMENT PLAN FOR
EMPLOYEES RESIDENT IN PUERTO RICO

                         By: /S/ ANTHONY MADDALUNA
                             ----------------------------------
                         Anthony Maddaluna
                                 General Manager,
                                 Pfizer Pharmaceuticals, Inc.
                                 Chair, Savings and
                                 Investment Plan Committee

Date: March 27,1997

13

Exhibit 23

CONSENT OF INDEPENDENT AUDITORS

To the Administrative Committee
Pfizer Savings and Investment Plan for
Employees Resident in Puerto Rico:

We consent to the use of our report included herein and incorporated by reference in the Registration Statement on Form S-8 dated November 18, 1991 (File No. 33-44053) of our report dated February 11, 1997, relating to the statements of net assets available for plan benefits of the Pfizer Savings and Investment Plan for Employees Resident in Puerto Rico as of December 31, 1996 and 1995, and the related statements of changes in net assets available for plan benefits for the years then ended, which report appears in the December 31, 1996 annual report on Form 11-K of the Pfizer Savings and Investment Plan for Employees Resident in Puerto Rico.

                            /s/ KPMG Peat Marwick LLP

                              KPMG Peat Marwick LLP

San Juan, Puerto Rico
March 27, 1997


EXHIBIT 21
SUBSIDIARIES OF THE REGISTRANT

The following is a list of subsidiaries of the Company as of the date hereof, omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary.

                                                               Where
       Name                                                    Incorporated
       ----                                                    ------------

(a)  Subsidiaries of Pfizer Inc.:

     Radiologic Sciences, Inc..............................    California
     Shiley Incorporated...................................    California
     Vesta Medical, Inc....................................    California
     Valleylab Inc.........................................    Colorado
     Pfizer Products Inc...................................    Connecticut
     Anaderm Research Corp.................................    Delaware
     Disease Management Sciences Inc.......................    Delaware
     Health Care Ventures, Inc.............................    Delaware
     Howmedica Inc.........................................    Delaware
     Pfizer Enterprises Inc................................    Delaware
     Pfizer Health Solutions Inc...........................    Delaware
     Pfizer International Properties, LLC..................    Delaware
     Pfizer Medical Systems, Inc. .........................    Delaware
     Pfizer Pharmaceuticals, Inc...........................    Delaware
     Pfizer Pigments, Inc..................................    Delaware
     Site Realty, Inc......................................    Delaware
     Corvita Corporation...................................    Florida
     Strato/Infusaid Inc...................................    Massachusetts
     American Medical Systems, Inc.........................    Minnesota
     Schneider (USA) Inc...................................    Minnesota
     Adforce Inc...........................................    New York
     Quigley Company Inc...................................    New York
     Pfizer International Inc..............................    New York
     Howmedica G.m.b.H.....................................    Austria
     Cadsand Medica N.V....................................    Belgium
     Laboratorios Pfizer Ltd...............................    Brazil
     Orsim, S.A............................................    France
     Van Cadsand Beheer B.V................................    Netherlands
     Pfizer Trading Corp...................................    Taiwan

(b)  Subsidiaries of Howmedica Inc.
     (a Subsidiary of Pfizer Inc.):

     Howmedica Leibinger Inc...............................     Delaware
     Howmedica Investments Pty. Ltd........................     Australia
     S.D. Investments Pty. Ltd.............................     Australia
     Howmedica G.m.b.H.....................................     Germany
     Howmedica International, Inc..........................     Panama
     Jaquet Orthopedie S.A.................................     Switzerland


(c) Subsidiary of Schneider (USA) Inc

      (a subsidiary of Pfizer Inc.):
      SCHNEIDER/NAMIC.....................................     Delaware

(c-1) Subsidiaries of SCHNEIDER/NAMIC
      NAMIC CARIBE, Inc...................................     Delaware
      NAMIC Eireann Limited...............................     Ireland
      NAMIC Eireann B.V...................................     Netherlands
      NAMIC Worldwide B.V.................................     Netherlands
      NAMIC International, Inc............................     Virgin Islands

(d)   Subsidiaries of Pfizer International Inc.
      (a Subsidiary of Pfizer Inc.):

      Pfizer Overseas Inc..................................    Delaware
      Pfizer H.C.P. Corporation............................    New York
      Pfizer Corporation Austria G.M.B.H...................    Austria
      Pfizer S.A...........................................    Belgium
      The Kodiak Company Ltd...............................    Bermuda
      Pfizer Canada Inc....................................    Canada
      Roerig S.A...........................................    Chile
      Pfizer Pharmaceutical Trading Limited
      Liability Company....................................    Hungary
      Pfizer (Ireland) Limited.............................    Ireland
      Pfizer Chemical Corp. Ltd............................    Isle Of Man
      Pfizer Pharmaceutics Israel Ltd......................    Israel
      Compania Distribuidora Del Centro, S.A. de C.V.......    Mexico
      Pfizer Holding Mexico, S. de R.L. de C.V.............    Mexico
      Pfizer, S.A. de C.V..................................    Mexico
      Laboratories Pfizer S.A..............................    Morocco
      Pfizer Specialties Limited...........................    Nigeria
      Pfizer Pharmaceuticals Production Corporation........    Panama
      Pfizer Polska Sp.z.o.o...............................    Poland
      A/O Pfizer...........................................    Russia
      Pfizer Healthcare Ltd................................    South Korea
      BINESA- Bioquimica Industrial Espanola, S.A..........    Spain
      Pfizer, S.A..........................................    Spain
      Pfizer Group Limited.................................    United Kingdom

(e)   Subsidiaries of Pfizer Pharmaceuticals Production
      Corporation (a subsidiary of Pfizer International
      Inc.):

      Pfizer European Service Center N.V...................    Belgium
      Pfizer Research and Development
      Company N.V./S.A.....................................    Belgium
      Pfizer International Bank Europe.....................    Ireland
      Pfizer Pension Trustees (Ireland) Limited............    Ireland
      Pfizer Service Company Ireland.......................    Ireland
      Pfizer Ringaskiddy Production Company................    Isle Of Man
      Roerig Farmaceutici Italiana S.p.A...................    Italy
      Pfizer Corporation...................................    Panama


(f)  Subsidiaries of Pfizer Corporation (a subsidiary of
     Pfizer Pharmaceuticals Production Corporation):

     Pficonprod Pty. Limited.. . . . . . . . . . . . . .      Australia
     Pfizer Agricare Pty. Ltd. . . . . . . . . . . . . .      Australia
     Pfizer Pty. Ltd.. . . . . . . . . . . . . . . . . .      Australia
     Pfizer S.A. . . . . . . . . . . . . . . . . . . . .      Colombia
     Pfizer S.A. . . . . . . . . . . . . . . . . . . . .      Costa Rica
     Pfizer C.A. . . . . . . . . . . . . . . . . . . . .      Ecuador
     Pfizer Egypt S.A.E. . . . . . . . . . . . . . . . .      Egypt
     Pfizer Limited. . . . . . . . . . . . . . . . . . .      Ghana
     Pfizer Hellas, A.E. . . . . . . . . . . . . . . . .      Greece
     Pfizer Limited. . . . . . . . . . . . . . . . . . .      India
     Pt. Pfizer Indonesia. . . . . . . . . . . . . . . .      Indonesia
     Pfizer Laboratories Limited.. . . . . . . . . . . .      Kenya
     Pfizer (Malaysia) Sendirian Berhad. . . . . . . . .      Malaysia
     Pfizer (Namibia) (Proprietary) Limited. . . . . . .      Namibia
     Pfizer Laboratories Limited.. . . . . . . . . . . .      New Zealand
     Pfizer Products PLC . . . . . . . . . . . . . . . .      Nigeria
     Pfizer A/S. . . . . . . . . . . . . . . . . . . . .      Norway
     Pfizer Laboratories Limited . . . . . . . . . . . .      Pakistan
     Harmag, Inc.. . . . . . . . . . . . . . . . . . . .      Panama
     Pfizer International Corporation. . . . . . . . . .      Panama
     Pfizer S.A. . . . . . . . . . . . . . . . . . . . .      Peru
     Pfizer, Inc.. . . . . . . . . . . . . . . . . . . .      Philippines
     Pfizer Private Limited. . . . . . . . . . . . . . .      Singapore
     Pfizer Laboratories (Proprietary) Limited . . . . .      South Africa
     SmithKline Animal Health (Proprietary) Limited. . .      South Africa
     Pfizer Korea Limited. . . . . . . . . . . . . . . .      South Korea
     Pfizer Limited. . . . . . . . . . . . . . . . . . .      South Korea
     Pfizer A.B. . . . . . . . . . . . . . . . . . . . .      Sweden
     Roerig A.B. . . . . . . . . . . . . . . . . . . . .      Sweden
     Pfizer Ltd. . . . . . . . . . . . . . . . . . . . .      Taiwan
     Pfizer Limited. . . . . . . . . . . . . . . . . . .      Tanzania
     Pfizer Limited. . . . . . . . . . . . . . . . . . .      Thailand
     Pfizer Ilaclari A.S.. . . . . . . . . . . . . . . .      Turkey
     Pfizer Limited. . . . . . . . . . . . . . . . . . .      Uganda
     Laboratorios Pfizer De Venezuela, S.A.. . . . . . .      Venezuela

(g)  Subsidiaries of Pfizer Research And Development
     Company N.V./S.A. (a subsidiary of Pfizer
     Pharmaceuticals Production Corporation):

     Pfizer A/S. . . . . . . . . . . . . . . . . . . . .      Denmark
     Pfizer Oy.. . . . . . . . . . . . . . . . . . . . .      Finland
     Pfizer S.A. . . . . . . . . . . . . . . . . . . . .      France
     Pfizer Holding Und Verwaltungs G.m.b.H. . . . . . .      Germany
     Pfizer Holdings Ireland . . . . . . . . . . . . . .      Ireland
     Pfizer Italiana S.P.A.. . . . . . . . . . . . . . .      Italy
     Pfizer Servicios de Mexico, S.A. de C.V.. . . . . .      Mexico
     Pfizer B.V. . . . . . . . . . . . . . . . . . . . .      Netherlands
     Pfizer S.G.P.S. Lda.. . . . . . . . . . . . . . . .      Portugal
     Howmedica Iberica, S.A. . . . . . . . . . . . . . .      Spain
     Rovifarma, S.A. . . . . . . . . . . . . . . . . . .      Spain
     Pfizer A.G. . . . . . . . . . . . . . . . . . . . .      Switzerland
     Schneider (Europe) A.G. . . . . . . . . . . . . . .      Switzerland


(h)  Miscellaneous Subsidiaries:

     Shiley International. . . . . . . . . . . . . . . .      California
     Community Care Health Solutions Inc.. . . . . . . .      Delaware
     Pfizer Pharm Algerie SPA. . . . . . . . . . . . . .      Algeria
     Pfizer S.A.C.I. . . . . . . . . . . . . . . . . . .      Argentina
     Valleylab Australia Pty. Ltd. . . . . . . . . . . .      Australia
     Pfizer Med-Inform Beratungs G.m.b.H . . . . . . . .      Austria
     Corvita Europe S.A. . . . . . . . . . . . . . . . .      Belgium
     Pfizer Animal Health S.A. . . . . . . . . . . . . .      Belgium
     Pfizer Hospital Products (Belgium) N.V. . . . . . .      Belgium
     Cardiovascular Innovations Canada, Inc. . . . . . .      Canada
     Corvita Canada, Inc.. . . . . . . . . . . . . . . .      Canada
     Kirchimie Ltee. . . . . . . . . . . . . . . . . . .      Canada
     Pqi Inc.. . . . . . . . . . . . . . . . . . . . . .      Canada
     Pfizer Zona Franca S.A. . . . . . . . . . . . . . .      Costa Rica
     Pfizer S.R.O. . . . . . . . . . . . . . . . . . . .      Czech Republic
     Benoist Girard & Cie S.C.A. . . . . . . . . . . . .      France
     Howmedica France S.C.A. . . . . . . . . . . . . . .      France
     Laboratoire Beral, S.A. . . . . . . . . . . . . . .      France
     Laboratoires Corvita S.A.R.L. . . . . . . . . . . .      France
     Leibinger S.A.R.L.. . . . . . . . . . . . . . . . .      France
     Heinrich Mack Nachf.. . . . . . . . . . . . . . . .      Germany
     Hilekes G.m.b.H . . . . . . . . . . . . . . . . . .      Germany
     Howmedica Leibinger G.m.b.H . . . . . . . . . . . .      Germany
     Pfizer G.m.b.H. . . . . . . . . . . . . . . . . . .      Germany
     Taylor Kosmetik G.m.b.H . . . . . . . . . . . . . .      Germany
     Pfizer LLC. . . . . . . . . . . . . . . . . . . . .      Hungary
     Duchem Laboratories Limited . . . . . . . . . . . .      India
     Leema Chemicals & Cosmetics Pvt. Ltd. . . . . . . .      India
     Biofin S.P.A. . . . . . . . . . . . . . . . . . . .      Italy
     Bioindustria Farmaceutici S.P.A.. . . . . . . . . .      Italy
     Blue Cross S.R.L. . . . . . . . . . . . . . . . . .      Italy
     Farkemo S.R.L.. . . . . . . . . . . . . . . . . . .      Italy
     Irkafarm S.R.L. . . . . . . . . . . . . . . . . . .      Italy
     Restiva S.R.L.. . . . . . . . . . . . . . . . . . .      Italy
     Sudfarma S.R.L. . . . . . . . . . . . . . . . . . .      Italy
     Pfizer Pharmaceuticals Inc. . . . . . . . . . . . .      Japan
     Pfizer Shoji Co., Ltd.. . . . . . . . . . . . . . .      Japan
     Schneider Japan K.K.. . . . . . . . . . . . . . . .      Japan
     Pfizer S.A. . . . . . . . . . . . . . . . . . . . .      Morocco
     A S Ruffel (Mozambique) Limitada. . . . . . . . . .      Mozambique
     Smithkline Animal Health (Swa) (Pty) Ltd. . . . . .      Namibia
     Cadsand Medica B.V. . . . . . . . . . . . . . . . .      Netherlands
     Pfizer Animal Health B.V. . . . . . . . . . . . . .      Netherlands
     Pfizer Hospital Products (Netherlands) B.V. . . . .      Netherlands
     Roerig B.V. . . . . . . . . . . . . . . . . . . . .      Netherlands
     Pfizer Pharmaceuticals Limited. . . . . . . . . . .      People's Republic
                                                                Of China
     Farminova, Produtos Farmaceuticos De
     Inovacao, Lda.. . . . . . . . . . . . . . . . . . .      Portugal
     Laboratorios Pfizer Lda.. . . . . . . . . . . . . .      Portugal
     Roerig, Produtos Farmaceuticos, Lda.. . . . . . . .      Portugal
     Smithkline Beecham Animal Health (Singapore)
     Private Limited . . . . . . . . . . . . . . . . . .      Singapore
     Pfizer Hospital Products A.B. . . . . . . . . . . .      Sweden
     Ams Medinvent S.A.. . . . . . . . . . . . . . . . .      Switzerland


Nilo Holding S.A.....................................    Switzerland
Smithkline Beecham Animal Health
(Taiwan) Limited.....................................    Taiwan
Biomedical Sensors (Holdings) Limited................    United Kingdom
Charwell Pharmaceuticals Limited.....................    United Kingdom
Howmedica International Limited......................    United Kingdom
Measureaim...........................................    United Kingdom
Pfizer Hospital Products Pension Trustees Limited....    United Kingdom
Pfizer Hospital Products, Limited....................    United Kingdom
Pfizer Limited.......................................    United Kingdom
Pfizer Pension Trustees Ltd..........................    United Kingdom
Shiley Ltd...........................................    United Kingdom
Unicliffe Limited....................................    United Kingdom
Pfizer Bioquimicos S.A...............................    Venezuela
Pfizer S.A...........................................    Venezuela
A S Ruffel (Private) Ltd.............................    Zimbabwe


EXHIBIT 23

CONSENT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS

To the Shareholders and Board of Directors of Pfizer Inc.:

We consent to the use of our report dated February 27, 1997 incorporated herein by reference on the consolidated balance sheet of Pfizer Inc. and subsidiary companies as of December 31, 1996, 1995 and 1994 and the related consolidated statements of income, shareholders' equity and cash flows for the years then ended, as contained in the Pfizer Inc. 1996 Annual Report to Shareholders. These consolidated financial statements and our report thereon are incorporated by reference in this Annual Report on Form 10-K for the year 1996.

We also consent to the incorporation by reference of our report in the Registration Statement on Form S-15 dated December 13, 1982 (File No. 2-80884), as amended, in the Registration Statement on Form S-8 dated October 27, 1983 (File No. 2-87473), as amended, in the Registration Statement on Form S-8 dated March 22, 1990 (File No. 33-34139), in the Registration Statement on Form S-8 dated January 24, 1991 (File No. 33-38708), in the Registration Statement on Form S-8 dated November 18, 1991 (File No. 33-44053), in the Registration Statement on Form S-3 dated May 27, 1993 (File No. 33-49629), in the Registration Statement on Form S-8 dated May 27, 1993 (File No. 33-49631), in the Registration Statement on Form S-8 dated May 19, 1994, (File No. 33-53713), in the Registration Statement on Form S-8 dated October 5, 1994 (File No. 33-55771), in the Registration Statement on Form S-3 dated November 14, 1994 (File No. 33-56435), in the Registration Statement on Form S-8 dated December 20, 1994 (File No. 33-56979), in the Registration Statement on Form S-4 dated February 14, 1995 (File No. 33-57709), and in the Registration Statement on Form S-8 dated March 29, 1996 (File No. 33-02061).

                                                  /s/ KPMG Peat Marwick LLP
                                                  ------------------------------
                                                  KPMG Peat Marwick LLP



New York, New York
March 27, 1997


ARTICLE 5
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM PFIZER INC. AND SUBSIDIARY COMPANIES CONSOLIDATED BALANCE SHEET AND CONSOLIDATED STATEMENT OF INCOME FOR THE PERIOD ENDED DECEMBER 31, 1996 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.


PERIOD TYPE 12 MOS
FISCAL YEAR END DEC 31 1996
PERIOD END DEC 31 1996
CASH 1,150
SECURITIES 487
RECEIVABLES 2,310
ALLOWANCES (58)
INVENTORY 1,589
CURRENT ASSETS 6,468
PP&E 6,005
DEPRECIATION (2,155)
TOTAL ASSETS 14,667
CURRENT LIABILITIES 5,640
BONDS 687
PREFERRED MANDATORY 0
PREFERRED 0
COMMON 34
OTHER SE 9,745
TOTAL LIABILITY AND EQUITY 14,667
SALES 11,306
TOTAL REVENUES 11,306
CGS 2,176
TOTAL COSTS 2,176
OTHER EXPENSES 1,684
LOSS PROVISION 0
INTEREST EXPENSE 165
INCOME PRETAX 2,804
INCOME TAX 869
INCOME CONTINUING 1,929
DISCONTINUED 0
EXTRAORDINARY 0
CHANGES 0
NET INCOME 1,929
EPS PRIMARY 2.99
EPS DILUTED 2.99